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Thesis abstract 
Abnormalities of the cervical or intracranial circulation, termed arteriopathies are the leading 
mechanism of both cause and recurrence of childhood arterial ischaemic stroke (AIS). 
Approximately 20% of children with AIS will have stroke recurrence but there are currently 
no robust biomarkers to identify this high risk group, and hence identification of patients 
who may be amenable to secondary preventative strategies has not been possible. This thesis 
attempts to address this unmet need by studying novel biomarkers to distinguish patients at 
risk of stroke recurrence. Indices of endothelial injury, repair and hypercoagulability were 
compared between patients with recurrent clinical disease course and children with a single 
event. Circulating endothelial cells (CECs) were higher in children with recurrent AIS, 
compared to those with no recurrence and controls. Further evidence of endothelial injury 
and cellular activation was derived by examining circulating microparticles (MP) profiles. 
Plasma from patients with AIS recurrence contained increased numbers of endothelial, 
platelet and neutrophil derived MP compared to those with no recurrence. These MPs were 
highly prothrombotic due to phosphatidylserine exposure providing a platform for the 
assembly and activation of coagulation factors; and also expression of tissue factor on some 
MP. An efficient in vitro assay to assess MP-related hypercoagulability by quantifying MP-
mediated thrombin generation was established. Children with recurrent AIS were shown to 
have an enhanced MP-mediated thrombin generation. Lastly, a disturbance in endothelial 
progenitor cells (EPCs) in children with AIS recurrence was observed suggesting that there 
could be impairment of endothelial repair in these patients. In conclusion, despite the wide 
spectrum of clinical and radiological presentation of childhood AIS, the studies undertaken 
in this thesis suggest that there is an unfavourable imbalance between endothelial injury and 
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repair, and excess hypecoagulability in children with recurrent AIS. These novel 
observations provide unique insights into the pathophysiology of paediatric AIS. 
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1 Introduction 
 
1.1 Arterial ischaemic stroke in children 
 
1.1.1 Definitions 
 
Stroke is defined by the World Health Organisation as “a clinical syndrome typified by 
rapidly developing signs of focal or global disturbance of cerebral functions, lasting more 
than 24 hours or leading to death, with no apparent causes other than of vascular 
origin”(Mackay et al. 2004).   
 
The broad definition of paediatric stroke includes ischaemic and haemorrhagic stroke 
(Amlie-Lefond et al. 2008). Ischaemic stroke (IS), includes arterial ischaemic stroke (AIS) 
and cerebral sinovenous thrombosis (CSVT), whereas haemorrhagic stroke includes intra-
cerebral and subarachnoid haemorrhage (Amlie-Lefond et al. 2008). AIS is defined as an 
acute-onset focal neurological deficit attributable to cerebral infarction in an arterial 
distribution associated with this clinical presentation (Mackay et al. 2011).  
 
Paediatric stroke can also be subdivided according to age of onset into ischaemic perinatal 
stroke (defined as a group of heterogeneous conditions in which there is focal disruption of 
cerebral blood flow secondary to arterial or cerebral venous thrombosis or embolization, 
between 20 weeks of fetal life through the 28th postnatal day, confirmed by neuroimaging or 
 21 
neuropathologic studies) and later childhood stroke (Amlie-Lefond et al. 2008; Raju et al. 
2007).  This thesis will focus on later childhood AIS as defined above. 
 
1.1.2 Epidemiology  
 
Worldwide, stroke is the third most common cause of death, responsible for over 5 million 
deaths per year (Gustavsson et al. 2011; Hachinski et al. 2010).  Many of these patients are 
left with permanent neurologic deficits, and stroke incurs a high cost to patients and their 
families, health care providers and societies (Gordon et al. 2002; MacGregor et al. 2000). 
The total cost of disorders of the brain in Europe was estimated at €798 billion in year 2010, 
with stroke accounting for 8% of these costs (Gustavsson et al. 2011).  In the light of this, 
remarkable efforts have been made over the last 10 years to increase public recognition of 
adult stroke, develop prevention strategies and improve treatment (Hachinski et al. 2010). In 
contrast childhood stroke is seldom considered as a significant health care problem (Amlie-
Lefond et al. 2008; deveber 2003). However among childhood diseases, stroke is not rare 
and the burden of illness related to the neurological damage and mortality from this disorder 
is significant (Fullerton et al. 2002). Stroke in children is at least as frequent as brain 
tumours and is among the top ten causes of death in childhood (Fullerton et al. 2002). In the 
US the cost per paediatric stroke acute admission ranges from $20 000 to $81 000 with 5-
year costs of $135 000 (Perkins et al. 2009). Health care utilisation costs and loss of 
productive years when stroke results in significant neurological or psychological deficits are 
also significant contributors to the burden of illness (Gardner et al. 2010; Lo et al. 2008). In 
addition it is likely that the cost of recurrent strokes over the lifetime of children with the 
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disease may be considerably increased compared to adults (Gardner et al. 2010; Lo et al. 
2008). 
 
Over the last 30 years several population-based studies have reported on varying incidence 
of childhood stroke (deveber 2000; Fullerton et al. 2003; Mallick and O'Callaghan 2010). 
Among these studies the inclusion criteria, methods of patient identification and 
geographical population evaluated have differed, with each study contributing differently to 
our understanding of incidence and subtypes of stroke (deveber 2000; Fullerton, Wu, Zhao, 
& Johnston 2003; Mallick & O'Callaghan 2010). Data from the Canadian Paediatric 
Ischaemic Stroke Registry provide an estimated incidence of 3.3 per 100,000 children per 
year for childhood ischaemic stroke (AIS and cerebral venous thrombosis) (deveber 2000). 
Retrospective analysis of a California-wide hospital discharge database estimated an 
incidence of stroke (AIS, cerebral venous thrombosis, and haemorrhagic stroke including 
subarachnoid haemorrhage) of 2.3 per 100,000 children per year (Fullerton, Wu, Zhao, & 
Johnston 2003). In addition a prospective study across United Kingdom and Ireland reported 
an incidence of stroke (AIS, cerebral venous thrombosis, and haemorrhagic stroke including 
subarachnoid haemorrhage) of 2.5 per 100,000 children (Williams et al. 2002). It is likely 
however that these figures are an underestimate, as the index of suspicion for AIS is 
typically low in the paediatric population.  
 
The risk of childhood stroke considerably varies according to age (Barnes et al. 2004; 
Fullerton, Wu, Zhao, & Johnston 2003; Ganesan et al. 2003). The majority of the studies 
report the greatest risk of childhood stroke in children aged less than 1 year (Barnes et al. 
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2004; Fullerton, Wu, Zhao, & Johnston 2003). In studies that analysed neonates (aged less 
than 1 month) separately, this group was found to be at particularly high risk, responsible for 
up to 35% of cases of childhood stroke (Barnes et al. 2004; Steinlin et al. 2005). Both 
Fullerton et al. and Kirkham et al. reported that after the age of 1 year the risk of overall 
stroke fell significantly between the ages of 5 and 9 years before rising again in adolescence 
(Fullerton, Wu, Zhao, & Johnston 2003; Kirkham et al. 2003).  
 
In addition, several paediatric studies have shown a male predominance in children with AIS 
(Golomb et al. 2009; Mackay et al. 2011).  The International Paediatric Stroke Study Group 
(IPSS) found a male to female ratio of 1.49 amongst the first 1187 patients enrolled (Mackay 
et al. 2011). A number of factors have been postulated to explain the male gender 
predominance. Hormonal factors such as oestrogen that has vaso-dilatory and anti-
inflammatory effects may offer relative protection from stroke to females (Mallick & 
O'Callaghan 2010; Reeves et al. 2008). Among boys, elevated testosterone levels have been 
shown to be independently associated with stroke risk (Golomb, Fullerton, & Nowak-Gottl 
2009). Differences in sports and other physical activities that have been associated with 
certain types of childhood stroke such as arterial dissection and AIS may partially explain 
gender differences too (Fullerton et al. 2001; Mallick & O'Callaghan 2010). Of note in the 
Californian cohort, the risk of stroke for black children was twice that for white children 
while the relative risk for Hispanics compared to whites was 0.76 and Asians and whites had 
equal risk (Fullerton, Wu, Zhao, & Johnston 2003). This increased risk remained significant 
even when cases of sickle cell disease were excluded (Fullerton, Wu, Zhao, & Johnston 
2003).  
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1.1.3 Clinical Presentation  
 
Childhood AIS commonly presents with acute hemiparesis (Ganesan and Kirkham 2011). 
Patients whose signs resolve within 24 hours or longer have transient ischaemic attacks 
(TIA) but may have cerebral infarction on imaging (Ganesan et al. 2003; Ganesan & 
Kirkham 2011). Other presenting features include altered mental status, aphasia and visual 
disturbance (Fox et al. 2012; Ganesan & Kirkham 2011). Children may also present with 
signs of raised intracranial hypertension and imminent central or uncal herniation and may 
require admission to paediatric intensive care units (Fox, Johnston, Sidney, & Fullerton 
2012; Ganesan & Kirkham 2011). Seizures and status epilepticus have also been described 
and are associated with a high likelihood of developing epilepsy later on in life 
(Chadehumbe et al. 2009). In addition, coma is a well recognised presentation in children 
with large middle cerebral artery (MCA) territory infarct (Fox, Johnston, Sidney, & 
Fullerton 2012; Ganesan & Kirkham 2011). Stroke in the posterior circulation can present as 
ataxia, vertigo, or vomiting (Ganesan et al. 2002). Younger children are more likely to 
present with encephalopathy and a decreased level of consciousness; and may on detailed 
neurological examination be found to have a focal neurological deficit (Zimmer et al. 2007).  
The rapidity of onset may help decide which investigations should be undertaken as abrupt 
onset (< 30 minutes to complete deficit) was documented in more than two thirds of those 
subsequently found to have non-arteriopathic AIS for example embolism, compared with 
only 32% of arteriopathic stroke (Braun et al. 2007).   
 
The differential diagnosis of children presenting with acute focal neurological deficit is wide 
and in addition to stroke includes: encephalitis, brain tumors, hemiplegic migraine, unilateral 
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hemispheric cerebral oedema (e.g secondary to diabetes, hyperammonaemia), haematoma, 
posterior reversible encephalopathy syndrome, venous sinus thrombosis, demyelinating 
disorders and mitochondrial enchepalopathy with stroke-like episodes (Ganesan & Kirkham 
2011; Kirkham 1999; Shellhaas et al. 2006).  Lack of clinical suspicion and the high 
frequency of these stroke mimics in the young, are some of the probable reasons for 
common delay in childhood stroke recognition (Braun et al. 2006; McGlennan and Ganesan 
2008; Rafay et al. 2009).   
 
1.1.4 Imaging confirmation of childhood arterial ischaemic stroke (AIS) 
 
 
Magnetic resonance imaging (MRI) is the imaging modality of choice for the investigation 
of paediatric AIS for the confirmation of stroke and the exclusion of alternative treatable 
pathologies (Fullerton et al. 2007; Jones, Ganesan, Saunders, & Chong 2010). The 
characteristic radiological features of AIS seen in children are similar to those of young 
adults (Hunter 2002; Jones, Ganesan, Saunders, & Chong 2010). MR imaging usually 
includes standard T2-weighted axial images that show tissue contrast well and sagittal and 
coronal T1 weighted images that maximize contrast between the cerebral tissue and 
cerebrospinal fluid (CSF) and provide morphological information (Baird and Warach 1998; 
Hunter 2002; Jones, Ganesan, Saunders, & Chong 2010). In addition fluid-attenuated 
inversion recovery (FLAIR) suppression of the signal from the CSF increases the visibility 
of periventricular lesions (Hunter 2002; Jones, Ganesan, Saunders, & Chong 2010). Of note, 
diffusion weighted imaging (DWI) is able to detect ischaemic regions of the brain before any 
changes are detectable on conventional MRI (Gadian et al. 2000; Jones, Ganesan, Saunders, 
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& Chong 2010). The biophysical mechanisms underlying these diffusion changes may be 
associated with cerebral oedema (Jones, Ganesan, Saunders, & Chong 2010). In addition, 
perfusion imaging allows demonstration of blood flow within the arterioles and capillaries of 
the brain (Calamante et al. 1999; Gadian et al. 2000; Jones, Ganesan, Saunders, & Chong 
2010).  
 
Immediate access to an MRI unit able to provide a timely and accurate diagnosis should be 
the gold standard approach (Jones, Ganesan, Saunders, & Chong 2010). However, practical 
considerations apply with regard to limitations of access to suitable imaging facilities (Jones, 
Ganesan, Saunders, & Chong 2010). Computed tomography (CT) scanning is still performed 
in some centres as it is more widely available and still has a role in excluding stroke mimics 
such as intracerebral haemorhage (Jones, Ganesan, Saunders, & Chong 2010). Acute infarcts 
however are more visible on MRI than CT, with over 80% of MRIs positive within the first 
24 hours compared with only 60% visible on CT (Bryan et al. 1991; Jones, Ganesan, 
Saunders, & Chong 2010). MRI is particularly superior in the detection of infarcts within the 
posterior circulation where CT is limited by beam hardening artifact from the skull base 
(Bryan et al. 1991;Jones, Ganesan, Saunders, & Chong 2010). In addition lacunar infarcts 
and small infarcts are better visualised with MRI (Wardlaw et al. 2001).  
 
Magnetic resonance spectroscopy (MRS) is a non-invasive method that allows the in vivo 
investigation of biochemical changes in stroke (Barker et al. 1994; Gillard et al. 1996). The 
application of this technique has made possible dynamic studies of intracellular metabolism 
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in cerebral ischaemia but to date remains a research tool (Barker et al. 1994; Gillard et al. 
1996).  
 
As far as infarct location is concerned, the majority of strokes in childhood AIS occur within 
the anterior circulation commonly involving the MCA territories (Ganesan et al. 1999; 
Jones, Ganesan, Saunders, & Chong 2010). The posterior circulation appears to be involved 
more frequently in cranio-cervical arterial dissection (Ganesan et al. 2002; Mackay et al. 
2010). Mackay et al. have recently reported on a cohort of children with posterior circulation 
AIS (Mackay, Prabhu, & Coleman 2010). Stroke subtypes included dissection, 
nonprogressive steno-occlusive cerebral arteriopathy, cardioembolic, moyamoya syndrome 
and other undetermined aetiology (Mackay, Prabhu, & Coleman 2010). Lastly, lacunar 
infarcts are rare in children (Williams et al. 1997).  
 
1.1.5 Classification of Childhood Arterial Ischaemic Stroke (AIS)  
 
 
The adoption of a uniformly agreed nomenclature and the subsequent validation of a 
classification system in adult AIS have been critical to the study of neurological outcomes, 
risk-stratified therapies and estimation of recurrence risk (Kang et al. 2003; Kolominsky-
Rabas et al. 2001). Over the past ten years, there was considerable progress in understanding 
the epidemiology, pathophysiology, outcomes, and prognostic factors for recurrence in 
childhood AIS (Amlie-Lefond et al. 2009; Bernard et al. 2012; Ganesan et al. 2003; Golomb, 
Fullerton, & Nowak-Gottl 2009; Mackay et al. 2011). However current research efforts are 
hampered by the lack of standardized nomenclature and classification systems to allow 
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distinction of various patient groups, enable comparisons for prospective studies of natural 
history and facilitate interventional therapeutic clinical trials as in adults (Bernard et al. 
2012). Use of adult criteria is not feasible as the majority of children with AIS do not meet 
criteria for atherothrombotic disease (Bernard et al. 2012). Efforts for establishing 
childhood-specific definitions and classification in AIS have been proposed over the years 
(Wraige et al. 2005). For instance, Wraige et al. in 2005 proposed a classification system of 
AIS identifying eight aetiological subtypes: sickle cell disease, cardioembolic, moyamoya 
syndrome, cervical arterial dissection, steno-occlusive cerebral arteriopathy, other 
determined aetiology, other undefined aetiology and cases with multiple aetiologies (Wraige 
et al. 2005). In addition, Sebire et al. proposed definitions for childhood arteriopathies 
(Sebire et al. 2004). To date however no single system has been widely adopted.  With that 
objective in mind the IPSS established a working group in childhood AIS classification in 
November 2007 that subsequently developed the Childhood AIS Standardized Classification 
and Diagnostic Evaluation (CASCADE) criteria (Bernard et al. 2012). Since the 
pathophysiology of childhood AIS is established in some cases, but not others, the primary 
classification in this system is based upon the anatomic location of any noted anomaly from 
the heart to the cerebrum (figure 1-1) (Bernard et al. 2012). The greatest subdivision occurs 
within the arteriopathies with an initial vascular diagnosis and a follow-up diagnosis at 3-6 
months that aims to capture any progression, stability or regression of the arteriopathy 
(primary classification chronic; figure 1-1) (Bernard et al. 2012).  The CASCADE criteria 
are described in detail in appendix 1. This classification system for childhood AIS has been 
validated and is expected to be widely adapted in future studies. 
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Figure 1-1: CASCADE Criteria Acute Primary Classification: anatomic features (adapted 
from Bernard et al. 2012). 
CASCADE= Childhood AIS Standardized Classification and Diagnostic Evaluation; 
AIS=Arterial ischaemic stroke.  
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 30 
1.2 Risk Factors for childhood arterial ischaemic stroke (AIS) 
 
1.2.1 Introduction 
 
Overall risk factors for AIS differ in children compared with adults (deveber 2003; 
Fullerton, Wu, Sidney, & Johnston 2007; Ganesan et al. 2003; Mackay et al. 2011). Adult 
risk factors for stroke relating to atherosclerosis (eg. hypertension, hyper-lipidaemia, 
diabetes, and smoking) are rarely thought to be related to AIS in children (deveber 2003; 
Fullerton, Wu, Sidney, & Johnston 2007; Ganesan et al. 2003; Mackay et al. 2011). Also in 
contrast to adults, socioeconomic status has not been shown to be associated with an 
increased stroke risk in children (deveber 2003; Fullerton, Wu, Sidney, & Johnston 2007; 
Ganesan et al. 2003; Mackay et al. 2011). Several studies of childhood AIS have reported on 
a wide range of underlying systemic risk factors in the setting of childhood stroke, 
particularly sickle cell disease, cardiac disorders, trauma, thrombophilia and infections such 
as meningitis, sepsis, and encephalitis (Mackey et al 2011; deveber 2003; Fullerton, Wu, 
Sidney, & Johnston 2007; Ganesan et al. 2003). Lo et al. identified congenital heart disease 
and infections (sepsis and meningitis/encephalitis) as commonly associated with childhood 
AIS in a US cohort ( Lo et al. 2009). Of note arrhythmias, hypertension, and coagulation 
defects were associated with both types of ischaemic and haemorrhagic stroke in that study 
(Lo et al. 2009). Ganesan et al. reported data on the known risk factors encountered in 
children presenting with a first AIS in a single UK based center (Ganesan et al. 2003). 
Cerebral arterial imaging was abnormal in 79% of patients who had vascular imaging, 
providing evidence that cerebral arteriopathies are important risk factors associated with AIS 
(Ganesan et al. 2003). Eight out of the 104 patients investigated with echocardiography, had 
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abnormal studies (Ganesan et al. 2003). Genetic or acquired conditions causing 
thrombophilia were rare in that study (Ganesan et al. 2003). Forty percent of patients were 
anaemic, and 21% either had elevated total plasma homocysteine or were homozygous for 
the thermolabile variant of the methylene tetrahydrofolate reductase gene (t-MTHFR) 
mutation (Ganesan et al. 2003). In addition, the most recent study by the IPSS, reported on a 
large group of children (a total of 676 children) with AIS across a number of geographical 
regions (Mackay et al. 2011). Risk factors associated with AIS included arteriopathies 
(53%), cardiac disorders (31%), infection (24%), acute head and neck disorders (23%), acute 
systemic conditions such as sepsis and dehydration (22%), chronic systemic conditions such 
as sickle cell disease and connective tissue disorders (19%), prothrombotic states (13%), 
chronic head and neck disorders (10%), atherosclerosis-related risk factors such as 
hypertension and hyperlipidaemia (2%), and other (22%) (Mackay et al. 2011). Importantly 
52% of the patients studied had more than 2 risk factors identified (Mackay et al. 2011). 
Risk factors in this study varied by age group; arteriopathy was most common in children 
aged 5 to 9 years, acute systemic conditions were more common in younger children, and 
chronic head and neck disorder in older children (Mackay et al. 2011). The study also 
reported on a lower prevalence of arteriopathy in Asia, lower prevalence of chronic systemic 
conditions in Europe and Australia, higher prevalence of prothrombotic states in Europe, and 
higher prevalence of acute systemic conditions in Asia and South America (Mackay et al. 
2011). Of note, variation in the diagnostic approach of these patients may contribute to the 
reported differences. Vascular imaging for instance was less frequently undertaken in Asia 
and South America than in other parts of the world, possibly reflecting the local healthcare 
setting or resource limitations and resulting in reduced frequency of detection of arteriopathy 
 32 
(Mackay et al. 2011). Not surprisingly, the prevalence of acute systemic illnesses was 
relatively higher in Asia and South America (Mackay et al. 2011).  
 
In summary, several studies confirm that risk factors, commonly multiple, are usually 
identified in childhood AIS; these appear to vary according to age and geography (Lo et al. 
2009; Ganesan et al. 2003; Mackay et al. 2011). The most important risk factors associated 
with childhood AIS appear to be nonatherosclerotic arteriopathies and cardiac disease, and 
this is the case across several geographical regions (Lo et al. 2009; Ganesan et al. 2003; 
Mackay et al. 2011). The following sections summarise our current knowledge for all 
established risk factors implicated in the pathogenesis of childhood AIS. The presence and 
morphology of arteriopathy as the single most important determinant of acute management 
and of recurrence risk are highlighted. 
 
 
1.2.2 Cerebral arteriopathy 
 
Cerebral arteriopathy, defined as arterial disease identified on vascular imaging, is one of the 
most common findings in the diagnostic evaluation of children presenting with AIS (Braun 
et al. 2009; Ganesan et al. 2003; Mackay et al. 2011). A California based study reported that 
of 52 children who had vascular imaging after AIS, 42% had stenosis due to arterial lesions 
(Fullerton, Wu, Sidney, & Johnston 2007). A larger study in the UK, reporting on a hospital 
series of 185 children with AIS, found vascular abnormalities in 147 (79%); the most 
common intracranial abnormalities were occlusion or narrowing of the proximal large 
arteries, which was seen in 95 patients (64%) (Ganesan et al. 2003). The recent IPSS also 
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reported that the majority of children who underwent cerebrovascular imaging had evidence 
of cerebral arterial abnormalities (Mackay et al. 2011).  
 
Sebire et al. have summarised the spectrum of arteriopathies encountered in children with 
AIS with varying frequency, including moyamoya, vasculitis, dissection, transient cerebral 
arteriopathy (TCA) and post varicella arteriopathy (PVA) (table 1-1) (Sebire et al. 2004). 
The nomenclature and classification for these arteriopathy subtypes are still in evolution.  
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Non-inflammatory vasculopathies 
Transient cerebral arteriopathy (TCA) 
Arterial dissection        
Sickle cell disease arteriopathy 
Moyamoya syndrome and primary moyamoya disease  
Neurofibromatosis 
Tuberous sclerosis           
Downs syndrome           
Post irradiation 
Congenital vessel hypoplasia/dysplasia 
Fibromuscular dysplasia                  
Vascular webs 
Drug-related vasculopathy 
Cocaine, Amphetamine, Methylphenidate, Phenylpropanolamine 
Primary vasculitides with CNS involvement 
Large vessel 
-Takayasu arteritis 
Medium vessel 
 -Polyarteritis nodosa 
-Kawasaki disease 
Small vessel 
-Primary CNS angiitis 
-Churg-Strauss syndrome, 
-Wegener’s granulomatosis 
-Henoch-Schönlein purpura 
Secondary vasculitides with CNS involvement 
Collagen vascular diseases 
Systemic lupus erythematosus 
Mixed connective tissue disease 
Infectious vasculitis 
Viral 
 -Varicella zoster 
-Cytomegalovirus 
-HIV 
Bacterial 
-Septic meningitis 
-Lyme disease 
-Tuberculosis 
Mycoses 
-Coccidioides 
-Aspergillus 
Parasites 
-Cysticercus 
Table 1-1: Cerebral arteriopathies associated with childhood arterial ischaemic stroke 
(AIS). Adapted from Sebire et al.2004 
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1.2.2.1 Focal cerebral arteriopathy (FCA)/ transient cerebral arteriopathy (TCA)/Post 
varicella arteriopathy (PVA) 
 
Historically, occlusive arteriopathies with no features of dissection or moyamoya were 
described as idiopathic arteriopathies (Chabrier et al. 1998; Sebire 2006). Unilateral cases 
were further classified retrospectively as transient cerebral arteriopathy (when improving 
over time) or chronic cerebral arteriopathy (if persistent) (Chabrier et al. 1998; Sebire 2006). 
The diagnostic criteria for transient cerebral arteriopathy (TCA) are that initial vascular 
imaging (within 3 months of the infarct) should show unilateral or focal segmental stenosis 
or occlusion involving the distal part of the internal carotid and initial segments and 
branches of the anterior and/or middle cerebral artery, though initial imaging can sometimes 
only find minimal or no stenosis or occlusion that then increases to a maximum stenosis or 
occlusion within 3 months of the infarct (Chabrier et al. 2006). The second criterion is that 
there should be non-progression or regression of the arterial lesions on follow-up imaging 6 
months after the infarct (Chabrier et al. 1998; Sebire 2006). It should be noted that 6 months 
is an arbitrary time period and it may be that cases which show improvement after 
considerably longer periods (up to 93 months in one study) may share the same natural 
history as those with improvement in the arteriopathy by 6 months (Chabrier et al. 1998; 
Sebire 2006). In some sense, the term “transient” cerebral arteriopathy is somewhat 
misleading. Although monophasic in the progression of stenosis, in many cases the arterial 
narrowing persists on long-term follow-up imaging. Furthermore when similar angiographic 
appearances are preceded by VZV infection in the preceding 12 months the arteriopathy is 
termed post varicella arteriopathy (PVA) (Lanthier et al. 2005; Sebire et al. 2004). Lanthier 
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et al. reported on the course of vascular changes in childhood PVA and its relationship to 
recurrent AIS or transient ischaemic attacks (TIAs) (Lanthier, Armstrong, & Domi 2005). 
This study suggested that vascular stenosis of childhood PVA takes a monophasic course, 
generally with subsequent stenosis regression and only occasional stenosis progression after 
AIS/TIA (Lanthier, Armstrong, & Domi 2005). In addition, Miravet et al. recently reported 
on 24 children with AIS at median of 4 months following VZV infection (Miravet et al. 
2007). All had infarction in the middle cerebral artery (MCA) territory and abnormalities of 
the M1 segment with arteriopathy affecting other arteries in 10 children (Miravet et al. 
2007).  Arterial disease improved in 11 children, was stable in four, and progressed in seven 
(of whom four had recurrent TIA and two had re-infarction) (Miravet et al. 2007). In 
general, this terminology is somewhat confusing as it encompasses description of disease 
processes (TCA) and aetiology (PVA) as well as heavily relying on radiological appearances 
to distinguish between these arteriopathies. 
 
In recognition of the limitations of classifying arteriopathies on initial imaging, the IPSS has 
recently suggested the term “focal cerebral arteriopathy” of childhood (FCA) to describe 
children with focal stenotic disease of large and/or medium sized vessels not meeting 
definitions for moyamoya, sickle cell vasculopathy, dissection or vasculitis and commonly 
with no identifiable aetiology (Amlie-Lefond et al. 2009). FCA represents up to 25% of all 
arteriopathies (Amlie-Lefond et al. 2009). This term is likely to replace TCA and does not 
depend on the long term course of these arteriopathies (Amlie-Lefond et al. 2009).  It must 
be noted however that both the terms TCA and FCA are simply descriptive and do not imply 
a specific pathophysiology. PVA is considered a subset of FCA characterised by unilateral 
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stenosis and AIS within 1 year of varicella infection.  The typical course of FCA is an initial 
worsening of the cerebral arterial stenosis within the first 3 to 6 months, followed by 
stabilization or improvement (Amlie-Lefond et al. 2009). Braun et al. characterized this 
pattern of vascular changes in 94% of 79 children with unilateral intracranial arteriopathy 
and AIS included in their study, while 6% in their cohort progressed to moyamoya (Braun et 
al. 2009). Of the cases with non-moyamoya AIS, complete resolution occurred in 24%, 
improvement without resolution occurred in 45%, and stabilization occurred in 32% (Braun 
et al. 2009).  
 
1.2.2.2 Arterial dissection 
 
Intracranial or cervical arterial dissection is increasingly recognised in association with AIS 
(up to 20% cases in some series), particularly in adolescents and is the only vascular 
diagnosis where acute anticoagulation is generally recommended (Rafay et al. 2006; Roach 
et al. 2008; Royal College of Physicians, 2004). A traumatic injury is the most frequent 
cause of a dissection; this includes major or minor direct neck or head trauma. However 
some cases are attributed to connective tissue disorders such as Ehlers-Danlos or Marfan 
syndrome while an immediate cause for dissection is often unclear (North et al. 1995; 
Yetman et al. 2003). Confirmation of the diagnosis of intracranial or cervical arterial 
dissection requires MRI/MRA or catheter angiography with one of the following three 
patterns: (1) angiographic findings of a double lumen, intimal flap, or pseudo aneurysm, or, 
on axial T1 fat saturation MRI images, a “bright crescent sign” in the arterial wall; (2) the 
sequence of cervical or cranial trauma, or neck pain, less than 6 weeks preceding 
angiographic findings of segmental arterial narrowing (or occlusion) located in the cervical 
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arteries; (3) angiographic segmental narrowing (or occlusion) of the vertebral artery at the 
level of the C2 vertebral body, even without known traumatic history (Sebire et al. 2004).  
 
1.2.2.3 Primary angiitis of the central nervous system 
 
Central nervous system (CNS) vasculitis in children is an increasingly recognized 
inflammatory brain disease that may occur as a primary disease isolated to the CNS (primary 
angiitis of the CNS, PACNS) or as a secondary manifestation of an underlying systemic 
condition (Benseler et al. 2006; Calabrese and Mallek 1988). A number of systemic 
inflammatory diseases (systemic lupus erythematosus, primary systemic vasculitides, 
Behçets disease, scleroderma amongst others) and infections (streptococcus, mycoplasma 
pneumonia, mycobacterium tuberculosis, Ebstein Barr virus, enteroviruses, human 
immunodeficiency virus, cytomegalovirus, candida, aspergillus amongst many others) can 
cause secondary CNS vasculitis (Benseler et al. 2006; Cellucci and Benseler 2010; Elbers 
and Benseler 2008).  
 
Diagnostic criteria for PACNS were proposed by Calabrese et al. in 1992 and were 
subsequently adapted for childhood PACNS (cPACNS) (Calabrese & Mallek 1988; Elbers 
& Benseler 2008).  These include the following: 
1. The presence of an acquired otherwise unexplained neurological or psychiatric 
deficit. 
2. The presence of either classic angiographic or histopathological features of angiitis 
within the CNS. 
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3. No evidence of systemic vasculitis or any disorder that could cause or mimic the 
angiographic or pathological features of the disease. 
Patients should meet all three criteria to be diagnosed with PACNS (Calabrese & Mallek 
1988). Childhood PACNS (cPACNS) mandates a patient age of ≤18 years at diagnosis and 
excludes neonates (1 month of age) (Cellucci & Benseler 2010).  Of note these diagnostic 
criteria even though widely used have not been validated (Cellucci & Benseler 2010; Elbers 
et al. 2010; Hutchinson et al. 2010). Childhood PACNS is broadly subdivided into two 
forms of the disease: (i) angiography positive large–medium vessel vasculitis (further 
divided into progressive and non-progressive, according to angiographic evidence of disease 
progression 3 months after diagnosis); (ii) angiography negative small vessel vasculitis 
confirmed by brain biopsy (Cellucci & Benseler 2010; Elbers et al. 2010). 
 
The clinical presentation of cPACNS is heterogeneous, with some children presenting with a 
rapidly progressive neurologic deficit, whereas others have a slowly evolving disease course 
over weeks or months (Benseler et al. 2006; Hutchinson et al. 2010). Headache is a common 
symptom and tends to vary in description, intensity, and pattern (Benseler et al. 2006; 
Hutchinson et al. 2010). Cognitive impairment can be insidious while stroke and TIAs are 
common (Benseler et al. 2006; Hutchinson et al. 2010). Additionally cranial nerve 
involvement including ocular nerves in addition to myelopathy, seizures and ataxia have 
been described (Benseler et al. 2006; Hutchinson et al. 2010). Children with angiography 
positive large to medium vessel cPACNS are likely to present with focal neurologic deficits, 
including hemiparesis, hemisensory deficits, fine motor deficits, and dysphagia while diffuse 
neurological deficits, such as cognitive dysfunction and behaviour changes are more 
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common in the group of children with small vessel vasculitis (Benseler et al. 2006; Cellucci 
et al. 2011). Seizures and constitutional symptoms are less common (Benseler et al. 2006; 
Cellucci, Tyrrell, Sheikh, & Benseler 2011; Hutchinson et al. 2010).   
 
A wide range of inflammatory and non-inflammatory disorders can mimic CNS vasculitis, 
summarized in table 1-2 and need to be considered in the differential diagnosis (Cellucci & 
Benseler 2010; Elbers & Benseler 2008). In terms of establishing a diagnosis of cPACNS 
there are no consistent or reliable laboratory abnormalities and normal inflammatory markers 
by no means exclude an active vasculitic process in the CNS (Cellucci & Benseler 2010; 
Elbers & Benseler 2008). Conventional acute phase reactants including erythrocyte 
sedimentation rate, and concentrations of C-reactive protein, C3 complement maybe raised 
while von-Willebrand-factor antigen is commonly mildly increased (Cellucci et al. 2009; 
Cellucci et al. 2012; Cellucci & Benseler 2010; Elbers & Benseler 2008). Cerebrospinal 
fluid (CSF) analysis might show a raised opening pressure, mild pleocytosis with 
predominant lymphocytes, and mildly raised protein concentration (Cellucci & Benseler 
2010; Elbers & Benseler 2008; Hutchinson et al. 2010). MRI brain/spine in cPACNS reveals 
areas of acute ischemia in a vascular distribution when large-medium vessels are affected. In 
cases of small vessel disease, the lesions may be multifocal and not necessarily conform to a 
specific vascular distribution (Cellucci & Benseler 2010; Elbers & Benseler 2008). The 
parenchymal lesions may involve both grey and white matter, and meningeal enhancement 
has also been described (Cellucci & Benseler 2010; Elbers & Benseler 2008). Diffusion 
weighted imaging (DWI) identifies areas of ischaemia in large vessel disease (Cellucci & 
Benseler 2010; Elbers & Benseler 2008). MRA provides an assessment of the vasculature 
 41 
and may reveal beading, tortuosity, stenosis, and occlusion of the vessels (Aviv et al. 2006; 
Cellucci & Benseler 2010; Elbers & Benseler 2008). Conventional CA continues to be the 
radiological gold-standard for identifying cerebrovascular changes in patients with suspected 
CNS vasculitis and is more sensitive than MRA at detecting distal lesions that affect small 
caliber vessels, and for lesions in the posterior part of the brain (Aviv et al. 2006; Cellucci & 
Benseler 2010; Elbers & Benseler 2008).   
 
Brain biopsy for confirmation of vasculitis should be considered in difficult cases, but is 
rarely performed in children due to the invasiveness of the procedure (Cellucci & Benseler 
2010; Elbers & Benseler 2008). It should however be strongly considered in cases of high 
clinical suspicion but with negative arteriography findings or in cases of poor response to 
therapy (Elbers et al. 2010). Specimens for brain biopsy should contain leptomeninges, 
cortical gray matter, and subcortical white matter (Elbers et al. 2010). Biopsy findings 
characteristically reveal segmental, non-granulomatous, intramural infiltration of arteries, 
arterioles, capillaries, or venules (Elbers et al. 2010). Non lesional biopsy may be considered 
when lesions identified on imaging are not easily accessible (Elbers et al. 2010). Elbers et al. 
have recently reported on the clinical and histopathological features of brain biopsies in 13 
children with small-vessel cPACNS (Elbers et al. 2010). Findings included intramural 
lymphocytic infiltrate with reactive endothelial cells and tubular reticular inclusion bodies 
identified on electron microscopy in 38% of the cases (Elbers et al. 2010). Reticulin staining 
(performed in some cases), revealed vessel wall reactivity in a lacelike pattern in all cases 
(Elbers et al. 2010). In adults with small-vessel PACNS studies describing biopsy findings 
have predominantly shown granulomatous inflammation with multinucleated giant cells 
 42 
(Elbers et al. 2010). Of note, the intramural distribution of inflammatory cells differentiates 
PACNS from the perivascular inflammation seen in other T-cell–mediated inflammatory 
brain diseases (Elbers et al. 2010). Conditions such as Rasmussen encephalitis can be further 
characterized by microglial nodules and neuronal dropout while in multiple sclerosis there is 
commonly evidence of myelin-laden macrophages, perivenous or confluent demyelination, 
and predominant axonal and oligodendrocyte injury (Elbers et al. 2010). The absence of viral 
inclusions helps differentiate small vessel cPACNS from infectious cerebritis (Elbers et al. 
2010). 
 
Celluci et al. recently reported on a series of patients with cPACNS comparing the clinical, 
laboratory, and imaging characteristics of cPACNS subtypes at diagnosis and during follow-
up (Cellucci, Tyrrell, Sheikh, & Benseler 2011).  Children with angiography-negative 
cPACNS in that study were more likely to be female and present with seizures, cognitive 
dysfunction, vision abnormalities, high inflammatory markers, and bilateral MRI findings; 
motor deficits and ischaemic MRI lesions were more common in angiography positive 
disease (Cellucci, Tyrrell, Sheikh, & Benseler 2011). Additionally seizures at diagnosis 
predicted higher disease activity over time (Cellucci, Tyrrell, Sheikh, & Benseler 2011).  
 
With regards to therapy there are to date no randomised control trials to guide treatment 
(Cellucci, Pullenayegum, Tyrrell, & Benseler 2009; Cellucci & Benseler 2010; Elbers & 
Benseler 2008). Current therapeutic recommendations are based on those for systemic 
vasculitis and include: Six months induction of remission therapy with intravenous 
cyclophosphamide: 500-1000 mg/m2 (max 1.2g) every 3-4 weeks (usually 7 doses); plus 
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corticosteroids and anti-platelet doses of aspirin (Cellucci, Pullenayegum, Tyrrell, & 
Benseler 2009; Cellucci & Benseler 2010; Elbers & Benseler 2008). Following successful 
induction of remission there follows 1-2 years maintenance therapy with azathioprine (1.5-3 
mg /kg/day), low dose daily or alternate day corticosteroid, and continuation of aspirin 
(Cellucci, Pullenayegum, Tyrrell, & Benseler 2009; Cellucci & Benseler 2010; Elbers & 
Benseler 2008). Even less data are available to guide total duration of therapy and the 
decision to withdraw treatment is individualised per case (Cellucci, Pullenayegum, Tyrrell, 
& Benseler 2009; Cellucci & Benseler 2010; Elbers & Benseler 2008). Mycophenolate 
mofetil (MMF) has also been reported to be effective in some cases to maintain remission 
(Sen et al. 2010). Full anti-coagulation may need to be considered on an individual patient 
basis (Cellucci, Pullenayegum, Tyrrell, & Benseler 2009; Cellucci & Benseler 2010; Elbers 
& Benseler 2008). Hutchinson et al. recently reported a single-centre open-label cohort study 
in 19 children with small vessel cPACNS exploring the efficacy of therapy with steroids and 
pulses of intravenous cyclophosphamide followed by maintenance therapy with either 
azathioprine or mycophenolate mofetil (Hutchinson et al. 2010). Thirteen patients completed 
24 months’ follow-up, nine of whom had a good neurological outcome (Hutchinson et al. 
2010). Eight of 19 patients experienced disease flares while 4 patients achieved remission of 
disease off medication (Hutchinson et al. 2010). Treatment of large vessel non-progressive 
disease remains controversial (Cellucci & Benseler 2010; Elbers & Benseler 2008). There 
may be a role for steroids and aspirin without cytotoxic immunosuppression (Cellucci & 
Benseler 2010; Elbers & Benseler 2008).   
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As far as the outcome of cPACNS is concerned a recent study of 62 children with cPACNS 
suggested a poorer prognosis for patients presenting with (1) a neurocognitive dysfunction, 
(2) multifocal parenchymal lesions on MRI or (3) evidence of distal stenoses on 
arteriography (Benseler et al. 2006). Further long-term follow-up studies are necessary to 
accurately define the prognosis of this condition in children (Benseler et al. 2006). 
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Arterial dissection  
Thromboembolic disease (congenital heart disease, inherited thrombophilia) 
Antiphospholipid syndrome 
Sickle cell disease  
Moyamoya disease (cerebral arteriopathy characterized by progressive steno-occlusive 
changes at the terminal portions of the bilateral internal carotid arteries with arterial 
collateral vessels at the base of the brain) 
Fibromuscular dysplasia  
Fabry’s disease 
Sneddon’s syndrome (morphologically fixed livedo reticularis and cerebrovascular 
accidents) 
CASADIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy) 
Susac’s syndrome (acute encephalopathy, branch retinal artery occlusions and sensorineural 
hearing loss)  
Amyloid angiopathy 
Hyperhomocysteinaemia  
Drug-exposure (cocaine, amphetamine, methylphenidate)  
Metabolic diseases 
Mitochondrial diseases  
Leukodystrophies  
Mucopolysaccharidoses  
Multiple sclerosis 
Acute disseminated encephalomyelitis (ADEM) 
Devic’s disease/Neuromyelitis optica (CNS demyelinating condition affecting 
predominantly the spinal cord and optic nerves characterized by the presence of aquaporin-4 
water channel IgG antibodies) 
Vitamin B12 deficiency  
Rasmussen syndrome (neurological disorder characterized intractable focal seizures, 
progressive hemiplegia and increasing cognitive impairement) 
Sarcoidosis  
Coeliac disease  
Primary and secondary haemophagocytic lymphohistiocytosis (HLH) 
Progressive multifocal leukoencephalopathy (JC virus)  
Lymphoma  
Glioma 
Migraine/Vasospasm  
Post radiation therapy for CNS tumour 
 
Table 1-2: Mimics of central nervous system (CNS) vasculitis in children. 
Adapted from Elbers et al. 2008. 
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1.2.2.4 Moyamoya 
 
First described by Takeuchi and Shimizu, moymoya is a cerebral arteriopathy with bilateral 
severe stenosis or occlusion of the terminal internal carotid artery (ICA), typically 
accompanied by basal collateral vessels (Takeuchi and Shimizu 1957). The name moyamoya 
derives from the Japanese word meaning ‘something hazy like a puff of smoke drifting in the 
air’ and describes the angiographic appearance of these collaterals. Moyamoya is best 
considered an angiographically defined phenomenon rather than a pathological entity and 
may either be idiopathic or occur in the context of a wide range of other disorders (Natori et 
al. 1997; Scott and Smith 2009).  Most of the patients have infarction after presentation with 
stroke, TIAs or seizures (Scott & Smith 2009). Calcification is also well documented and 
haemorrhage can occur even though more common in adults (Kitahara et al. 1986; Mori et 
al. 2008). The term ‘moymoya disease’ should be restricted to idiopathic Japanese cases 
(Fukui et al. 2000). The term ‘moymoya syndrome’ refers to non-japanese patients with 
unilateral or bilateral terminal ICA stenosis or occlusion with basal collaterals whether 
idiopathic or secondary (Scott & Smith 2009). Children with neurofibromatosis, sickle cell 
disease, trisomy 21, or history of central nervous system radiation have an increased risk for 
developing moyamoya (secondary moyamoya) (Scott & Smith 2009). Symptomatic 
unilateral cases demonstrate the same pathology and are amenable to similar diagnostic and 
therapeutic approaches while the majority appear to progress to become bilateral although 
stabilisation is also well documented (Hirotsune et al. 1997; Seol et al. 2006b). In general the 
presence of moymoya arteriopathy is associated with an increased risk of stroke recurrence a 
finding supported by several studies (Braun et al. 2009; Ganesan et al. 2006). Familial cases 
 47 
and ethnic differences support a genetic basis for moyamoya but no single causal gene has 
yet been identified (Ikeda et al. 1999; Seol et al. 2006a). Histopathology studies in 
moyamoya show fibro-cellular intimal thickening without evidence of atherosclerosis, 
inflammation or emboli (Hosoda et al. 1997). Endothelial cell dysfunction and dysregulation 
of growth factors has been postulated as a possible mechanism of disease (Yamamoto et al. 
1998; Yoshimoto et al. 1996). Given that haemodynamic failure is responsible for cerebral 
ischaemia in the majority of cases, a variety of surgical interventions have been used to 
improve perfusion in this group of children. Procedures can broadly be considered in two 
groups: direct extracranial-intracranial (EC-IC) bypass and indirect revascularisation 
procedures (Fung et al. 2005; Golby et al. 1999). The optimal surgical technique remains 
controversial (Fung, Thompson, & Ganesan 2005; Golby et al. 1999).  
 
1.2.2.5 Other arteriopathies 
 
Several other arteriopathies are encountered in childhood AIS some of which are discussed 
below. Fibro-muscular dysplasia (FMD) is a nonatherosclerotic, noninflammatory disease 
characterised by focal hyperplasia of blood vessels throughout the arterial tree, but often 
involving cervico-cranial vascular network, most commonly the internal carotid artery 
(Slovut and Olin 2004). On catheter angiography, FMD vessels may have a classic ‘string of 
beads’ appearance, or show a smooth focal stenosis or long tubular stenosis (Osborn and 
Anderson 1977). The prevalence of symptomatic renal FMD in the general population is 
estimated to about 4 ⁄ 1000 and cervico-cephalic FMD is probably half as common as renal 
FMD (Begelman and Olin 2000; Slovut & Olin 2004). Renal FMD can lead to hypertension 
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and progressive renal atrophy (Begelman & Olin 2000; Slovut & Olin 2004). Cervico-
cephalic FMD can result in ischaemic or haemorrhagic stroke, cervical artery dissection and 
may be associated with intracerebral aneurysms, with risk of subarachnoid haemorrhage 
(Begelman & Olin 2000; Slovut & Olin 2004).  
 
Neurofibromatosis type 1 (NF1) is associated with intracerebral arteriopathies (Rea et al. 
2009). Rea et al. recently showed that arteriopathy was more common in patients with NF1 
and optic gliomas (Rea et al. 2009). Follow-up at a mean of 7 years after diagnosis of 
arteriopathy showed that 35% had progressive arteriopathy requiring revascularization 
surgery (Rea et al. 2009).  
 
Loeys-Dietz syndrome (LDS) is caused by mutation in the genes encoding the transforming 
growth factor beta receptor 1 and 2 (TGFBR1 and TGFRB2) and is characterised by arterial 
tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate (LeMaire et al. 2007; 
Pagon et al. 2008; Singh et al. 2006). The arterial disease is widespread and can involve all 
aortic segments and major branching arteries, necessitating cardiovascular imaging beyond 
the aortic root segment (LeMaire et al. 2007; Pagon et al. 2008; Singh et al. 2006). 
Cerebral/cervical involvement includes dissection of the carotid and vertebrobasilar arteries 
and intracranial aneurysms (Pagon et al. 2008). 
 
Arterial tortuosity syndrome (ATS) is a rare autosomal recessive connective tissue disorder 
characterized by tortuosity and elongation of the large and medium-sized arteries, propensity 
to aneurysms formation, vascular dissection, and pulmonary arteries stenosis (Callewaert et 
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al. 2008; Coucke et al. 2006; Satish et al. 2008). Other typical manifestations are dysmorphic 
features, hyperextensible skin, cutis laxa, herniae, skeletal abnormalities, joints 
hypermobility, and congenital contractures (Callewaert et al. 2008; Coucke et al. 2006; 
Satish, Nampoothiri, & Kappanayil 2008). ATS is due to mutations in SLC2A10 gene, 
located on chromosome 20q13.1 and encoding for the 541 amino acid facilitative glucose 
transporter 10 (GLUT10), consisting in 12 transmembrane hydrophobic segments connected 
by 5 intracellular and 6 extracellular loops (Callewaert et al. 2008; Coucke et al. 2006; 
Satish, Nampoothiri, & Kappanayil 2008). 
 
Aicardi–Goutieres syndrome (AGS) is a genetically determined encephalopathy, which, in 
its classical presentation, shows phenotypic overlap with the sequelae of congenital infection 
It is a genetically heterogeneous disorder caused by mutations in any of the genes encoding 
the 3´ to 5´ exonuclease TREX1 (AGS1), the three non-allelic components of the RNASEH2 
endonuclease complex (AGS2, 3, and 4) and the SAMHD1 protein (AGS5) (Crow et al. 
2006a; Crow et al. 2006b; Rice et al. 2009). Xin et al. describe an autosomal recessive 
condition characterized with cerebral vasculopathy and early onset of stroke caused by 
mutations in SAMHD1 (Xin et al. 2011). Cerebral vasculopathy was a major hallmark of the 
condition with a common theme of multifocal stenoses and aneurysms in large arteries, 
accompanied by chronic ischaemic changes, moyamoya morphology, and evidence of prior 
acute infarction and haemorrhage (Xin et al. 2011). Early signs of the disease included mild 
intrauterine growth restriction, infantile hypotonia, and irritability, followed by failure to 
thrive and short stature (Xin et al. 2011). Acrocyanosis, Raynaud's phenomenon, chilblain 
lesions, low-pitch hoarse voice, glaucoma, migraine headache, and arthritis were frequently 
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observed (Xin et al. 2011). Ramesh et al. have also reported on 5 patients with a clinical 
diagnosis of AGS who developed intracranial large artery disease that was primarily 
occlusive. All patients were shown to harbor mutations biallelic mutations in SAMHD1 
(Ramesh et al. 2010).  
 
The vascular smooth muscle cell (SMC)-specific isoform of a-actin (ACTA2) is a major 
component of the contractile apparatus in SMCs located throughout the arterial system 
(Milewicz et al. 2010; Munot et al. 2011a). Heterozygous ACTA2 mutations cause familial 
thoracic aortic aneurysms and dissections (TAAD), but only half of mutation carriers have 
aortic disease (Guo et al. 2007). Linkage analysis and association studies of individuals in 20 
families with ACTA2 mutations indicate that mutation carriers can have a diversity of 
vascular diseases, including premature onset of coronary artery disease and premature 
ischaemic strokes (including Moyamoya disease) as well as previously defined TAAD (Guo 
et al. 2007). Sequencing of DNA from patients with nonfamilial TAAD and from premature-
onset CAD patients independently identified ACTA2 mutations in these patients and 
premature onset strokes in family members with ACTA2 mutations (Guo et al. 2007). 
 
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy 
(CADASIL) remains the most common hereditary small vessel disease caused by >190 
different mutations in the NOTCH3 gene on chromosome 19 which encodes a 
transmembrane receptor primarily expressed in arterial smooth muscle cells (SMCs43) 
involved in the NOTCH signaling pathway (Joutel et al. 1996). Mutant NOTCH3 instigates 
degeneration of vascular smooth muscle cells in small arteries and arterioles leading to 
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recurrent lacunar infarcts (Joutel et al. 1996). The most common clinical manifestations are 
migraine headaches and transient ischaemic attacks or strokes, which usually occur between 
40 and 50 years of age, although MRI is able to detect signs of the disease years prior to 
clinical manifestation of disease (Choi 2010; Fattapposta et al. 2004; Munot, Crow, & 
Ganesan 2011a). Whilst the predominant cerebrovascular manifestations are in a small 
vessel distribution, large artery disease has also been observed (Choi et al. 2005). 
Genetically confirmed CASADIL has also been described in the paediatric population 
(Hartley et al. 2010). 
 
The COL4A1 gene encodes the alpha-1 chain of type IV collagen, the main constituent of 
basement membranes widely expressed in all tissues, including vascular beds (Munot, Crow, 
& Ganesan 2011a; Plaisier et al. 2007). Mutant COL4A1 likely disrupts the extracellular 
matrix resulting in fragile vessel walls (Munot, Crow, & Ganesan 2011a; Plaisier et al. 
2007).  A wide range of phenotypes with overlapping systemic and central nervous system 
features have been described in association with COL4A1 mutations, including idiopathic 
cerebral small-vessel disease in children (Plaisier et al. 2007; Shah et al. 2010). Occlusive 
and aneurysmal cerebral arteriopathies, resulting in ischaemic and haemorrhagic stroke can 
occur in the same family (Gould et al. 2006; Plaisier et al. 2007).  
 
PHACE(S) is a neurocutaneous disorder comprising a cervicofacial haemangioma with one 
or more of a posterior fossa malformation, arterial, cardiac and eye abnormalities or a sternal 
pit (Heyer et al. 2008). The arteriopathy of PHACES includes dysplasia or hypoplasia as 
well as steno-occlusive disease (Heyer et al. 2008).  
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1.2.2.6 Imaging evaluation of cerebral arteriopathies  
 
The majority of children presenting with an acute AIS demonstrate non-atherosclerotic intra- 
or extracranial cerebral arteriopathies (Fullerton, Wu, Sidney, & Johnston 2007; 
GANESAN, Prengler, Wade, & Kirkham 2006; Mackay et al. 2011). Given the importance 
of arterial disease in the aetiology of childhood AIS accurate and timely detection are clearly 
key issues (Fullerton, Wu, Sidney, & Johnston 2007; Ganesan, Prengler, Wade, & Kirkham 
2006; Mackay et al. 2011). Currently, there are several imaging modalities that can be 
employed for the evaluation of the cerebral circulation, namely ultrasound, magnetic 
resonance angiography (MRA) with or without contrast, computed tomography angiography 
(CTA) and catheter cerebral angiography (CA)(Jones, Ganesan, Saunders, & Chong 2010; 
Roach et al. 2008). Arterial disease is most commonly intracranial but may be cervical and 
thus an adequate examination should include the arterial circulation from the aortic arch to 
the circle of Willis (Fullerton, Wu, Sidney, & Johnston 2007; Ganesan, Prengler, Wade, & 
Kirkham 2006; Mackay et al. 2011). Ultrasound has relatively limited applications in 
paediatric AIS, other than in screening and follow-up of children with sickle cell disease 
(Adams et al. 1992; Kenton et al. 1997). Of note, early or small parenchymal lesions and 
lesions located in the posterior fossa can be missed with CT scans (Hinshaw Jr et al. 1980; 
Jones, Ganesan, Saunders, & Chong 2010). 3D time-of-flight (TOF) MRA is commonly 
used for detecting intracranial stenotic or occlusive disease (Husson et al. 2002). MRA can 
be combined with cross sectional imaging of the brain with MRI – the latter is usually 
required in order to differentiate between AIS and stroke mimics (Hunter 2002; Husson et al. 
2002). However TOF is insensitive to slow flow or in-plane flow which leads to 
overestimation of the severity and length of a stenosis especially when there is dephasing 
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secondary to turbulence (Aviv et al. 2006; Eleftheriou et al. 2010; Rollins et al. 2000). Of 
note, the spatial resolution of MRA also limits its ability to visualise medium and small sized 
arteries (Aviv et al. 2006; Eleftheriou et al. 2010; Rollins, Dowling, Booth, & Purdy 2000). 
Contrast enhanced MRA may help overcome these difficulties (Ishimaru et al. 2007; Kuker 
et al. 2008). Ishimaru et al. evaluated the use of 3D TOF MRA with and without contrast in 
comparison to CA, in a small series of adult patients with acute ischaemic stroke and found 
that post contrast 3D TOF MRA more accurately delineated the extent of stenotic or 
occlusive arterial disease (Ishimaru et al. 2007). Cases of AIS with normal MRA are well 
described in the literature (Jones, Ganesan, Saunders, & Chong 2010; Munot et al. 2011b). 
Munot et al. recently reported on a series of forty children with AIS and normal MRA 
(Munot et al. 2011b). Although similar in terms of age and gender to those with abnormal 
MRA, children with normal MRA were significantly more likely to have at least 1 other risk 
factor (P=0.012) while abnormal MRA was significantly associated with clinical recurrence 
(P=0.001) (Munot et al. 2011b). Notably however CA imaging findings are not discussed in 
this study.  
 
CTA is increasingly used in adults with ischaemic stroke and appears to be more accurate 
than MRA for delineating intracranial stenosis and occlusion, especially in the posterior 
circulation (Knauth et al. 1997; Roach et al.2008; Shrier et al. 1997). The disadvantages of 
CTA in children include exposure to radiation and the need for intravenous contrast (Jones, 
Ganesan, Saunders, & Chong 2010; Roach et al. 2008). CTA has an evolving role in the 
evaluation of children with intracranial haemorrhage but has not been evaluated in 
comparison with either MRA or CA in childhood AIS (Demchuk et al. 2012; Roach et 
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al.2008). In general most children with AIS can be investigated with MRA combined with 
MRI. CTA may have a role in providing further endoluminal visualisation of a specific area 
of concern but is unlikely to supersede CA in the near future (Borisch et al. 2007; Chamoun 
et al. 2008; Knauth, von Kummer, Jansen, & Sartor 1997; Roach et al. 2008; Shrier et al. 
1997). 
 
 CA remains the gold standard for cerebrovascular imaging, especially for the evaluation of 
the posterior circulation and the distal intracranial cerebral arterial circulation (Aviv et al. 
2006; Eleftheriou et al. 2010; Rollins, Dowling, Booth, & Purdy 2000). CA also provides 
dynamic information about the cerebral circulation (Aviv et al. 2006; Eleftheriou et al. 2010; 
Rollins, Dowling, Booth, & Purdy 2000). Rollins et al. compared MRA and CA findings in 
18 children with idiopathic AIS and reported a positive predictive value of MRA for 
arteriopathy of 100%, with a negative predictive value of 88%.  MRA was equivalent to CA 
in the detection and depiction of proximal MCA disease (Rollins, Dowling, Booth, & Purdy 
2000); however, delineation of disease in the ICA and detection of peripheral embolic 
disease were better with CA than MRA (Rollins, Dowling, Booth, & Purdy 2000).  Aviv et 
al. reported only a fair correlation between CA and MRA lesion identification in 25 children 
with cPACNS (Aviv et al. 2006). Most of the lesions identified on CA and not MRA within 
the distal, posterior circulation. Similarly we have previously reported on moderate 
agreement between the two modalities (қ=0.51 95%CI 0.37-0.66) in a case series of 14 
children with suspected CNS vasculitis (Eleftheriou et al. 2010). The risk of complications 
of CA appears to be very low in expert hands (Aviv et al. 2006; Eleftheriou et al. 2010). In 
general, despite the non-invasive modalities described above, CA has a continuing role in the 
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investigation of childhood AIS, in particular where infarction affects more than one arterial 
territory or is confined to small vessel distribution (to look for evidence of vasculitis), where 
infarction is in the posterior circulation territory (to look for vertebral dissection), in 
moyamoya when revascularisation is being considered and in other arteriopathies which 
might be amenable to endovascular interventions (e.g. angioplasty or stenting) (Aviv et al. 
2006; Eleftheriou et al. 2010; Rollins, Dowling, Booth, & Purdy 2000). In addition, some 
conditions, including extracranial arterial dissections, particularly involving the posterior 
circulation, and small-vessel vasculitis, are difficult to exclude on MRA (Jones, Ganesan, 
Saunders, & Chong 2010; Roach et al. 2008).   
 
1.2.3 Cardiac abnormalities 
 
Cardiac procedures such as heart surgery, catheterization, and extracorporeal membrane 
oxygenation (ECMO) are all well documented risk factors for childhood AIS, likely 
mediated through a mechanism that involves cardioembolism (Fallon et al. 1995; Jonas 
1998; Segal et al. 2001). In addition, congenital heart disease including valvular heart 
disease, cardiac arrhythmias, and cardiomyopathy are also associated with childhood AIS 
regardless of invasive cardiac procedures (Kumar 2000; Phornphutkul et al. 1973). Aberrant 
blood flow and thrombosis that can embolize to the cerebral vessels are possibly implicated 
in AIS in the presence of these risk factors. Lo et al. actually reported that congenital heart 
disease was the most frequent comorbidity in children with AIS in their study (Lo et al. 
2009).  Of note, nearly 25% of children diagnosed with AIS in the Canadian Registry had 
cardiac disease at presentation (Fullerton, Wu, Sidney, & Johnston 2007). Similarly, 
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Ganesan et al. reported that 28% of children in their UK based childhood AIS cohort study 
had cardiac abnormalities (Ganesan et al. 2003).  
 
Moreover, it remains uncertain if a patent foramen ovale (PFO) is a significant risk factor for 
childhood AIS. PFO is the most commonly persistent abnormality of fetal origin, with 
prevalence on echocardiography of 15–25% in the general population (Di Tullio et al. 2007). 
Although the presence of PFO has been associated with an increased risk of AIS in studies 
of young adults a causative relationship has not been established (Mas et al. 2001). It is not 
known whether children with cryptogenic AIS have a similarly increased incidence of PFO 
relative to healthy children (Benedik et al. 2011; Kirkham et al. 2011). However, PFO is 
more common in children than in adults and thrombosis within the venous system (the 
putative source of embolism) much less so (Benedik, Zaletel, Megli-ì, & Podnar 2011; 
Kirkham, Salmon, & Khambadkone 2011). At present the evidence base to recommend PFO 
closure in children with AIS and a right-to-left shunt intracardiac shunt is lacking (Kirkham, 
Salmon, & Khambadkone 2011). However, extrapolation from adult data suggests there may 
be a place for PFO closure in selected children with cryptogenic AIS and a significant right 
to left shunt, with no other risk factors but the decision should be carefully considered on a 
case by case basis (Kirkham, Salmon, & Khambadkone 2011). 
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1.2.4 Sickle cell disease  
 
Sickle cell disease (SCD) is the most common cause of childhood stroke in certain parts of 
the world (Kirkham 2007). SCD is a disorder caused by elevations of intraerythrocyte and 
total blood viscosity (Verduzco and Nathan 2009). Hypoxia induces gelation of haemoglobin 
S (HbS) that deforms the erythrocyte and its membrane and causes cation loss and increased 
erythrocyte surface expression of adhesion molecule receptors (Verduzco & Nathan 2009). 
This results in obstructive adhesion of sickle cells to each other and to vascular endothelium 
(Verduzco & Nathan 2009). The obstruction and inflammation in turn cause further hypoxia 
and acidosis and, consequently, further sickling (Verduzco & Nathan 2009). Approximately 
11% of SCD patients have clinically apparent strokes before the age of 20 (Ohene-Frempong 
et al. 1998). That risk increases to 24% by the age of 45 (Ohene-Frempong et al. 2009). The 
risk of stroke is highest during the first decade, and it is most significant between ages 2 and 
5, when it reaches 1.02% per year (Ohene-Frempong et al. 1998). The risk is lowest before 
the age of 2, probably because of the protective influence of fetal haemoglobin on sickling 
(Ohene-Frempong et al. 2009). A child with SCD has a stroke risk that is 333 times greater 
than that of a healthy child without SCD or heart disease (Broderick et al. 1993; Ohene-
Frempong et al. 1998; Verduzco & Nathan 2009). In children with “abnormal” transcranial 
doppler (noninvasive ultrasound that allows real-time evaluation of the intracranial cerebral 
circulation) studies, the risk is more than 3000 times greater (Adams et al. 1997; Verduzco & 
Nathan 2009).  Silent infarcts defined as increased signal intensity on T2-weighted MR 
images and no history of physical findings of a focal neurologic deficit lasting more than 24 
hours, are the most frequent type of neuroischaemic damage in SCD, occurring in 
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approximately 20% of the patients without overt stroke by 14 years of age and are associated 
with significant cognitive deficits (Moser et al. 1996; Pavlakis et al. 1988).  
 
SCD is commonly associated with a progressive occlusive arteriopathy (a secondary form of 
moyamoya syndrome) that involves the internal carotid arteries and proximal middle 
cerebral arteries, with relative sparing of the posterior circulation (Stockman et al. 1972; 
Verduzco & Nathan 2009). Moyamoya morphology is a risk factor for subsequent strokes 
(Dobson et al. 2002). Other risk factors for stroke in SCD include hypertension, raised 
peripheral blood white cell count, previous transient ischaemic attacks, priapism, acute 
anaemia, recent acute chest syndrome, or history of transfusion within the past 2 weeks 
(Ohene-Frempong et al. 1998). In addition a recent case–control study reported an increased 
incidence of PFO in these patients (Dowling et al. 2010).  
 
Of note although stroke risk in children with SCD is high, this is the only case where there is 
a proven method for primary stroke prevention (Adams et al. 1998 ;Adams and Brambilla 
2005; Roach et al. 2008). In the Stroke Prevention Trial in Sickle Cell Anaemia children 2 to 
16 years of age with HbSS who had no prior stroke history but an “abnormal” transcranial 
Doppler value were randomly assigned to either chronic blood transfusions every 3 to 4 
weeks (goal HbS <30%) or standard care (Adams et al. 1998). The trial was terminated early 
when 12 strokes occurred, 11 of which were in the standard care group (Adams et al. 1998). 
The introduction of chronic transfusions for primary stroke prevention ever since had an 
immediate impact on stroke rates that dropped by a factor of 5 within 2 years (Fullerton et al. 
2004). In addition, the Primary Stroke Prevention in Sickle Cell Anemia (STOP II) trial data 
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suggest that lifelong blood transfusions may be necessary, as there is a high risk of 
recurrence relatively soon after transfusion cessation (Adams & Brambilla 2005).  
 
1.2.5 Genetic and acquired thrombophilias as risk factors for AIS 
 
As thrombo-embolic phenomena prevail in the pathophysiology of childhood AIS, 
investigation of the contribution of thrombophilias to risk of incident and recurrent AIS in 
childhood is crucial. Thrombophilia refers to a systemic predisposition to thrombosis and 
may be genetic or acquired (Kenet et al. 2010; Trenor III and Michelson 2010; Walker et al. 
2001). 
 
1.2.5.1 Genetic thrombophilias 
 
An increased frequency of heterozygous factor V Leiden (FVL) polymorphism in childhood-
onset AIS cases as compared to healthy controls has been demonstrated by several studies 
(Duran et al. 2005; Kenet et al. 2000; Nowak-Gottl et al. 1999). In the study by Nowak et al. 
approximately 20% of AIS cases were heterozygous for  FVL, as compared to 4% of 
controls (OR 6; 95% CI 2.97-12.1) (Nowak-Gottl et al. 1999). In addition the prothrombin 
G20210A polymorphism was found in 6% of patients as compared to 1 % of controls (OR 
4.7; 95% CI 1.4 to 15.6) (Nowak-Gottl et al. 1999). Furthermore, protein S and protein C 
deficiency have also been reported in association with AIS in several case reports and case 
control studies (Brown et al. 1993; Haywood et al. 2005; Nowak-Gottl et al. 1999). In a 
cohort series of 310 German children protein C deficiency was confirmed as a relative risk 
of recurrent childhood-onset AIS of 3.5 (95% CI 1.1-10.9) (Sträter et al. 2002a). The same 
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series reported on a high recurrence risk for AIS for children with elevated lipoprotein (a) 
(RR=4.4, 95% CI=1.9-10.5) (Sträter et al. 2002a). Furthermore, the recent meta-analysis of 
Kenet et al. demonstrated that the MTHFR C677T mutation was found more frequently in 
childhood AIS than in healthy controls; however, it is uncertain whether this serves as an 
independent risk factor or in relation to plasma homocysteine levels (Kenet et al. 2010). Of 
note, Alsayouf et al. also analyzed the potential link between MTHFR 677C>T 
homozygosity and childhood stroke demonstrating that there was no difference in the 
prevalence of the MTHFR 677C>T  mutation in the studied cohort compared with the 
general population (Alsayouf et al. 2011). In addition, the Kenet et al. meta-analysis 
confirmed many of the associations discussed above (Kenet et al. 2010). Specifically a 
significant association with AIS for FVL (OR 3.70; CI 2.82–4.85), factor II G2O210A (OR 
2.60; 95% CI 1.66–4.08), protein C deficiency (OR 11.0; 95% CI 5.13-23.59), lipoprotein 
(a) (OR 6.53; 95% CI 4.46–9.55) and MTHFR C677T mutation (OR 1.58; 95% CI 1.20–
2.08) was demonstrated (Kenet et al. 2010). Of note however this meta-analysis summarised 
data on both studies of childhood-onset AIS and neonatal AIS.  Furthermore, the relationship 
between the timing of the cerebrovascular event and the timing of the blood sample for 
thrombophilia testing is not specified in most studies discussed. This is an important 
confounding factor because thrombosis can, for instance, result in transient, acquired low 
levels of antithrombin, protein C, and/or protein S (Trenor III & Michelson 2010). Lastly 
widely varying results between the above discussed studies are likely to reflect ethnic 
differences between studied cohorts. 
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1.2.5.2 Acquired thrombophilias 
 
One retrospective case-control study demonstrated elevated levels of factor VIII activity in 
65% of childhood AIS patients tested four months after incident stroke as compared to 
12.5% of controls (Cangöz et al. 2004). Sträter et al. demonstrated that the prevalence of 
anticardiolipin antibodies (IgG or IgM) was 10% in a group of children with cardioembolic 
AIS (Sträter et al. 1999). Another case-control study reported a greater than 6-fold increase 
in the odds of stroke in patients with antiphospholipid antibodies (aPL; lupus anticoagulant 
or anticardiolipin antibodies) in childhood AIS cases as compared to healthy controls (Kenet 
et al. 2000). In the Kenet et al. meta-analysis, a pooled examination of aPL antibodies of 
multiple types demonstrated a significant association between aPL antibodies and childhood 
AIS (neonates included-OR 6.95; CI 3.67-13.14) (Kenet et al. 2010). Of note however, 
transient aPL are commonly found after even mild viral infections and it is unknown 
whether these transient antibodies confer an increased thrombotic risk to these children 
(Bernard et al. 2011). More recently other coagulation cascade activation markers have been 
proposed as prognostic factors in childhood AIS (Bernard et al. 2010; Bernard, Manco-
Johnson, & Goldenberg 2011). A recent cohort study has demonstrated that D-dimer (a 
marker of ongoing coagulation activation) is acutely elevated in patients with childhood-
onset AIS, particularly patients with cardioembolic stroke (Bernard et al. 2010). Perhaps in 
many cases, transient acquired risk factors particularly in the setting of systemic infection 
may be more potent than modest genetic thrombophilias.  
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1.3 Infection and inflammation in the pathogenesis of cerebral 
arteriopathies and childhood arterial ischaemic stroke 
 
A wide range of mechanisms have been suggested to link inflammation and infection to the 
pathophysiology of ischaemic stroke (Emsley and Tyrrell 2002; Macko et al. 1996a; McColl 
et al. 2009). As a general response to tissue injury, inflammation is ubiquitous (Emsley & 
Tyrrell 2002; Frijns and Kappelle 2002; Sullivan et al. 2000; Zoppo et al. 2000). It is now 
well established that one of the fundamental features of the immune response is an 
inflammatory cascade that can also cause extensive damage to host tissues (Emsley & 
Tyrrell 2002; Frijns & Kappelle 2002; Sullivan, Sarembock, & Linden 2000; Zoppo et al. 
2000). In that context inflammation is a major contributing factor to many vascular events, 
including atherosclerotic plaque development and rupture, aortic aneurysm formation, 
angiogenesis, and ischaemia/reperfusion injury (Emsley & Tyrrell 2002; Libby et al. 2002; 
Romagnani et al. 2004; Sullivan, Sarembock, & Linden 2000). This immune response is 
mediated by both circulating and resident leukocytes and a number of cells that the 
leukocytes interact with such as vascular endothelium and smooth muscle cells (Frijns & 
Kappelle 2002; Sullivan, Sarembock, & Linden 2000). In addition, the process involves up 
regulation of a series of adhesion molecules on leukocytes and underlying vascular 
endothelium and the release of various pro-inflammatory cytokines, and chemokines (Frijns 
& Kappelle 2002; Sullivan, Sarembock, & Linden 2000). In acute stroke there are several 
areas in which inflammation may be important: in association with underlying vascular 
disease predisposing to stroke; as a precipitating factor triggering an acute event; once a 
stroke has occurred, as an acute response to tissue injury, perhaps exacerbating the injury or 
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its consequences; or as a prognostic marker for recurrent cardiovascular events (Emsley & 
Tyrrell 2002; McColl, Allan, & Rothwell 2009). Notably atherosclerosis is now widely 
considered an inflammatory disease while multiple mechanisms have been proposed to link 
inflammatory stimuli to the development and progression of atherosclerotic plaque (Emsley 
& Tyrrell 2002; Hegele 1996; Libby, Ridker, & Maseri 2002). These involve a direct effect 
of C-reactive protein to human arterial endothelial cells with a subsequent recruitment of 
inflammatory cells, release of cytokines such as TNF-α  and IL-1 and smooth muscle cell 
proliferation fibrous plaque formation (Emsley & Tyrrell 2002; Hegele 1996; Libby, Ridker, 
& Maseri 2002).  
 
Inflammation is also a main feature of the host defence response to infection and is 
necessary for the containment and removal of any pathogen as well as for promoting tissue 
repair (Crozat et al. 2009; McColl, Allan, & Rothwell 2009). However, in some cases, there 
appears to be a disruption of the equilibrium between the beneficial effects of infection 
induced inflammation and the potential aggravation of inflammatory pathways that 
predispose to and/or exacerbate acute ischaemic brain injury and accelerate the progression 
of arterial disease (Crozat, Vivier, & Dalod 2009; McColl, Allan, & Rothwell 2009). In adult 
stroke, numerous clinical studies have suggested a link between systemic infection and 
increased stroke susceptibility (Cook et al. 1998; Heuschmann et al. 2001; McColl, Allan, & 
Rothwell 2009; Ridker et al. 1998). In patients with bacteraemia, thromboembolic 
complications are relatively common, occurring for instance in approximately 20% of 
patients with infective endocarditis (Valtonen et al. 1993). Tuberculosis (TB) has also been 
associated with cerebral infarction mainly in the anterior circulation although a few reported 
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cases involved the posterior territories (Leiguarda et al. 1988; Sheu et al. 2010). A 
progressive vasculopathy has been described in TB meningitis with evidence of stenosis or 
spasm initially followed by progressive occlusion that may result in re-infarction (Leiguarda 
et al. 1988; Sheu et al. 2010). In addition, Borellia burgdorferi can penetrate the blood-brain 
barrier and cause neuroborreliosis or trigger vasculitis (Logigian et al. 1990). In malaria 
cortical haemorrhagic infarcts relating to generalized cerebral oedema and reduced cerebral 
perfusion are well described (Brewster et al. 1990). Several chronic infectious pathogens 
such as Chlamydia pneumonia and Helicobacter Pylori, acute bacterial and viral infections 
have been associated with an increased risk of cerebrovascular disease in adults (Cook et al. 
1998; Heuschmann et al. 2001; McColl, Allan, & Rothwell 2009; Ridker, Hennekens, 
Stampfer, & Wang 1998). In general these infections appear to induce a transient state of 
increased stroke susceptibility, particularly in the weeks following infection (Emsley & 
Tyrrell 2002; McColl, Allan, & Rothwell 2009). The greatest risk period after infection 
coincides with the high-level pro-inflammatory phase of the immune response suggesting 
that acutely elevated systemic inflammation maybe a stroke trigger (Emsley & Tyrrell 2002; 
McColl, Allan, & Rothwell 2009). 
 
Infection may also promote a shift toward a pro-thrombotic tendency by creating an 
imbalance in coagulation and fibrinolysis (Ameriso et al. 1991; Emsley & Tyrrell 2002; 
Macko et al. 1996b).  A prothrombotic state has been described in inflammation and 
infection-associated stroke (Ameriso, Wong, Quismorio, & Fisher 1991; Emsley & Tyrrell 
2002; Macko et al. 1996b). Examples of components of the coagulation system that are 
modified in inflammation or infection-associated stroke include elevated C4b-binding 
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protein, reduced circulating antithrombotic activated protein C, and a low ratio of tissue 
plasminogen activator to plasminogen activator inhibitor (Emsley & Tyrrell 2002; Macko et 
al. 1996b; McColl, Allan, & Rothwell 2009). Increased fibrin D-dimer levels and fibrinogen 
levels also occur in patients with acute ischaemic stroke in the context of systemic infection 
(Ameriso, Wong, Quismorio, & Fisher 1991; Emsley & Tyrrell 2002; McColl, Allan, & 
Rothwell 2009). Furthermore microvascular obstruction may also contribute to a reduction 
in tissue perfusion and worsen cerebral ischaemia (Emsley & Tyrrell 2002). Increased levels 
of CRP that promotes localized coagulation, and therefore thrombosis, by stimulating 
monocytes to produce tissue factor, additionally contribute to a prothrombotic state (Cermak 
et al. 1993a; Emsley & Tyrrell 2002). Of note elevated circulating IL-6 levels in patients 
with acute ischaemic stroke have been associated with decreased levels of free protein S 
(Emsley & Tyrrell 2002; Vila et al. 2000). In addition, endotoxins, other bacterial toxins, 
and proinflammatory cytokines such as IL-1 and TNF-α may well contribute to thrombosis 
via effects on endothelial function (Emsley & Tyrrell 2002; Yudkin et al. 1999). 
 
 
Augmentation of endothelial dysfunction by infections could further increase susceptibility 
to stroke (Emsley & Tyrrell 2002; Oshima et al. 2005; Prasad et al. 2002).  A link between 
chronic infections, an inflammatory state, and endothelial dysfunction has been reported by 
several studies in adults (Emsley & Tyrrell 2002; Oshima et al. 2005; Prasad et al. 2002; 
Vallance et al. 1997). In children Charakida et al. have shown that acute infection in 
childhood is associated with impaired endothelium-dependent vasodilation suggesting that 
even a minor infectious stimulus in childhood relevant to normal daily life is associated with 
vascular dysfunction (Charakida et al. 2005).  
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Infection and inflammation have also been implicated in the pathophysiology of childhood 
AIS (Amlie-Lefond et al. 2009; Amlie-Lefond and Fullerton 2010; Askalan et al. 2001; 
Fullerton et al. 2011; Sebire et al. 1999). In particular, the link between childhood AIS and 
infection was first proposed because of the temporal association with varicella zoster 
infection (Askalan et al. 2001; Sebire, Meyer, & Chabrier 1999). Sebire et al. reported on a 
case control study of children with AIS, showing that 64% of children who had strokes had 
varicella within the 9 month period prior to stroke versus 9% in the control group (Sebire, 
Meyer, & Chabrier 1999). Furthermore, Askalan et al. in 2001 reported on a prospective 
cohort study conducted in young children (aged 6 months to 10 years) with AIS at 2 
Canadian institutions, showing that 22 (31%) of 70 consecutive children with AIS had a 
varicella infection in the preceding year compared with 9% in the healthy population 
(Askalan et al. 2001). Children in the varicella cohort were more likely to have basal ganglia 
infarcts (P<0.001), abnormal cerebral vascular imaging (P<0.05), and recurrent AIS or TIAs 
(P<0.05) than those in the non-varicella cohort (Askalan et al. 2001). The authors concluded 
that the 31% incidence of varicella within the preceding year in their paediatric AIS cohort 
represents a 3-fold increase over the 9% annual incidence of varicella in Canadian children 
(Askalan et al. 2001). Of note, however, no varicella studies (anti VZV IgG or VZV DNA 
PCR in either peripheral blood or cerebrospinal fluid testing) were systematically reviewed 
in any of these cohorts. Furthermore, Braun et al. demonstrated recently that stroke was 
preceded by chickenpox in 44% of children with unilateral cerebral arteriopathies within one 
year period prior to stroke (Braun et al. 2009).  
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The underlying mechanism for VZV vasculopathy causing AIS remains unknown. Multiple 
mechanisms have been proposed including a reactivation of latent infection housed in the 
cranial nerve and dorsal root ganglia, with migration of VZV towards the anterior cerebral 
circulation causing direct infection of cerebral arteries, and possibly leading to thrombosis, 
necrosis, dissection and aneurysm (Gilden et al. 2009; Gilden et al. 2000; Mueller et al. 
2008; Nagel et al. 2010). Animal studies have identified afferent fibers from trigeminal and 
dorsal root ganglia to both intracranial and extracranial blood vessels, providing an anatomic 
pathway for possible trans-axonal spread of virus (Mayberg et al. 1981). In addition 
pathological and virological analyses of cerebral arteries from adults patients who died from 
VZV vasculopathy have revealed herpes virions, VZV antigen and VZV DNA in the walls 
of cerebral arteries (Gilden, Cohrs, Mahalingam, & Nagel 2009; Nagel et al. 2008; Nagel, 
Mahalingam, Cohrs, & Gilden 2010; Nagel et al. 2011). Nagel et al. recently reported on a 
series of 30 patients with VZV vasculopathy and demonstrated cerebro-spinal fluid (CSF) 
pleocytosis in 20 (67%), and imaging abnormalities in 29 (97%) (Nagel et al. 2008). 
Angiography revealed abnormalities in 70% of the patients who had vascular imaging 
(Nagel et al. 2008). Large and small arteries were involved in 50% of studied cases. CSF of 
9 (30%) patients contained VZV DNA while 28 (93%) had anti-VZV IgG antibody in CSF; 
in each of these patients, reduced serum/CSF ratio of VZV IgG confirmed intrathecal 
synthesis (Nagel et al. 2008). In addition the same group reported on their findings on 
histological and by immunohistochemical examination of normal and VZV-infected cerebral 
and temporal arteries in 3 patients with VZV vasculopathy (Nagel et al. 2011). They showed 
that all VZV-infected arteries contained a disrupted internal elastic lamina; a hyperplastic 
intima composed of cells expressing a-smooth muscle actin and smooth muscle myosin 
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heavy chain but not endothelial cells expressing CD31; and decreased medial smooth muscle 
cells (Nagel et al. 2011). The finding of VZV presence primarily in the adventitia early in 
infection and in the media and intima later supports the theory that after reactivation from 
ganglia, VZV spreads transaxonally to the arterial adventitia followed by transmural spread 
of virus (Nagel et al. 2011). The authors suggested that stroke in VZV vasculopathy may 
result from changes in arterial caliber and contractility produced in part by abnormal 
accumulation of smooth muscle cells and myofibroblasts in thickened neointima and 
disruption of the media (Nagel et al. 2011). Another potential cofactor that has emerged in 
VZV-associated AIS is the role of transient auto-antibodies to phospholipids and coagulation 
cascade activation during or after varicella infection (Josephson et al. 2001; Manco-Johnson 
et al. 1996; Regnault et al. 2005). Both the presence of lupus anticoagulant and a transient 
protein S deficiency were found in a child with disseminated intravascular coagulation 
during varicella (Josephson et al. 2001; Manco-Johnson et al. 1996; Regnault et al. 2005).  
 
Furthermore, multiple other infectious agents have also been linked to case reports of 
arteriopathies and stroke in children such as enterovirus, Mycoplasma pneumoniae and 
Parvovirus B19 (Fu et al. 1998; Guidi et al. 2003; RibaI et al. 2003). Borrelia infection has 
also been reported in association with childhood AIS (Cox et al. 2005). Cerebral infarction is 
not uncommon in meningitis particularly in children under the age of 1 year old with 
streptococcus pneumonia and salmonella (Chang et al. 2003). Haemophilus influenza was 
also described as a cause of acute stroke in 5% of patients in the pre-vaccination era (Kerr 
and Filloux 1992; Taft et al. 1986). Various types of cerebrovascular disease including 
aneurysms and occlusive disease have been reported in association with HIV1 infection 
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either at presentation or during the course of the disease (Dubrovsky et al. 1998; Leeuwis et 
al. 2007). In addition Bandaru et al. have recently reported on a cohort of 42 children with 
AIS at a single centre examining the role of Chlamydia Pneumoniae infection as a risk factor 
for AIS and showed C. pneumoniae seropositivity (IgG) in 14 of the 42 (33.3%) stroke 
patients (Bandaru et al. 2010).  
 
 
Strengthening this hypothesis, the IPSS an international registry of childhood AIS cases 
enrolled at 30 centres, reported recently on epidemiological data also suggesting an 
association between childhood cerebral arteriopathies and recent minor infections (Amlie-
Lefond et al. 2009). Among 508 children enrolled with AIS a recent upper respiratory 
infection was noted in 9.1% of those with a cerebral arteriopathy, compared with 4.5% of 
those without an arteriopathy (OR, 2.1; P=0.048) (Amlie-Lefond et al. 2009). In this study, 
25% of the children were classified as having FCA, higher in frequency than either 
moyamoya (22%) or dissection (20%) (Amlie-Lefond et al. 2009).  This association with 
upper respiratory infection was stronger for children with idiopathic arterial stenosis versus 
those with other arteriopathy (eg, arterial dissection, moyamoya) or no arteriopathy (OR, 
2.8; P=0.003; 95% CI, 1.3-6.1) (Amlie-Lefond et al. 2009).  The only predictor of FCA was 
recent upper respiratory infection (OR, 2.81; 95% CI, 1.28 to 6.12; P=0.003), thus 
suggesting a possible role for burden of infection in the pathogenesis of cerebral arteriopathy 
in children (Amlie-Lefond et al. 2009). The Vascular Effects of Infection in Paediatric 
Stroke (VIPS) study is an ongoing international study conducted under the auspices of IPSS 
 70 
that aims to further improve our understanding of the role of infection in the development of 
childhood cerebral arteriopathies and AIS (Fullerton et al. 2011). 
 
So in summary, several reports suggest that inflammatory events outside the brain such as 
infection are associated with an elevated systemic inflammatory profile and may thus have 
an important impact on stroke susceptibility. 
 
1.4 Genetics  
 
Current theories with regards to the aetiopathogenesis of childhood AIS suggest that perhaps 
one or more widely distributed infectious agents evoke an abnormal immunological response 
in genetically susceptible individuals, leading to the characteristic clinical presentation of the 
disease (Eleftheriou and Ganesan 2009; Fullerton et al. 2011; Munot, Crow, & Ganesan 
2011a). In that context a number of candidate gene association studies have evaluated the 
significance of genetic polymorphisms in prothrombotic, inflammatory, immune mediated or 
metabolic pathways contributing to paediatric AIS. Voetsch et al. studied the plasma 
glutathione peroxidase (GPx-3)-GPx-3 gene promoter in a population of childhood stroke 
compared to controls (Voetsch et al. 2007). Eight novel strongly linked polymorphisms in 
the GPx-3 gene promoter that formed 2 main haplotypes (H1 and H2) were identified 
(Voetsch et al. 2007). The H2 haplotype that reduces the gene's transcriptional activity, 
thereby compromising gene expression and plasma antioxidant and antithrombotic activities 
was associated with an independent increase of AIS in children (odds ratio=2.13, 95% 
CI=1.23 to 4.90; P=0.027) (Voetsch et al. 2007).  In addition, Wang et al investigated the 
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association of the genetic variants in the CTLA-4 and CD28 genes of children who suffered 
idiopathic AIS using a case-control design (Wang et al. 2009). A single nucleotide 
polymorphism (SNP), CTLA-4+49A/G located in exon 1 of the CTLA-4 gene, showed 
nominal association with the disease (OR 2.09, 95% CI 1.17-3.73, p = 0.012) using allele-
based analysis (Wang et al. 2009). The CD28IVS3 +17TT genotype was found to be more 
common in the patients than in the controls (P = 0.039, OR = 2.96, 95% CI = 1.02-8.58) 
(Wang et al. 2009). Furthermore Shi et al. genotyped polymorphisms in the TNF-α promoter 
region in Chinese children with idiopathic AIS and controls (Shi et al. 2009). Among totally 
7 single nucleotide polymorphisms identified in the TNF--α promoter region, the variant of 
the -863C/A was associated with increased risk of AIS in that study (Shi et al. 2009). The 
TNF--α (-308) A allele has also been linked to stroke in sickle cell disease (Shi et al. 2009). 
Additionally, there is considerable evidence that primary moyamoya disease has a genetic 
basis, albeit probably polygenic (Hashikata et al. 2008; Roder et al. 2010). Approximately 
10% of primary cases are familial and 80% of monozygotic twins are concordant (Hashikata 
et al. 2008; Roder et al. 2010). Although familial occurrence accounts for approximately 9% 
of moyamoya syndrome, the majority of cases are sporadic (Hashikata et al. 2010). Linkage 
analyses have shown associations with loci 3p24.2– p26, 6q25, 8q23, 12p12, and 17q2524 
(Roder et al. 2010). Inoue et al. performed a linkage study to confirm their hypothesis that 
familial moyamoya disease is associated with human leukocyte antigens (HLAs) (Inoue et 
al. 1997). The HLA gene is located on chromosome 6, and a marker in chromosome 6q25 
was shared by 16 of 19 Japanese families with moyamoya disease that were studied (Inoue et 
al. 1997). Overall however these candidate gene association studies have generally been 
hampered by relatively small numbers of patients studied, are relevant to certain ethnic 
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populations and have been seldom replicated by other groups, thus limiting the conclusions 
that can be drawn. 
 
Advances in molecular genetics have enabled identification of several monogenic conditions 
involving the cerebral vasculature and predisposing to ischaemic and haemorrhagic strokes 
(Munot, Crow, & Ganesan 2011a). Even though relatively uncommon, association of 
childhood AIS with Mendelian genetic disorders has been recently established and may 
provide immediate insights into disease pathogenesis (Munot, Crow, & Ganesan 2011a). The 
presenting features and key neuroradiological findings in some monogenic disorders 
complicated by childhood AIS are summarised in table 1-3 (Munot, Crow, & Ganesan 
2011a). 
 
 
Condition/ 
inheritance 
Gene/disease 
mechanism of 
pathway implicated 
Other features 
additional to stroke 
Key 
neuroradiological 
features 
COL4A1 (AD)  
 
COL4A1 (abnormal 
vessel-wall integrity) 
Migraine, renal cysts, 
nephropathy, cerebral 
palsy, muscle cramps, 
cataracts, retinal 
tortuosity 
 
Occlusive or 
aneurysmal 
cerebral 
arteriopathy; 
intracranial 
haemorrhage, 
including 
microbleeds; 
cerebral infarction; 
porencephaly 
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Pseudoxanthoma 
elasticum (AR) 
 
ABCC6 (abnormal 
vascular 
homoeostasis) 
Increased skin 
laxity, redundant 
skin folds, peau 
d’orange, 
angioid streaks, 
neovascularisation, 
haemorrhage, 
papular skin lesions, 
peripheral artery 
disease, 
visceral calcification 
 
Lacunar infarcts, 
small-vessel 
disease, 
haemorrhage, 
white-matter signal 
abnormalities 
ACTA2-associated 
disorders (AD) 
. 
 
ACTA-2 (smooth 
muscle proliferation) 
Hypotonic bladder, 
congenital 
mydriasis, livedo 
reticularis 
PDA,thoracic aortic 
aneurysms and 
dissection, premature 
coronary artery 
 
Occlusive disease 
including 
Moyamoya; 
aneurysms in other 
arterial beds  
 
Neurofibromatosis 
type 1 (AD) 
 
NF1 (smooth muscle 
proliferation) 
Seizures, optic 
glioma, glioma, 
sphenoid dysplasia, 
scoliosis, Lisch 
nodules, optic 
gliomas, café-au-lait 
patches, 
axillary  freckling, 
neurofibromas 
 
 
White matter 
lesions, 
hamartomas 
Williams 
syndrome 
(sporadic or AD) 
 
ELN gene (encodes 
elastin) 
Developmental delay, 
dysmorphism; 
supravalvular 
aortic stenosis in 
pulmonary, renal, 
coronary, 
and mesenteric vessels 
 
Occlusive cerebral 
arteriopathy 
(including 
moyamoya) 
CADASIL (AD)  
 
NOTCH 3(Notch 
signalling) 
Migraine with aura, 
cognitive 
impairment, 
psychiatric 
features 
 
Usually subcortical 
white-matter 
infarction though 
large-artery infarcts 
described 
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Alagille syndrome 
(AD) 
 
JAG1(Notch 
signalling) 
Developmental delay, 
butterfly vertebrae, 
posterior 
embryotoxon, 
dysmorphism, PDA, 
intra-hepatic bile-duct 
paucity, peripheral 
pulmonary stenosis 
 
Occlusive or 
aneurysmal 
cerebral 
arteriopathy 
(including 
moyamoya) 
CARASIL (AR)  
 
 
HTRA1 (TGFβ 
pathway) 
Dementia, psychiatric 
features spondylosis 
deformans, alopecia 
 
White-matter 
signal 
abnormalities 
and lacunar lesions 
Aicardi-Goutières 
syndrome (AR) 
 
SAMHD1 (possibly 
immune response 
and vascular 
homeostasis) 
Severe 
encephalopathy, 
regression, 
developmental 
delay, contracture, 
arthropathy, chilblains 
or 
Raynaud’s 
phenomenon 
CSF lymphocytosis or 
raised 
CSF IFN-α (or both) 
 
Occlusive or 
aneurysmal 
cerebral 
arteriopathy 
(including 
moyamoya); 
basal ganglia 
calcification, 
leukoencephalopat
hy 
MOPD II (AR)  
 
PCNT (unknown) Motor delay, skeletal 
dysplasia,microcephal
y, short 
stature, abnormal 
teeth, café-au-lait 
patches, 
dysmorphism, type 2 
diabetes, precocious 
puberty 
 
Occlusive or 
aneurysmal 
cerebral 
arteriopathy 
(including 
moyamoya) 
Menkes disease 
(XLR) 
 
ATP7A gene 
(abnormal response 
to vascular or 
endothelial 
injury due to 
infection, trauma, 
oxidative stress) 
Hypotonia, 
developmental 
delay, seizures, 
regression, joint 
laxity,osteoporosis, 
kinky hair 
Ischaemic and 
haemorrhagic 
cerebrovascular 
disease 
Arterial tortuosity 
syndrome (AD) 
 
SLC2A10/GLUT10 
(Abnormal response 
to vascular or 
Arachnodactyly, 
joint and skin laxity 
 
Intracranial and 
extracranial 
dissections and 
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endothelial 
injury due to 
infection, trauma, 
oxidative stress 
aneurysms, 
craniosynostosis, 
Chiari 
malformation 
Homocysteinuria 
(AR) 
 
CBS/MHTFR 
genes(Vascular 
injury due to 
accumulation of 
abnormal 
metabolites) 
Tall stature, dislocated 
lens, aortic dissection 
Large vessel or 
lacunar strokes 
Fabry’s disease 
(XLR) 
 
GLA (Vascular 
injury due to 
accumulation of 
abnormal 
metabolites) 
Acroparaesthesia 
hypohidrosis, 
exercise intolerance, 
cataracts, corneal 
opacity, 
angiokeratoderma, 
proteinuria or renal 
tubular 
dysfunction, coronary 
artery 
disease, arrhythmia, 
gut 
dysfunction 
 
Posterior 
circulation 
infarction more 
common, stroke 
phenotype includes 
haemorrhage and 
ischaemia 
 
Table 1-3: Single-gene disorders in children with arterial ischaemic stroke and cerebral 
arteriopathy. 
Adapted from Munot et al. 2011a. AIS=arterial ischaemic stroke; AD=autosomal dominant; 
AR=autosomal recessive; PDA=patent ductus arteriosus; CADASIL=cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy; 
CARASIL=cerebral autosomal recessive arteriopathy with subcortical infarcts and 
leukoencephalopathy; CSF=cerebrospinal fluid. IFN-α=interferon alpha; 
MOPD=microcephalic osteodysplastic primordial dwarfism type II; XLR=X-linked 
recessive; COL4A1 =collagen alpha-1(IV) gene; ABCC6= ATP-binding cassette, sub-family 
C, member 6; PCNT=pericentrin; SC SLC2A10/GLUT10 = Solute carrier family 2, 
facilitated glucose transporter number 10; CBS= cystathionine-beta-synthase; MHTFR= 
methylenetetrahydrofolate reductase; GLA=galactosidase alpha.  
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1.5 Risk factors for arterial ischaemic stroke (AIS) recurrence  
 
Defining the risk of recurrent acute ischaemic stroke in individual patients is challenging 
given the diverse range of risk factors which may be present in different combinations in 
each case. In untreated children who suffer first AIS outside the neonatal period, the risk of 
recurrence is 10-25% overall but maybe as high as 92% in patients with SCD who receive no 
treatment (Barnes et al. 2004; Chabrier et al. 2000; Dobson et al. 2002; Fullerton, Wu, 
Sidney, & Johnston 2007; Ganesan et al. 2006). In the context of SCD the risk of recurrence 
appears to be highest in children with moyamoya (Dobson et al. 2002). There are a few long 
term follow up data for patients who develop AIS in the context of cardiac disease but both 
symptomatic and clinically silent recurrence have been described. In symptomatic and 
cryptogenic cases of childhood AIS recurrence is commoner if there are > 2 risk factors 
(Lanthier et al. 2000), and in those with arteriopathy particularly if it is progressive or if 
moyamoya collaterals are demonstrated angiographically and in those with low birth weight 
(Fullerton, Wu, Sidney, & Johnston 2007; Ganesan et al. 2006). Children with arterial 
disease or moyamoya have a risk of recurrence as high as 66% (Danchaivijitr et al. 2006; 
Fullerton, Wu, Sidney, & Johnston 2007; Ganesan et al. 2006). However the severity of 
recurrent symptoms with moyamoya varies considerably between patients with some having 
TIAs and others having fewer but devastating recurrent strokes (Danchaivijitr, Cox, 
Saunders, & Ganesan 2006; Fullerton, Wu, Sidney, & Johnston 2007; Ganesan et al. 2006). 
 
Chabrier et al. demonstrated that patients with cardiac disease, moyamoya or systemic 
disease could have recurrence many years after the original stroke whereas those with 
TCA/FCA or dissection were more likely to have early recurrence (Chabrier et al. 2000). In 
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a UK based cohort genetic thrombophilias were significantly commoner in children with 
cryptogenic stroke who recurred (Ganesan et al. 2006). Furthermore, Braun et al. recently 
characterised the course of childhood unilateral intracranial arteriopathies in a cohort of 79 
children and demonstrated a progressive arteriopathy, with increasing unilateral disease or 
bilateral involvement in 6% of the cases (Braun et al. 2009). This progressive arteriopathy 
was associated with recurrence as was arterial occlusion (Braun et al. 2009). In addition, 
Benseler et al. reported on 62 children with cerebral arteriopathies meeting the Calabrese 
criteria for a diagnosis of cPACNS and defined that those children at risk of progression had 
more often a clinical presentation of neurocognitive dysfunction, multifocal parenchymal 
lesions on MR imaging, and evidence of distal stenoses on angiography (Benseler et al. 
2006). The authors proposed that these characteristic features at diagnosis could be used to 
predict later progression, and identify a distinct high at risk of progression cohort of children 
with cerebral arteriopathies that may benefit from immunosuppressive therapy (Benseler et 
al. 2006).   
 
In summary, it is now clearly recognised that arterial disease is observed in the majority of 
children with AIS and that its presence and morphology are important predictors of 
subsequent course (Fullerton, Wu, Sidney, & Johnston 2007; Ganesan et al. 2006; Mackay et 
al. 2011). As discussed above some of these arteriopathies are due to defined causes such as 
arterial dissection, connective tissue disorders, inherited monogenic vascular disorders and 
SCD (Ganesan et al. 2003; Mackay et al. 2011).  However, in up to 30% of children 
presenting with a first AIS, a focal arterial stenosis is identified but none of the classic 
underlying causes are discovered (Braun et al. 2009; Chabrier et al. 1998; Sebire et al. 2004). 
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To date, the underlying mechanisms for these unilateral, monophasic arteriopathies referred 
to as TCA and more recently as FCA are poorly understood despite the increased attendant 
risk of recurrent events of up to 20% in some case series of childhood arteriopathic stroke 
(Braun et al. 2009; Chabrier et al. 1998; Sebire et al. 2004).  
 
1.6 CNS vasculopathy or vasculitis- semantic confusion and 
key area of controversy 
 
As the aetiology of cerebral arteriopathy presenting with AIS, specifically the role of 
infection and inflammation remains unclear, semantic confusion has arisen as to whether this 
cerebrovascular disease represents a true vasculitic process (Amlie-Lefond et al. 2009; 
Benseler et al. 2006; Braun et al. 2009; Eleftheriou & Ganesan 2009).  Strong 
epidemiological evidence for an association between the proximal stenotic arterial disease in 
PVA and preceding VZV infection as well as the link of burden of recent upper respiratory 
tract infections to incident FCA, suggest that infectious agents, or the host response to 
infection, may be implicated in the pathogenesis of childhood cerebral arteriopathy and thus 
AIS (Amlie-Lefond et al. 2009; Askalan et al. 2001; Fullerton et al. 2011; Sebire, Meyer, & 
Chabrier 1999).  In addition, some of the angiographic appearances of TCA/FCA and PVA, 
with beading and irregular multi-segmental involvement, as well as the radiological course 
with early progression and subsequent stabilization would be compatible with an 
inflammatory process (Aviv et al. 2006; Braun et al. 2009; Eleftheriou et al. 2010). Based on 
these arguments some authors (primarily rheumatologists) have suggested that these children 
have an isolated CNS vasculitis, referred to as primary angiitis of the CNS in childhood 
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(cPACNS) (Benseler et al. 2006; Eleftheriou & Ganesan 2009; Hutchinson et al. 2010). 
Indeed this group of patients would fulfil the diagnostic criteria for cPACNS as proposed by 
Calabrese et al (Calabrese & Mallek 1988). The difficulty in distinguishing between 
cPACNS and presumed non-inflammatory monophasic TCA/FCA is related to the 
insensitivity of currently available investigations for cPACNS (Benseler et al. 2006; 
Eleftheriou & Ganesan 2009; Hutchinson et al. 2010). Essentially recognition and 
monitoring of cPACNS is heavily reliant upon imaging investigations that have no well-
established or limited sensitivity and specificity (Aviv et al. 2006; Benseler et al. 2006; 
Eleftheriou et al. 2010; Eleftheriou & Ganesan 2009; Hutchinson et al. 2010). In addition, 
histology obtained by brain biopsy can provide definitive confirmation of vasculitis in a 
minority of cases, but unfortunately is invasive, lacks sensitivity (due to the patchy nature of 
the disease), and generally identifies parenchymal injury secondary to ischaemia which has 
resulted from vascular dysfunction rather than definitive evidence of vasculitis (Elbers et al. 
2010; Elbers & Benseler 2008). Furthermore, in most series of cPACNS conventional 
circulating acute phase markers are lacking and specific circulating markers of cerebral 
vascular injury have yet to be defined (Benseler et al. 2006; Cellucci, Tyrrell, Sheikh, & 
Benseler 2011; Eleftheriou & Ganesan 2009; Hutchinson et al. 2010). As a consequence of 
these difficulties in distinguishing FCA from cPACNS, there are two parallel strands in the 
current literature, describing patients with very similar clinical and radiological features but 
to whom different diagnostic labels have been attached (cPACNS vs. FCA/PVA) and 
divergent management strategies adopted (Benseler et al. 2006; Braun et al. 2009; 
Eleftheriou & Ganesan 2009; Hutchinson et al. 2010). For example, Aviv et al describe 
vascular changes (typically unilateral stenosis of the proximal middle cerebral artery-MCA) 
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attributed to cPACNS (Aviv et al. 2006). In reports by Miravet et al and by Danchaivijitr et 
al very similar proximal lesions are interpreted as TCA/FCA (Danchaivijitr, Cox, Saunders, 
& Ganesan 2006 Miravet et al. 2007). Essentially both FCA and cPACNS manifest focal 
proximal occlusive disease of the intracranial arteries radiologically. However, FCA is 
generally monophasic, while PACNS typically has a recurrent course, possibly due to 
persistence of an aberrant inflammatory response, which is potentially modifiable by steroids 
and immunosuppressants (Benseler et al. 2006; Eleftheriou & Ganesan 2009; Hutchinson et 
al. 2010). The importance of making this distinction is more than semantic as 
immunosuppression is advocated for cPACNS but not for TCA/FCA which is thought to be 
a monophasic process. This controversy highlights the urgent need for studies into the 
pathogenetic mechanisms implicated in childhood cerebral arteriopathies and childhood AIS.  
Previous studies have proposed radiological and clinical predictors of arteriopathy 
progression and AIS recurrence but neither these nor any currently described biomarker, 
robustly distinguish between patients with a likely monophasic or a likely recurrent course 
thus complicating current management strategies (Benseler et al. 2006; Braun et al. 2011).  
 
1.7 Treatment 
 
With the exception of SCD, the best available evidence for treatment of childhood ischaemic 
stroke is based on theory, extrapolation from adult studies, and cohort studies in children 
(Eleftheriou and Ganesan 2008). In the absence of acute treatments to limit brain injury, and 
absence of a population screening programme for risk factors for paediatric stroke, current 
approaches focus primarily on preventing stroke recurrence (Monagle et al 2004; Roach, 
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2008; Royal College of Physicians, 2004). Three separate treatment guidelines for childhood 
stroke have been published: the American College of Chest Physicians (ACCP) in the 
United States, the Royal College of Physicians (RCP) guidelines in the United Kingdom; 
and most recently the American Heart Association (AHA) Stroke Council scientific 
statement for management of stroke in children (Monagle et al 2004; Roach, 2008; Royal 
College of Physicians, 2004). Additionally the British Committee on Standards of 
Haematology (BCSH) have published evidence based recommendations on the therapy of 
cerebral sinovenous thrombosis (CSVT) in children (British Hematology society, 2007). All 
guidelines were created by expert groups that included paediatric neurologists and 
haematologists from multiple centres (Monagle et al 2004; Roach, 2008; Royal College of 
Physicians, 2004). They all acknowledge the lack of randomised control trials and therefore 
emphasize the limitations of the recommendations which are largely based on expert 
consensus (Monagle et al 2004; Roach, 2008; Royal College of Physicians, 2004). 
 
Treatment guidance is broadly divided into therapy for the acute phase of AIS and 
prophylaxis to prevent stroke recurrence (Monagle et al 2004; Roach, 2008; Royal College 
of Physicians, 2004). The ACCP guidance supports early initiation of anti-coagulation with 
either low molecular weight heparin (LMWH) or unfractioned heparin for the first 5-7 days 
after AIS and until a cardiac source or dissection has been excluded (Monagle et al. 2004). 
Children are usually then changed to aspirin (3-5 mg/kg/d) or remain on anti-coagulation in 
cases due to cardiogenic embolism or dissection (Monagle et al. 2004). Similarly the AHA 
Stroke Council recommends that the administration of LMWH may be considered in 
children for up to 1 week after an ischaemic stroke pending further evaluation to determine 
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the cause of the stroke (Roach et al. 2008). In contrast, the RCP guideline recommends the 
initiation of aspirin at 5 mg/kg/day except in patients with the contraindications of 
intracranial haemorrhage or children with SCD (Royal College of Physicians, 2004). Early 
anti-coagulation is supported only in cases of proven arterial dissection and is considered in 
suspected cardiac thromboembolism (Royal College of Physicians, 2004). For children with 
arterial dissection or cardiac embolism, all three guidelines recommend anticoagulant 
therapy with warfarin or LMWH for 3–6 months (Monagle et al 2004; Roach, 2008; Royal 
College of Physicians, 2004). Even though clinical trials on adult patients with AIS have 
shown reduced morbidity and mortality in patients treated with intravenous tissue 
plasminogen activator (tPA) within hours from stroke onset, the theoretical risks and lack of 
evidence in children resulted in neither the RCP, the AHA Stroke Council or the ACCP 
guidelines recommending the use of thrombolytics in paediatric stroke (Monagle et al 2004; 
Roach, 2008; Royal College of Physicians, 2004). These current treatment guidelines also 
differ in their recommendations for long-term treatment of children after AIS, with the 
ACCP guidance recommending maintenance aspirin in all patients and the others only in 
children with vasculopathy (Monagle et al 2004; Roach, 2008; Royal College of Physicians, 
2004). Management of stroke in SCD includes initial and maintenance blood transfusions 
(see section on SCD 1.2.4) (Adams et al. 1998; Monagle et al 2004; Roach, 2008; Royal 
College of Physicians, 2004). Endovascular therapies are increasingly used particularly in 
moyamoya arteriopathy (Khan et al. 2003; Scott et al. 2004). Treatment of cPACNS is 
summarised in 1.2.2.3. Clinical trials to address areas of divergent opinion and improve the 
evidence base for rational treatment of childhood stroke in the near future are urgently 
needed. The three clinical guidelines are summarised in table 1-4. 
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Acute 
Childhood 
AIS 
RCP guidelines 
(2004) 
ACCP guidelines 
(Monagle et al. 2004) 
AHA Stroke Council 
(Roach et al. 2008) 
General  Aspirin 
5mg/kg/day 
UFH or LMWH for 5 to 7 
days and until 
cardioembolic and 
dissection have been 
excluded as causes 
The administration of 
LMWH or UFH may be 
considered in children 
for up to 1 week after an 
ischaemic stroke 
pending further 
evaluation to determine 
the cause 
of the stroke. 
Sickle cell 
disease 
Exchange 
transfusion 
to HbS<30% 
Intravenous hydration and 
exchange transfusion to 
HbS<30% 
Intravenous hydration 
exchange transfusion to 
reduce HbS to <30% 
total haemoglobin 
Thrombolysis Not recommended Not recommended Not recommended 
Maintenance 
therapy in 
childhood 
AIS 
   
General  Aspirin 
5mg/kg/day 
For all children with AIS 
treat with ASA 2–5 
mg/kg/day after 
anticoagulation therapy  
has been stopped 
 
 
Dissection Consider anti-
coagulation until 
evidence of vessel 
healing or up to 6 
months 
After 5–7 days UFH or 
LMWH, treat with LMWH 
or warfarin for 3–6 months 
 
For extracranial 
dissection LMWH or 
warfarin for 
3 to 6 months or an 
antiplatelet agent should 
be considered. Extend 
therapy beyond 6 months 
for individuals who 
develop recurrent 
symptoms or when there 
is radiographic evidence 
of a residual abnormality 
of the dissected artery. 
Anti-coagulation not 
recommended for 
intracranial dissection. 
Cardioembolic Consider 
anticoagulation 
After 5–7 days UFH or 
LMWH, treat with LMWH 
or warfarin for 3–6 months 
Cardioembolic unrelated 
to PFO after initial 
therapy with UFH or 
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Table 1-4: Treatment guidelines for paediatric stroke-antithrombotic therapy. 
ACCP=American College of Clinical Pharmacy; RCP=Royal College of Physicians; 
AHA=American Heart Association; AIS=arterial ischaemic stroke; INR=international 
normalised ratio; LMWH=low molecular weight heparin; UFH=Unfractioned heparin. 
Child defined as 28 days to 18 years (ACCP), 1 month to 16 years (RCP), 28 days to 16 
years (AHA Stroke Council). 
 
 LMWH, treat with 
LMWH or warfarin for 
3-6 months. 
For children with a 
suspected cardiac 
embolism unrelated to a 
PFO with a lower or 
unknown risk of stroke, 
it is reasonable to begin 
aspirin and to continue it 
for at least 1 year. 
Vasculopathy Aspirin 1-3 
mg/kg/day 
Aspirin 2–5 mg/kg/day 
after anticoagulation 
therapy has been stopped 
Aspirin 3-5mg/kg/day 
Sickle cell 
disease 
Blood transfusion 
every 3–6 weeks  
Long-term 
transfusion 
programme  
to HbS 30%  
After 3 years aim 
for HbS 50%  
If no transfusion, 
hydroxyurea  
Consider bone-
marrow transplant 
Long-term transfusion 
programme 
 
Long term transfusion 
programme.Hydroxyurea 
may be considered in 
patients who cannot 
continue on 
long-term transfusion. 
Consider bone marrow 
transplant 
Recurrent 
stroke  
on aspirin 
Consider 
anticoagulation 
Not addressed Not addressed 
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1.8 Outcome 
 
The reported mortality after AIS in childhood varies widely between different series from 3 
to 23% (Ganesan et al. 2000; Gordon, Ganesan, Towell, & Kirkham 2002; MacGregor, 
Curtis, & Mayank 2000; Neuner et al. 2011). Childhood AIS also has the potential for life-
long morbidity (Ganesan  et al. 2000; Gordon, Ganesan, Towell, & Kirkham 2002; 
MacGregor, Curtis, & Mayank 2000; Neuner et al. 2011). The primary outcome of 
childhood AIS based on Pediatric Stroke Outcome Measure (PSOM) assessments in a recent 
study by DeVeber et al. suggested moderate to severe deficits in the majority of patients 
(MacGregor, Curtis, & Mayank 2000). Multivariate analysis showed that AIS, associated 
neurologic disorders, and presence of rehabilitation therapy were independent predictors of 
poor outcome (P < 0.02) (MacGregor, Curtis, & Mayank 2000). In addition, Neuner et al. 
showed in a recent study of 133 survivors of childhood AIS that 65% exhibited at least 1 
neurologic disability years after incident stroke (Neuner et al. 2011). Paediatric stroke 
survivors also reported lower overall well-being compared with healthy controls (Neuner et 
al. 2011). Lastly, Gordon et al. recently reported on the functional consequences of 
childhood AIS in terms of activity limitation showing that this was evident in the domains of 
education, self-care, and motor skills (Gordon, Ganesan, Towell, & Kirkham 2002). There 
was in addition a clear relationship between radiologically apparent extent of brain damage, 
degree of impairment, and functional outcome (Gordon, Ganesan, Towell, & Kirkham 
2002).  
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1.9 Conclusion 
 
In summary AIS is an increasingly recognised childhood neurological disorder resulting in 
long term morbidity in two thirds of survivors and recurrence in a fifth (Ganesan et al. 2000; 
Gordon, Ganesan, Towell, & Kirkham 2002; MacGregor, Curtis, & Mayank 2000; Neuner et 
al. 2011). AIS is usually secondary to cerebral arteriopathy, the morphology and evolution of 
which is highly predictive of recurrence (Fullerton, Wu, Sidney, & Johnston 2007; Ganesan, 
Prengler, Wade, & Kirkham 2006; Mackay et al. 2011). Preceding VZV infection has been 
identified as a predisposing factor to cerebral arteriopathies while minor upper respiratory 
tract infections have been reported as an independent risk factor for focal cerebral 
arteriopathies, providing clues that viral infection and/or a secondary inflammatory response 
may be involved in the pathophysiology of these conditions (Amlie-Lefond et al. 2009; 
Askalan et al. 2001; Sebire, Meyer, & Chabrier 1999). In addition, inherited or acquired 
thrombophilias likely interact in concert with other identified risk factors mainly cerebral 
arteriopathy to initiate and/or propagate thromboembolism in childhood AIS patients 
(Bernard et al. 2010; Kenet et al. 2010). Several clinical studies have attempted to identify a 
“high” risk profile of children with AIS and cerebral arteriopathy that are more at risk of a 
second stroke but to date no currently described biomarker robustly distinguishes between 
those children with a monophasic disease course and those with recurrence (Benseler et al. 
2006; Braun et al. 2009; Cellucci, Tyrrell, Sheikh, & Benseler 2011). Progression of cerebral 
arteriopathy and AIS recurrence may be related to persistence of cerebral arterial injury and 
chronic sub-clinical endothelial activation conferring an increased thrombotic risk. If this is 
the case there may be a role for novel interventions, such as anti-inflammatory agents, in 
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secondary stroke prevention. As these treatments have potential side effects identification of 
biomarkers of vascular injury and prothrombotic risk associated with AIS recurrence, could 
allow us to select those children more at risk of AIS recurrence who may benefit from 
immunosuppression whilst avoiding unnecessary cytotoxic treatment in those with a more 
benign course. Recently described methods for detecting endothelial cell components in 
peripheral blood may allow early detection of endothelial injury indicative of persistence 
and/or propagation of cerebral vascular inflammation in these children with AIS recurrence 
and would be of considerable clinical interest (Hirschi et al. 2008; Morel et al. 2006; 
Woywodt et al. 2002).  
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1.10 Non-invasive detection of endothelial injury and repair 
capacity 
 
1.10.1 Dynamics between endothelial injury and repair 
 
Once considered to serve no other purpose than that of a physical barrier between blood and 
tissue the multifunctional nature of the endothelium was discovered in the later part of the 
20th century (Sabatier et al. 2009). The endothelium is a highly dynamic tissue in equilibrium 
with the circulating compartment and composed of various sub-populations offering 
important opportunities for a non-invasive exploration (Sabatier et al. 2009). It is now well 
recognized that the balance between vascular injury and repair is critical for the maintenance 
of vessel integrity (Sabatier et al. 2009). In addition, disruption of endothelial integrity and 
altered endothelial function represent an important mechanism in the development of 
cardiovascular disorders (CVD) including cerebrovascular disease (Blann et al. 2002; 
Felmeden et al. 2003; Sabatier et al. 2009). Chronic exposure to cardiovascular risk factors 
(CRF) alters the regulatory function of the endothelium that progresses from a quiescent 
state to activation, apoptosis and death (Bazzoni and Dejana 2004; Sabatier et al. 2009; 
Varani and Ward 1994). As a result the endothelium not only displays altered functions, but 
also loses its integrity (Sabatier et al. 2009). Microparticles (membrane vesicles <1 µm in 
size and rich in phosphatidylserine) released from activated or apoptotic endothelial cells 
and whole endothelial cells detached from injured vessels (circulating endothelial cells; 
CEC) constitute a fundamental feature of these injurious responses affecting the vessel wall 
(Blann et al. 2005; Dignat-George and Boulanger 2011; Piccin et al. 2007; Woywodt et al. 
2003). In response to injury, regenerative mechanisms are activated to restore endothelium 
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integrity (Hirschi, Ingram, & Yoder 2008; Sabatier et al. 2009; Yoder et al. 2007). In the 
past, endothelial repair was considered to solely involve adjacent endothelial cells able to 
replicate locally and replace the lost cells (Hirschi, Ingram, & Yoder 2008; Rabelink et al. 
2010; Richardson and Yoder 2011). Since the original study by Asahara et al. it has become 
obvious that the recruitment of endothelial progenitor cells (EPC) represents an additional 
mechanism for vascular repair (Asahara et al. 1997; Hill et al. 2003; Hirschi, Ingram, & 
Yoder 2008; Werner et al. 2005; Yoder, et al. 2007). These stem cells are mobilized from the 
bone marrow and are able to differentiate into mature cells, restoring endothelial integrity at 
sites of vascular injury (Asahara et al. 1997). This spectrum of endothelial responses can be 
thus considered in a dynamic triad ‘activation/injury/repair’ which has critically transformed 
our understanding of endothelial biology (figure 1-2) (Sabatier et al.  2009). Whereas the 
determination of CEC and endothelial derived MP levels have raised considerable interest to 
appreciate the status of activated/ damaged endothelium, EPC levels  have been used to 
evaluate the endogenous repair potential (Erdbruegger et al. 2008; Hill et al.2003; Sabatier et 
al. 2009; Werner et al. 2005; Woywodt, 2003). Combined measurement of these indices 
offers a non-invasive and original way to estimate vascular competence in individual 
patients at different time points (Clarke et al. 2010; Sabatier et al. 2009).  We can therefore 
begin to develop biomarker strategies to identify patients with high vascular risk such as 
perhaps children with AIS at risk of recurrence, and potentially monitor their response to 
treatment by assessing the balance between injury and repair markers as an index of overall 
endothelial integrity.  
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Figure 1-2: Dynamics of endothelial injury and repair. 
Disruption of endothelial integrity is associated with a spectrum of responses including 
detachment of whole endothelial cells (CEC) and release of endothelial microparticles 
(EMP). In response to injury, endothelial progenitors cells (EPC), recruited from the bone 
marrow play a role in restoring endothelial integrity. 
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1.11 Hypothesis and aims of this thesis 
 
1.11.1 Hypothesis 
 
This thesis explored the following hypothesis: 
In some children with AIS and cerebral arteriopathy, there is persistent sub-clinical cerebral 
arterial endothelial activation and injury long after the inciting insult has disappeared. 
Simultaneously, abnormalities in repair of chronic endothelial injury due to altered 
endothelial progenitor cell responses impair recovery from childhood AIS. This unfavorable 
balance of endothelial injury and repair contributes to AIS recurrence and further 
neurological events.  
 
1.11.2 Aims: 
 
The aims of this thesis were to: 
1) Investigate whether biomarkers of endothelial injury can be detected in the peripheral 
circulation of children with AIS and occlusive cerebral arteriopathy (with the exclusion 
of children with sickle cell disease or other systemic vascular disorders) and whether 
these indices differentiate children with recurrent AIS from those with a monophasic 
disease course. 
2) Evaluate novel biomarkers of thrombotic propensity in children with AIS and cerebral 
arteriopathy and explore whether these are associated with recurrent AIS.  
3) Assess whether AIS recurrence is associated in part with altered endothelial progenitor 
cell responses impairing recovery from childhood AIS.  
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2 Methods and materials 
2.1 Introduction 
This section contains predominantly materials and methods that are used in more than one 
chapter. Methods applicable to one chapter only or those that have been developed or 
adapted specifically for this study will be discussed in detail in the relevant chapter. 
 
2.2 Subjects  
 
2.2.1 Study design and patient population 
 
Cross-sectional study of children aged >28 days old with arterial ischaemic stroke (AIS) and 
imaging evidence of cerebral/cervical arteriopathy presenting to Great Ormond Street 
Hospital (GOSH) from October 2007 to January 2012. GOSH is the tertiary paediatric 
neurology center serving north London, United Kingdom. Patients were identified by a 
search of the paediatric neurology service outpatient and inpatient database. 
 
AIS was defined as an acute focal neurological deficit attributable to cerebral infarction in a 
corresponding arterial distribution. Cerebral/cervical arteriopathy was defined as focal or 
segmental stenosis or occlusion, with regular or irregular abnormalities of the arterial wall 
(Braun et al. 2009) and categorized according to the consensus definitions published by 
Sebire et al. (Sebire et al. 2004). However, the category of transient cerebral arteriopathy 
(TCA) in this classification has more recently been superseded by the term focal cerebral 
 93 
arteriopathy (FCA) which was used in this study (Amlie-Lefond et al. 2009). The Childhood 
AIS Standardized Classification And Diagnostic Evaluation (CASCADE) categorisation is 
also provided for comparison (see appendix 1 for details) (Bernard et al. 2012). This is a 
comprehensive consensus-based classification system for childhood AIS recently proposed 
and validated by the International Paediatric Stroke Study (IPSS) group (Bernard et al. 
2012).  
 
Exclusion criteria were: patients with other systemic conditions that can cause endothelial 
injury (sickle cell disease, systemic vasculitis, systemic lupus erythematosus or other 
autoimmune connective tissue disease); those with known cardiac disease; those with 
histopathologically confirmed cerebral vasculitis; syndromic moyamoya and those with 
other potentially confounding syndromic diagnoses. Patients with arterial occlusion but no 
other arterial wall changes were also excluded from the study as these radiological 
appearances could result from cardioembolic or paradoxical embolism.  
 
In addition to the cross sectional study, children with a new presentation of AIS and 
cervical/cerebral arteriopathy were identified at presentation to the neurology services at 
GOSH and evaluated prospectively over a 12 month period.  
 
2.2.2  Healthy controls and disease controls 
 
Blood samples were obtained from healthy controls comprised of an unselected sequential 
group of children attending the surgical ward at GOSH between October 2007 and January 
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2012 and undergoing minor surgical procedures (such as hernia repair; pre-operative blood 
samples obtained) with no identifiable medical history of acute or chronic illnesses or 
syndromic diagnosis, and in particular no evidence of intercurrent infection. Healthy adult 
volunteers were staff from within the Infection and Immunity Theme at the Institute of Child 
Health, University College London (UCL). 
 
A disease control group was included comprising of children with cerebral arteriovenous 
malformations (AVM) as these patients have non-inflammatory vascular pathologies. 
 
Informed consent was obtained from all parents/guardians and participants/child healthy 
controls with local ethics approval (COREC 07/Q0508/58).   
 
2.2.3 Clinical, laboratory and radiological data 
 
All children with AIS routinely underwent magnetic resonance (MR) imaging and MR 
angiography within 48 hours of presentation for confirmation of the diagnosis and 
identification of possible cerebral/cervical arteriopathy.  
 
MRI and MRA were performed on a 1.5-Tesla MR scanner using a standard imaging 
protocol, including T2-weighted turbo spin-echo imaging in the axial plane, fluid-attenuated 
inversion recovery (FLAIR) sequence in the coronal plane, T1-weighted spin-echo imaging 
in the sagittal plane, and three-dimensional short-echo time-of-flight MRA of the circle of 
Willis. In the under 2 age group, the axial T2-weighted imaging was replaced by dual echo 
stimulated echo (deSTIR) imaging sequence and the coronal FLAIR sequence was not 
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acquired. Catheter cerebral arteriography (CA) was performed on a biplane angiographic 
system with selective catheterization and contrast injections into both internal carotid arteries 
(ICA) and into at least one vertebral artery (VA). CA was performed at the clinician’s 
discretion, as this may provide adjunctive yield for detection of arteriopathy (Eleftheriou et 
al. 2010). Blood was drawn before CA was performed to exclude procedure-related 
endothelial injury. Cerebral/cervical arteriopathy was identified on MRA, and/or CA where 
available, and categorised using currently recommended definitions. Proximal, distal, or 
whole segment involvement was identified. Distal involvement was defined as involvement 
beyond the M1 or A1 segments. Presence of collateral vessels was determined. Patients were 
re-imaged with MRI/MRA at 6 and 12 months following index AIS and annually thereafter 
for clinical monitoring.  
 
All children underwent comprehensive investigation for AIS risk factors (appendix 2).  
These included: erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP); clotting 
profile and thrombophilia screen specifically testing for protein C, protein S, antithrombin 
III, plasminogen, lupus anti-coagulant and antiphospholipid antibodies, activated protein C 
resistance ratio, Factor V Leiden, thermolabile variant of methylenetetrahydrofolate 
reductase (t-MTHFR) and prothrombin 20210 gene mutations; plasma amino acids, 
homocysteine, urate, ammonia, lactate; and lipoprotein(a) levels. Intercurrent infection as a 
potential important confounding factor was excluded based on detailed history and clinical 
examination. Treatment was based on current international management guidelines 
(Monagle et al 2004; Roach, 2008; Royal College of Physicians, 2004). Two treatment 
guidelines for childhood ischaemic stroke have been published and are those of the Royal 
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College of Physicians in the UK and more recently the American Heart Association Stroke 
Council (Roach, 2008; Royal College of Physicians, 2004). In addition, the American 
College of Chest Physicians provides guidance on the use of anticoagulants and 
antithrombotic therapy in childhood stroke (Monagle et al. 2004). Supportive care and 
neuroprotective strategies are important considerations in children with ischaemic stroke 
(Eleftheriou & Ganesan 2008; Roach et al. 2008). Antithrombotic strategies are advocated; 
the choice of agent varies according to the underlying risk factors (Monagle et al 2004; 
Roach, 2008; Royal College of Physicians, 2004). Due to the theoretical risks and lack of 
evidence thrombolytic treatment is not generally recommended in paediatric stroke 
(Monagle et al 2004; Roach, 2008; Royal College of Physicians, 2004). Lastly, specific 
pathologies may require targeted management, for example surgical revascularization for 
moyamoya (Eleftheriou & Ganesan 2008; Roach et al. 2008).  
 
2.2.4 Patient groups 
 
Patients were categorised into two groups according to AIS recurrence. AIS recurrence was 
defined as a sudden onset of new neurological deficit with radiological evidence of re-
infarction and identified at re-presentation to our institution. Of note since the mode of 
presentation of AIS in children is often fluctuating and recurring, recurrent AIS was defined 
only when the new clinical event occurred > 1 week after presentation (Braun et al. 2009). 
Where clinical recurrence did occur, children underwent additional MRI/MRA imaging to 
identify new areas of arterial territory infarction and/or progression of arteriopathy, defined 
as progression of previously identified arterial disease (more extensive segment involved, 
 97 
more severe occlusive disease) and/or involvement of previously unaffected vessels and/or 
new arterial occlusion in the presence of arterial wall changes. 
2.3 Materials 
 
2.3.1 Reagents for blood collection 
 
After blood was collected it was aliquoted into one or more of the following collection 
bottles depending on use: 1.4ml of 3.2% trisodium citrate (Sartsedt), 5 ml 
Ethylenediaminetetraacetic acid (EDTA; International specific supplies), 5 ml polypropelene 
containing no anticoagulant or sterile 20 ml universal bottles containing 40µl of preservative 
free heparin (monoparin, CP pharmaceuticals Ltd, 1000 U/ml).  
 
2.3.2 Fluorochrome conjugated antibodies for flow cytometry 
 
The fluorochrome antibodies used are listed in table 2-1. Antibodies were diluted with 0.01 
M phosphate buffered saline with 0.1% sodium azide for staining of peripheral blood 
mononuclear cells (PBMC) and Human Umbilical Vein Endothelial Cells (HUVEC). For 
staining of microparticles (MPs) antibodies were diluted with sterile filtered RPMI 1640 
supplemented with 5% heat inactivated FCS and 0.1% sodium azide. All antibodies were 
titrated by plotting a dilution curve against median fluorescence index, the relevant dilution 
for each antibody corresponding to the shoulder of the curve. Each antibody was also 
checked against an appropriate isotype-control antibody with the same protein concentration, 
as per manufacturers’ recommendation. For peripheral blood mononuclear cells (PBMC) 
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staining FC receptor blocking reagent (Miltenyi biotech) was used to further reduce 
nonspecific binding.  
 
Specificity Isotype Conjugate Company Clone Dilution  
CD41  Mouse 
IgG1 
TRICOLOR Caltag 
laboratories 
Clone 
VIPL3 
1/50 
CD42a Mouse 
IgG1 
PERCP BD 
PharMingen 
Beb1 1/50 
activation epitope- 
CD11b  
Mouse 
IgG1, κ 
PE Biolegend CBRM1/5, 1/50 
CD142  Mouse 
IgG1 
FITC American 
Diagnostica 
clone VD8, 1/50 
CD62e Mouse 
IgG1  
PE BD 
PharMingen 
clone 68-
5H11 
1/50 
CD54 Mouse 
IgG1 
PE BD 
PharMingen 
LB-2 1/50 
CD106 Mouse 
IgG1 
PE BD 
PharMingen 
51-10C9 1/50 
CD31 Mouse 
IgG1 
PE BD 
PharMingen 
L133.1  1/50 
CD62P Mouse 
IgG1 
PE BD 
PharMingen 
AC1.2 1/50 
CD66b Mouse 
IgG1 
PE BD 
PharMingen 
G10F5 1/50 
CD14 Mouse 
IgG1 
PE-Cy5 AbD Serotec 61D3 1/50 
CD162 Mouse 
IgG1 
PE BD Pharmingen KPL-1 1/50 
CD133 Mouse 
IgG1 
PE Miltenyi Biotec 
 
clone 
AC133 
1/10 
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CD34 Mouse 
IgG1 
PERCP BD Pharmingen clone 8G12 1/10 
VEGFR2 Mouse 
IgG1 
Biotin Sigma Aldrich clone 
KDR2 
1/10 
CD144 Polyclonal 
IgG 
FITC AbD Serotec n/a 1/10 
Streptavidin n/a FITC AbD Serotec n/a 1/150 
 
 
Table 2-1: Fluorochrome conjugated antibodies/reagents for flow cytometry. 
 
 
2.3.3 Tissue culture media 
 
The following tissue culture media were used: RPMI-1640 culture medium containing 2 mM 
L-glutamine (Life Technologies, Gibco BRL) and supplemented with antibiotics (100 IU/ml 
penicillin; 10 µg/ml streptomycin, and 25 ng/ml amphotericin B); foetal calf serum (heat 
inactivated at 56o C for 60 minutes to destroy complement); endothelial Cell Growth 
Medium 2 (EGM-2;Promocell) comprising of basal endothelial growth medium 
supplemented with  2% foetal calf serum (FCS), 5ng/ml of epidermal growth factor, 10 
ng/ml of basic fibroblast growth factor, 10 ng/ml of insulin growth factor, 0.5 ng/ml of 
Vascular Endothelial Growth Factor (VEGF), 1 µg/ml of ascorbic acid, 0.2 µg/ml of 
hydrocortisone and 90 μg/ml of heparin as per manufacturer’s instructions.  
 
2.3.4 Cytokine and protein reagents 
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The following cytokine was used: recombinant TNF-α (100 ng/ml, Sigma Aldrich). The 
following peptides were used formyl-methyl-leucyl-phenylalanin (fMLP; 1µM from Sigma 
Aldrich), lipopolysaccharide (LPS) derived from E. Coli, O55:B5 (5 µg/ml, Sigma). The 
following fluorochrome conjugated proteins were used: annexin V (unconjugated, FITC, PE 
or PE-Cy5 labeled; 1:50 dilution, BD); Ulex europaeus I agglutinin (UEA-I FITC 
conjugated, 10 mg/ml, Sigma Aldrich), Streptavidin (FITC, 1:150 dilution, Serotec). 
Trypsin-EDTA (Promo cell) and trypsin neutralizing solution /TNS (0.05 % trypsin 
inhibitor, 0.1 % BSA; Promo cell) were used for detachment of human umblical vein 
endothelial cells (HUVEC) from culture. Corn trypsin inhibitor (30 µg/ml; Sigma) was used 
to inhibit in vitro contact activation of the coagulation cascade in the thrombin generation 
assay (TGA).  
 
 
2.3.5 Bead based extraction reagents 
 
DYNAL bead technology (Invitrogen) was used for isolation of circulating endothelial cells 
(CECs): Dynabead Pan mouse IgG were labeled with an unconjugated IgG1 antibody to 
CD146, clone s-endo1 (Biocytex). The Dynal MCP-L magnet which holds 1-8 ml tubes was 
also used. 
 
2.3.6 ELISA kits 
 
Levels of von Willebrand factor were determined using a commercially available kit 
(American Diagnostica) as per manufacturer recommendation.  
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2.3.7 Other reagents 
 
Other reagents included:  
 For isolation of peripheral blood mononuclear cells (PBMC) the density 
centrifugation separation reagent LymphoprepTM (Axis-Shield) was used.   
 PolymorphprepTM (Axis Shield) sterile and endotoxin tested solution for the isolation 
of polymorphonuclear cells containing 13.8% (w/v) sodium diatrizoate and 8.0% 
(w/v) polysaccharide was used for the isolation of peripheral blood neutrophils.  
 Tyrode's buffer (Sigma Aldrich) containing 0.1% glucose, 0.1% BSA, 137.5 mmol/L 
NaCl, 12 mmol/L NaHCO3, 2.6 mmol/L KCl was used for the isolation of peripheral 
blood platelets.  
 Annexin V binding buffer (BD Pharmingen) 10 x concentrate composed of 0.2 μm 
sterile filtered 0.1M Hepes (pH 7.4), 1.4M NaCl, and 25 mM CaCl2 solution. Prior to 
staining, an appropriate quantity of a working solution was made by diluting the 
concentrate 1:10 with distilled water.  
 Cell fix buffer (BD Biosciences): filtered distilled water plus 10% formaldehyde. 
 Low-density lipoprotein from human plasma, acetylated, DiI complex (Di I Ac-LDL; 
Invitrogen). 
 BD Matrigel Basement Membrane Matrix (BD Biosciences) is a solubilized 
basement membrane preparation extracted from the Engelbreth-Holm-Swarm (EHS) 
mouse sarcoma, a tumor rich in extracellular matrix proteins. Its major component is 
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laminin, followed by collagen IV, heparan sulfate proteoglycans, entactin/nidogen.  
BD Matrigel Basement Membrane Matrix also contains TGF-beta, epidermal growth 
factor, insulin-like growth factor, fibroblast growth factor, tissue plasminogen 
activator, and other growth factors which occur naturally in the EHS tumor. 
 Calcium-fluorogenic substrate (0.5 mM/L of Z-Gly-Gly-Arg-7-Amino-4-
Methylcoumarin and 7.5 mM/L of calcium final reagent concentrations, Pathway 
Diagnostics) for the thrombin generation assay. 
 Human tissue factor pro-coagulant activity was measured using a commercially 
available kit (American Diagnostica) as per manufacturer recommendation.  
 The following latex beads were used to investigate forward and side scatter 
(FSC/SSC) flow cytometric characteristics of particles: 1µ and 3 µm beads (Sigma).  
 
 
2.4 Preparation of blood and tissue samples 
 
All human blood and tissue samples were collected with full ethical approval and informed 
consent (COREC 07/Q0508/58).   
 
 
2.4.1 Human umbilical vein endothelial cells (HUVEC) culture 
 
Commercially available HUVEC bought frozen from Promo Cell were resuspended in 10ml 
of EGM2 (Promocell) supplemented with 2% Fetal Calf Serum (FCS) and growth factors as 
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supplied by the manufacturer, and were then transferred to 25cm2 flask. These were 
incubated at 37oC and 5% CO2. Cells were washed in fresh culture media the following day 
and inspected under phase contrast microscopy. HUVEC could be identified as small 
clusters of oval adherent cells. Cultures were inspected each day for growth. When cells 
were approaching confluence (which usually occurred after 72 hours culture), they were sub-
cultured. For experimental purposes, fully confluent HUVEC at passages 2–3 were pre-
incubated overnight with 0.5% FCS in EGM-2 prior to addition of factors and other 
experimental conditions described in the relevant sections.  
 
2.4.2 HUVEC culture passage 
 
HUVEC that were near-confluent were washed three times in warmed PBS to remove non-
adherent cells and protein in FCS. Cells were then washed once in 1.5 ml Trypsin-EDTA 
solution (per 25-cm2 flask) which was then removed and cells were inspected under phase-
contrast microscopy, and when rounding and becoming dislodged (usually after 30 seconds), 
the flask was tapped against the bench top to aid removal and a further 1.5-ml trypsin-
neutralising solution added. The detached cells were quickly resuspended in warmed 
HUVEC culture medium and transferred to a 50-ml sterile conical tube. These were then 
seeded into 6 or 12 well flat-bottom tissue culture plates. Tissue culture plates were then 
incubated at 37°C in 5% CO2 until cells were treated with trypsin again prior to use in 
various assay described in relevant sections. Of note as HUVEC morphology and cell 
adhesion molecule expression in response to inflammatory stimuli may alter after serial 
passage, the cells used throughout this study were always first to third sub-culture passage.   
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2.4.3 Isolation of peripheral blood mononuclear cells (PBMC) 
 
Blood samples for PBMC isolation were collected into sterile universals containing 40 units 
of preservative free heparin (CP Pharmaceuticals LTD, Wrexham) and processed within 2 
hours. Blood was diluted with an equal volume of culture medium containing RPMI 1640 
medium (Invitrogen, Paisley, UK) and 100U/ml Penicillin/100μg/ml Streptamycin 
(Invitrogen). Blood-RPMI mix was layered onto 10 ml of Lymphoprep TM (Axis Shield). 
These samples were then centrifuged at room temperature at 800g for 25 minutes with no 
brake. The resulting PBMC interface was removed and an equal volume of culture medium 
was added and centrifuged at 500g for 10 minutes. The resulting pellet was resuspended in 
40 ml of culture medium by gentle flicking and the PBMC counted as described in 3.4.4. 
Cells were centrifuged at 500g for 10 minutes and then resuspended in appropriate volume 
of freezing medium or EGM-2 (Promo-cell) before culturing. 
 
2.4.4 Counting viable cells 
 
Viable cells were quantified as follows: 10 μl of cell suspension was mixed with 10 μl of 
0.4% trypan blue (Sigma). Half of the mix was placed on Neubauer counting chamber and 
cells enumerated by light microscopy. Unstained live cells were counted in the specified 25-
box field and the total number calculated. Number of cells in 25-box field x 2 (dilution 
factor) x 104=total number of viable cells per ml. Cell preparations were typically composed 
of > 97% viable cells.  
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2.4.5 Freezing cells 
 
Processed cells were cryopreserved in liquid nitrogen for long term storage. After counting 
cells were centrifuged and re-suspended at a concentration of 2x106/ml in freezing medium 
(FCS supplemented with 10% v/v dimethyl sulphoxide from Sigma). 1 ml aliquots were 
transferred into individual cryovials which were placed into a freezing pot with isopropanol 
coolant for 24 hours at -800C (allowing slow cooling) over night before transfer to liquid 
nitrogen storage. 
 
 
2.4.6 Recovering of frozen cells 
 
Cryo-preserved cells were removed from liquid nitrogen and rapidly thawed in a 370C water 
bath. Cells were then transferred to 2 ml of FCS in a drop wise fashion. Culture medium was 
added prior to centrifugation (500g for 10 minutes) before being counted. 
 
 
2.4.7 Isolation of peripheral blood monocytes 
 
PBMCs isolated as above were resuspended at 2 x10 6 in RPMI 1640 medium (Invitrogen), 
plated into a 6 well plate and incubated for 3 hours to allow adherence of monocytes to the 
plate. Non adherent cells were removed and the adherent cell layer washed twice, each time 
with 10 ml  RPMI (to remove any residual nonadherent cells) and then replaced with 10 ml 
fresh, serum-free RPMI 1640 medium supplemented with 100U/ml Penicillin/100μg/ml 
Streptamycin (Invitrogen). Adherent monocytes were removed by gently scraping with a 
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plastic cell scraper. Cell were then transferred to a 15-ml conical tube and centrifuged for 10 
min at 300 × g, room in room temperature prior to resuspension in appropriate volume of 
culture medium and used in experimental conditions as discussed in the relevant chapters. 
. 
2.4.8 Isolation of peripheral blood neutrophils 
 
Neutrophils were isolated using PolymorphprepTM (Axis Shield) from 5-20 mls of blood 
obtained from adult volunteers and anti-coagulated with preservative-free heparin 
(Monoparin, CP Pharmaceuticals Ltd, 1000 U/ml). Briefly blood was carefully layered onto 
equal volume of Polymorphprep TM (Axis Shield). These samples were then centrifuged at 
500g for 35 minutes with no brake. The resulting polymorphonuclear cell interface was 
harvested and an equal volume of culture medium containing RPMI 1640 medium 
(Invitrogen, Paisley, UK) diluted with water (1:1) was added and centrifuged at 400g for 10 
minutes. The resulting pellet was re-suspended in 40 ml of culture medium by gentle 
flicking and the cells counted, washed twice and finally re-suspended in an appropriate 
volume of culture medium before used in experimental conditions as discussed in the 
relevant chapters.  
 
 
2.4.9 Isolation of peripheral blood platelets 
 
Platelet-rich plasma was prepared by centrifugation of citrated blood at 1000 × g for 3 min. 
Immediately after 0.5 nM prostacyclin (Sigma Aldrich) was added to prevent in vitro platelet 
aggregation. To obtain a platelet pellet, platelet rich plasma was then centrifuged at at 5000g 
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for 15 minutes and the platelets were gently resuspended in Tyrode's buffer (Sigma Aldrich) 
and washed twice before stimulation in various experimental conditions as described in the 
relevant chapters.  
 
 
 
2.4.10 Preparation of platelet poor plasma 
 
Blood from patients/child controls and adult healthy volunteers was collected in 3.2% 
buffered citrate and centrifuged at 5000 g for 5 min twice to obtain platelet-poor plasma 
(PPP). PPP samples were divided into aliquots and stored at –80°C for future batch testing. 
PPP samples were used for detection of microparticles and ELISA for von Willebrand 
factor.  
 
2.5 Statistical analysis 
 
A number of parametric and non-parametric statistical analyses were used in this thesis. 
Description of tests and their application is given in the relevant chapters. Parametric tests 
used were student’s t-test and paired t-tests. Non parametric tests used were: the Kruskal-
Wallis test, Mann-Whitney U test, the Wilcoxon signed rank test and Spearman’s rank 
correlation coefficient. Receiver operator characteristic (ROC) curves, sensitivity, 
specificity, positive and negative predictive values, and likelihood ratios were calculated to 
examine the diagnostic characteristics of indices described. ROC curve were reported as area 
under the curve (AUC) and 95% confidence intervals (CI). Levels of agreement for CEC 
counts between different investigators were summarised using Bland–Altman plots. Bland-
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Altman plots were in addition performed when comparison of methodology was required. 
Results were expressed as bias SD and 95% CI of limit of agreement. P-values of less than 
0.05 (two sided) were regarded as significant. Statistical analysis was performed using SPSS 
versions 16 and 17. Data are presented using GraphPad Prism (San Diego, CA). 
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3  Circulating endothelial cells in children with 
arterial ischaemic stroke  
 
3.1  Summary 
 
Background: Arterial ischaemic stroke (AIS) is commonly associated with abnormalities 
(arteriopathies) of the cervical or intracranial circulation the morphology and course of 
which predicts recurrence risk. These are currently categorized on radiological grounds and 
it is likely that they represent distinct pathological entities.  Currently however there are no 
reliable means of differentiating those children with a monophasic disease course from those 
with recurrence or progressive arteriopathy. Circulating endothelial cells (CECs) are necrotic 
or highly activated endothelial cells that have become detached from the vessel wall, and 
have been recently shown to be a sensitive biomarker for detection of vascular injury and 
damage.  
Objective: Test the hypothesis that it is possible to non-invasively track persistent 
endothelial injury (elevated CEC) in children with AIS recurrence compared to those with a 
single AIS event. 
Methods: Single centre cross-sectional study of 46 children with AIS and cerebral 
arteriopathy matched with 20 paediatric controls. AIS recurrence was defined as new acute 
neurological deficit with radiological evidence of further cerebral infarction. Patients were 
considered in two groups based on AIS recurrence. CECs were identified using 
immunomagnetic bead extraction according to an international consensus protocol. Results 
were expressed as median and range. 
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Results: Forty six children with AIS aged 8.4 (0·9-17.4) years and 20 paediatric controls 
aged 9 (1.2-16) years were included. Ten children had AIS recurrence while 36 had a single 
AIS event. CECs were significantly raised in children with recurrent AIS, compared to those 
with no recurrence (p = 0·0001); and controls, p= 0·0001. In two out of 8 children studied 
prospectively AIS recurrence was associated with a sustained increased in CECs. Six 
children had a monophasic disease course reflected on persistently low CEC counts.  CEC as 
a biomarker of AIS recurrence was complimentary to current approaches based on 
radiological and clinical criteria.  
Conclusion: Despite the wide spectrum of clinical and radiological presentation of 
childhood AIS indices of endothelial injury are different in patients with single and recurrent 
events. This novel observation has potential for furthering understanding of AIS 
pathophysiology and prognosis.  
 
3.2 Introduction 
 
Childhood arterial ischaemic stroke (AIS) results in neurological morbidity in over 2/3rds of 
survivors and recurrence in up to 20% (Fullerton, Wu, Sidney, & Johnston 2007; Ganesan et 
al.2006; Gordon, Ganesan, Towell, & Kirkham 2002). In the absence of acute treatments to 
limit brain injury, current approaches are focused on prevention of recurrence (Monagle et al 
2004; Roach, 2008; Royal College of Physicians, 2004). The majority of affected children 
have arteriopathies of the cervical or intracranial circulation, which although radiologically 
similar, are likely to represent distinct pathological entities (Braun et al. 2009; Fullerton, 
Wu, Sidney, & Johnston 2007; Ganesan et al. 2003; Mackay, Wiznitzer, Benedict, Lee, 
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deVeber, & Ganesan 2011). The temporal association of VZV infection and arteriopathy as 
well as recent epidemiologic data from the International Paediatric Stroke Study (IPSS), 
suggest that common childhood infections may play a role in the genesis of this arteriopathy 
(Amlie-Lefond et al. 2009; Askalan et al. 2001; Sebire, Meyer, & Chabrier 1999). Other 
lines of evidence suggest that those affected could be genetically susceptible to generating an 
abnormal immunological response to such infections, resulting in vascular inflammation, 
cerebrovascular endothelial injury and a thrombogenic response (Amlie-Lefond & Fullerton 
2010; Eleftheriou & Ganesan 2009; Fullerton et al. 2011; Kenet et al. 2010; Munot, Crow, & 
Ganesan 2011a). Although on radiological grounds both focal cerebral arteriopathy (FCA) 
and primary angiitis of the central nervous system (PACNS) are examples of arteriopathies 
that result in focal proximal occlusive disease of the intracranial arteries, the former is 
generally monophasic, while the latter has a recurrent course, possibly due to persistence of 
the aberrant inflammatory response described above, and potentially modifiable by steroids 
and immunosuppressants (Amlie-Lefond et al. 2009; Braun et al. 2009; Hutchinson, Elbers 
et al. 2010). However the distinction between these entities remains controversial (Braun et 
al. 2009; Eleftheriou & Ganesan 2009). Although previous studies have proposed 
radiological predictors of arteriopathy progression and AIS recurrence there is no clinically 
robust biomarker distinguishing between patients with a likely monophasic or a likely 
recurrent course (Braun et al. 2009; Cellucci et al. 2011). This inevitably leads to excessive 
or inadequate use of immunosuppression. 
 
Endothelial cells adhere to a basement membrane and in health remain in this location with 
very few cells lost in the blood and cleared away through the reticuloendothelial system 
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(Sabatier et al. 2009). Pathological conditions associated with damage to the endothelium 
lead to endothelial cell detachment resulting in increased number of circulating endothelial 
cells (CEC) in the blood stream (Clarke, et al. 2010; Mutin et al. 1999; Smadja et al. 2009; 
Woywodt et al. 2002; Woywodt et al. 2003). The mechanisms involved in cell detachment 
are complex and are likely to involve several factors such as mechanical injury, 
atherosclerosis, alteration of cellular adhesion molecules, defective binding to anchoring 
matrix proteins, and cellular apoptosis with decreased survival of cytoskeletal proteins 
(Erdbruegger et al. 2006; Michel 2003; Sabatier et al. 2009). CECs are necrotic or highly 
activated endothelial cells that have become detached from the vessel wall in response to 
vascular injury (Clarke et al. 2010; Erdbruegger, Haubitz, & Woywodt 2006; Woywodt et al. 
2003). CEC were initially detected in 1970 in smears of peripheral blood with techniques 
such as vital light microscopy (Hladovec and Rossmann 1973; Wright and Giacometti 
1972). Cells were separated by Ficoll density centrifugation and identified based on their 
morphology and Giemsa staining (Hladovec & Rossmann 1973; Wright & Giacometti 
1972). Immunohistochemistry of peripheral blood smears using antibodies to endothelial 
markers such as Von Willebrand Factor or cell adhesion molecules was employed years later 
(Jaffe 1987; Percivalle et al. 1993; Watanabe and Tokunaga 1990). However some smaller 
endothelial cell fragments were difficult to detect using this methodology and cell 
permalisation was necessary thus increasing cell loss (Blann et al. 2005). Overall these early 
studies were heavily reliant on morphology and were technically challenging.  In addition, 
the poor specificity of these techniques and the low yield of cells complicated the research 
efforts in this area and highlighted the need for a reliable, endothelial-specific cell surface 
molecule that could be used as an appropriate tool (Blann et al. 2005).  
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Due to the low numbers of CEC in peripheral blood, an important step in their identification 
has since been the development of sensitive technologies for the detection of rare events 
based on immunolabelling with monoclonal antibodies to endothelial antigens (Blann et al. 
2005). In 1991, two groups reported simultaneously monoclonal antibodies to new cell 
surface antigens on endothelial cells (HEC 19 and S-Endo 1) and used them to quantify 
blood-borne CECs (George et al. 1992; Sbarbati et al. 1991). Bardin et al. subsequently 
demonstrated that their antibody was recognizing the CD146 molecule and used it to 
demonstrate CECs in several conditions including rickettsial infection, sickle cell disease, 
thrombotic thrombocytopenia and acute coronary syndromes (Bardin et al. 1996a; Bardin et 
al. 1996b). This adhesion molecule is concentrated at the endothelial junction, where it plays 
a key role in the control of cell–cell cohesion, permeability, and signalization (Bardin et al. 
2001). CD146 is more specific for endothelial cells (although it is found on some activated 
T-cells and melanoma cells) compared to other endothelial cell surface markers such as 
CD31 (also found on platelets, monocytes, neutrophils and T-cells), or CD105 (found on 
activated monocytes, macrophages and erythrocyte precursors) (Blann et al. 2005; Mutin et 
al. 1997).  
 
 In 1997, Solovey et al. used a monoclonal antibody (P1H12) against CD146 to detect CECs 
in sickle cell anaemia (Solovey et al. 1997). Immunomagnetic bead extraction has since 
become the consensus methodology for CEC identification and enumeration and is described 
in more detail in section 3.4.2 (Woywodt et al. 2003;Woywodt et al. 2006). The CECs are 
counted in whole blood using 4.5-µm magnetic particles bound to an anti-CD146 
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monoclonal antibody (Woywodt et al. 2006). The use of an Fc-blocking agent (to prevent 
nonspecific leukocyte binding) and relatively endothelial-specific Ulex europaeus lectin 1 
has improved the specificity of this technique (Woywodt et al. 2006).  A CEC is defined as 
an event of appropriate size > 10 µm that binds (forms a rosette with) 5 or more beads 
(Woywodt et al. 2006).  
 
Alternative methodologies for CEC counting include flow cytometry, which has been largely 
used to detect CEC in cancer patients amongst others (Bertolini et al. 2006; Fürstenberger et 
al. 2006; Mancuso et al. 2001; Rajagopalan et al. 2004; Sabatier et al. 2009). An advantage 
of flow cytometry is rapid multiparametric analysis, and the ability to detect sub-populations 
(Bertolini, Shaked, Mancuso, & Kerbel 2006; Fürstenberger et al. 2006; Mancuso et al. 
2001; Rajagopalan et al. 2004; Sabatier et al. 2009). However, the methodology is not 
standardized with normal values using flow cytometry varying between publications and 
about 100–1000-fold higher compared to those from immunomagnetic bead extraction 
(Clarke et al. 2008; Shantsila and Lip 2008). These differences may be secondary to 
isolation procedure and inadequate standardization of flow cytometric conditions and are 
discussed in more detail is section 3.7. 
 
Recently various groups have reported increased numbers of CECs in many diverse diseases 
including infectious (George et al. 1993) and cardiovascular diseases such as acute coronary 
syndromes (Boos et al. 2006; Mutin et al.1999), diabetes (McClung et al. 2005), pulmonary 
hypertension (Smadja et al. 2009), chronic renal failure (Rodriguez-Ayala et al. 2006) and 
cancer (Mancuso et al. 2001). Low levels have been documented in healthy individuals of all 
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ages (Blann et al. 2005; Sbarbati et al. 1991). CECs are also increased in other pathological 
situations associated with vascular inflammation including lupus and systemic vasculitis 
(Clancy et al. 2001; Clarke et al. 2010; Woywodt et al. 2003). In various diseases, the 
longitudinal quantification of CECs has demonstrated that their levels vary according to the 
clinical condition/severity (Clancy et al. 2001; Clarke et al. 2010; Woywodt et al. 2003). In 
systemic vasculitis for instance Woywodt et al. have shown that patients with antineutrophil 
cytoplasmic antibody associated vasculitis (AAV) have increased numbers of CEC that 
decreased in response to 6 months of treatment to induce remission (Woywodt et al. 2003). 
Similarly Clarke et al. have shown in children with primary systemic vasculitis that CEC are 
a sensitive marker of disease activity and can be used to monitor response to therapy (Clarke 
et al. 2010). An important feature of CEC is that their levels are predominantly affected by 
disease activity and endothelial injury and not treatment per se (Clarke et al. 2010; Woywodt 
et al. 2003). Patients during vasculitis flares mounted a response by increasing their CECs 
despite receiving immunosuppressive treatment (Clarke et al. 2010; Woywodt et al. 2003). 
Interestingly, Nadar et al. recently studied adults who presented with an acute stroke and 
showed an increase in numbers of CECs in the acute phase correlating with other markers of 
endothelial dysfunction or damage such as soluble E-selectin and plasma vWF (Nadar et al. 
2005). In addition, Woywodt et al. have also demonstrated high numbers of CEC during 
acute adult stroke (Woywodt et al. 2011). These clinical studies indicate that CEC levels are 
indicative of disease activity and generally correlate with functional or plasma markers of 
endothelial injury.  
 
 116 
In summary, CECs have been used as markers of endothelial damage across an ever 
widening variety of diseases, including systemic vasculitis and adult stroke (Clarke et al. 
2010; Nadar et al. 2005; Woywodt et al.2003; Woywodt et al. 2011). CECs could therefore 
be an attractive candidate biomarker to detect persistence of endothelial injury and how this 
relates to risk of recurrent childhood AIS.   
 
3.3 Aims 
To explore whether children with recurrent AIS have evidence of increased endothelial 
injury as detected by raised CEC count compared with those with a single AIS event.  
 
3.4 Methods 
 
3.4.1 Preparation of immunomagnetic beads 
 
Dynabeads (pan mouse IgG) were resuspended and then 350 µl of the suspension was added 
to a 5ml polypropylene tube. The tube used was then placed into the magnet (MPC-L; Dynal 
Biotech) for 2 minutes to allow the beads to attach to the side of the tube. The supernatant 
was discarded and the beads resuspended in 1ml phosphate buffered saline (PBS; Sigma) 
with 0.1% bovine serum albumin (BSA; Sigma) added. The tube was placed in the magnet 
again and the supernatant discarded as above. The beads were then resuspended in 950 µl of 
PBS (with 0.1% BSA) and 400 µl of s-endo-1 antibody (Biocytex) were added (final 
concentration of 25 µg/ml). The tube was sealed and the sample mixed on a roller mixer at 2 
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hours at 40 C.  Beads were washed 3 times as before and resuspended in a final volume of 1 
ml for further use.  
 
 
3.4.2 CEC extraction from peripheral blood 
 
CEC were detected as described previously based on an international consensus protocol 
(Woywodt et al. 2006). Briefly venous blood (1 ml) collected into tubes containing EDTA 
was mixed with buffer (1 ml of PBS containing 0.1% BSA and 0.6% sodium citrate) and 
20μl of Fc receptor–blocking reagent (Miltenyi Biotec) and incubated for 5 minutes at room 
temperature. Fifty μl of a preparation of anti-CD146–coated immunomagnetic beads (clone 
S-endo-1; BioCytex and Dynal Biotech) was added, and the sample was incubated at 4°C for 
30 minutes with rotation. Bead-bound cells were separated using a magnet (MPC-L; Dynal 
Biotech) and washed 3 times with buffer. Cells were then resuspended in 100 μl of buffer 
containing 10 μl of a 2-mg/ml preparation of FITC-labeled Ulex europaeus lectin (Sigma-
Aldrich) and incubated for 1 hour at room temperature in the dark. Cells were then washed 
again three times and re-suspended in a final volume of 200 μl buffer. 
 
 
3.4.3 Counting CEC 
 
CECs in the sample were counted using a Nageotte chamber on a fluorescence microscope. 
CECs were defined according to an international consensus protocol as Ulex bright cells that 
were >10 μm in size, with 5 magnetic beads attached, figure 3-1 (Woywodt et al. 2006). 
20 μm 
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Nageotte counting champer is designed for counting of rare events and holds 50 µl of sample 
over 40 lines. CEC were counted over the 40 lines and multiplied by 4 to get the total 
volume per ml of whole blood. 
 
 
 
 
 
 
 
 
 
Figure 3-1: Fluorescence microscopy image of a circulating endothelial cell (CEC) from a 
4 year old child with cerebral arteriopathy and arterial ischaemic stroke.  
CECs were separated from whole blood using immunomagnetic bead extraction, where cells 
bind to magnetic particles coated with anti-CD146 antibody and then are stained with 
FITC-conjugated Ulex europaeus lectin. CECs are defined as Ulex bright cells that were 
>10 μm in size, with a minimum of 5 magnetic beads attached.  
 
 
3.4.4 Reproducibility of the technique 
 
To establish the reproducibility of the immunomagnetic bead extraction technique, CEC 
from a child with AIS, one child with active systemic vasculitis (associated with increased 
endothelial injury) and a healthy child were prepared from 3 individual 1 ml blood samples. 
20m 
 
20m 
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As a positive control blood was spiked with HUVEC 1000 cells/ml and 3 samples of 1 ml 
each prepared.  As depicted in figure 3-2 there was little variation in all samples measured 
with the greater variation in the spiked with HUVEC blood sample. For healthy control 
sample mean CEC count was 10 cells/ml SD 4 cell/ml; for AIS 34 cells/ml with SD 4 
cells/ml; systemic vasculitis 120 cells/ml SD 8 cells/ml and for spiked blood with HUVEC 
776 cells/ml with SD 21 cells/ml. 
 
 
 
 
 
 
 
 
 
Figure 3-2: Reproducibility of circulating endothelial cells with immunomagnetic bead 
extraction.  
Blood samples from a child with arterial ischaemic stroke (AIS), a child with systemic 
vasculitis and a healthy control sample were divided into 3 and circulating endothelial cells 
(CEC) counted. As a positive control a sample of healthy control blood was spiked with 
human umbilical vein endothelial cells (HUVEC) 1000 cells/ml. The mean CEC count in the 
healthy control sample was 10 cells/ml SD 4 cell/ml; for AIS 34 cells/ml with SD 4 cells/ml; 
systemic vasculitis 120 cells/ml SD 8 cells/ml and for spiked blood 776 cells/ml with SD 21 
cells/ml. 
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3.4.5  Circulating endothelial cell enumeration-interobserver variability 
 
Bland Altman plots of CEC counts (expressed as cells/cell chamber) for 10 consecutive 
patients with AIS and cerebral arteriopathy as counted by an experienced research fellow (Dr 
Ying Hong) and myself, both blinded to the classification of the patient are summarized in 
figure 3-3 below. Bland Altman analysis was performed to determine the inter-observer 
variability for CEC enumeration, showing a bias of -0.325 with SD 3.4  and 95% CI of 
agreement -7 to 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3: Circulating endothelial cell (CEC) enumeration- interobserver variability.  
Bland-Altman plot of CEC counts for 10 consecutive patients exploring the agreement 
between two blinded investigators for enumeration of CECs. Analysis shows a bias of -0.325 
with SD 3.4 and 95% CI of agreement -7 to 6.   
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3.4.6 Effect of time to preparation and storage on CEC enumeration 
 
Blood donated by an adult healthy volunteer and a sample from a child with AIS was 
divided into 1 ml aliquots and kept 40C before processing and counting CEC at 2 hours, 4 
hours and 24 hours. As previously described by Woywodt et al. CEC had declined by 24 
hours in all samples (figure 3-4). Therefore all samples were processed immediately or 
within a 2 hour window and kept cold at 40 C. 
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Figure 3-4: Effect of storage on circulating endothelial cell (CEC) counts. 
 Samples from an adult healthy volunteer and a child with arterial ischaemic stroke 
(marked in red) were kept at 40C before processing at 2, 4 and 24 hours. By 24 hours 
CEC counts were decreased in all samples.  
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3.5 Evaluation of circulating endothelial cells in children with 
arterial ischaemic stroke 
 
3.5.1 Patient population and study design 
 
This was a cross-sectional study of children aged >28 days old with AIS and imaging 
evidence of cerebral/cervical arteriopathy presenting to Great Ormond Street Hospital 
(GOSH) from September 2007 to January 2012. Children/families were approached for 
recruitment to the study during their clinic follow up appointments or during inpatient stay at 
a median of 8 (6-24 months) following recent AIS. For definitions and inclusion/exclusion 
criteria see section 2.2.  For healthy controls and disease controls see section 2.2.2. In 
addition to the cross sectional study, children with a new presentation of AIS and 
cervical/cerebral arteriopathy were evaluated prospectively over a 12 month period. 
 
3.5.2 Statistical analysis 
 
Numeric results were summarised as median and range. The Kruskal-Wallis test was used to 
examine overall differences in experimental laboratory markers between the study groups 
followed by the Mann-Whitney U test. Fisher’s exact test was used to compare categorical 
data between groups. The Wilcoxon matched pairs signed ranks test was used to compare 
CEC counts at initial presentation and at latest follow up for those monitored prospectively. 
The independent association of CEC on the primary outcome of AIS recurrence was 
assessed using a multivariable logistic regression model, unadjusted and adjusted for age, 
gender, and time from stroke event to blood test sampling. Common confounding factors 
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such as age and sex but also time from stroke event to blood test sampling were entered into 
a univariate analysis initially and significant variables (p<0.1) were then entered into the 
multivariable model. Results were expressed as odds ratios (OR) with corresponding 95% 
confidence intervals (CI) and P-values. Sensitivity, specificity and likelihood ratios were 
then calculated to examine the potential diagnostic test characteristics of CECs for the 
identification of AIS recurrence. P-values of less than 0.05 (two sided) were regarded as 
significant. Statistical analysis was performed using SPSS version 17. 
 
3.6 Results 
 
3.6.1  Clinical, laboratory and radiological data 
 
 
A total 116 children with AIS were identified during the study period (figure 3-5). Of those 
54 met the inclusion criteria; however eight patients/families refused participation. Of the 46 
participants (age 8.8, range 0.9-17.4 years), 10 had AIS recurrence and 36 did not have AIS 
recurrence. The children who refused consent had an age of 6.2 (4.2-8.4 years old) and none 
had recurrent events. None of the children with a single AIS event had evidence of clinically 
silent infarction on repeat imaging at 6 and 12 months after index AIS. Healthy control 
children had an age of 9 (range 1.2-16) years old. The disease control group included 10 
children median age 9 (3-16 years old) with cerebral AVM four of which had a history of 
intracerebral haemorrhage. The demographics of the study population, the routine clinical 
laboratory parameters, imaging features and arteriopathy classification are summarised in 
tables 3-1 and 3-2.  
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None of the children studied had clinical signs or symptoms of a systemic inflammatory 
disease.  Evaluation took place at a median of 7 (6-13 months) following recent AIS for 
those children with AIS recurrence compared to 11 (6-24 months) for those with no 
recurrence, (p= 0.1000). Recurrent AIS was confirmed at median of 7 (3-15 months) from 
index event. Considering the Sebire et al. classification there were 3 children with cervical 
arterial dissection (30%), one child with PACNS (10%), one child with moyamoya (10%), 
one child with PVA (10%) and 4 with an unclassified (40%) vasculopathy in the group of 
children with AIS recurrence. In the group of children with a single event there were 19 
children with TCA/FCA (52%), 4 children with cervical arterial dissection (11%), 3 children 
with PVA (8%), 5 children with moyamoya (14.5%) and the remaining 5 (14.5%) had an 
unclassified vasculopathy. The CASCADE classification is provided for comparison in table 
3-1.  
 
Of note, children with recurrent AIS more commonly had diffuse neurological deficits 
(p=0.0006), headaches (p=0.0031), multifocal and bilateral lesions (p=0.0002), and lesions 
in both anterior and posterior circulation territories on MR imaging (p=0.0006). They were 
also more likely to have been treated with steroids (p=0.0057). Treatment with 
corticosteroids, cyclophosphamide and surgical revascularisation was initiated following 
AIS recurrence. In addition, there were no differences in ESR and CRP levels between the 
two groups (p=0.561 and 0.873 respectively). With regards to thrombophilia screen one 
child in the group with recurrence was heterozygous for MTHFR mutations (10%) and one 
had initially low protein S (10%) that subsequently recovered to normal levels. In the group 
of children with no recurrence two patients had protein S deficiency (5%); one child was 
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MTHFR mutation homozygous (3%) with 3 being heterozygous (8%); lastly one child was 
heterozygous for factor V Leiden deficiency (3%).   
 
Follow up MRI and MRA imaging data for the 10 children with AIS recurrence are 
summarised in table 3-3.  All children had evidence of additional brain infarction. There was 
progression of previously identified arterial disease in 6 children (60%), involvement of 
previously unaffected vessels in 8 children (80%) and new arterial occlusion in the presence 
of other arterial wall changes in 2 patients (20%). Follow up MRI and MRA imaging data 
for the 36 children with no AIS recurrence are summarised in table 3-4.  
 
Three out of the 10 children with AIS recurrence had cervical arteriopathy on initial MRA 
imaging. At the time of AIS recurrence all 3 children had evidence of progression of their 
cervical arteriopathy and in addition new evidence of intracranial arteriopathy. Five of the 36 
children in the no recurrence group with cervical arteriopathy had no evidence of 
progression of this arteriopathy on follow up imaging and there was no new intra-cerebral 
circulation involvement identified.  
 
In addition to the cross sectional study, 8 children, with age 6.5 (5-13 years) were studied 
prospectively at initial presentation with AIS and at latest follow up of 12 (9-18 months). Six 
had a monophasic disease course with no AIS recurrence following the initial event; while 
two children (treated with aspirin and warfarin but no immunosuppression) re-presented with 
AIS recurrence during follow-up (see table 3-5 and 3-6).  
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Figure 3-5: Study profile. 
 
12 with sickle cell disease 
11 with systemic 
vasculitis/systemic chronic 
inflammatory disease 
3 with systemic infection 
6 with syndromic diagnosis 
were excluded 
10 had negative MR 
angiography for cerebral 
arteriopathy 
86 had positive MR 
angiography for cerebral 
arteriopathy 
15 children with 
cardiac disease and 
AIS excluded 
116 children with AIS identified 
46 children with AIS and 
cerebral arteriopathy 
included in the study 
5 patients with 
perinatal AIS excluded 
8 refused 
participation to the 
study 
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Demographics AIS recurrence n=10 (%) AIS no recurrence n=36 
(%) 
P value 
Sex (M:F) 6:4 16:20 0.4839 
Age (median, range) 
years 
8.2 (0.9-15.4)  9.4 (2.7-17.4)  0.681 
Clinical features    
Focal neurological 
deficit  
10 (100%) 35 (97%) 1.0000 
Diffuse neurological 
deficits 
 
7 (70%) 4 (11%) 0.0006 
Headache 5 (50%) 2 (5%) 0.0031 
Seizures 1 (10%) 1 (3%) 0.3913 
Sebire et al. 
classification of 
cerebral arteriopathy 
(Sebire et al. 2004) 
N=3 Arterial dissection 
(30%) 
N=1 PACNS (10%) 
N=1 PVA (10%) 
N=1 Moyamoya (10%) 
N= 4 Unclassified (40%) 
N=19 TCA/FCA (52%) 
N=4 Arterial dissection 
(11%) 
N=3 PVA (8 %) 
N=5 Moyamoya (14%) 
N=5 Un-classified (14%) 
N/a 
CASCADE primary 
classification (Bernard 
et al. 2012) 
N=3Aortic/cervical 
arteriopathy (30%) 
N=1 Small vessel 
arteriopathy of childhood 
(10%) 
N=1 Unilateral FCA (10%) 
N=4 Bilateral arteriopathy 
with collaterals (40%) 
N=1 Bilateral arteriopathy 
without collaterals (10%) 
 
N=22 Unilateral FCA 
(61%) 
N=4 Aortic/cervical 
arteriopathy (11%). 
N=5 Bilateral 
arteriopathy with 
collaterals (14%) 
N=3 Bilateral 
arteriopathy without 
collaterals (8%) 
N=2 Other (5%) 
N/a 
ESR mm/h (median, 
range) 
(normal range 0-10 
mm/h) 
5.4 (1-12) mm/h 6.6 (1-28) mm/h 0.561 
CRP mg/L (median, 
range) 
(normal range <10 
mg/L) 
5 (3-16) mg/L 5 (3-6) mg /L 0.873 
Cerebrospinal fluid 
analysis  
Normal (6/6 studies) Normal (n=5/5 studies) 1 
Thrombophilia screen Any abnormality n=2 (20%) 
 
MTHFR heterozygous n=1 
(10%) 
Low protein S n=1 (10%) 
Any abnormality n=7 
(19%) 
Protein S deficiency n=2 
(5%) 
MTHFR homozygous 
n=1 (3%) 
Heterozygous n=3 (8%) 
1 
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Table 3-1: Study population characteristics. 
Focal neurological deficits included hemiparesis, facial weakness and hemisensory loss. 
Diffuse neurological deficits included neurocognitive dysfunction, personality changes and 
concentration difficulties. M=male; F=Female; TCA=Transient cerebral arteriopathy; 
FCA=Focal cerebral arteriopathy; PACNS=primary angiitis of the central nervous system; 
ESR=erythrocyte sedimentation rate; CRP=C-reactive protein; MTHFR= Methylene-
tetrahydrofolate reductase; PVA=Post varicella arteriopathy; N/a=not applicable. P values 
were calculated using Fisher’s exact test for categorical data and Mann Whitney U for 
continuous variables. P-values of less than 0.05 (two sided) were regarded as significant. 
 
 
 
 
 
 
 
 
 
Factor V Leiden 
heterozygous n=1 (3%) 
Treatment    
Aspirin 10 (100%) 36 (100%) 1 
Anticoagulation 
(heparin/warfarin) 
3 (30%) 5 (14%) 0.0149 
Corticosteroids 4 (40%) 1 (3%) 0.0057 
Cyclophosphamide  2 (20%) 1 (3%) 0.1147 
Surgical 
revascularization 
2 (20%) 4 (11%) 0.5975 
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Table 3-2: Imaging findings for 46 children with arterial ischaemic stroke (AIS). 
MRI= magnetic resonance imaging; MRA=magnetic resonance angiography. P values were 
calculated using Fisher’s exact test for categorical data and Mann Whitney U for 
continuous variables. P-values of less than 0.05 (two sided) were regarded as significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Imaging modality AIS recurrence n=10 
(%) 
AIS no recurrence n=36 
(%) 
P value 
MRI    
Multifocal  and bilateral 
lesions 
9 (90%) 8 (22%) 0.0002 
MRA    
Multifocal and bilateral 
lesions 
9 (90%) 8 (22%) 0.0002 
Proximal lesions 10 (100%) 36 (100%) 1 
Distal lesions 8 (80%) 3 (8%) 0.0001 
Anterior circulation only 2 (20%) 30 (83%) 0.004 
Posterior circulation only 2 (20%) 6 (16%) 1 
Anterior and posterior 
 circulation 
7 (70%) 4 (11%) 0.0006 
Collaterals 4 (40%) 3 (8%) 0.0311 
Catheter angiography 
(total patients) 
  
10 14   
Multifocal and bilateral 
lesions 
9 (90%) 8 (57%) 0.1718 
Anterior and posterior 
circulation  
7 (70%) 6 (43%)  0.2397 
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Table 3-3: Magnetic resonance imaging and angiography findings in 10 children with 
arterial ischaemic stroke (AIS) recurrence. 
 
 
Table 3-4: Magnetic resonance imaging and angiography findings in 36 children with  no 
arterial ischaemic stroke (AIS) recurrence. 
 
 
 
 
Magnetic resonance imaging (MRI) Patients N=10 (100%) 
Additional brain infarction 10 (100%) 
Magnetic resonance angiography (MRA)  
 
 
Progression of previously identified  arterial disease 6 (60%) 
Involvement of previously unaffected vessels 
 
8 (80%) 
New arterial occlusion in the presence of other 
arterial wall changes 
 
2 (20%) 
Magnetic resonance imaging (MRI) Patients N=36 (100%) 
Additional brain infarction 0 (0%) 
Magnetic resonance angiography (MRA)  
 
 
Progression of previously identified  arterial disease 4 (11%) 
Involvement of previously unaffected vessels 
 
0 (0%) 
New arterial occlusion in the presence of other 
arterial wall changes 
 
0 (0%) 
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Demographics Recurrence n=2 
(%) 
No recurrence 
n=6 (%) 
P value 
Sex (M:F) 2:0 4:2 1 
Age (median, range) years 8 (6-12) 7 (6.5-13) 0.581 
Clinical features    
Focal neurological deficit 
(hemiparesis, facial weakness, 
hemisensory loss) 
2 (100%) 6 (100%) 1 
Diffuse neurological deficits 
(neurocognitive dysfunction, 
personality changes, 
concentration difficulties) 
2 (100%) 1 (50%) 0.1 
Headache 2 (100%) 0 (0%) 0.03 
Seizures 1 (50%) 0 (0%) 0.3913 
Sebire et al. classification of 
cerebral arteriopathy (Sebire 
et al. 2004) 
N=2 unclassified 
(40%) 
N=2 TCA/FCA 
(33%) 
N=2 arterial 
dissection (33%) 
N=1 PVA (16%) 
N=1 un-classified 
(16%) 
N/a 
CASCADE primary 
classification (Bernard et al. 
2012) 
N=1 Bilateral 
arteriopathy with 
collaterals (50%) 
N=1 Bilateral 
arteriopathy without 
collaterals ( 50%) 
 
N=3 Unilateral 
FCA (50%) 
N=2 
Aortic/cervical 
arteriopathy (33%) 
N=1 Bilateral 
arteriopathy 
without collaterals 
(16%) 
 
N/a 
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Table 3-5: Characteristics of the population studied prospectively. 
Focal neurological deficits included hemiparesis, facial weakness and hemisensory loss. 
Diffuse neurological deficits included neurocognitive dysfunction, personality changes and 
concentration difficulties. M=male; F=Female; TCA=Transient cerebral arteriopathy; 
FCA=Focal cerebral arteriopathy; PACNS=primary angiitis of the central nervous system; 
ESR=erythrocyte sedimentation rate; CRP=C-reactive protein; MTHFR= Methylene-
tetrahydrofolate reductase; PVA=Post varicella arteriopathy; N/a=not applicable. P values 
were calculated using Fisher’s exact test for categorical data and Mann Whitney U for 
continuous variables. P-values of less than 0.05 (two sided) were regarded as significant. 
 
 
ESR mm/h (median, range) 
(normal range 0-10 mm/h) 
15 (1-20) mm/h 10 (1-25) mm/h 0.478 
CRP mg/L (median, range) 
(normal range <10 mg/L) 
10 (3-20) mg/L 5 (3-10) mg /L 0.561 
Treatment    
Aspirin 2 (100%) 6 (100%) 1 
Anticoagulation 
(heparin/warfarin) 
2 (100%) 1 (16%) 0.1 
Corticosteroids 0 (0%) 0 (0%) 1 
Cyclophosphamide  0 (0%) 0 (0%) 1 
Surgical revascularization 0 (0%) 0 (0%) 1 
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Table 3-6: Imaging findings for population studied prospectively. 
MRI= magnetic resonance imaging; MRA=magnetic resonance angiography. P values were 
calculated using Fisher’s exact test for categorical data and Mann Whitney U for 
continuous variables. P-values of less than 0.05 (two sided) were regarded as significant 
 
 
3.6.2 Circulating endothelial cells track endothelial injury in childhood 
AIS recurrence 
 
Levels of peripheral blood CEC were significantly higher in 46 children with AIS and 
cerebral/cervical arteriopathy (median count 40/ml, range 0-736) compared to 20 healthy 
controls (median count 24/ml, range 0–60) in p=0·03 (figure 3-6A).  The CEC count in the 
MRI    
Multifocal  and bilateral 
lesions 
2 (100%) 1 (16%) 0.1 
MRA    
Multifocal and bilateral 
lesions 
2 (100%) 1 (16%) 0.1 
Proximal lesions 2 (100%) 6 (100%) 1 
Distal lesions 2 (100%) 0 (0%) 0.03 
Anterior circulation only 0 (0%) 4 (66%) 0.42 
Posterior circulation only 0 (0%) 2 (33%) 1 
Anterior and posterior 
circulation 
2 (100%) 0 (0%) 0.03 
Collaterals 1 (50%) 0 (0%) 0.25 
Catheter angiography(total 
patients) 
2 (100%) 1 (16%) 0.1 
Multifocal and bilateral 
lesions 
2 (100%) 0 (0%) 0.33 
Anterior and posterior 
circulation 
2 (100%) 0 (0%) 0.33 
Collaterals 1 (50%) 0 (0%) 1 
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10 children with AIS recurrence was significantly higher at 120/ml (64-732) compared to 
32/ml (0–64) in the 36 children with no recurrence (p = 0.0001); 24/ml (0–60) in 20 child 
controls (p=0·0001); and in 10 children with cerebral AVM (p=0.0002) (figure 3-6B). There 
were no significant differences between CEC in children with AIS and a single event 
compared to controls (p= 0.188) and children with cerebral AVM (p=0.117). 
 
The study population was then considered into 2 groups based on arteriopathy progression 
(progression of previously identified arterial disease; new arterial disease defined as 
involvement of previously unaffected vessels; new arterial occlusion in the presence of other 
arterial wall changes). Figure 3-7 shows the differences between CEC counts in children 
with progressive arteriopathy (n=14) median 92/ml (40-736) compared to those children 
with no progressive arteriopathy (n=32) median 24/ml (0-60), p=0.0001 and healthy controls 
24/ml (0-60), p=0.0001. Patients were also considered in two groups based on the possible 
inflammatory nature of the arteriopathy: the group of “presumed” inflammatory 
arteriopathies (TCA/PVA/PACNS) and the “presumed” non-inflammatory arteriopathies 
(moyamoya, dissection, unclassified). Twenty four children were included in the first group 
with the remaining 22 in the second group. Median CEC count in the presumed 
inflammatory arteriopathy group was 36 (0-736) cells/ml compared to a median of 64 (0-
392) cells/ml in the presumed non inflammatory arteriopathy group (p=0.320; figure 3-8).  
 
To ascertain the statistical power of CEC as a test to detect differences between study groups 
given the small number of healthy controls recruited a retrospective power calculation was 
conducted. Based on a sample size of 20 healthy control children, a mean CEC of 30 
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cells/ml for the control group and mean CEC of 70 cells/ml for the group of children with 
AIS, SD 18 cells/ml and an observed value of p=0.03 revealed a power of 90% for this 
study. 
 
The phenotype of the 2 children with the highest CEC counts (736 cells/ml and 392 cells/ml) 
is described below:  
Case 1. A healthy 14-year-old male with no history of trauma or infection presented with 
acute left hemiparesis secondary to right basal ganglia infarct and evidence of right MCA 
focal arteriopathy. Additional investigations were normal (echocardiogram, CRP, ESR, 
antinuclear antibodies, antineutrophil cytoplasmic antibodies, anticardiolipin antibody, lupus 
anticoagulant, complement, immunoglobulins, varicella zoster virus serology, and 
thrombophilia screening) and CSF revealed no pleocytosis or presence of oligoclonal bands. 
He was then started on aspirin therapy. Nine months later he represented with a right sided 
hemiparesis. Repeat MRI brain revealed left posterior lentiform nucleus, left thalamus, right 
caudate and periventricular region white matter lesions. Vascular imaging including MRA 
and conventional angiography revealed arteriopathy with irregular areas of stenosis and 
dilatation of the left common and lateral segment of the left internal carotid, both of the 
anterior cerebral and middle cerebral arteries proximally and distally and posterior 
circulation involvement without dissection or collaterals. On suspicion of cerebral vasculitis 
and severe progression of arteriopathy with multiple recurrent strokes, he was treated with 
IV methylprednisolone (30 mg/kg, 3 days) followed by prednisolone (1 mg/kg initially, 6 
month wean) and monthly cyclophosphamide (500 mg-750 mg/m2 per dose; total of 6 
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doses). At 18 months, repeat MRI brain showed maturation of the previously noted infarcts 
and no new lesion. 
Case 2. A 3 year old boy with a history of mild fine and gross motor skill developmental 
delay presented with acute right hemiparesis secondary to left MCA infarction. Vascular 
imaging including MRA and conventional angiography revealed stenosis of the left internal 
carotid artery and left proximal MCA. Additional investigations were normal 
(echocardiogram, CRP, ESR, antinuclear antibodies, antineutrophil cytoplasmic antibodies, 
anticardiolipin antibody, lupus anticoagulant, complement, immunoglobulins, varicella 
zoster virus serology, and thrombophilia screening). His arteriopathy was best classified as 
FCA and he was started on aspirin. Four months later he re-presented with a new episode of 
right sided hemiparesis and seizures. Repeat imaging revealed progression of the 
arteriopathy in the left ICA and MCA both in length and severity and new involvement of 
the A1 segment; normal posterior circulation no dissection or collaterals identified. 
Anticoagulation with warfarin was added to his therapy. He subsequently had 4 further 
episodes of acute neurological presentation associated with AIS recurrence and further 
arteriopathy progression (new stenosis of the right ICA, MCA and vertebral arteries 
irregularity) suggesting a multifocal vasculopathy. Two years following his initial 
presentation he successfully underwent an EC-IC by pass and remains currently stable.  
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Figure 3-6: Circulating endothelial cells (CECs) non-invasively track ongoing endothelial 
injury in children with recurrent arterial ischaemic stroke (AIS).  
(A) CEC were significantly higher in children with AIS and cerebral/cervical arteriopathy 
compared to healthy controls, p=0·03. CEC counts for children with recurrent AIS are 
marked in red. (B) CEC count in children with recurrent AIS was significantly higher 
compared to children with no recurrence, p = 0.0001; children with cerebral arterio-venous 
malformation (AVM), p=0.0002; and child controls, p=0.0001. The Kruskal-Wallis test 
followed by the Mann-Whitney U test was used to examine differences between the study 
groups. *P<0.05, **P< 0.005, **P< 0.0005 (two sided).  
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Figure 3-7: Circulating endothelial cells (CECs) in children with progressive arteriopathy 
and arterial ischaemic stroke (AIS).  
CEC were significantly higher in children with AIS and cerebral arteriopathy progression 
compared to those with no progressive arteriopathy (p=0.0001) and healthy controls 
(p=0·0001. The Kruskal-Wallis test followed by the Mann-Whitney U test was used to 
examine differences between the study groups. *P<0.05, **P< 0.005, **P< 0.0005 (two 
sided).  
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Figure 3-8: Circulating endothelial cells (CECs) in children with presumed inflammatory 
cerebral arteriopathy and arterial ischaemic stroke (AIS).  
Focal cerebral arteriopathy, post varicella arteriopathy and primary central nervous system 
vasculitis were considered as inflammatory arteriopathies. Moyamoya arteriopathy, arterial 
dissection and other vasculopathies were considered non-inflammatory. There were no 
significant differences in CEC between children with AIS and presumed inflammatory 
cerebral arteriopathy (n=24) and those with presumed non-inflammatory arteriopathy 
(n=22; p=0.375) and healthy controls, p=0·05. The Kruskal-Wallis test followed by the 
Mann-Whitney U test was used to examine differences between the study groups.  
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3.6.3 Longitudinal changes in CEC in children with arterial ischaemic 
stroke recurrence and cerebral arteriopathy 
 
 
For 8 children CEC were prospectively assessed at initial presentation with AIS and at latest 
follow up of median 12 months (9-18 months). Six of these children had a monophasic 
disease course with no recurrence following the initial event and were treated with aspirin 
alone. CEC at presentation for these 6 children were 36 (8-40) cells/ml and at follow up 24 
(0-32) cells/ml (p=0.1198). For 2 children there was clinical AIS recurrence associated with 
cerebral arteriopathy progression. One child had recurrence 6 months after the initial AIS 
while the other child had 2 recurrences at 2 and 8 months following initial presentation. The 
CEC counts for these children with AIS recurrence was raised at 180 (120-240) cells/ml at 
presentation and remained high at 186 (140-232) cells/ml at 12 months follow up (figure 3-
9). These two children were treated with aspirin and additional anticoagulation (heparin and 
warfarin) following recurrence.  
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Figure 3-9: Prospective changes in circulating endothelial cell (CEC) count in 8 children 
with arteriopathy and arterial ischaemic stroke (AIS).  
CECs at presentation for 6 children with a monophasic disease course were 36 (8-40) 
cells/ml and at follow up 24 (0-32) cells/ml. For 2 children there was clinical AIS recurrence 
associated with cerebral arteriopathy progression (shown in red). The CEC counts for these 
children was raised at 180 (120-240) cells/ml at presentation and remained high at 
184(136-232) cells/ml at 12 months follow up. 
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3.6.4 Logistic regression analysis of CEC for AIS recurrence 
 
Logistic regression analysis was used to examine the relationship of CECs to AIS 
recurrence. Table 3-7 gives the unadjusted odds ratios, and odds ratios adjusted for common 
confounding factors such as age and gender. As the time from recent AIS event to blood 
sampling was shorter in the group of children with recurrent AIS (median 7, range 6-13 
months) compared to those with a single event (median 11, range 6-24 months) and could 
affect the relationship of CEC to the primary outcome of AIS recurrence, this parameter was 
also examined in the regression analysis. CECs were significantly associated with AIS 
recurrence in the unadjusted analysis (OR 2·238; 95% CI 2·060-2·445, p= 0.005) and this 
association remained significant in the adjusted analysis (OR 2·021; 95% CI 2·004-2·038, 
p= 0.016. 
 
Table 3-7: Unadjusted and adjusted odds ratios by multivariable logistic regression 
analysis for arterial ischaemic stroke recurrence (AIS). 
Adjusted odd ratios for age/gender/time from AIS to evaluation; OR=odds ratio; 
CI=confidence intervals. P<0.05 was considered significant. 
 
Biomarker            Unadjusted  
 
  
  OR        95%CI               P 
Adjusted (age/gender/time from    
AIS to evaluation) 
 
  OR          95%CI                 P 
Circulating 
endothelial cells 
(CECs) 
2.438   2.060-2.645        0.005 2.021      2.004-2.038         0.016     
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3.6.5 Test characteristics of CEC for identification of children at risk of 
AIS recurrence 
 
On the basis of this multivariable analysis demonstrating that high CECs strongly associated 
with recurrent AIS, the test characteristics of CECs for identification of AIS recurrence by 
plotting ROC curves were then examined. The ROC curve for CECs at varying definitions 
of positivity is shown in figure 3-10. ROC analysis for CECs as a diagnostic test for 
identification of recurrence was significant with an AUC 0·98, SE 0·01 and 95% CI of 0·95-
1·000, p=0·0001. The full test characteristics of CECs for identification of AIS recurrence 
are summarized in table 3-8. We then considered the radiological features (arterial occlusion 
and/or arteriopathy progression) predicting AIS recurrence described by Braun and 
colleagues (Braun et al. 2009) and examined whether the additional assessment of CECs 
increased the sensitivity and/or specificity of identifying children with recurrence (table 3-8). 
A pre-test probability for AIS recurrence was based on a childhood AIS recurrence rate of 
19% as reported in previous studies (Fullerton, Wu, Sidney, & Johnston 2007). Considering 
the Braun et al. radiological criteria alone, the post-test probability for correctly identifying 
patients with recurrence within this cohort was 67% (95% CI 44-79%). The combination of 
these radiological criteria and a CEC count cut off of > 64 cells/ml (above the upper limit of 
healthy control CEC counts) resulted in a post-test probability of 86% (95% CI 55-94%). 
Thus, inclusion of the CEC count enhanced the predictive potential of the existing 
radiological criteria for identification of those at risk of AIS recurrence. 
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Figure 3-10: Receiver operator characteristic (ROC) curve for circulating endothelial 
cells (CEC) as a diagnostic test for arterial ischaemic stroke (AIS) recurrence.  
Definitions of test positivity were considered at varying levels of CEC counts as shown here.  
ROC analysis was significant with area under the curve (AUC) of 0·98, SE 0·01 and 95% CI 
of 0·95-1·000, p=0·0001. P-values of less than 0.05 (two sided) were regarded as significant.  
 
 
 
 
 
0 25 50 75 100
0
25
50
75
100
125
100% - Specificity%
S
e
n
s
it
iv
it
y
 1
0
0
%
Definition of test positivity- Circulating 
endothelial cells /ml: 
1. >4     
2. >12  
3. >20  
4. >28   
5. >36  
6. >42  
7. >50  
8. >58  
9.  >62 
10.>65 
11.>78 
12.>90 
13. >106 
14. >124 
15. >139 
16. >191 
17. >312 
18. >564  
AUC 0·98 
SE 0·01 
P=0·0001 
 145 
 
 
 
Table 3-8: Test characteristics of circulating endothelial cells (CEC) for identification of 
arterial ischaemic stroke (AIS) recurrence.  
LR+ = Likelihood ratio for a positive test result LR-=Likelihood ratio for a negative test 
result CI confidence intervals CEC=Circulating endothelial cells. Pre-test probability was 
based on a childhood arterial ischaemic stroke (AIS) recurrence rate of 19% as per previous 
publications( Fullerton et al. 2007). 
 
 
 
 
 
CEC 
level 
Cutoff Sensitivity% 95% CI Specificity% 95% CI LR+ LR- 
Post-test 
probability 
% 95%CI 
> 4 100 72-100% 17 7-34% 1.2 0 22% 18-25% 
> 12 100 72-100% 29 15-46% 1.4 0 25% 20-26% 
> 20 100 72 100% 34 19- 52% 1.5 0 26% 21-31% 
> 28 100 72-100% 50 34-69% 2.06 0 32% 24-39% 
> 36 100 72-100% 58 42 -76% 2.4 0 36% 27-42% 
> 42 100 72-100% 69 54-85% 3.22 0 43% 31-53% 
> 50 100 72-100% 74 57-88% 3.60 0 47% 33-59% 
> 58 100 72-100% 75 60-90% 4.00 0 48% 34-63% 
> 62 100 72-100% 86 73-97% 7.20 0 63% 42-81% 
> 65 100 72-100% 91 81-99% 12 0 72% 47-85% 
> 67 81 48- 98% 94 81- 99% 16.20 0.2 75% 48-92% 
> 78 80 39- 94% 97 85- 99% 29 0.21 86% 52-97% 
> 90 80 39 -94% 100 90- 100% Infinity 0.2 100% 49-100% 
> 106 70 31-89% 100 90 -100% Infinity 0.3 100% 46-100% 
> 124 50 17-77% 100 90-100% Infinity 0.5 100% 35-100% 
> 139 40 11-69% 100 90- 100% Infinity 0.6 100% 32-100% 
> 191 30 6- 61% 100 90-100% Infinity 0.7 100% 26-100% 
> 312 20 2- 52% 100 90- 100% Infinity 0.8 100% 19-100% 
> 564 10 0.2-41% 100 90 -100% Infinity 0.9 100% 10-100% 
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Table 3-9: Circulating endothelial cell counts (CECs) and radiological features identify 
high risk profile of children at risk of arterial ischaemic stroke (AIS) recurrence. 
 Circulating endothelial cell (CEC) testing was considered positive at a cut off of > 64 
cells/ml of whole blood (above the upper limit of CEC counts for healthy controls studied 
here). Pre-test probability was based on a childhood arterial ischaemic stroke (AIS) 
recurrence rate of 19% as per previous publications (Fullerton, Wu, Sidney, & Johnston 
2007). LR+=Likelihood ratio for a positive test; LR-=likelihood ratio for a negative test; 
CI=Confidence interval. † Radiological criteria: arterial occlusion and/or arteriopathy 
progression (Braun et al. 2009). 
 
Profile/test Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
Post-test 
probability 
(95% CI) 
Radiological 
criteria† (Braun, 
et al. 2009) 
100 (68-
100)% 
88 (65-90)% 8.33 (3.34-16) 0 (0-0.79)     67 (44-79)% 
CECs alone 100 (68-
100)% 
90 (75-96)% 10 (3.65-21) 0 (0-0.77) 70 (46-83)% 
CECs and  
radiological 
criteria† (Braun, 
et al. 2009) 
100 (68-
100)% 
96 (81 -99)% 25 (45.05-70) 0 (0-0.72) 86 (55-94)% 
 147 
3.7 Discussion 
 
 
In this cross sectional study of a group of children with AIS and cerebral arteriopathy, CEC 
counts were identified as a biomarker that tracks endothelial injury and differs significantly 
between children with recurrent AIS and those with a monophasic disease course. CECs are 
a non-invasive surrogate marker of vascular injury that may be useful to stratify stroke 
recurrence risk in children with AIS and cerebral arteriopathy. 
 
AIS in children is increasingly recognised as an important cause of lifelong morbidity, with 
personal, social and economic consequences (Ganesan et al. 2000; Goldenberg et al. 2009; 
Gordon, Ganesan, Towell, & Kirkham 2002; MacGregor, Curtis, & Mayank 2000). Since 
the advent of noninvasive cerebral arterial imaging, in particular MRA, it has become 
evident that cerebral arterial abnormalities are found in between 50 and 80% of these 
children (Ganesan et al. 2003; Mackay et al. 2011). The morphology and course of these 
cerebral/cervical arteriopathies are the most important determinants of recurrence thus far 
identified in childhood AIS (Fullerton, Wu, Sidney, & Johnston 2007; Ganesan et al. 2006). 
Current classifications are radiological, although it is well recognized that MRA and catheter 
angiography have limitations in identifying and differentiating between distinct pathological 
entities (Aviv et al. 2006; Bernard et al. 2012; Eleftheriou et al. 2010; Sebire, Fullerton, 
Riou, & deveber 2004). In this study patients were classified based solely on AIS recurrence 
(corroborated both clinically and radiologically) as this is a robust, verifiable and clinically 
important event. Furthermore, progression of cerebral arteriopathy and AIS recurrence is 
most likely multifactorial but the degree and extent of involvement of inflammation, 
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endothelial injury and hyper-coagulability predisposing to and/or exacerbating acute 
ischaemic brain injury and accelerating the progression of cerebral arterial disease is largely 
undefined. As a result, distinguishing between patients likely to have a static or progressive 
course on radiological and clinical grounds at initial presentation remains challenging 
leading to variation in current management approaches. In addition, secondary preventative 
treatments are empiric, rather than specifically targeted to underlying disease (Monagle et al 
2004; Roach, 2008; Royal College of Physicians, 2004). 
 
CECs are matured differentiated cells that are shed from the vessel wall as a result of 
pathophysiologic conditions that affect the endothelium (Blann et al. 2005; Woywodt et al. 
2003). CEC are present at very low levels in healthy subjects, representing physiological 
endothelial turnover, whereas elevated levels have been reported in several pathologic 
situations including cardiovascular diseases, immune-mediated disorders, infectious 
diseases, cancer and systemic vasculitis (Blann et al. 2005; Sabatier et al. 2009). This study 
now suggests that elevated CECs, and therefore persistence of endothelial injury vary 
between children with single and recurrent AIS. CECs could therefore be an attractive 
candidate biomarker to detect those at risk of recurrent AIS, a finding that is consistent with 
the strong correlation between CECs and disease activity in patients with systemic vasculitis 
(Clarke et al. 2010; Woywodt et al. 2003). Of note the CEC count, even when corrected for 
time of sampling from AIS event as this could be an important confounding factor, remained 
a significant predictor of AIS recurrence in a multivariable logistic regression model. 
Furthermore, in keeping with previous studies in systemic vasculitis, the few children 
studied (n=4) who were receiving immunosuppression at the time of AIS recurrence were 
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able to mount a high CEC response, indicating that CECs are a sensitive marker of 
endothelial injury and disease activity irrespective of therapy. Treatment would be in general 
expected to modify these biomarkers but when this is failing and endothelial injury occurs 
despite treatment, this can still be detected using CEC counts. 
 
 
The findings reported here have several implications. First, they suggest that despite the wide 
spectrum of presentations of this heterogeneous condition and the lack of conventional 
circulating acute phase reactants, indices of endothelial injury can for the first time clearly 
separate disease groups with regards to AIS recurrence. In particular in this cross- sectional 
study CEC count was complementary to current radiological criteria in identifying patients 
with AIS recurrence. The preliminary prospective data presented herein additionally support 
the prognostic role of CEC. These observations if validated in larger prospective cohorts 
may enable a stratified approach, targeting therapy at those children with high risk of 
recurrence. Furthermore, our ability to study the endothelium non-invasively by studying 
CECs provides us with invaluable insights into the pathophysiology of childhood AIS. This 
could potentially at the individual patient level enable therapeutic options to integrate the 
predominant pathogenic mechanism.  Those children for instance with evidence of ongoing 
endothelial activation and injury may benefit from immunosuppressive protocols (such as 
corticosteroids and cyclophosphamide) employed in systemic vasculitis and more recently in 
small vessel vasculitis of the brain whilst this may not be the case for those with a 
monophasic disease course (Eleftheriou et al. 2009; Hutchinson et al. 2010). 
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In this thesis immunomagnetic bead extraction was used to detect and quantify CEC. Owing 
to CEC scarcity, this is the most widely used method for CEC enumeration based on a first 
step of enrichment by immunomagnetic separation followed by visual counting using a 
fluorescence microscope (Erdbruegger, Haubitz, & Woywodt 2006; Woywodt et al. 2006). 
Notably, the consensus definition of CECs and a standardized protocol by Woywodt et al. 
have led to good agreement among laboratories with regard to CEC levels in normal 
populations (Woywodt et al. 2006). This is also reflected herein in the little variation on 
CEC counts observed between different blinded observers counting CEC in the same patient 
sample. However, the identification and counting of CECs using fluorescence microscopy 
remains laborious and requires operator training. To date, flow cytometry measurement, the 
main alternative approach for CEC measurement, has been rather disappointing regarding 
accuracy of CEC quantification, although clearly is attractive since it would allow more 
detailed multi-parametric phenotyping of CECs. For instance the normal values for CECs 
derived by flow cytometry vary widely and in most cases, are higher (sometimes by orders 
of magnitude) than the values obtained using immunomagnetic bead extraction (Sabatier et 
al. 2008). Furthermore, there is no consensus regarding the combination of markers used to 
identify CEC.  One other major issue is whether or not flow cytometry is sensitive enough to 
count cells in blood at low frequency. Clarke et al. recently reported on a study comparing 
immunomagnetic bead extraction and flow cytometry for the quantitative detection of CECs 
in systemic vasculitis (Clarke et al. 2008).  Appropriate gating was identified as an important 
factor that needs further optimisation in flow cytometric protocols particularly in view of the 
fact that CECs often represent denucleated carcasses and parts of cells, hence not 
surprisingly will be smaller than HUVECs and appear in the mononuclear region of 
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FSC/SSC gating (Clarke et al. 2008).  Additionally the use of lysing buffer may result in 
reduced recovery of CECs particularly in conditions such as systemic vasculitis where these 
cells are probably too vulnerable to survive after the flow cytometry preparation procedure 
(Clarke et al. 2008). Interestingly, Widemann et al. recently described a new hybrid assay for 
CEC detection that combines pre-enrichment of CD146+ circulating cells using magnetic 
nanoparticles and multiparametric flow cytometry analysis (Widemann et al. 2008).  This 
promising approach combines a first step of enrichment that is compatible with CEC scarcity 
in peripheral blood, followed by flow cytometry of enriched cells that uses a multiparametric 
characterization of CEC and may be an automated counting alternative to microscopic 
observation (Widemann et al. 2008).  It would be of considerable interest to adapt a similar 
technique and study the CEC phenotype in the circulation of children with AIS. This 
approach is additionally particularly attractive for large-scale clinical studies, to further 
establish the clinical value of CECs in vascular disorders.  
 
Another important issue is whether the vascular bed origin of CECs varies according to the 
disease process and can be established using specific antigens. In addition to the structural 
heterogeneity, the endothelium displays different functions associated with the expression of 
specific surface antigens (Aird 2007; Chi et al. 2003; Sabatier et al.  2009). For instance 
CD36, a maker of microvasculature, has been used to attempt to document the anatomical 
origin of CEC at least in terms of size of vessel of origin (Lin et al. 2000; Sabatier et al. 
2009; Solovey et al. 1997). In addition, a number of other constitutive or inducible antigens 
such as E-selectin, CD31, VCAM-1 or tissue factor have been used to identify pro-
inflammatory and pro-coagulant activation of endothelial cells (Sabatier et al. 2009). 
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Assuming that CECs are representative of the vessel they derived from, analysis of their 
phenotype using new approaches of flow cytometric identification discussed above may 
provide important insights not only on their anatomical origin of these cells (cerebrovascular 
bed, peripheral endothelium etc.) but also on their biological role. The precise origin of CEC 
in this study however remains unclear.  
 
This study has a number of limitations. It is possible that the intergroup differences may 
reflect the extent of endothelial injury relating to the bilateral multifocal arteriopathy seen in 
the group of children with AIS recurrence rather than recurrence risk per se. It will be of 
considerable interest to establish the specificity of these findings by comparison with 
patients with AIS without arteriopathy (who may have small vessel vasculitis of the brain as 
suggested by some authors), and in relation to other well-established risk factors such as 
cardiac disease. This study initially focused on children with AIS and cerebral arteriopathy 
specifically in order to inform the controversy surrounding the role of persistent vascular 
inflammation contributing to progression of arteriopathy in this group. Secondly, no 
cerebrovascular biopsies were performed to confirm persistent cerebral vasculitis, but this is 
reflective of current paediatric clinical practice where cerebro-arterial or other CNS biopsy is 
rarely undertaken (Benseler et al. 2006; Eleftheriou & Ganesan 2009). Of note, the time 
from recent AIS to evaluation was shorter in the group of children with recurrence compared 
to those with a single event. To control for this potentially confounding factor however a 
multivariable logistic regression was performed that showed CEC remained significantly 
associated with AIS recurrence after adjustment for this variable. Furthermore, longer 
duration of follow up is needed to ensure non recurrence of AIS in all patients studied. The 
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sample size of this study was small and restricted by patient numbers in this single centre 
cohort and referral bias cannot additionally be excluded. The small sample size also limits 
the interpretation of the logistic regression analysis and ROC analysis results. Additional 
criticism is that the ROC curve extends beyond the clinically relevant area of potential 
clinical interpretation while the AUC does not incorporate the pre-test probability of a 
disease. Lastly, further prospective studies to confirm or refute these observations are now 
needed and will require multicentre collaboration. 
 
In conclusion, these data suggest that persistent endothelial injury could be an important 
mechanism underlying recurrent childhood AIS. The study of CECs provided a window to 
the activated endothelium in vivo and could lead to further understanding of stroke 
pathophysiology in children. Prospective validation of these findings is now required to 
firmly establish the role of these biomarkers as prognostic markers in childhood AIS and 
cerebral arteriopathy. 
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4 Circulating microparticles in children with 
arterial ischaemic stroke  
4.1 Summary 
 
 
Background/objective: Circulating microparticles (MP) are membrane derived vesicles 
released from cells (endothelial cells, platelets and leucocytes) in response to activation or 
apoptosis and are rich in procoagulant phospholipids, particularly phosphatidylserine (PS). 
Detailed profiling of these blood endothelial and other cellular markers may adumbrate the 
pathogenesis of arterial ischaemic stroke (AIS) in children or enable determination of the 
risk for AIS recurrence. In this chapter MP profiles in children with cerebral arteriopathy and 
AIS recurrence were compared to those children who had a single event.  
Methods: Single centre cross-sectional study of 46 children with AIS and cerebral 
arteriopathy matched with 10 paediatric controls and 10 children with cerebral arteriovenous 
malformation (disease control group). AIS recurrence was defined as new acute neurological 
deficit with radiological evidence of further cerebral infarction. Microparticles were 
analysed using flow cytometry. Results were expressed as median and range.  
Results: Total circulating Annexin V+ (PS rich) MPs were significantly higher in those with 
AIS recurrence compared to those children with no recurrence, p=0·002; healthy controls, 
p=0·0001 and children with cerebral AVM, p=0·0001. These MPs were of endothelial, 
platelet, neutrophil origin and monocytic origin. Tissue factor expressing MPs were elevated 
in children with recurrence compared to those with a single event, p=0.0040; healthy control 
children, p=0·0001; and children with cerebral AVM, p=0·0030. Monocytic MP also 
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expressed P-selectin glycoprotein ligand-1 (PSGL-1) that facilities TF transfer onto activated 
platelets and thus further promotes thrombus formation. 
Conclusions: Circulating MP profiles reflect distinct phenotypes of childhood AIS with 
cerebral arteriopathy and are markers of vascular pathology, platelet activation and 
thrombotic propensity relating to AIS recurrence. 
 
4.2 Introduction 
 
In chapter 3 it was established that CEC non-invasively track endothelial injury associated 
with AIS recurrence and effectively differentiate between children with progressive and non-
progressive disease courses. In acute AIS the mechanisms of brain ischaemia are however 
not only critically dependent on endothelial activation and vascular injury but also involve 
platelet activation, leukocyte migration and release of several soluble inflammatory 
mediators triggered during the ischaemic insult (Danton and Dietrich 2003; Dougherty et al. 
1977). Recruitment of platelets subsequently results in activation of the coagulation cascade 
initiated mainly by tissue factor and leading to formation of fibrin (Lane et al. 1983). In 
physiological conditions regulatory mechanisms prevent thrombus from forming, but in 
pathological processes these mechanisms are overwhelmed and thromboses develop (Danton 
& Dietrich 2003; Lane et al. 1983). The relative contribution of these mechanisms to the 
dynamic and structural formation of a thrombus as the inciting event of AIS in children 
remains unclear however. Thus gaining some insight into the activation state of other cells 
besides endothelial cells that may play a pivotal role in disease pathogenesis and childhood 
AIS recurrence is crucial and may help us improve recurrence risk stratification strategies as 
well as develop more targeted therapies.  
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Cell activation and apoptosis is associated with the shedding of fragments from the plasma 
membrane termed microparticles (MPs) (Fadok et al. 2000; Fadok et al. 2001; Hugel et al. 
2005; Morel et al. 2004). When cells are subjected to pro-inflammatory or pro-apoptotic 
stimuli there is a swift egress of negatively charged aminophospholipids to the outer leaflet 
of the plasma membrane, membrane budding and ultimately MP release (Hugel et al. 2004; 
Morel et al. 2006). MPs are thus cytosol-containing vesicles (100 nm to 1 µm in diameter) 
comprised of bi-lipid membrane with an antigen distribution representative of the parent cell 
of origin, and enriched with procoagulant aminophospholipids, particularly 
phosphatidylserine (PS), in their exoplasmic leaflet (Dignat-George & Boulanger 2011; 
Leroyer et al. 2010; Morel, Toti, Hugel, & Freyssinet 2004). The protein content of MPs 
reflects that of the cell membrane from which they are released allowing us to differentiate 
MP of endothelial, platelet and leukocyte origin (Dignat-George & Boulanger 2011; Leroyer 
et al. 2010; Morel, Toti, Hugel, & Freyssinet 2004). Besides the cellular origin the nature of 
the trigger may also influence the number and phenotype of MPs. MPs have recently 
received attention as potent bioeffective vectors with multiple roles in inflammation, 
endothelial activation and thrombosis (Dignat-George & Boulanger 2011; Leroyer et al. 
2010; Morel, Toti, Hugel, & Freyssinet 2004). The following sections provide an overview 
of MP formation, analytical methods and their pathophysiological roles in health and 
disease. 
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4.2.1 Mechanisms of microparticle formation 
 
Although initially met with scepticism, the existence of a large number of extracellular 
vesicles including exosomes, activation- or apoptosis-induced microparticles and apoptotic 
bodies is well established (György et al. 2011). These structures are released via separate 
mechanisms and have different biological roles (György et al. 2011). The key features of 
cellular microparticles that distinguish them from these other microvesicles are summarised 
in table 4-1. 
 
Our current understanding of the mechanism underlying the process of MP formation and 
release is based on a series of in vitro studies examining MP formation following activation 
of cells (endothelial, neutrophil, platelets and leukocytes) in response to a variety of stimuli 
(Dignat-George & Boulanger 2011). Combes et al. were amongst the first to describe the 
release of endothelial microparticles (EMP) from HUVEC in response to TNF-α stimulation 
(Combes et al. 1999).  
 
Under physiological conditions aminophospholipids such as phosphatidylserine (PS) and 
phosphatidyl-ethanolamine (PE) are specifically enriched in the inner leaflet, whereas 
phosphatidylcholine (PC) and sphingomyelin are segregated in the external one (Hugel et al. 
2005). The maintenance of lipid asymmetry relies on an adenosine triphosphate (ATP)-
dependent transporter, the aminophospholipid translocase, governing inward (flip) or 
outward (flop) translocation that specifically and rapidly conveys PS and PE from the outer 
to the inner leaflet and that is inhibited by calcium ions (Hugel et al. 2005; Seigneuret et al. 
1984; Zwaal and Schroit 1997). Membrane remodelling and disruption of the basal 
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membrane lipid asymmetry is a central event to cells undergoing activation or apoptosis 
(Hugel et al. 2005; Seigneuret, Zachowski, Hermann, & Devaux 1984; Zwaal & Schroit 
1997). With an aim of providing a pro-coagulant surface transporters facilitate the rapid 
egress of PS at the outer leaflet in cells undergoing apoptosis (Hugel et al. 2005; Seigneuret, 
Zachowski, Hermann, & Devaux 1984; Zwaal & Schroit 1997). Translocators include 
members of the floppase family (transporters including the ATP-binding cassette transporter 
A1, ABCA1), and the calcium-dependent scramblase that facilitate bidirectional movement 
between membrane leaflets (Morel et al. 2010).  Cell stimulation results in increased 
cytosolic [Ca2+] concentration and the rapid translocation of aminophospholipids to the 
outer leaflet, while flippase activity is reduced and there is an increased floppase/ scramblase 
activity favouring phospholipid exchanges between the two leaflets (Morel, Toti, Jesel, & 
Freyssinet 2010). Surface tension and membrane budding ultimately lead into MP shedding 
(Morel, Toti, Jesel, & Freyssinet 2010).  
 
Lipid rafts may also have a role in membrane responses to activation and apoptosis (Del 
Conde et al. 2005b; Kunzelmann-Marche et al. 2002; Simons and Toomre 2000). Rafts are 
functional transbilayer domains that serve as organizing centres for the assembly of 
particular proteins and lipids as well as influence membrane fluidicity and membrane protein 
trafficking (Simons & Toomre 2000). PS exposure is significantly reduced after raft 
disruption and proteins with strong cytoskeleton interactions are not represented as 
frequently in MPs (Davizon et al. 2010; Del Conde et al. 2005b; Kunzelmann-Marche et al. 
2002).  
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Furthermore, a number of studies have recently explored the molecular mechanisms 
governing the release of endothelial derived MP (EMP) in particular. Sapet et al. used gene 
profiling analysis and identified an original pathway induced by thrombin, depending on 
nuclear factor-kB activation, and involving the Rho-kinase ROCK-II activation by caspase 2 
in the absence of cell death (Sapet et al. 2006).  The process involves 2 steps: a first phase 
that follows thrombin binding to its receptor protease-activated receptor-1 (PAR-1) and a 
second phase that relies on transcriptional events mediated by thrombin and involving 
TRAIL/Apo2L, a cytokine belonging to the TNF-α superfamily (Sapet et al. 2006; 
Simoncini et al. 2009). Gene profiling studies additionally identified interleukin-1 and 
interleukin- 1Ra, as additional players of thrombin-induced EMP (Leroyer et al. 2010). 
Thrombin stimulation of human microvascular endothelial cells (HMEC-1) resulted in an 
increase in IL-1R1 expression, a concomitant decrease in IL-1Ra and a low secretion of IL-1 
(Leroyer et al. 2010). Thrombin-induced EMP release was inhibited by specifically silencing 
of IL-1R1 or IL-1 (Leroyer et al. 2010). Furthermore, the engagement of IL-1R1 resulted in 
the recruitment of adaptor proteins TRAF6 (TNF receptor associated protein 6) and IRAQ1 
that activated a signalling pathway leading to the amplification of EMP release by thrombin 
(Leroyer et al. 2010). Lastly, another study showed that p38 mitogen-activated protein 
kinase is a critical pathway in the production of EMP (Curtis et al. 2009).  
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 Exosomes Microparticles Apoptotic 
bodies 
Size range 
 
Approximately 50–
100 nm 
 
100–1,000 nm  1–5 μm 
Mechanism 
of generation 
 
By exocytosis of multi-
vesicular bodies 
 
By budding/blebbing of the 
plasma membrane 
 
By release from 
blebs of cells 
undergoing 
apoptosis 
Isolation Differential 
centrifugation and 
sucrose gradient 
ultracentrifugation, 
100,000–200,000g, 
vesicle density is 1.13–
1.19 g/mL 
Differential centrifugation 
15,000–20,000g 
Established 
protocols are 
essentially 
lacking; most 
studies use co-
culture with 
apoptotic cells 
instead of 
isolating 
apoptotic bodies 
Detection Electron microscopy, 
western blotting, mass 
spectrometry, flow 
cytometry  
Flow cytometry Flow cytometry 
Best 
characterised 
cellular 
sources 
Immune cells and 
tumors 
Platelets, red  and white  
blood cells and endothelial 
cells 
Cell lines 
Markers Annexin V binding, 
CD63, CD81, CD9, 
LAMP1 and TSG101 
Annexin V binding, tissue 
factor and cell-specific 
markers 
Annexin V 
binding, DNA 
content 
Lipid 
composition 
Cheramides, cholesterol Cholesterol Not known 
Intracellular 
storage 
Yes No No 
 
Table 4-1:  Key features of microvesicles. Adapted from Gyorgy et al. (2011)  
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4.2.2 Current methods to identify and enumerate microparticles 
 
Several anticoagulants have been used to collect blood for MP analysis (Yuana et al. 2011). 
Sodium citrate with a concentration of 3.2% or 3.8% is the most widely used anticoagulant 
currently (Jy et al. 2004). Other anticoagulants that have been used include 
ethylenediaminetetraacetic acid (EDTA) a strong chelator of calcium ions, and heparin 
which will preserve extracellular calcium (Aras et al. 2004; Ueba et al. 2008;Yuana, Bertina, 
& Osanto 2011). However, levels of annexin V-positive MPs are not directly comparable in 
blood samples collected in EDTA to those collected in sodium citrate (Connor et al. 2009; 
Yuana, Bertina, & Osanto 2011). In addition, platelets need to be removed from the plasma 
when processing samples for MP analysis in order to avoid platelet activation leading to 
inadvertent production of MPs (Jy, Horstman, Jimenez, & Ahn 2004). Hence MP are usually 
analysed in platelet poor plasma samples (Jy, Horstman, Jimenez, & Ahn 2004). 
Furthermore, cold activation of citrated blood samples has been reported to result in falsely 
elevated levels of (activated) factor VII (FVII) and factor VIII (FVIII) (Favaloro et al. 2004). 
Therefore, the temperature is generally kept at room temperature (20–25°C) for centrifuging 
citrated blood (Jy, Horstman, Jimenez, & Ahn 2004; Yuana, Bertina, & Osanto 2011). 
Furthermore, during centrifugation the use of brakes should be avoided and plasma should 
be carefully collected without disturbing the platelet layer to prevent remixing of the plasma 
with the platelets (Yuana, Bertina, & Osanto 2011). Ideally, plasma is prepared immediately 
after blood collection however from the practical point of view time samples may need to be 
stored prior to analysis (Jy, Horstman, Jimenez, & Ahn 2004; Yuana, Bertina, & Osanto 
2011). During storage blood samples should be maintained at room temperature while 
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mechanical agitation is avoided for reasons discussed above (Jy, Horstman, Jimenez, & Ahn 
2004; Yuana, Bertina, & Osanto 2011).  
 
Flow cytometry has been widely used to quantify MP in clinical studies although a number 
of limitations are recognized (Jy, Horstman, Jimenez, & Ahn 2004; Kim et al. 2002; Lacroix 
et al. 2010a; Yuana, Bertina, & Osanto 2011). Certain properties of MP are used to identify 
and enumerate MP: MPs are vesicles found in platelet-poor plasma, with size ranging for 
0.1–1 l µm and expressing specific antigens of the cell they derived from (Brogan et al. 
2004; Leroyer et al. 2010; Morel, Toti, Hugel, & Freyssinet 2004). Generally, the use of 
beads as an internal standard provides standardized conditions for accurate numeration of 
circulating MPs (Aras et al. 2004; Brogan et al. 2004; Kim et al. 2002). These are calibrated 
polypropylene latex beads that are fluorescent across a range of excitation and emission 
wavelengths. Counting beads are processed as a sample at the same flow cytometry settings/ 
conditions used for the samples (Brogan et al. 2004; Clarke et al. 2010; Hong et al. 2012; 
Shet et al. 2003). The flow cytometer counts the number of beads and/or MPs in the sample 
until the set acquisition time is reached and with these numbers, the concentration of MPs in 
plasma can be calculated (Brogan et al. 2004; Clarke et al. 2010; Hong et al. 2012; Shet et al. 
2003). As far as the flow cytometry settings are concerned, the MP population is defined by 
using beads of 1 μm diameter (Aras et al. 2004; Hong et al. 2012; Kim et al. 2002). These 
calibrated beads define the upper limit of the MP population and help discriminate the MP 
population from platelets (Aras et al. 2004; Hong et al. 2012; Kim et al. 2002). Other 
investigators have more recently used a mixture of fluorescent beads with diameters of 0.5, 
0.9, and 3 μm (Megamix beads) to cover the MP (0.5 and 0.9 μm) and platelet populations 
(0.9 and 3 μm) ranges (Lacroix et al. 2010b).  The majority of MPs expose PS therefore 
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fluorescently labelled annexin V that binds to PS is commonly used to measure the total 
number of MPs with flow cytometry (Brogan et al. 2004; Clarke et al. 2010; Hong et al. 
2012). Of note the binding of annexin V to MPs is influenced by the calcium concentration 
and the membrane PS content (Yuana, Bertina, & Osanto 2011).  In addition, the cellular 
origin of MP can be assessed by staining MPs with relevant monoclonal antibodies (Brogan 
et al. 2004; Clarke et al. 2010; Hong et al. 2012). Considering the heterogeneity of MPs, an 
ideal marker should insure specificity toward one cell type and be expressed whatever the 
potential mechanisms that trigger vesiculation (Brogan et al. 2004; Clarke et al. 2010; Hong 
et al. 2012). 
 
Notably, pre-analytical conditions still represent an important source of variability in the 
analysis of MP (Robert et al. 2009; Yuana, Bertina, & Osanto 2011). The type of instrument, 
instrument settings, and resolution also influence flow cytometric measurements (Robert et 
al. 2009; Yuana, Bertina, & Osanto 2011). Recently, the Vascular Biology group of the 
Scientific and Standardisation Committee (SSC) of the International Society on Thrombosis 
and Haemostasis (ISTH) proposed the use of calibrated beads to standardise the enumeration 
of MPs >0.5 μm by using flow cytometry (Robert et al. 2009). Forty laboratories from 14 
countries participated in the study  using several types of flow cytometer such as 
FACSCalibur, FACSCanto II, and LSRII (all from Becton Dickinson, Le Pont de Claix 
Cedex, France) and EPICS XL, Gallios and FC500 (all rom Beckman Coulter, Paris, France) 
(Robert et al. 2009). In addition Lacroix et al. have recently studied the relative impact of 
different preanalytical parameters on circulating MP and identified the pre-analytical 
processing of the samples from healthy donors, agitation during transportation, time-delay, 
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and centrifugation conditions were identified as the three major parameters that have the 
strongest effects on MP measurement (Lacroix et al. 2012). At present, standardisation of 
pre-analytical and analytical methods for the measurement of MPs remains challenging 
(Robert et al. 2009; Yuana, Bertina, & Osanto 2011). 
 
 
4.2.3 Non flow cytometric methods used to evaluate microparticles  
 
Electron and fluorescence confocal laser scan microscopy have also been used to evaluate 
MP populations (Yuana, Bertina, & Osanto 2011). Electron microscopy (EM) has been 
employed to study the morphology and membrane composition of MPs (Bernimoulin et al. 
2009; Heijnen et al. 1999). In addition staining with immunogold-labelled antibodies can 
provide formation on the antigenic composition of isolated MPs (Bernimoulin et al. 2009; 
Heijnen et al. 1999). Using EM, Bernimoulin et al. for instance were able to show that MPs 
derived from THP-1 cells contain cytoskeletal proteins organised into a complex cytoskeletal 
network (Bernimoulin et al. 2009). Confocal laser microscopy permits identification of 
subsets of MPs based on their antigen expression (Yuana, Bertina, & Osanto 2011). Dale et 
al. employed confocal laser microscopy to characterise platelet MPs (PMPs) (Dale et al. 
2005). These PMPs were 0.3–0.5 μm in diameter and positive for glycoprotein IIb/IIIa, 
glycoprotein Ib, CD9, and PS, but negative for fibrinogen and thrombospondin (Dale, 
Remenyi, & Friese 2005). EM and fluorescence confocal laser scan microscopy in general 
give information on morphological features of MPs (e.g. size, membrane structure, 
cytoskeleton) but the operation of both methods is laborious and they are not suitable for 
direct detection and quantification of MPs in plasma for clinical studies (Yuana, Bertina, & 
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Osanto 2011).  For capture-based assays, wells are coated with an antibody (usually annexin 
V) that specifically binds a subset of MPs from plasma (Nomura et al. 2009; Ueba et al. 
2008). Captured MPs can then be quantified/ characterised by using a second antibody or by 
exploring the functional properties of the captured microparticles, for instance their 
procoagulant activity (Nomura et al. 2009; Ueba et al. 2008). At present however there is 
limited experience with this type of approach. Mass spectrometry (MS)-based proteomic 
analysis provides an opportunity to characterise the protein composition of MPs (Miguet et 
al. 2007; Yuana, Bertina, & Osanto 2011). Generally this method requires extraction, 
separation, trypsin digestion, MS analysis, and identification of proteins and is not yet 
widely used (Miguet et al. 2007; Yuana, Bertina, & Osanto 2011).  
 
 
4.2.4 Microparticles as important thrombotic protagonists 
 
A very important aspect of the role of MP in health and disease is there prothrombotic 
potential (Morel et al. 2006; Piccin, Murphy, & Smith 2007). MPs fulfill a haemostatic 
function under physiological conditions through one of their main defining characteristics, 
the exposure of the anionic aminophospholipid, PS in their surface that provides a platform 
for the assembly and activation of coagulation factors (Piccin, Murphy, & Smith 2007). 
Scott syndrome is a well described inherited haematological disorder characterized by 
impaired transmembrane migration of procoagulant PS and defective MP formation that is 
associated with haemorrhagic complications, thus highlighting the important role of MPs in 
physiological haemostasis (Toti et al. 1996). MPs are protective in case of bleeding but their 
dramatic release could favour thrombotic complications in the arterial or venous circulation 
(Morel et al. 2006; Piccin, Murphy, & Smith 2007). An excess of production MPs could be 
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involved in shifting the homeostatic balance between pro- and anticoagulant forces in favor 
of coagulation (Piccin, Murphy, & Smith 2007). This could be mediated through PS 
exposure providing a surface for the amplification of coagulation enzymes to induce a pro-
thrombotic state (Holme et al. 1998; Sabatier et al. 2002). In addition some MPs carry tissue 
factor (TF), the initiator of the extrinsic coagulation pathway (Zwicker et al. 2011). MPs 
notably constitute the main reservoir of blood-borne TF released from monocytes, 
endothelial cells or vascular smooth cells and fibroblasts (Giesen et al. 1999; Morel et al. 
2006). Cytokines, thrombin, low shear stress, oxidative stress, hyperglycemia, dylipidemia, 
complement activation amongst others induce procoagulant PS exposure and TF induction 
on MPs (Cermak et al. 1993b; Gûrlach et al. 2000; Muhlfelder et al. 1979; Penn et al. 2000). 
TF acts synergistically with PS when expressed by the membrane of stimulated cells to 
initiate coagulation (Mackman et al. 2007; Morel et al.  2006). The actual composition of the 
phospholipid surface on MPs surrounding the TF/FVIIa complex is an essential determinant 
of its activity, with anionic phospholipids greatly potentiating the TF cofactor function even 
if it is marginally expressed (Bach 2006).  
 
This procoagulant potential of MP was first demonstrated by Combes et al. that observed a 
reduction of the clotting time of normal plasma incubated with increasing amounts of 
endothelial derived MP released in vitro (Combes et al. 1999).  The thrombogenic capacity 
of MP was then confirmed by the demonstration that MP triggered TF-dependent thrombin 
formation in vitro and thrombus formation in vivo (Del Conde et al. 2005a; Falati et al. 
2002; Falati et al. 2003). Experimental models have also shown that when thrombosis begins 
there is accumulation of leukocyte-derived MPs harbouring TF activities whereas the level 
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of platelet-derived MPs mostly depends on the extent of platelet stimulation (Falati et al. 
2002; Falati et al. 2003; Gross et al. 2005; Morel et al. 2009; Ramacciotti et al. 2009). 
Notably, Ramacciotti et al. demonstrated significant differences in the involvement of 
leukocyte and platelet MPs in the thrombogenic process (Ramacciotti et al. 2009). In an 
experimental mouse model of venous thrombosis, circulating leukocyte-derived MP levels 
were negatively correlated with the thrombus weight, suggesting their early incorporation 
within the growing thrombus while platelet-derived MPs were positively correlated with the 
thrombus growth (Ramacciotti et al. 2009). Interestingly Hrachovinova et al. demonstrated 
that the infusion of soluble P-selectin results in the generation of leukocyte derived MPs that 
are then able to correct the bleeding diathesis in a mouse mod el of haemophilia A 
(Hrachovinova et al. 2003). Other mechanisms triggered by P-selectin that induce a 
prothrombotic state include: promotion of PS exposure and TF expression on monocytes 
(Celi et al. 1994; Celi et al. 2004); transfer of TF sorted from rafts into monocyte derived 
MPs that then get delivered to activated platelets (Del Conde et al. 2005a); and generation of 
monocyte MPs enriched in lymphocyte function-associated-antigen-1(LFA-1;CD11a/CD18) 
that enable interactions between leukocytes and endothelial cells (Bernimoulin et al. 2009).  
In addition, several studies have shown that the recruitment at the edge of thrombus of 
leukocytes and leukocyte MPs is dependant on P selectin and P-selectin glycoprotein ligand-
1 interactions (Falati et al. 2002; Falati et al. 2003; Thomas et al. 2009). Moreover, TF-
positive MP can bind to other cell types, such as monocytes, and transfer bioactive TF 
(Rauch et al. 2000; Sabatier et al. 2002). Mesri et al. have demonstrated up-regulation of 
circulating leukocyte MPs in vivo and induction of stress signalling pathways in endothelial 
cells, resulting in to increased TF activity (Mesri and Altieri 1999).  Additionally monocyte-
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derived-MPs up-regulated the expression of active TF by endothelial cells and induced a 
rapid expression of von Willebrand factor at the endothelial cell surface (Essayagh et al. 
2007). In vitro experiments demonstrated that these two major cell responses are under the 
control of reactive oxygen species (ROS) delivered by MPs (Essayagh et al. 2007).  
 
 In parallel to this leukocyte-platelet-endothelium interaction that play a major role in 
thrombus generation, other cellular lineages may contribute to MP-driven blood coagulation. 
In traumatic brain injury, Morel et al. have demonstrated an increased generation of 
procoagulant MPs in the cerebrospinal fluid that may reflect neuronal apoptosis (Morel et al. 
2008a). In addition, a number of studies have shown that erythrocyte derived MPs correlate 
with the extent of blood coagulation activation (Mfonkeu et al. 2010; Van Beers et al. 2009). 
Therefore by exposing PS and TF, MP contribute significantly to a procoagulant potential 
and could be important thrombotic protagonists in the context of several vascular disorders.  
Notably, a series of clinical studies have confirmed the presence of procoagulant MP in 
atherosclerosis, sickle cell anaemia and in patients with acute coronary syndrome (Chironi et 
al. 2006; Koga et al. 2005; Shet et al. 2003;Werner et al. 2006). 
 
4.2.5 Microparticles: inflammatory and anti-inflammatory effects 
 
 
Several studies have demonstrated the proinflammatory effects of MPs on the endothelium. 
MPs may affect the endothelial phenotype via a transcellular platelet-derived microparticles 
(PMP)-mediated delivery of arachidonic acid to endothelial cells and the concomitant 
expression of cyclooxygenase type 2 (Barry et al. 1997). In addition, MPs have been shown 
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to induce the release of proinflammatory cytokines, including IL-6 or MCP-1 from 
endothelial cells and stimulate the up regulation of ICAM-1, VCAM-1 and E-selectin on the 
surface of endothelial cells (Barry et al.1997; Mesri and Altieri 1998;Mesri & Altieri 1999; 
Müller et al. 2009; Nomura et al. 2001). More recently, ccirculating PMPs were shown to 
serve as a transcellular delivery system for RANTES, triggering monocyte arrest to 
inflammed and atherosclerotic endothelium (Mause et al. 2005). In addition monocyte-
derived MPs have been shown to secrete IL-1β (MacKenzie et al. 2001). Furthermore a 
growing number of clinical studies support the proinflammatory character of MPs (Morel, 
Toti, Jesel, & Freyssinet 2010). In the synovial fluid of patients with rheumatoid arthritis 
(RA), MPs from monocytes, granulocytes and more recently platelets have been identified as 
modulators of chemokine and cytokine production by fibroblast like synoviocytes (FLS) 
(Berckmans et al. 2002;Boilard et al. 2010). Cerebral malaria is another example of the MP 
pro-inflammatory potential with experimental data having established the important role of 
erythrocytes-derived MPs during malaria infection (Faille et al. 2009). In sepsis, NO and 
bacterial elements are responsible for the generation of PMP that have an active role in 
vascular signaling (Gambim et al. 2007; Morel, Toti, Jesel, & Freyssinet 2010).  
 
Of note, a series of studies have specifically explored the role of neutrophil microparticles 
(NMP) as inflammatory mediators in vascular disorders (Dalli et al. 2008; Daniel et al. 2006; 
Gasser and Schifferli 2004; Hong et al. 2012). In adults with systemic vasculitis, Daniel et 
al. observed increased plasma neutrophil microparticles although the pathogenic potential of 
these were not investigated (Daniel et al. 2006). Subsequently, Hong et al. also showed an 
increase in neutrophil microparticles in the plasma of children with antineutrophil 
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cytoplasmic antibody (ANCA) associated vasculitis compared with that in healthy controls 
or those with inactive vasculitis (Hong et al. 2012). In the same study it was demonstrated 
that ANCA induced the release of neutrophil microparticles from primed neutrophils (Hong 
et al. 2012). These microparticles expressed a variety of markers, bound endothelial cells via 
a CD18-mediated mechanism and induced an increase in endothelial ICAM-1 expression, 
production of endothelial reactive oxygen species, and release of endothelial IL-6 and IL-8 
(Hong et al. 2012).   
 
Interestingly, Gasser et al. also showed that NMPs could exert anti-inflammatory influence 
on monocytes by suppressing proinflammatory cytokine production and increasing TGF-b 
secretion (Gasser & Schifferli 2004). Dalli et al. also proposed that certain NMP 
subpopulations may exert an anti-inflammatory role (Dalli et al. 2008). They generated 
NMPs by coculture of neutrophils with human umbilical vein endothelial cells (HUVECs) in 
the presence of fMLP (Dalli et al. 2008). The NMPs derived from the neutrophils adherent to 
HUVECs were rich in the anti-inflammatory protein annexin 1, and demonstrated the ability 
to inhibit further neutrophil adhesion to endothelium (Dalli et al. 2008). Importantly, these 
anti-inflammatory NMPs represented the nonadherent NMP population generated in this 
model, and it is possible that proinflammatory NMPs were removed by binding HUVECs 
and would not have been included in the NMP analysis and could explain the apparent 
conflicting results between these studies of NMP (Hong et al. 2012).   
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4.2.6 Microparticles and angiogenesis 
MPs have also been shown to play a major role in angiogenesis either through MP 
production of pro-angiogenic factors or in some cases by decreasing the production of anti-
angiogenic factors (Agouni et al. 2007; Benameur et al. 2010a; Benameur et al. 2010b; Kim 
et al. 2004; Martinez et al. 2005; Martinez et al. 2006; Mause et al. 2010; Soleti et al. 2009). 
Recently, Benameur et al. have shown that circulating MPs from peroxisome proliferator-
activated receptor-a-wildtype mice, but not from knockout mice, induce the formation of 
capillary-like structures of endothelial cells (Benameur et al. 2010b). In addition, Kim et al. 
demonstrated that PMP can stimulate human endothelial cells to proliferate, migrate and 
form tubes essential for angiogenesis, in vitro (Kim et al. 2004). Both protein and lipid 
growth factors were involved but it seemed that the effects of the latter were greater (Kim et 
al. 2004). Moreover, MPs generated from either activated or apoptotic T-lymphocytes 
express the morphogen Sonic hedgehog (MPsShh+) on their surface and promote angiogenesis 
(Benameur et al. 2010a; Benameur et al. 2010b; Martinez, Tesse, Zobairi, & 
Andriantsitohaina 2005; Martinez et al. 2006; Soleti et al. 2009). In vivo treatment of hind 
limb ischaemic mice with MPsShh+ enhanced the neovascularization in the ischemic leg 
(Benameur et al. 2010a). Furthermore, several reports show that MPs from endothelial cells 
can affect endothelial progenitor cell (EPC) function and angiogenesis (Benameur et al. 
2010b; Mause et al.  2010).  Mause et al. observed that treatment of EPC with PMP 
increased expression of mature endothelial cell markers on the progenitor cells and promoted 
both endothelial cell adhesion and paracrine activity, leading to improved endothelial 
healing (Mause et al. 2010). Thus these reports suggest that MPs from ischaemic tissues 
could act as endogenous survival signals for vascular repair (Agouni et al. 2007; Benameur 
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et al. 2010a; Benameur et al. 2010b; Kim et al. 2004; Martinez, Tesse, Zobairi, & 
Andriantsitohaina 2005; Martinez et al. 2006; Mause et al.  2010; Soleti et al. 2009). 
 
 
4.2.7 Microparticles in relation to vascular injury and endothelial 
dysfunction 
 
MPs are considered reliable markers of cell damage detectable in biologic fluids (Morel et 
al. 2006; Piccin, Murphy, & Smith 2007). It has been previously demonstrated that it is 
possible to monitor endothelial injury in systemic vascular disorders by the detection of 
circulating EMPs expressing E-selectin, or CD105 (Brogan et al.2004; Clarke et al. 2010; 
Daniel et al. 2006; Erdbruegger et al. 2008). In children with systemic vasculitis Brogan et 
al. demonstrated an elevation in circulating E-selectin and CD105 expressing EMPs as well 
as CD42a (platelet) derived MP  during active disease (Brogan et al. 2004). In addition, 
Daniel at al. showed an elevation in neutrophil microparticles (NMP) expressing CD66b and 
platelet MPs in adult patients with anti-neutrophil cytoplasmic anybody associated vasculitis 
(AAV) during active disease compared to controls (Daniel et al. 2006). NMP were also 
shown to decline in numbers with therapy and in disease remission (Daniel et al. 2006).  
Erdbruegger et al. examined EMP in adults with AAV confirming an increase in EMP and 
platelet MP during active disease (Erdbruegger et al. 2008). Notably, Clarke et al. recently 
studied MP profiles in children with systemic vasculitis at various diseases stages 
establishing circulating MP as a robust biomarker of endothelial injury and platelet 
activation in this disease (Clarke et al. 2010).  
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MPs have also been studied in several other cardiovascular diseases (Bakouboula et al. 2008; 
Koga et al. 2005; Preston et al. 2003; Yuana, Bertina, & Osanto 2011). Current lines of 
evidence suggest that increased circulating levels of EMP for instance are associated with 
coronary artery disease (CAD) and vascular risk factors such as arterial hypertension, 
diabetes, hyperlipidaemia and others (Bakouboula et al. 2008; Koga et al. 2005; Preston et 
al. 2003;Yuana, Bertina, & Osanto 2011). Levels of EMP are also related to poor clinical 
cardiovascular outcome in these subjects (Bakouboula et al. 2008; Koga et al. 2005; Preston 
et al. 2003; Yuana, Bertina, & Osanto 2011). Circulating MPs could additionally be an 
important regulator of the vascular tone. Platelet microparticles have been shown to act as a 
cellular source of thromboxane A2 and enhance arachidonic acid–induced contractions in the 
rabbit aorta (Pfister 2004). Furthermore, Martin et al. demonstrated that MPs from apoptotic 
T lymphocytes impair endothelial function and regulate endothelial protein expression 
(Martin et al. 2004). Tesse at al. observed that circulating MP from pre-eclamptic women 
induce vascular hyperactivity in vessels form pregnant mice through an overproduction of 
NO (Tesse et al. 2007). Lastly, MP from apoptotic smooth muscle cells (SMCs) have been 
shown to induce endothelial dysfunction by diminishing NO production in mouse aorta 
(Essayagh et al. 2005) 
 
 
4.2.8 Microparticles in cerebrovascular diseases 
 
There are limited but promising data relating to MP profiles in cerebrovascular diseases 
(Jung et al. 2009; Shirafuji et al. 2008; Simak et al. 2006). In adults Jung et al. prospectively 
examined 348 consecutive patients with cerebrovascular disease: 73 patients with acute 
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stroke and 275 patients with vascular risk factors but no stroke events (Jung et al. 2009). 
Recent ischaemic episodes were found to be more strongly associated with greater E-selectin 
(CD62E+) endothelial derived MP levels (EMP) than with levels of other phenotypes (Jung 
et al. 2009). Increased National Institutes of Health Stroke Scale scores and infarct volumes 
in acute stroke patients were significantly associated with greater CD62E+EMP levels (Jung 
et al. 2009). The ratio of CD62E+ to CD31+/CD42b- or CD31+/AV+ EMP level 
significantly discriminated extra cranial and intracranial arterial stenosis (Jung et al. 2009). 
Thus circulating EMP phenotypic profiles could reflect distinct phenotypes of 
cerebrovascular disease, and provide additional information on anatomic origin and 
pathogenetic mechanisms (Jung et al. 2009).  Simak et al. demonstrated significantly higher 
PS positive EMP counts during acute ischaemic stroke while EMP counts correlated 
significantly with brain lesion volume and discharge clinical outcomes (Simak et al. 2006). 
Lastly, Shirafuji et al. demonstrated elevated levels of platelet derived MP in patients with 
chronic cerebral infarction regardless of the use of anti-platelet therapy (Shirafuji, 
Hamaguchi, & Kanda 2008).  
 
To date, however, circulating MP profiles in children with AIS and cerebral arteriopathy 
have not been studied. It would be of considerable interest to establish whether children with 
AIS recurrence have altered MP signatures indicative of platelet and endothelial activation. 
Moreover, these MP could exert important prothrombotic influence in those with progressive 
AIS due to PS and tissue factor expression if present in the circulation of these children. In 
this chapter MP are examined in this context. 
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4.3 Aims  
 
To investigated whether MP profiles differ between children with cerebral arteriopathy and 
AIS recurrence compared to those with a single event, as a consequence of neutrophil, 
monocyte and platelet activation in children with AIS recurrence.  
4.4 Methods 
 
4.4.1 Patients 
 
This was a cross sectional study of children > 28 days old presenting to Great Ormond Street 
Hospital with AIS. For inclusion and exclusion criteria, patient group classification, healthy 
controls and disease controls see chapter 2.  
 
4.4.2 Isolation of microparticles from platelet poor plasma 
 
One to 4 mls of whole blood was collected into bottles containing 3.2% trisodium citrate 
(Becton Dickinson). Platelet poor plasma (PPP) was obtained by immediate centrifugation of 
the whole blood at 5000g for 5 minutes twice. Plasma was then stored at –80o C for batch 
analysis. Prior to analysis PPP was thawed rapidly in a 370C water bath. Exact volumes of 
plasma (200-400µl) were then centrifuged at 17000 g for 60 minutes and the supernatant 
decanted to obtain the microparticle pellet. The MP were then reconstituted in An V binding 
buffer (BD PharMingen, Oxford, United Kingdom), divided into 40 μl aliquots and plated 
onto the wells of a 96 well U-bottomed plate prior to staining with Annexin V and other 
monoclonal antibodies.  
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4.4.3 Labelling of microparticles with annexin V and monoclonal 
antibodies  
 
The labelling and quantification of MP was achieved as follows: 5 μl of a 1 in 5 dilution 
Annexin V conjugated with fluorescein isothiocyanate (FITC; BD Pharmingen) or -
phycoerythrin (PE; BD Pharmingen) or PERCP-Cy5·5 (BD, Pharmingen) was added to 
every well in a 96 well U bottomed plate. For measuring endothelial derived MPs (EMPs) 
samples were additionally incubated with mouse (PE)-labeled anti-human CD62e (Clone 68-
5H11, BD Pharmingen), mouse (PE)-labeled anti-human CD31 (clone L133.1, BD 
Pharmingen), mouse (PE) labeled anti human CD54 (clone LB-2, BD pharmingen) and 
mouse (PE) labeled anti human CD 106 (clone 51-10C9, BD Pharmingen). In platelet 
derived MPs (PMPs) expression of the platelet activation marker P selectin was assessed 
with staining with mouse (PE) labeled anti human CD62P (clone AC1.2, BD Pharmingen). 
For neutrophil derived MPs (NMPs) MP were stained with mouse (PE)-labeled anti-human 
CD11b activation epitope (clone CBRM1/5, Biolegend, UK). All samples were additionally 
stained with the constitutively expressed platelet marker CD42a (mouse IgG1 anti-human 
CD42a-PERCP, BD Pharmingen) to exclude a platelet origin for these MPs as well as the 
relevant isotype controls (as per manufacturer recommendation). To assess P-selectin 
glycoprotein ligand 1 (PSGL-1) and tissue factor (TF) expression on monocyte MPs, 
samples stained with mouse (Cy5)-labeled anti-human CD14 (clone 61D3,AbD Serotec) 
were additionally incubated with mouse (FITC–labeled anti-human TF (clone VD8, 
American Diagnostica, USA) and mouse (PE)-labeled anti human PSGL-1 (clone KPL1, BD 
Pharmingen). All antibodies were used at final dilutions listed in table 2-1. MPs were 
incubated with the labeled antibodies and annexin V for 20 minutes at room temperature in 
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the dark with gentle shaking. The incubation was then terminated by adding 200 μl of 
annexin V buffer to each well, and the samples transferred to small FACS tubes prior to flow 
cytometry. The plate plans used for MP detection are shown in appendix 3.  
 
4.4.4 Optimization of gating strategy for flow cytometric analysis of 
microparticles 
 
To establish the limits of detection and optimize the gating strategy standard latex beads size 
of 0.2 µm, 0.3 µm, 1.1 µm and 3 µm (Sigma) were used. Of note these beads provide an 
approximate estimate of size and may not be directly comparable to MP size as they have 
different optical properties. As shown in figure 4-1, 1.1 µm beads lie within a similar FSC 
location as platelets when whole blood was examined and thus could be used to set the upper 
boundary of the FSC region of interest and gate for MP population to < 1.1 µm. In order to 
establish the lower limits of detection 0.2 and 0.3 µm beads and sterile filter water were 
examined.  The background noise detected using sterile filter water using a 0.2 µm pore size 
filter was considered electrical noise (figure 4-2).  Using this threshold the 0.2 and 0.3 µm 
beads were examined. As depicted in figure 4-2 the 0.3 µm beads could be distinguished 
from noise but not the 0.2 µm beads.  Therefore as MP cannot be entirely distinguished from 
background electrical noise based on their FSC and SSC properties alone, emphasizing the 
importance of using AnV (binding to PS) labeled with FITC, PE or PERCP as a constitutive 
MP marker.  Figure 4-2 shows that 0.2 µm FITC labeled beads are indeed detectable on the 
FL1 channel.  The MP population was therefore in this study defined as AnV+ and size < 
1.1µm (figure 4-2D).   
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Figure 4-1: Gating strategy.  
Figure 4-1 shows that 1.1 µm beads lie within a similar FSC location as platelets when 
whole blood was examined and thus could be used to set the upper boundary of the FSC 
region of interest and gate for MP population to < 1.1 µm. 
 
 
 
 
 
 
 
 
 
1.1µm beads  
Platelets 
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Figure 4-2: Optimization of gating strategy for microparticle detection.  
(A) Indicates that 0.3, 1.1 and 3 µm beads are distinguishable from the background noise 
within the system. (B) Signal derived from 0.2 µm pore size filtered water. (C) 0.2 µm beads 
are not distinguishable based on their FSC and SSC properties but can be detected when 
labeled with FITC on the FL1 channel. (D) Dot plot demonstrating the gating strategy. The 
MP gate was defined by forward-scatter characteristics corresponding with a size, 1.1 mm 
and positive annexin V labelling.                                                        
 
A 
B 
0.2 µm beads FITC  
FSC-H 
D 
C 
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4.4.5 Flow cytometric analysis of microparticles 
 
All analysis was performed on a FACScalibur flow cytometer (Becton Dickinson). To obtain 
optimal forward and side scatter instrument settings for MP 1.1 μm latex beads (Sigma) were 
run and logarithmic forward and side scatter plots obtained. Gates were then set to include 
particles less than approximately 1.1μm, but to exclude the first forward scatter channel 
containing maximal noise. Optimal compensation was set for green, red and far-red 
fluorescence. Specific binding for each antibody was determined using isotype control 
antibodies with equal protein: fluorochrome ratios, and at the same final dilution as per 
manufacturer recommendation. Since annexin V is a protein and not an antibody (and hence 
no isotype control antibody exists), the threshold for annexin V binding was determined by 
using the fluorescence threshold established for MP in the absence labeled annexin V. 
Particles less than 1.1 μm in size and binding annexin V were then selected (figure 4-3).  
Platelet derived MPS were defined as particles < 1.1 μm in size, staining for CD42a+/AnV+ 
(figure 4-3). Endothelial derived MPs were defined as CD62E+/AnV+/CD42a-, 
CD54+/AnV+/CD42a-, CD106+/AnV+/CD42a- or CD31+/AnV+/CD42a- MPs. Neutrophil 
MPs were defined as aCD11b+/AnV+/CD42a- or CD66b+/AnV+/CD42a- MPs and lastly 
monocyte derived MPs baring TF or PSGL-1 were identified as TF+/AnV+/CD14+ or 
PSGL-1+CD14+AnV+ MPs. MP samples were run at medium flow rate with a cut-off time 
of 1 minute, which resulted in capture of approximately 10000 gated bead events. Beads 
were used as an internal standard for enumeration- see next section for further details. A 
representative set of flow cytometric plots, and the gating protocol are shown in figure 4-3. 
Data were analysed using FlowJo (Treestar Inc, Ashland, OR). The instrument settings are 
shown in appendix 4. 
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Figure 4-3: Flow cytometric detection of circulating microparticles (MPs).  
Standard latex beads, size of 1.1 μm were used to set the gating of MP < 1.1 μm. The MP 
population with AnV+ and size < 1.1μm was selected. Figure 4-3B Platelet MPs (PMPs) 
were defined as particles AnV+CD42a+. Endothelial and neutrophil derived MPs were 
characterised in an identical way using appropriate monoclonal antibodies. Figure 4-3C 
Tissue factor positive monocytes derived MPs. Figure 4-3-D 3 μm beads were run 
concurrently to enable determination of absolute number of MPs/ml of plasma. 
A B 
C 
MP gate  
1 µm beads 
PMPs 
TF+MP 
D 
3 μm beads 
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4.4.6 Determination of absolute microparticle number per ml of plasma 
 
To convert flow cytometer counts to an estimate of the number of MP per ml of plasma, a 
predetermined number (always 200000, calculated as per manufacturer recommendations) of 
3 μm latex beads (Sigma) were run concurrently with the microparticle samples. The 
absolute number of annexin V binding microparticles per ml of plasma was then determined 
by using the proportion of beads counted and the exact volume of plasma from which the 
microparticles were analysed, as described by Brogan et al. (Brogan et al. 2004). The 
following equation was thus derived to convert flow cytometer counts to an estimate of the 
number of MP per ml of plasma (figure 4-4). Since samples from each individual were 
multiple times, microparticle counts from individual subjects were expressed as the mean 
number per ml of plasma, with standard error of the mean based on multiple measurements. 
To determine the absolute number of MP derived from different cellular populations (i.e. 
platelet, or endothelial) the absolute number of total MP derived from the above equation 
was multiplied by the percentage positivity for that particular marker. 
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Figure 4-4: Conversion equation for calculation of microparticle (MP) number per ml of 
plasma from flow cytometer counts. 
 
 
4.4.7 In vitro MP generation as positive controls for set up experiments 
 
In order to detect the different MP populations in patient samples, MPs were generated in 
vivo from activated parent cells of varying types. Commercially available Human Umbilical 
Vein Endothelial Cells (HUVECs), neutrophils, monocytes and platelets isolated from blood 
donated from adult healthy control volunteers were used for stimulation experiments to 
induced release of pure endothelial (EMP), neutrophil (NMP), monocyte (MMP) and platelet 
MPs (PMP). To induce in vitro MP formation, primary cells isolated and cultured as 
described above in chapter 2 were stimulated with various inflammatory stimuli (for all MP: 
10 nM calcium ionophore A23187; EMP: 100ng/ml TNF-α for 24h; NMP: fMLP 10 µg/ml 
for 2 hours; PMP: ADP 5 µM for 1hour; MMP: LPS 5µg/ml for 4 hours). MP were isolated 
from the respective cell cultures after clearance of cell fragments (centrifugation 5000 x g, 5 
Total number of MP/ ml of plasma = 
 
(200 000    /    no. of beads counted) X (no. of MP counted per well) X n 
    
              Number of mls of plasma 
 
Usually 15000  
Number of beads added per 
well Usually 200-400 
L 
The number of wells 
into which the sample 
was divided 
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min) by centrifugation of supernatants (15000 x g for 60 min). The MP pellets were then 
frozen at –80°C for future use. The phenotype of MP generated and their activated parent 
cells is shown in appendix 5. 
 
4.4.8 Reproducibility of MP analysis from different plasma volumes 
 
To establish the reproducibility of MP analysis, MP derived from supernatants taken from 
monolayers of HUVEC stimulated with 100 ng/ml of TNF- (Sigma) at 24 hours from n=3 
different experiments were labelled with AnV-FITC and analysed in triplicate. As shown in 
figure 4-5 each aliquot gave similar mean results for total AnV+ MP enumeration, verifying 
an acceptable re-producibility of the technique of different volumes of frozen plasma.  
 
 
 
 
 
 
 
 
Figure 4-5: Microparticle reproducibility. 
Supernatants taken from monolayers of human umbilical vein endothelial cells (HUVEC) 
stimulated with 100 ng/ml of TNF- for 24 hours from 3 different experiments were labeled 
with AnV-FITC and analysed in triplicates to provide an estimate of MP reproducibility. 
EMP=Endothelial derived microparticles. 
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4.4.9 Effect of freeze thaw and storage on MP analysis 
 
 
The effect of repeat freeze-thaw cycles and storage on the intra-subject reproducibility of 
total MP number was assessed. MP derived from supernatants taken from monolayers of 
HUVEC stimulated with 100 ng/ml of TNF- (Sigma) at 24 hours from n=3 different 
experiments were analysed at baseline and then frozen and thawed at 24 hours, 48 hours and 
7 days of storage. Total AnV+ MP count was not significantly affected by freeze-thaw or 
storage. Median total AnV+MP count at T=0 was 9.1x105 (range 9-10x 105 /ml) compared to 
T=24 h with a median of 9x 105 /ml (range 8.9-9.9x 105 /ml), p=0.4   T=48h median 
9.05x105/ml (range 8.9-9.9 105 /ml), p=0.7 and  T=7 days median 9 (range 8.9-9.895 x105 
/ml)p=0.4, figure 4-6. 
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Figure 4-6: Effect of freeze thaw and storage on MP analysis.  
Supernatants taken from monolayers of HUVEC stimulated with 100 ng/ml of TNF-  for 24 
hours from 3 different experiments were analysed at baseline and then frozen and thawed at 
24hours, 48hours and 7 days of storage. MP number was not significantly affected by freeze-
thaw. Median MP count at T=0 was 9.1x105 (range 9-10x 105 /ml) compared to T=7 days 
median 9 (range 8.9-9.895 x105 /ml), p=0.4. 
 
4.5 Statistical analysis 
 
Numeric results were summarised as median and range. The Kruskal-Wallis test was used to 
examine overall differences in experimental laboratory markers between the study groups 
followed by the Mann-Whitney U test. Associations between CEC and MP were assessed 
using Spearman’s rank correlation coefficient. The Wilcoxon matched paired signed ranks 
test was used to compare MP at initial presentation and at latest follow up for children 
studied prospectively. The independent association of total annexin V+ MPs on the primary 
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outcome of AIS recurrence was assessed using a multivariate logistic regression model, 
unadjusted and adjusted for age, gender, and time from stroke event to blood sampling. 
Results were expressed as odds ratios (OR) with corresponding 95% confidence intervals 
(CI) and P-values. P-values of less than 0.05 (two sided) were regarded as significant. 
Statistical analysis was performed using SPSS versions 16 and 17. 
 
4.6 Results 
 
4.6.1 Circulating cellular microparticles in children with arterial ischaemic 
stroke  
 
Circulating MP levels and phenotype in the plasma of children with AIS recurrence or stable 
disease, cerebral AVM and healthy child controls were compared. Total AnV+ MPs were 
significantly higher in the 10 children with recurrence at 659 (136-1616) x 103/ml compared 
to those with no recurrence 226 (49-893) x 103/ml, p=0.002; in healthy controls 89 (25-236) 
x 103/ml, p=0.0001 and in children with cerebral AVM 90 (20-160) x 103/ml, p=0.0001 
(figure 4-7). 
 
CEC counts correlated significantly with circulating AnV+ MPs, rs=0·45 (p=0·0015; figure 
4-8). Platelet derived MP (CD42a+Anv+) were elevated in children with recurrence 461 (95-
980) x 103/ml compared to those with no recurrence 158 (40-220) x 103/ml, p=0·0010; 
children with AVM 80 (45-150) x 103/ml, p=0.0001 and child controls 62 (40-120) x 103/ml, 
p= 0.0002. Platelet derived MPs expressing  CD42a and the platelet activation marker P 
selectin (CD62P; CD42a+CD62P+ AnV+MPs) were also significantly higher in the group of 
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children with recurrence: 93 x 10 3/ml (18-220 x 10 3/ml), versus the group with no 
recurrence 44 x 10 3/ml ( 2-120 x 10 3/ml ), p=0·0100;  children with cerebral AVM  12 (5-
15) 10 3/ml, p=0.0001  and child controls 11 x 10 3/ml (5-20 x 103/ml), p= 0·0002 (table 4-
2), providing evidence for persistent platelet activation in those with recurrence. In addition, 
endothelial MPs (EMPs) expressing the endothelial activation marker CD62E (E-selectin) 
but negative for the platelet marker CD42a (CD62E+CD42a-AnV+ EMPs) were 
significantly higher in children with recurrence 85 x 10 3/ml (44-164 x10 3/ml) compared to 
children with no recurrence 38 x 10 3/ml (1-105 x10 3/ml), p=0·0001; children with cerebral 
AVM 15 x10 3/ml (2-35) 10 3/ml, p=0·002; and healthy controls 0·5 x 10 3/ml (0·2-10 x10 
3/ml), p=0·0001, (table 4-2). Similar significant differences were seen for EMPs expressing 
CD31+ between the two patient groups, 80 x10 3/ml (55-130) 10 3/ml  for those with 
recurrence compared to 40 x10 3/ml (15-90) x 10 3/ml, p=0.002 for those with a single event; 
for children with cerebral AVM 5 x10 3/ml (2-10 )x 10 3/ml, p=0.003 and 2 x10 3/ml (1-
9)x10 3/ml for child controls, p=0.0001. There were no significant differences between 
groups for EMP expressing CD 106, p=0.548. Of note circulating EMPs expressing CD62E 
correlated significantly with CECs, rs=0·67, p=0·0001 suggesting a significant association 
between both biomarkers of endothelial injury (figure 4-9). 
 
Neutrophil derived MPs defined as aCD11b+CD42a-AnV+ MPs were significantly higher in 
the group with recurrence 60 x 10 3/ml (8-125 x 10 3/ml) compared to the group with no 
recurrence 21 x 10 3/ml (1-40 x 10 3/ml), p=0.0200; children with cerebral AVM 19 x 10 
3/ml (1-40) x 10 3/ml, p=0·0030; and controls 4 x 10 3/ml (0·5-17 x 10 3/ml), p=0·0040 
providing evidence for neutrophil activation (table 4-2).  
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Tissue factor (TF) expression on MP of monocytic (CD14) origin was then compared 
between the groups since these are known to be highly prothrombotic. TF+CD14+AnV+ 
MPs were significantly elevated in those with AIS recurrence 70 (22- 190) x 103/ml 
compared to these with a single event 29 (1-146) x 103/ml, p=0.0040; healthy control 
children 2 (0·2- 6·7) x 103/ml, p=0.0001; and children with cerebral AVM 10 (2-30) x 
103/ml, p=0·0030, table 4-2.  
 
As TF activity at the thrombus edge has been previously shown to depend on interactions 
between platelet P-selectin and P-selectin glycoprotein ligand -1 (PSGL-1)(Falati et al. 
2003) on monocyte MPs I then determined whether there were any differences in PSGL-
1+CD14+AnV+ MPs  between the patient groups. The AIS recurrence group had 
significantly higher PSGL-1+CD14+AnV+ MPs of 35 x10 3/ml (15-98 x10 3/ml) compared 
to 12 x10 3/ml (5 -58x10 3/ml), p=0.0200 in the group of those children with no recurrence; 
in the children with cerebral AVM  5x10 3/ml (1.2-8.2)x 10 3/ml, p=0.003 and 1·3 x10 3/ml 
(1·1-1·5x10 3/ml), p=0.0200 in healthy controls. 
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Figure 4-7: Circulating total AnnexinV+microparticles in children with arterial ischemic 
stroke (AIS).  
Total Annexin V+ (phosphatidylserine rich) microparticles were significantly elevated in 
children with AIS compared to those with a single event (p=0.002) and children with 
cerebral arteriovenous malformation (AVM; p=0.0001) and healthy child controls 
(p=0.0001). ***P<0.0005 with Mann Whitney U test. 
 
 
 
 
 
 
 
 
 
Figure 4-8: Circulating endothelial cell counts (CEC) and total Annexin V+ 
microparticles (MP). CEC correlated significantly with circulating Annexin V+ MP 
(rs=0·45; p=0·0015). 
0 500 1000 1500 2000
0
200
400
600
800
AnV+ MPs x 10
3
/ml
C
E
C
s
/m
l
r=0.45 
p=0.0015 
A
IS
 re
cu
rr
en
ce
A
IS
 n
o 
re
cu
rr
en
ce
H
ea
lth
y 
co
nt
ro
ls
A
VM
0
250
500
750
1000
1250
1500
1750
***
***
**
A
n
V
+
M
P
s
x
 1
0
3
/m
l
 191 
 
Microparticles 
(median, range) x 10 
3/ml 
AIS 
recurrence 
N=10  
AIS no 
recurrence 
N=36 
Healthy 
controls 
N=10  
Cerebral 
AVM 
N=   10       
Total AnV+MPs 
 
659 (136-
1616)  
226 (49-893); 
p=0·002 
89 (25-236); 
p=0·0001 
90 (20-160); 
p=0·0001 
EMP 
AnV+CD62E+CD42a- 
 
85 (44-164)   38 (1-105); 
p=0·0001 
0·5 (0·2- 10); 
p=0·0001 
15(2-35); 
p=0·002 
EMP 
AnV+CD31+CD42a- 
80 (55-130) 40 (15-90); 
p=0·0.002 
2 (1-9); 
p=0·0001 
5 (2-10); 
p=0·003 
PMP  
AnV+CD42a+ 
 
461(95-980) 158 (40-220); 
p=0·0010 
62 (40-120);  
p= 0·0002 
80(45-150); 
p=0·0001 
PMP 
AnV+CD42a+CD62P+ 
93 (18 -220)  44 (2-120); 
p=0·0100 
11 (5-20);  
p= 0·0002 
12 (5-15); 
p=0·0001 
NMP 
AnV+aCD11b+CD42a- 
 
60 (8-125) 
 
21 (1-40); 
p=0·0200 
4 (0.5-17); 
p=0·0040 
19 (1-40); 
p=0·0030 
TF+CD14+AnV+ 
 
70 (22- 190) 29 (1-146); 
p=0.0040 
2 (0.2- 6·7); 
p=0·0001 
10 (2-30); 
p=0·0030 
PSGL-1+ CD14+AnV+ 
 
35 (15-98 ) 12 (5-58); 
p=0·0200 
1.3 (1·1-1·5); 
p=0·0200 
5 (1.2-8.2); 
p=0·0030 
Table 4-2: Circulating microparticle profiles in children with arterial ischaemic stroke, 
cerebral arteriovenous malformation and child healthy controls.  
AIS=arterial ischaemic stroke; AVM=arteriovenous malformation; EMP=endothelial 
derived MP; PMP=platelet derived MP; NMP=neutrophil derived MP; TF=tissue factor; 
PSGL-1=P selectin glycoprotein ligand-1. The Mann Whitney U test was used to compare 
MP counts between groups. P values refer to comparison with the group of children with 
recurrent AIS. 
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Figure 4-9: Circulating endothelial cell counts (CEC) and endothelial microparticles 
(EMP). Circulating EMPs expressing the activation marker CD62E correlated significantly 
with CEC, rs=0·67, p=0·0001 suggesting a significant association between both biomarkers 
of endothelial injury. 
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4.6.2 Longitudinal changes of microparticles (MP) in children with 
arterial ischaemic stroke  
 
Figure 4-10 summarises the longitudinal changes in total AnV+ MPs in 6 children with a 
stable course with no AIS recurrence: 130 x 103/ml, range 120-190 x 10 3/ml at initial 
assessment to 115 x 103/ml, range 120-150x103/ml at follow up and in 2 children with 
recurrence: median 390, range 300-480 x103/ml at presentation to a median of 375, range 
290-440 x103/ml at follow up (p=0.3). Of note the 2 children with recurrence had been 
treated with aspirin and warfarin but no immunosuppression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-10: Longitudinal changes in total Annexin V+ microparticles (MP) in children 
with arterial ischaemic stroke (AIS) and cerebral arteriopathy. 
Total AnV+ microparticles in 6 children with a stable course with no AIS recurrence and in 
2 children with recurrence. The 2 children with recurrence had been treated with aspirin 
and warfarin but no immunosuppression.  
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4.6.3 Logistic regression analysis of annexin V microparticles for arterial 
ischaemic stroke recurrence 
 
Logistic regression analysis was used to examine the relationship of total AnV+MPs to AIS 
recurrence. Table 4-3 gives the unadjusted odds ratios, and odds ratios adjusted for age, 
gender, and time from recent AIS event to blood sampling. Total AnV+MPs were 
significantly associated with AIS recurrence in the unadjusted model (OR 1.410 95% CI 
1.100-1.545, p=0.004) and remained significant in the adjusted analysis, (OR 1.220; 95% CI 
1·039-1·317, p= 0·020). 
 
Table 4-3: Unadjusted and adjusted odds ratios by multivariable logistic regression 
analysis of total Annexin V+ microparticles (MP) for arterial ischaemic stroke recurrence 
(AIS).  
Adjusted odd ratios for age/gender/time from AIS to evaluation. OR=odds ratio; 
CI=confidence intervals. P<0.05 was considered significant. 
 
 
 
Biomarker            Unadjusted  
 
  
OR        95%CI               P 
Adjusted (age/gender/time 
from    AIS to evaluation) 
 
OR          95%CI                 P 
Annexin V+ 
microparticles 
(AnV+MPs) 
1.410    1.100-1.545       0.004 1.220       1.039-1.317       0.020 
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4.6.4 Test characteristics of MPs for identification of AIS recurrence 
 
On the basis of this regression analysis demonstrating that total AnV+ MPs strongly 
associated with recurrent AIS, the test characteristics of MPs for identification of AIS 
recurrence were then examined by plotting ROC curves. The ROC curve for MPs at varying 
definitions of positivity is shown in figure 4-11. ROC analysis for MPs as a diagnostic test 
for identification of recurrence was significant with an AUC of 0.8236, SE 0.08 and 95% CI 
of 0·66-0.98, p=0.0019. The full test characteristics of MPs for identification of AIS 
recurrence are summarized in table 4-4. The cut-off values for test positivity in table 4-4 
correspond to individual points on the ROC curves. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-11: Receiver operator characteristic curve (ROC) for total Annexin V positive 
(PS rich) microparticles for the identification of arterial ischaemic stroke (AIS) 
recurrence. ROC analysis was significant with an area under the curve (AUC) of 0.82 (95% 
CI 0.66-0.98), p=0.0019. 
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AnV+ 
MPs 
Sensitivity 
(%) 
95% 
CI 
Specificity 
(%) 
95% CI LR+ LR- PPV NPV 
> 70.93 100 69- 100 2.778 0-14 1.03 0 50 100 
> 102.7 100 69-100 8.333 2-22 1.09 0 52 100 
> 121.2 100 69- 100 13.89 5-29 1.16 0 53 100 
> 133.1 100 69-100 19.44 8-36 1.24 0 55 100 
> 138.3 90 55-99 19.44 8-36 1.12 0.51 52 65 
> 141.9 90 55-99 22.22 10-39 1.16 0.45 53 68 
> 143.9 90 55-99 27.78 14- 45 1.25 0.35 55 73 
> 154.3 90 55-99 33.33 18-51 1.35 0.30 57 76 
> 165.8 90 55-99 38.89 23-56 1.47 0.25 59 79 
> 169.2 90 55-99 44.44 27- 61 1.62 0.22 61 81 
> 189.2 90 55-99 47.22 30-64 1.71 0.21 63 82 
> 226.7 90 55-99 50 32-67 1.8 0.20 64 83 
> 275.7 90 55-99 52.78 35-69 1.91 0.19 65 83 
> 311.7 90 55-99 58.33 40-74 2.16 0.17 68 85 
> 324.5 90 55-99 61.11 43-76 2.31 0.16 69 85 
> 336.5 90 55-99 63.89 46-79 2.49 0.15 71 86 
> 345.6 90 55-99 69.44 51- 83 2.95 0.14 74 87 
> 369.9 90 55-99 72.22 54-85 3.24 0.13 76 87 
> 406.0 80 44-97 72.22 54-85 2.88 0.27 74 74 
> 424.5 70 34- 93 72.22 54-85 2.52 0.41 71 70 
> 456.5 70 34-93 77.78 60-89 3.15 0.38 75 71 
> 492.5 70 34- 93 83.33 67-93 4.2 0.36 80 73 
> 527.7 60 26-87 83.33 67- 93 3.6 0.48 77 67 
> 572.2 50 18-81 83.33 67-93 3 0.60 74 62 
> 600.0 50 18-81 88.89 73-96 4.5 0.56 96 63 
> 611.7 50 18-81 94.44 81-99 9 0.52 89 65 
> 687.6 50 18-81 97.22 85-99 18 0.51 94 65 
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> 781.4 40 12-73 97.22 85-99 14.4 0.61 94 70 
> 846.6 30 6-65 97.22 85-99 10.8 0.72 90 58 
> 1173 20 2-55 100 90-100        Infin
ity 0.80 
100 55 
> 1534 10 0-44 100 90-100 Infin
ity 0.90 
100 52 
 
Table 4-4 Test characteristics of total Annexin V positive microparticles for identification 
of arterial ischaemic stroke (AIS) recurrence. 
PPV= positive predictive value; NPV= negative predictive value; LR+ = Likelihood ratio 
for a positive test result; LR- = Likelihood ratio for a negative test result. 
 
 
4.7 Discussion 
 
Total circulating AnV+ (PS-rich) MPs were higher in children with AIS recurrence than in 
those with a stable disease course (figure 4-7). These included increased AnV+MPs of 
activated platelet (expressing CD62P), endothelial (expressing CD62E, with strong 
correlation to CECs) and neutrophil (CD11b) origin. Notably, monocytic MPs expressing 
tissue factor and PSGL-1 were significantly raised in the circulation of children with AIS 
recurrence conferring an increased pro-thrombotic risk in these children. These novel 
findings suggest that circulating MP profiles effectively differentiate between subtypes of 
childhood AIS and provide useful insights into endothelial, platelet, monocyte and 
neutrophil activation as major contributors to the pathogenesis of AIS recurrence.  
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EMP are released from endothelial plasma membrane blebbing and carry a variety of 
endothelial proteins such as intercellular cell adhesion molecule (ICAM)-1, E-selectin, 
endoglin, vascular endothelial cadherin, platelet endothelial cell adhesion molecule-1 
(PECAM-1)(Dignat-George & Boulanger 2011). Determining the endothelial origin of 
circulating MP involves the use of specific markers for flow cytometry analysis. Of note 
however some of these surface markers such as PECAM-1 (CD31) are not exclusively 
expressed on endothelium (Newman 1997). Hence the need to develop strategies combining 
multiple markers to exclude possible contaminating subpopulations and accurately assess the 
endothelial origin of MP in biological fluids. In this study additional staining with CD42-a (a 
constitutively expressed platelet marker) was performed for this reason. Although EMP 
represent a sparse population of circulating MP, changes in their plasma levels reflect an 
active balance between MP generation and clearance and might carry important clinical 
information in healthy subjects and in patients with cardiovascular disorders (Dignat-George 
& Boulanger 2011; Koga et al. 2005; VanWijk et al. 2003; Werner et al. 2006). So far 
several studies have investigated the prognostic potential of the measurement of EMP 
plasma levels (Dignat-George & Boulanger 2011; Koga et al. 2005; VanWijk et al. 
2003;Werner et al.2006). In patients with coronary artery disease levels of circulating EMP 
relate to endothelial dysfunction independently of age and blood pressure (Koga et al. 2005; 
Werner et al. 2006). In adult patients with acute ischaemic stroke, EMP levels are associated 
with lesion volume and clinical outcome (Jung et al. 2009; Simak et al. 2006). In pulmonary 
hypertension, circulating EMP expressing E-selectin predicted the 1-year outcome of these 
patients (Bakouboula et al. 2008). These data suggest that EMP levels are a biomarker of 
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endothelial injury and may be used for stratification of patients with a high risk of 
developing cardiovascular complications.  
 
Similarly, in this cohort of children with AIS, EMPs expressing a variety of endothelial 
surface markers were significantly elevated in those with recurrence and arteriopathy 
progression compared to children with a single event. Importantly, children do not have 
atherosclerosis, which may be a confounding factor when studying endothelial 
microparticles in adult disease states. In addition EMP correlated well with CEC suggesting 
that both these indices permit the study of the endothelium in vivo although a direct causal 
link between these parameters remains to be confirmed and these are unlikely to be 
independent biomarkers since both relate to endothelial injury and/or activation.  
 
Due to their high membrane plasticity and high membrane surface area platelets are the main 
provider of circulating MPs in healthy individuals (Morel et al. 2006; Morel et al. 2008b). In 
other cells scrambling is not as effective, with the lowest ability for MP released being found 
in red blood cells (Morel et al. 2006; Piccin, Murphy, & Smith 2007). An increased number 
of microparticles of platelet origin expressing CD42a in the group of children with AIS 
recurrence were observed in this study comprising 70-80 % of the whole MP population. 
The PMP were previously reported to be increased in both acute and chronic phase of 
cerebral infarction in adults.  Cherian et al. demonstrated a correlation between the elevated 
blood PMP and endothelial dysfunction markers like P-selectin and E-selectin in acute phase 
of cerebral infarction (Cherian et al. 2003). Kuriyama et al. additionally showed that 
elevated PMP level significantly correlated with intima media thickness and with 
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concomitant intracranial stenosis of carotid arteries (Kuriyama et al. 2010). The levels of 
PMP were also significantly elevated in the patients with cerebral infarction in anterior, 
posterior, middle cerebral arteries, and lacunar stroke in contrast with the group of the 
patients with cardioembolic stroke (Kuriyama et al. 2010). Of note, in this study there were 
also significant differences between patient groups in PMP expressing the activation marker 
P-selectin, known to play an important role in the recruitment and aggregation of platelets 
through platelet-fibrin and platelet-platelet binding at areas of vascular injury (Kuriyama et 
al. 2010). Additionally other mechanisms triggered by P-selectin could contribute to 
increased thrombotic propensity. P-selectin facilitates the transfer of TF sorted from raft into 
monocyte-derived MPs and this is then delivered as a functional entity to platelets (Del 
Conde, Shrimpton, Thiagarajan, & Löpez 2005b). P-selectin also promotes PS exposure by 
monocytes and TF expression (Del Conde et al. 2005a). Finally, Mesri et al. have shown that 
P-selectin stimulation of monocytes generated MP enriched in lymphocyte function-
associated antigen-1 (LFA-1; CD11a/CD18) that enable interactions between leukocytes and 
endothelial cells (Mesri & Altieri 1998; Mesri & Altieri 1999). Of note, high plasma levels 
of soluble P-selectin were previously demonstrated to be predictive of venous 
thromboembolism in several diseases (Ay et al. 2008; Kyrle et al. 2007). Thus the release 
and levels of circulating PMP relate to platelet activation and are likely to have direct 
functional significance in ischaemic vascular diseases such as childhood AIS.  
 
Additionally, elevated numbers of NMP expressing the activation epitope aCD11b were 
observed in children with AIS recurrence. Neutrophil microparticles have not been 
previously studied in AIS or other cerebrovascular diseases. Most experimental and clinical 
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studies however support the importance of neutrophil infiltration in ischaemic stroke 
(Bednar et al. 1991; Emerich et al. 2002; Kochanek and Hallenbeck 1992). The brain’s 
inflammatory response to ischaemia is well characterized by a rapid activation of resident 
cells (mainly microglial cells), followed by the infiltration of circulating inflammatory cells, 
including neutrophils, T cells, monocyte/ macrophages as demonstrated in animal model 
(Amantea et al. 2009; Jin et al. 2010; Schilling et al. 2003 Tanaka et al. 2003). Genetic 
deficiency or antibody blockade of leukocyte adhesion molecules (e.g., ICAM-1, CD11b/ 
CD18, P-selectin) has been shown to reduce infarct volume, brain oedema, neurological 
deficits, and mortality in animal models of ischaemic stroke (Jin, Yang, & Li 2010; 
Kitagawa et al. 1998; Zhang et al. 2003; Zhang et al. 1995).  Furthermore, studies in humans 
have suggested that neutrophil accumulation is correlated with the severity of the brain tissue 
damage and poor neurological outcome after ischaemic stroke (Akopov et al. 1996; Jin, 
Yang, & Li 2010; Price et al. 2004). Potential mechanisms that may explain how activation 
and accumulation of neutrophils contribute to the pathogenesis of ischaemic stroke include: 
excessive production of ROS, such as superoxide and hypochlorous acid via NADPH 
oxidase and MPO, respectively; and release of a variety of proinflammatory cytokines and 
chemokines and enhancing expression of adhesion molecules (PSGL-1, L-selectin) (Jin, 
Yang, & Li 2010). By these mechanisms, infiltrating neutrophils further amplify cerebral 
inflammatory responses. NMP have also been previously shown to exert potent 
inflammatory responses into endothelial cells, induce oxidative stress and impair 
angiogenesis (Hong et al. 2012). Of note neutrophil infiltration may play a more prominent 
role in the pathogenesis of ischaemic stroke in individuals with elevated systemic 
inflammation such as in patients with prior infection (Amlie-Lefond et al. 2009; Fullerton et 
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al. 2011). This is of considerable interest for the pathogenesis of childhood AIS particularly 
in view of the fact that several studies have previously suggested a link between common 
systemic infections and the development of cerebral arteriopathies leading to AIS in 
children. In this regard, it is critical to better understand the exact roles of circulating 
neutrophils and perhaps NMP as a window to neutrophil activation in the pathogenesis of 
ischaemic stroke under clinically relevant conditions.  
 
Intriguingly, elevated levels of monocytic MP expressing TF and PSGL-1 were observed in 
children with AIS recurrence and may contribute to the thromboembolic events associated 
with AIS.  PS on the outer surface of MPs directly contributing to activation of the extrinsic 
coagulation pathway by activating factor X but  also indirectly by enhancing the capability 
of tissue factor (TF)(Bach 2006; Giesen et al. 1999). Further pro-thrombotic potential of 
circulating MPs could be mediated via interaction of TF+PSGL1+ monocyte MPs and P 
selectin+ PMPs, as previously suggested by animal data supporting the delivery of TF in the 
thrombus edge via the aforementioned MPs (Falati et al. 2003). Falati et al. using intravital 
real time microscopy have established that the swift recruitment at the edge of the thrombus 
of leukocytes and leukocyte-derived MPs through P-selection/P-SGL-1 interactions 
promotes thrombus growth (Falati, Gross, Merrill-Skoloff, Furie, & Furie 2002). The 
importance of such interactions was confirmed in mice lacking PSGL-1 or P-selectin, TF 
accumulation within the thrombus being minimal (Falati, Gross, Merrill-Skoloff, Furie, & 
Furie 2002). We confirmed the presence of TF+ and PGSL-1+ monocyte MPs and P 
selectin+ PMPs in higher numbers in the plasma of children with arteriopathy progression. 
These observations apart from providing diagnostic information offer additionally an 
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intriguing pathophysiological insight into the hitherto undefined thrombotic propensity 
underpinning childhood AIS recurrence and will be considered in more detail in chapter 5.  
 
On the whole, the test characteristics of circulating microparticles for prediction of AIS 
recurrence based on a limited number of children with AIS are encouraging. A number of 
endothelial surface markers of varying specificity were utilised to characterise the 
microparticles as being of endothelial or platelet origin. Furthermore longitudinal 
measurements may be useful in individual patients to monitor disease activity and predict 
recurrence. The preliminary prospective data presented here suggest that MP in children at 
risk of recurrence remain elevated and may contribute to thrombosis. Examining the changes 
of MP at several time points during the disease course for individual patients may provide 
additional information on the activatory phase of the disease and effect of treatment.  Future 
studies may also give insights into the origin of EMP in AIS, to establish whether these MPs 
are from generalized endothelial stimulation or from local ischaemia and stimulation, or 
both. Overall however the study of EMP permits the status of the endothelium to be studied 
in vivo, providing a novel approach that has promising potential for further understanding of 
stroke pathophysiology 
 
The use of flow cytometry to characterise MP subpopulations undoubtedly has some 
limitations. MP at the lowest range of size are likely to have been beyond the detection 
limits of flow cytometry, particularly since standard protocols set thresholds to exclude the 
first FSC channel to limit background noise. In addition, a multiparametric approach with 
combination of other surface markers would provide additional information regarding MP 
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phenotype, particularly in relation to activation status and more definitive data regarding MP 
subpopulations. Latex beads were used for an approximation of size but circulating MP may 
have different optical properties hence the gating strategy employed herein may need further 
optimisation (Yuana, Bertina, & Osanto 2011). New approaches such as impedance based 
flow cytometry where the labelling efficiency is independent of the particle shape and 
(surface) composition may help overcome these difficulties but are yet in their infancy 
(Yuana, Bertina, & Osanto 2011). Of note, MPs externalize PS and thus bind annexin V in a 
calcium-dependent manner. However, annexin V–negative membrane vesicles expressing 
endothelial or other cell markers have been identified in human plasma, suggesting that 
circulating MP may not all externalize PS, or that for yet unknown reasons, PS is 
unavailable for annexin V binding (PerezPujol et al. 2007;Yuana, Bertina, & Osanto 2011). 
Staining with lactadherin, a milk-derived protein maybe more sensitive to small changes in 
PS expression than annexin V and it can detect PS-positive MPs in a calcium-free 
environment, such as citrate- or EDTA-anticoagulated plasma samples (Hou et al. 2011; 
Lacroix, Robert, Poncelet, & Dignat-George 2010a). Of interest, these MPs with reduced PS 
exposure may be evading macrophage removal from the peripheral circulation and could be 
important pathogenic mediators that merit further study.  
 
In conclusion significant differences were observed in circulating endothelial, platelet, 
monocyte and neutrophil MP signatures between patient groups, and differentiate patients 
with stroke recurrence from those with a single event. These observations complement the 
findings relating to CEC described in previous sections.  These findings not only provide 
additional evidence for ongoing endothelial injury and platelet activation in those with 
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recurrent AIS, but could also have major pathophysiological implications.  The functional 
relevance of circulating MP to the pathogenesis of AIS particularly with respects to their 
procoagulant activity contributing to the thromboembolic phenomena associated with re-
infarction is examined in more detail in chapter 5.  
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5 Microparticle-mediated thrombin generation: 
novel means of assessing microparticle related 
procoagulant activity 
 
5.1 Summary 
 
Background: Microparticles (MPs) are membrane fragments rich in phosphatidylserine and 
have been previously shown to be elevated in a wide range of vascular disorders including 
systemic vasculitis and now as shown in chapter 4 childhood AIS. However the functional 
significance of these findings particularly the relative contribution of MP to the thrombotic 
propensity associated with these conditions remains to be defined. As thromboembolic 
disease is a well established complication of systemic vasculitis the prothrombotic potential 
of MP in this systemic vascular inflammatory disorder is examined first prior to using a 
similar approach in childhood arteriopathic AIS a condition confined to the cerebral 
vasculature.  
Objective: Assess the pro-coagulant activity of plasma MPs in children with active systemic 
vasculitis and in relation to thromboses.  
Methods: Children with systemic vasculitis with or without thromboses were studied during 
active or inactive disease as assessed by the Birmingham Vasculitis Activity Score (BVAS) 
and evidence of endothelial injury (circulating endothelial cells, CECs). Annexin V+ MPs 
were quantified using flow cytometry. The MP related thrombin generating capacity was 
quantified using a novel fluorometric thrombin generation assay. 
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Results: 25 children of median age 8 (1.2-16.1) years with vasculitis were studied. Fifteen 
children with active disease (BVAS 7/63, range 5-20/63; CECs 240/ml, range 112-1600 
cells/ml) exhibited significantly higher peak thrombin of 145.85 nM, (80.4-189.2 nM) 
compared to 10 children with inactive vasculitis (BVAS=0/63 in all; CECs 46/ml, range 40-
112 cells/ml): peak thrombin 53.6 nM (45-131.4 nM), p=0.002; and healthy age-matched 
controls: peak thrombin 45 nM (24-60 nM), p=0.001. Peak thrombin correlated significantly 
with the total number of plasma MPs, rs=0.83, p=0.0001. Children (n=7) with vasculitis and 
thrombosis had higher peak thrombin than those without, p=0.0184. Receiver operator 
characteristic analysis of peak thrombin as a tool to diagnose thrombosis was significant, 
p<0.0005.  
Conclusions: Enhanced MP-mediated thrombin generation was demonstrated in children 
with active vasculitis, and was even higher in those with thrombosis. MP-mediated thrombin 
generation combined with endothelial injury could account for the thrombo-embolic 
complications in vasculitis. MP mediated thrombin generation assay provides novel means 
of assessing thrombotic propensity.  
 
 
5.2  Introduction 
 
5.2.1 Thrombosis in systemic vasculitis 
 
 
Thromboembolic disease is a serious complication of systemic vasculitis and is associated 
with significant morbidity and mortality (Merkel et al. 2005; Tomasson et al. 2009; Weidner 
et al. 2006).  In particular arterial and venous thrombosis leading to ischaemic and/or 
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embolic events complicate Kawasaki disease (KD), polyarteritis nodosa (PAN), Takayasu 
arteritis (TA), Behçet’s disease (BD), and more recently have been reported in small vessel 
vasculitides such as antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis 
(AAV) (Houman et al. 2001; Kato et al. 1986;Tomasson, Monach, & Merkel 2009). Merkel 
et al. in 2005 reported on the incidence of venous thrombotic events (VTE) in patients with 
AAV enrolled in the Wegener’s Granulomatosis Etanercept Trial (WGET) in the United 
States. All VTEs were clinically apparent and confirmed with diagnostic studies (Merkel et 
al. 2005).  Among the 167 patients without a history of VTE, 16 experienced events during 
228 person-years of observation, an incidence of 7.0 VTEs per 100 person-years (95% CI, 
4.0 to 11.4) (Merkel et al. 2005). These thrombotic events included either deep venous 
thrombosis (DVT) of lower extremities or pulmonary embolism (Merkel et al. 2005). 
Notably, most VTEs occurred during or closely following periods of active disease (Merkel 
et al. 2005).  In addition, Weidner et al. retrospectively reviewed all patients who were 
treated for AAV at a single nephrology clinic during a 16-year period (Weidner et al. 2006). 
Thirteen of 105 patients had VTEs during the 367.5 person-years of observation, resulting in 
an incidence of 4.3 events per 100 person-years (Weidner et al. 2006). Importantly, no 
patients with VTEs in this cohort were found to have protein C, protein S, or antithrombin 
III deficiencies, antiphospholipid antibodies, factor V Leiden mutation, or nephrotic 
syndrome (Weidner et al. 2006). In another study, Stassen et al. looked at VTE in a cohort of 
198 patients with AAV (Stassen et al. 2008).  During a median follow-up period of 6.1 
years, 25 VTEs occurred in 25 patients, an incidence of 1.8 events per 100 person years 
(Stassen et al. 2008). Similar to what was found in the two above-outlined studies, a much 
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higher incidence of thrombosis (6.7 per 100 person years) was observed during periods of 
active disease (Asahara et al. 1999b; Rehman et al. 2003).  
 
Despite this well established thrombotic propensity associated with vasculitis, the underlying 
mechanism of hypercoagulability remains however poorly defined. For instance the 
prevalences of antiphospholipid antibodies and common genetic mutations associated with 
hypercoagulability were recently determined among individuals in the WGET study 
(Sebastian et al. 2007). Although there was a slightly increase prevalence of 
antiphospholipid antibodies among persons with granulomatosis with polyangiitis (GPA; 
formerly known as Wegener’s granulomatosis) compared with the general population 
(confirming prior reports), there was no association found between the presence of 
anticardiolipin antibodies and VTE (Sebastian et al. 2007). Additionally, the same study 
showed that the prevalences of mutations in factor V Leiden, prothrombin G20210A, and 
methylentetrahydrofolate reductase were not different among patients with GPA and VTE 
compared with rates in the general population (Sebastian et al. 2007). Therefore these reports 
have not demonstrated any increased prevalence of traditional acquired or genetic 
thrombophilia in patients with vasculitis complicated by thromboses compared to the general 
population. 
 
Vasculitis could increase thrombotic risk via several mechanisms (Libby and Simon 2001; 
Trifiletti et al. 2009). The initiating event in activation of the coagulation cascade in vivo is 
expression of active tissue factor (TF), which leads to serial activation of individual 
coagulation factors that lead to fibrin  generation and formation of a thrombus (figure 5-1) 
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(Furie and Furie 2008;Nemerson 1988). Active TF comes in contact with the other 
components of the coagulation cascade through two main pathways. First, disruption of the 
endothelial layer as a result of vascular injury exposes active TF on the underlying 
connective tissue (Rauch and Nemerson 2000; Tomasson, Monach, & Merkel 2009). 
Secondly several inflammatory cytokines that can induce TF expression on endothelial cells 
and circulating monocytes are secreted in systemic vasculitis that may upregulate TF 
expression on endothelial cells and monocytes (Rauch & Nemerson 2000; Tomasson, 
Monach, & Merkel 2009). In addition, activated platelets could also play role in thrombosis 
in vasculitis. Activated platelets release several cytokines including CD40 ligand and 
vascular endothelial growth factor (VEGF), which then stimulate coagulation by induction 
of TF expression on both monocytes and endothelial cells (Henn et al. 1998; Slupsky et al. 
1998; Tomasson, Monach, & Merkel 2009). Other potential mechanisms of association 
between systemic vasculitis and thrombosis include widespread endothelial dysfunction 
resulting in a decreased production of thrombomodulin and other anticoagulant factors 
(Trifiletti, Scamardi, Bagnato, & Gaudio 2009); structural arterial injury including aneurysm 
formation and /or stenoses resulting in altered shear stress forces and flow dynamics (Brogan 
et al. 2002); and anti plasminogen antibodies compromising fibrinolysis (Berden et al. 
2010). Our lack of clear understanding of the relative contribution of each of these 
possibilities however makes primary thrombosis prevention strategies challenging, with lack 
of suitable biomarkers that could define risk in routine clinical practice (Tomasson, Monach, 
& Merkel 2009). The only notable exception is for patients with Kawasaki disease with giant 
coronary artery aneurysms (>8mm), in whom combined use of antiplatelet therapy and 
anticoagulation is well established to reduce the risk of myocardial infarction (Sugahara et 
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al. 2008). Therefore in the absence of a clear mechanism to explain the thrombosis in 
vasculitis, it has been difficult to define a biomarker which could identify patients at risk of 
this complication. Consequently, clinical practice relating to this issue varies widely and 
published guidance mainly focuses on treatment of thrombosis after the event, and secondary 
prevention (Tomasson, Monach, & Merkel 2009).  
 
5.2.2 Thrombin generation assays 
 
Thrombin generation is the endpoint of a series of proteolytic reactions that start with the 
formation of tissue factor-activated factor VII (FVII) complex following vessel wall injury 
(figure 5-1)(Hemker et al. 2004; Van Veen et al. 2008). This results in the generation of 
small amounts of thrombin through activation of the prothrombinase complex, insufficient to 
cause full conversion of fibrinogen to fibrin but causing feedback activation of factor V 
(FV), factor VIII (FVIII) and factor XI (FXI) subsequently leading to a thrombin burst 
converting fibrinogen to fibrin (figure 5-1) (Gailani and Broze Jr 1991; Hemker and Beguin 
1995; Van Veen, Gatt, & Makris 2008). Cell surfaces containing phosphatidylserine (PS) are 
considered to provide a template for these reactions and importantly are now thought to 
actively coordinate the process (Hoffman and Monroe 2001).  Thrombin accelerates its own 
generation by positive feedback systems but also inhibits it through its interaction with 
thrombomodulin (Stassen et al. 2004; Van Veen, Gatt, & Makris 2008). By binding to this 
endothelial receptor, thrombin loses its procoagulant function and can then activate protein 
C. Activated protein C (APC) inhibits activated FVIII (FVIIIa) and activated FV (FVa) with 
protein S acting as a vital cofactor (Esmon and Schwarz 1995;Walker and Fay 1992). In 
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addition, antithrombin is a further major natural anticoagulant inhibiting thrombin 
generation (Lawson et al. 1993). Lastly, after the injured tissue is repaired, clot degradation 
occurs to allow sufficient blood flow (Vassalli et al. 1991). Both tissue-type plasminogen 
activator (tPA) and plasminogen bind to the fibrin fibres followed by the formation of 
plasmin that then lyses the clot (Vassalli, Sappino, & Belin 1991). A number of natural 
inhibitors will inhibit excess levels of plasmin: α1-antitrypsin, α2-antiplasmin, C1-inhibitor 
and α2-macroglobulin (α2M) (van Geffen and van Heerde 2012). By the continuous 
degradation of fibrin, new C-terminal lysine residues become available creating a growing 
surface for extra stimulation of the formation of plasmin (van Geffen & van Heerde 2012). 
This enhanced stimulation is inhibited by the activation of thrombin activatable fibrinolysis 
inhibitor (TAFI) (van Geffen & van Heerde 2012; van Tilburg et al. 2000). 
  
Conventional coagulation tests, such as the prothrombin time (PT) and activated partial 
thromboplastin time (APTT), are not capable of assessing the whole coagulation system 
(Van Veen, Gatt, & Makris 2008). These tests use clot formation as their endpoint which 
occurs when only around 5% of all physiologically relevant thrombin is formed and also are 
insensitive to identifying prothrombotic states (Hemker & Beguin 1995; Rand et al. 1996; 
Van Veen, Gatt, & Makris 2008). Measurement of the thrombin generating capacity, 
however, captures the end result of the interaction between proteases and their inhibitors and 
is therefore potentially more useful as a reflection of a thrombotic (high thrombin 
generation) or bleeding diathesis phenotype (low thrombin generation) compared to 
traditional coagulation tests (Hemker, Al Dieri, & Beguin 2004; Van Veen, Gatt, & Makris 
2008). Measurement of thrombin generation was initially described in 1953 and involved 
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timed subsampling of aliquots from clotting blood or plasma onto a solution of diluted 
bovine plasma (without Ca++) and assessing the thrombin concentration in the sample from 
the clotting time observed (Macfarlane and Biggs 1953). The method used was however 
laborious and subject to high variability. Hemker et al. were the first who reported the use of 
a chromogenic substrate to determine thrombin generation in plasma late 1980s (Hemker et 
al. 1986; Hemker et al. 1993). Subsampling onto a chromogenic thrombin substrate allowed 
automatic recording of the sampling time and semi-automatic measurement of the thrombin 
activities making it possible for several parallel experiments to be done (Hemker, Wielders, 
Kessels, & Beguin 1993; Van Veen, Gatt, & Makris 2008). This substrate used was split by 
thrombin as it was generated in the recalcified plasma and released p-nitroaniline that was 
then measured spectrophotometrically (Hemker, Wielders, Kessels, & Beguin 1993; Van 
Veen, Gatt, & Makris 2008). However there were certain limitations of this assay. The 
conversion of prothrombin to thrombin and subsequent feedback activation usually leads to 
mechanisms to control thrombin formation. One of these mechanisms involved, is the 
covalent binding of thrombin to α2M (Hemker et al. 2007;van Geffen & van Heerde 2012; 
Van Veen, Gatt, & Makris 2008; Wagenvoord et al. 2010). This interaction inhibits the 
activity of thrombin towards it natural substrates, but still allows the conversion of small, 
synthetic substrates leading to residual substrate conversion (Hemker, De Smedt, & Al Dieri 
2007; Van Veen, Gatt, & Makris 2008; Wagenvoord, Deinum, Elg, & Hemker 2010). 
Therefore the final concentration of the thrombin-α2M complex is proportional to the total 
thrombin generation (Hemker et al. 2000; van Geffen & van Heerde 2012; Van Veen, Gatt, 
& Makris 2008). Two methods were developed to overcome this issue:  First, the residual 
activity in the thrombin generation curve was corrected by mathematical modelling and also 
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hydroxylamine or a metalloprotease were employed to remove the α2M activity (Rijkers et 
al. 1998; Hemker et al. 2000; van Geffen & van Heerde 2012;Van Veen, Gatt, & Makris 
2008). Of note, another limitation of using chromogenic substrates is that these emit a signal 
with a wavelength in the visual spectrum (Hemker et al. 2000; van Geffen & van Heerde 
2012; Van Veen, Gatt, & Makris 2008). Therefore defibrinated and platelet-poor plasma is 
required, because the change in turbidity during coagulation interferes with the emitted 
signal of the split product (Hemker et al. 2000; van Geffen & van Heerde 2012; Van Veen, 
Gatt, & Makris 2008).  
 
The drawback of turbidity can fortunately be overcome by the use of fluorescent substrates 
that have since been developed (Hemker et al. 2000; van Geffen & van Heerde 2012;Van 
Veen, Gatt, & Makris 2008). Hemker et al. specifically developed a fluorescent substrate Z-
Gly-Gly-Arg coupled to 7-amino-4- methylcoumarin (AMC) which has been subsequently 
widely used for thrombin generation measurements (Hemker et al. 2000). Upon cleavage by 
thrombin, this substrate releases the AMC fluorophore that has an excitation wavelength of 
390 nm and an emission wavelength of 460 nm (Hemker et al. 2000). There were, however, 
limitations associated with the use of fluorogenic substrates that had to be overcome. Firstly, 
plasma absorbs a significant and variable amount of the light (van Geffen & van Heerde 
2012). There is also variation between apparently normal plasma (van Geffen & van Heerde 
2012). Using the available substrates, the proportionality between reaction velocity and 
product formation can not be maintained during the experiment and as a result, the same 
amount of thrombin activity causes a far greater increase of signal at the beginning of the 
experiment than towards the end (van Geffen & van Heerde 2012). Moreover, the readings 
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are very sensitive to the colour of the plasma, for instance even for minimal haemolysis (van 
Geffen & van Heerde 2012). These drawbacks of fluorescent methods have to be dealt with 
by continuous calibration of every sample (van Geffen & van Heerde 2012). In this 
technique, a fixed amount of constant thrombin activity is added to a parallel sample (van 
Geffen & van Heerde 2012). From the resulting curve, the calibration factor at any level of 
fluorescence is read and the exact thrombin concentration in the sample where thrombin 
generation is taking place can be calculated (van Geffen & van Heerde 2012).   
 
These modifications have led to standardisation of the technique, with good reproducibility 
and little variation thus permitting wider use of thrombin generation measurements in 
clinical studies (Hemker, Al Dieri, & Beguin 2004; Hemker et al. 2000;van Geffen & van 
Heerde 2012). The parameters measured include: (i) the lag time defined as the moment that 
the signal deviates by more than 2 standard deviations from the horizontal baseline; (ii) peak 
thrombin generation; (iii) velocity index which is defined as the rate of thrombin formation 
and (iv) the endogenous thrombin potential (ETP) equivalent to the area under the curve 
(Hemker, Al Dieri, & Beguin 2004; Hemker et al. 2000;van Geffen & van Heerde 2012). A 
typical trace is shown in figure 5-2. Thrombin generation measuring the cumulative effect of 
pro-thrombotic tendencies has since been used as a predictive parameter for thrombosis 
recurrence (Hemker, Al Dieri, & Beguin 2004; Hemker et al. 2000; van Geffen & van 
Heerde 2012). A number of previous studies have established that the presence of 
(prothrombin G20210A) mutation and hereditary deficiencies of protein C, protein S and 
antithrombin are all associated with increased thrombin generation (van Geffen & van 
Heerde 2012). Table 5-1 summarises the data of recent studies examining the relationship 
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between thrombin generation and hypercoagulable states, limited to studies using a 
fluorogenic thrombin generation method. Therefore thrombin generation as a global test for 
overall function of the plasmatic coagulation can be profitably applied to establish 
thrombotic tendencies in clinical practice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1: The coagulation cascade.  
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Figure 5-2: Thrombin generation assay curves. 
Measures recorded are (i) peak height, in nM thrombin, (ii) lag time (time to onset of 
thrombin generation), (iii) velocity index = rate of thrombin generation, and (iv) 
endogenous thrombin potential (ETP) referring to the area under the curve. 
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Studies Subjects Plasma Result 
Andresen et al. (2004) 
 
24 patients with heritable 
thrombophilia 
(7 previous VTE) and 24 
controls 
PPP Mean ETP in patients > 
controls. Patients with 
AT deficiency (n = 6) 
>upper 
limit normal 
Ay et al. (2011) 1033 patients with 
malignancies. VTE 
occurred in 7.5% 
PPP Patients with elevated 
peak thrombin (≥ 611 
nM thrombin) had an 
increased risk of VTE 
Castoldi et al. (2007) 302 individuals from 
unrelated families. 
167 heterozygous (39 with 
previous 
thrombosis) and 3 
homozygous for the F2 
G20210A mutation vs. 132 
non carriers (14 
with previous thrombosis) 
PPP Significantly increased 
thrombin generation in 
patients with increased 
FII concentration due to 
the F2 G20210A 
mutation compared to 
non carriers and 
increased FII not 
associated with this 
mutation 
Chaireti et al. (2009) 98 patients with the FV 
Leiden and 15 with the 
prothrombin mutation 
and an equal number of 
age- and gender-
matched controls.  
PPP Prolonged time both 
for the initiation and 
termination of 
thrombin generation 
in patients with 
thrombosis 
Dargaud et al. (2006) 
 
71 normal subjects, 11  
women on the COCP, 89  
patients after first DVT  
 
PPP ETP >mean + 2SD of 
normal was associated 
with OR 40.5 in patients 
with congenital 
thrombophilia and OR 
5.85 without 
thrombophilic makers 
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for 1st DVT 
Hezard et al. (2006) 
 
169 patients with personal 
or family history of VTE 
t-PRP Significant APC 
resistance in patients 
with protein S 
deficiency and F5 
R506Q compared to 
patients without 
heritable thrombophilia 
Hezard et al. (2007) 
 
102 patients with personal 
or family 
history of VTE 
t-PRP Significant APC 
resistance in patients 
with protein C/S 
deficiency and F5 
R506Q compared to 
patients 
without heritable 
thrombophilia 
Hron et al.  (2006) 
 
914 patients with 1st VTE  
of which 100 had a  
recurrence 
 
PPP Recurrence risk 6.5% if 
peak thrombin <400 
nmol/l and 20% 
if peak thrombin >400 
nmol/l 
Lecompte et al. (2007) 
 
40 patients with 
antiphospholipid 
antibodies (24 with 
thrombosis) and 19 
controls 
PRP Significant activated 
protein C resistance with 
OR for thrombosis up to 
7 
Liestol et al. (2007) 
 
81 patients with LA (52 
APS, 34 on warfarin) 
and 91 controls 
PPP Thrombin generation in 
LA plasma is increased 
independent of warfarin 
use and the degree of 
APC appears to be 
associated with 
thrombotic events 
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Lutsey et al. (2009) 434 cases and 1004 
controls.  
 
PPP Relative to the first 
quartile of peak 
thrombin generation, 
the odds ratio of VTE 
for those above the 
median was 1.74 
(95% CI 1.28-2.37) 
Sonnevi et al. (2008) 243 women with a first 
VTE. In women without 
factor V Leiden 
(n=117), samples 
analysed in the absence 
and in the presence of 
APC 
PPP Increase in ETP and 
peak height in the 
presence of APC 
correlated 
significantly with 
higher risk of 
recurrence. 
Tappenden et al. 
(2007) 
 
50 patients with VTE 
(56% idiopathic) 
and 31 controls 
PPP/PRP/WB 
± CTI 
Thrombin generation 
was significantly 
increased in VTE 
patients in the WB assay 
only 
van Hylckama Vlieg 
et al. (2007) 
360 patients after a first  
VTE  and 404 controls 
PPP OR 1:5 for 1st VTE  
Table 5-1: Studies exploring the relation between thrombin generation and 
hypercoagulable states, limited to those using a fluorogenic method. 
Adapted from van Veen et al. (2008). VTE= venous thromboembolism; AT=anti-thrombin; 
LA=lupus anticoagulant; FVIII: C=FVIII coagulant activity; COCP=combined oral 
contraceptive pill; DVT= deep vein thrombosis; APS=antiphopsholipid syndrome; PPP= 
platelet poor plasma; (ft-) PRP, (frozen-thawed-) platelet rich plasma; WB= whole blood; 
CTI= corn trypsin inhibitor; ETP= endogenous thrombin potential; OR= odds ratio; APC= 
activated protein C; CI=confidence intervals.  
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5.2.3 Pro-coagulant microparticles  
 
As described in chapter 4 MPs are plasma membrane vesicles released from cells during 
activation and apoptosis (Morel et al. 2006; Piccin, Murphy, & Smith 2007;Sabatier et al. 
2009). These circulating MPs are known to alter crucial biologic functions by eliciting 
inflammation, oxidative stress or apoptosis and thrombosis (Morel et al. 2006; Piccin, 
Murphy, & Smith 2007; Sabatier et al. 2009). Normal haemostasis is characterised by a 
dynamic balance between the procoagulant and anticoagulant components of the coagulation 
cascade. MPs may potentially shift this equilibrium in favor of a procoagulant phenotype 
(Morel et al. 2006; Piccin, Murphy, & Smith 2007; Sabatier et al. 2009). The currently 
proposed prothrombotic properties of MPs include: the provision of a large 
phosphatidylserine (PS) surface area for the assembly and activation of coagulation enzyme 
complexes; expression of tissue factor (TF) (Morel et al. 2006; Piccin, Murphy, & Smith 
2007; Sabatier et al. 2009); and the ability to directly activate platelets in the immediate 
vicinity of thrombus formation (Morel et al. 2006; Piccin, Murphy, & Smith 2007; Sabatier 
et al. 2009). Under physiological conditions, very little TF is present in circulation; however, 
during inflammatory states, endothelial cells and monocytes are able to synthesize TF and 
shed it in microparticles (Giesen et al.1999; Shet et al. 2003; Zwicker et al. 2011).  In 
monocytes, TF-bearing microparticles arise from membrane regions that are rich in lipid-raft 
domains which endow the microparticles with other raft-associated proteins such as PSGL-1, 
the primary vascular counter-receptor for P-selectin (Falati et al. 2003). When platelets are 
activated they express P-selectin, allowing microparticles to attach to and fuse with the 
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platelets by a phosphatidylserine-dependent mechanism (Del Conde et al. 2005a; Del Conde, 
Shrimpton, Thiagarajan, & Löpez 2005b). This fusion further increases the procoagulant 
activity of the TF (Del Conde, Shrimpton, Thiagarajan, & Löpez 2005b). Additionally, a 
recent study showed that in vitro activated neutrophils generate microparticles that expose 
the integrin CD11b/CD18 in an active conformation capable of binding GP Iba and 
activating platelets (Pluskota et al. 2008).  
 
In systemic vasculitis the presence of elevated MP during active disease states has been 
previously established by multiple studies (Brogan et al. 2004; Clarke et al. 2010; 
Erdbruegger et al. 2008). However the majority of these have focused on identification and 
enumeration of circulating MP in plasma without examining their functional properties 
particularly their pro-coagulant potential (Brogan et al. 2004; Clarke et al. 2010; 
Erdbruegger et al. 2008). A modification of the traditional thrombin generation assay 
described above could provide a reproducible and precise method of directly measuring the 
MP procoagulant properties and allow us to define the MP contribution to thrombosis in 
systemic vasculitis and other vascular disorders. 
 
5.3 Aims  
 
Children with active vasculitis have been previously shown to have increased annexin V+ 
circulating MPs of endothelial and platelet origin. In this chapter the hypothesis that these 
MP are prothrombotic and could differentiate patients with and without clinical thrombotic 
complications is explored.  The aim of this study was thus to define the pro-coagulant 
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activity of plasma MPs and in relation to clinical thrombotic events in children with systemic 
vasculitis.  
 
5.4 Methods 
 
 
5.4.1 Subjects, classification of vasculitic syndromes and relation to 
disease activity 
 
Children with primary systemic vasculitis attending a single centre (Great Ormond Street 
Hospital, London) between October 2008 and June 2010 were studied. Inclusion criteria 
were: age <18 years, a diagnosis of primary systemic vasculitis confirmed by 
histopathologic and/or arteriographic assessment and exclusion of secondary causes of the 
vasculitis (infection, connective tissue disease, or malignancy).  Control samples were 
obtained from healthy age- and sex-matched children. The study was approved by the 
Institutional Ethics Committee (project ethics number 04/Q0508/117). Fully informed 
written consent was obtained from all subjects studied.  
 
The vasculitis subtype was classified using the new European League Against Rheumatism/ 
Paediatric Rheumatology International Trials Organisation/Paediatric Rheumatology 
European Sociaty (EULAR/PRINTO/PRES) classification criteria for paediatric vasculitides 
by Ozen et al. for polyarteritis nodosa (PAN) and GPA (formerly known as Wegener’s 
granulomatosis; WG) (Ozen et al. 2010). Definitions for Kawasaki Disease (KD), Behçets 
Disease (BD), and Churg Strauss syndrome (CSS) are not included in this classification 
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scheme. KD was thus defined as patients fulfilling at least 5/6 American Heart Association 
criteria (Newburger et al. 2004); BD was defined based on the International Study Group for 
BD published set of diagnostic criteria (International study group for Behçets disease, 1990). 
CSS was defined using the Chapel Hill consensus criteria (Jennette et al. 1994). Patients 
with unclassified vasculitis had histologically proven vasculitis but did not satisfy criteria for 
any one category.  
 
Disease activity was assessed using a modified paediatric Birmingham Vasculitis Activity 
Score (BVAS) incorporating age specific laboratory reference ranges, as previously 
described (see appendix 6) (Brogan et al. 2004; Luqmani et al. 1994). Active vasculitis was 
defined as a score greater than zero for BVAS items attributable to vasculitis that newly 
appeared or worsened during the preceding 4 weeks and for which other causes such as 
infection were excluded (Brogan et al. 2004; Luqmani et al. 1994). The following routine 
laboratory markers providing adjunctive information related to vasculitis activity were 
determined: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) levels. 
Thrombosis was classified based on clinical events and confirmed by vascular ultrasound, 
computed tomography, magnetic resonance or catheter angiography. Samples were taken at 
the onset of thrombotic events. Supporting evidence of ongoing endothelial injury was 
provided by enumeration of CECs as described previously in chapter 3. 
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5.4.2 Assessment of routine prothrombotic risk factors  
 
Conventional risk factors for thrombosis were assayed routinely by the haematology clinical 
laboratory at Great Ormond Street Hospital. These included assessments for deficiency of 
protein C, protein S, antithrombin III, presence of anticardiolipin antibodies and lupus 
anticoagulant,  genetic mutations of factor V Leiden gene, prothrombin gene G20210 and 
methylene tetrahydrofolate reductase (MTHFR C677T). Measurement of antithrombin III 
was based on a functional chromogenic assay performed using Siemens reagents supplied by 
Sysmex. Protein C was measured using a functional chromogenic assay performed with 
Unimate reagents supplied by Pathway Diagnostics. APC resistance was based on a Factor V 
dependent prothrombin activator isolated from snake venom using reagents supplied by Hart 
Biological. Protein S was assayed using an immunoturbidometric assay performed using 
reagents Stago diagnostic reagents.  Dilute Russel Viper Venom Test (DRVVT) was assayed 
using Unitest reagents supplied by Pathway Diagnostics. All above assays were performed 
on a Sysemex CA1500 coagulation analyser. The titres of anticardiolipin antibodies were 
measured using an ELISA test AESKULISA CardiolipinGM supplied by Grifols.  
 
Testing for the identification of the factor V Leiden (FVL) mutation, the pro-thrombin gene 
mutation (G20210), and the   methylenetetrahydrofolatereductase (MTHFR) gene mutation 
was performed in the clinical haematology lab of Great Ormond Street Hospital using allelic 
discrimination by fast chemistry real time PCR according to published methods (Sebastian, 
Voetsch, Stone, Romay-Penabad, Lo, Allen, Davis Jr, Hoffman, McCune, & St Clair 2007).  
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5.4.3  Cellular microparticle identification by flow cytometry  
 
MPs were identified by flow cytometry as previously described in chapter 4. MPs 
sedimented from 200μl of PPP after centrifugation at 15000g for 60 min were re-suspended 
in An V binding buffer (BD PharMingen, Oxford, United Kingdom) and stained with 
annexin V conjugated with fluorescein isothiocyanate (FITC; BD PharMingen) or annexin 
V-phycoerythrin (PE; BD PharMingen, UK).  For measuring EMP, PMP, NMP and TF 
staining  samples were additionally incubated with mouse (PE)-labeled anti-human CD62e 
(Clone 68-5H11, BD PharMingen, UK), mouse TRI-COLOR labeled anti-human CD41 
(Clone VIPL3, Caltag laboratories, UK), PE-conjugated anti-human CD11b activation 
epitope (clone CBRM1/5, Biolegend, UK), and mouse FITC–conjugated  anti-human TF 
(clone VD8, American Diagnostica, USA) respectively as well as the relevant isotype 
controls (as per manufacturer recommendation) for 20 minutes at room temperature. 
Samples were analyzed with a FACSCalibur flow cytometer (Becton Dickinson). 
 
5.4.4 Thrombin generation assay (TGA) 
 
The TGA measures the amount of active thrombin produced in plasma or whole blood after 
re-calcification by monitoring the conversion of a fluorogenic substrate cleaved by thrombin 
as the latter is generated (Hemker et al. 2008).  Direct calculation of molecular 
concentrations of thrombin are possible by comparison to a concurrently run calibrator (see 
appendix 7). For the thrombin generation assay MPs sedimented from PPP as above were re-
suspended in 200 µL of control microparticle-free plasma (MPFP): MP free plasma prepared 
after MP sedimentation from approximately 50-60 mL plasma from adult healthy volunteers, 
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with 30 µg/ml of corn trypsin inhibitor (Sigma) added to prevent potential in vitro contact 
activation of the coagulation cascade.  Subsequently 40 µL of MPs suspended in control 
MPFP was added to the plate well, followed by 50 µL of calcium-fluorogenic substrate (0.5 
mM/L of Z-G-G-R-AMC and 7.5 mM/L of calcium final reagent concentrations, Pathway 
Diagnostics). No exogenous TF or phospholipids were added at this stage to ensure that the 
thrombin generated was solely dependent on MP related coagulant activity. The thrombin 
generated was measured by fluorogenic excitation/ emission at 360/460 nm at 1 minute time 
intervals for 90 minutes against a standard thrombin calibrator  (Pathway Diagnostics) in an 
Optima fluorescence plate reader (BMG). Measures recorded were: (i) height of peak 
thrombin (nM); (ii) lag time (time to onset of thrombin generation); (iii) velocity index = 
rate of thrombin generation; and (iv) endogenous thrombin potential (ETP) = the area under 
the curve (Figure 5-2). 
 
5.4.5 In vitro microparticle mediated thrombin generation  
 
A number of potent stimulants were used to induce in vitro MP formation in whole blood (5 
µg/ml of LPS derived from E. Coli, O55:B5 stimulation for 4 hours; TNF-α 100 ng/ml for 5 
hours; and calcium A23187 10 nM for 1 hour). Unstimulated samples were used as controls. 
PPP was prepared from these samples following centrifugation at 5000g twice. MP presence 
was confirmed with flow cytometry as previously described. As EMP normally represent a 
sparse population of MP, whole blood stimulated with LPS was also spiked with EMPs 
pelleted from supernatants derived from HUVEC stimulated with TNF-α (100 ng/ml for 24 
hours). MP pellets derived from thus stimulated and control unstimulated samples were then 
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resuspended in MPFP and processed for TGA as described in 5.4.4.  All samples were 
analysed in triplicate to establish the reproducibility of the technique.  
 
 
5.4.6 Thrombin generation capacity of plasma following removal of MPs 
by filtration  
 
PPP samples obtained from whole blood stimulated with lipopolysaccharide (LPS derived 
from E. Coli, O55:B5, Sigma) at 5 µg/ml for 4 hours to induce MP formation spiked with 
EMP (pelleted from supernatants derived from HUVEC stimulated with TNF-α at 100 ng/ml 
for 24 hours) were filtered through a 0.2 μm, low protein binding filter to remove MPs. MPs 
were recovered from filters by rinsing with an equal volume of MPFP. The thrombin 
generating capacity of filtered and unfiltered samples was assessed.  
 
5.4.7 Relative contribution of PS and tissue factor to MP mediated 
thrombin generation 
 
To investigate the relative contribution of PS and TF to MP mediated thrombin generation, 
MPs isolated from LPS stimulated whole blood (5 µg/ml for 4 hours) spiked with EMP 
(pelleted from supernatants derived from HUVEC stimulated with TNF-α at 100 ng/ml for 
24 hours) were pre-incubated with increasing concentrations of purified recombinant AnV 
protein (BD Pharmingen) to inhibit PS; or a blocking monoclonal antibody against TF 
(epitope areas of amino acids 1-25 of TF, American Diagnostica) or control purified IgG1 
antibody (Biolegend) at 370 C for 20 minutes. MPs pre-treated in these experiments were 
then re-suspended in control MPFP (prepared as described above) and the thrombin 
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generating capacity was determined. Dose response curves were thus obtained and allowed 
optimal concentrations for these blocking reagents to be established: 1µg/106 MPs for AnV; 
and 20 µg/106 MPs for TF. These concentrations were then used in similar inhibition 
experiments using MP derived from vasculitis and control patient samples.  
 
 
5.4.8 Differential contributions of monocyte and platelet-derived 
microparticles towards thrombin generation and tissue factor pro-
coagulant activity 
 
In order to examine the specific contributions of monocyte and platelet-derived MPs to 
thrombin generation MPs were prepared from stimulated human platelets and monocytes as 
described in chapter 4. MPs were then resuspended at a concentration of 106 /ml in MPFP 
and then compared as for their ability to initiate thrombin generation.  
 
FXa generation per MP was also measured by chromogenic substrate cleavage and 
referenced to a standard curve of lipidated recombinant human TF (TF activity kit, American 
Diagnostica). In brief PPP samples prepared as above were mixed with human factor VIIa 
and human factor X and incubated at 370C during which time the tissue factor/factor VIIa 
complex is formed and the complex converts the human factor X to Factor Xa. The Factor 
Xa generation was measured by chromogenic substrate cleavage (spectrozyme FXa that is 
highly specific to factor Xa) and referenced to a standard curve of lipidated recombinant 
human TF. Solution absorbance was read at 405 nm in an Optima plate reader (BMG). 
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These experiments comparing the differential contributions of monocyte and platelet MP to 
thrombin generation and TF activity were repeated with MPs pre-incubated with anti-TF 
antibody (20 µg/106 MP) or an isotype-matched control IgG for 15 min at 370 C. 
 
 
5.5 Statistical analysis 
 
All experiments were performed at least in triplicate, and values are presented as mean +/-
SEM unless otherwise specified. Statistical differences for in vitro experiments between 
groups were determined by two-way ANOVA, followed by unpaired two-tailed t test. 
Patient demographics and comparisons between groups were summarized as median and 
range unless otherwise specified. The Kruskal-Wallis test was used to examine overall 
differences in experimental laboratory markers between the study groups. Following this, 
statistical differences between groups were determined by Mann-Whitney U test. 
Associations between cumulative MP counts and peak thrombin generated were assessed 
using Spearman’s rank correlation coefficient. Receiver operator characteristic (ROC) 
curves, sensitivity, specificity, positive and negative predictive values, and likelihood ratios 
were calculated to examine the diagnostic test characteristics of peak thrombin for 
thrombosis in active vasculitis. ROC analysis was reported as area under the curve (AUC) 
and 95% confidence intervals (CI). P-values of less than 0.05 (two sided) were regarded as 
significant. Statistical analysis was performed using SPSS version 17.  
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5.6 Results 
 
5.6.1 Patients and controls  
 
Twenty five children, 8 male, with a median age of 10 years (range 1.2-16.1) at diagnosis 
with systemic vasculitis were studied. There were 15/25 children with active vasculitis (PAN 
n=7; KD n= 3; WG n=3; CSS n=1; BD n=1) with BVAS 7/63 (5-20/63), ESR 56.5 (40–159) 
mm/h, CRP 45 (10–270) mg/L and CECs 240 (112-1600) cells/ml; and 10 children with 
inactive vasculitis (PAN n=3, WG n=4, unclassified n=2, CSS n=1) BVAS=0/63 in all, ESR 
5 (5–10) mm/h, CRP 7 (5–15) mg/ L and CECs 46, range 40-112 cells/ml. Five children 
with active vasculitis were on corticosteroids and one child had received one dose of 
intravenous (i.v.) cyclophosphamide. Six children with inactive vasculitis were on oral 
corticosteroids and i.v. cyclophosphamide; two were receiving azathioprine and two were on 
mycophenolate mofetil. 
 
Of those patients with active vasculitis, 7/15 presented with thrombotic events: cerebral 
arterial infarction n=2 (both with PAN); cerebral sinovenous thrombosis n=1 (BD); 
myocardial infarction n=1 (KD); digital infarction n=2 (both with PAN); thrombotic 
peripheral gangrene n=1 (WG). Two of these children whose disease was complicated by 
thromboses (a patient with PAN and cerebral arterial infarction and the patient with WG and 
peripheral skin gangrene) were also studied following treatment of vasculitis after remission 
of vasculitis had been induced.  
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Five children out of 25 (including 2 who had a thrombotic event) were found to be 
heterozygous for MTHFR C677T mutations. The rest of the screen for conventional pro-
thrombotic risk factors was negative for all remaining patients. None of the children were 
receiving anti-coagulant therapy at the time of sampling. All children with KD were on high 
“anti-inflammatory” dose aspirin 40 mg/kg/day. There were 10 paediatric healthy controls, 3 
male, median age 9.8 years (2-16 years) with a median CEC count of 24 cells/ml (range 0-80 
cells/ml).  
 
 
5.6.2 LPS stimulation of whole blood results in increased MP-mediated 
thrombin generation  
 
The ability to detect the MP mediated thrombin generating capacity by using a potent 
inflammatory stimulus was initially confirmed. MP suspensions from LPS stimulated whole 
blood (5 µg/ml for 4 hours) contained significantly higher number of circulating total 
Annexin V+ MPs  1200 (range 800-1400) x 103/ml compared to healthy control blood 200 
(50-250) x 103/ml, p=0.001 (figure 5-3A). Representative thrombin generation curves for 
LPS-stimulated and un-stimulated samples are shown in figure 5-3B. These MP suspensions 
also exhibited significantly greater MP-related peak thrombin median 167 (range 160-175 
nM) and ETP median 3286 (range 2656-3661) nM x min compared to healthy control blood 
not treated with LPS: median peak thrombin 65, range 60-70 nM, p=0.02; and median ETP 
1528 (range 1376-2269) nM x min, p=0.02 (n=3; figure 5-3B). There additionally was a 
shorter lag time median 11 min (range 10-15 min) and increased velocity index 17 nM/min 
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(range 15-25 nM/min) for MP suspensions derived from stimulated whole blood compared 
to controls lag time 17 min (range 15-21), p=0.001 and velocity index 7 nM/min (5-12 
nM/min), p=0.002. For control MPFP alone (no MPs added) there was negligible 
contribution to thrombin generation (Figure 5-3C). The average coefficient of variation for 
these measurements was 5.2% (range 1.7-8.2%) suggesting a good reproducibility of the 
technique. Increasing concentrations of plasma MPs resulted in shorter lag time, higher peak 
of thrombin; increased velocity index and enhanced ETP (figure 5-4). Similar results were 
obtained with other stimulants (TNF-α and calcium A23187) and also when LPS stimulated 
whole blood was spiked with EMP harvested from the supernatants of HUVEC stimulated 
with TNFα (100ng/ml for 24 hours).   
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Figure 5-3: LPS stimulation of whole blood induces microparticle formation with 
thrombin generating capacity. (A) Microparticle suspensions from LPS stimulated whole 
blood contained significantly higher number of total AnnexinV+ MPs compared to control 
blood, p=0.001. (B) Representative thrombin generation curves for LPS-stimulated and un-
stimulated samples. (C) Microparticle suspensions from LPS stimulated whole blood 
exhibited significantly greater MP-related peak thrombin compared to healthy control 
blood, p=0.02 (n=3). MPFP=Microparticle free plasma. ***P<0.005 with student t test.  
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Figure 5-4: Increasing concentrations of plasma microparticles resulted in shorter lag 
time; higher peak of thrombin; increased velocity index and enhanced endogenous 
thrombin potential.  
 
 
5.6.3 Filtration of plasma removes MPs and abrogates MP-mediated 
thrombin generation 
 
Filtration of MP samples through a 0.2µm filter resulted in removal of the majority > 95% of 
circulating MPs from a count of 1300 (SEM 200) x103 /ml prior to filtration to 50 (SEM 20) 
x103 /ml following filtration (Figure 5-5 A). There was also significant reduction of the 
thrombin generating capacity of the sample down to 10% (SEM 2.5%) of the baseline 
thrombin generating capacity (Figure 5-5 B). MPs rinsed off the filter and reconstituted in 
200µl of MPFP prepared as described above recovered their thrombin generation potential 
95% (SEM 2.3%) of baseline peak thrombin (Figure 5-5B). 
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Figure 5-5: Filtration of plasma removes microparticles (MPs) and abrogates MP-
mediated thrombin generation.  
Filtration of plasma through a 0.2 µm pore size filter abrogated thrombin generation by 
removing the majority of circulating microparticles (MP). The thrombin generating capacity 
of these MP could be almost completely recovered by rinsing these off the filter.  
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5.6.4 MP- mediated thrombin generation is increased in active vasculitis 
patients with thrombotic complications 
 
Children with active vasculitis exhibited a significantly higher peak thrombin of 145.85 
(80.4-189.2) nM compared to the children with inactive vasculitis, median peak thrombin 
53.6 (45-131.4) nM, p=0.002; and healthy controls, peak thrombin 45 (24-60) nM, p=0.001; 
Figure 5-6 A. For children with active vasculitis there was in addition a shorter lag time of 
median 18 minutes (12-18); higher velocity index  median 15 nM/min (5.7-22); and higher 
median ETP of 3500 (1963-4639) nM x min compared to children with inactive vasculitis 
with lag time median 23 minutes (18-31), p=0.02; velocity index median 2.9 nM/min (1.6-
8.9), p=0.0001; median ETP 1818 (783-3963) nM x min, p=0.0005; and healthy controls 
with median lag time 32 minutes (27-38), p=0.002; median velocity index 1.5 nM/min (0.06-
2.2), p=0.0001; median ETP 1373 (501-1800) nM x min, p= 0.0005; (Figure  5-6 B, C and 
D). The peak thrombin generated correlated significantly with the total number of plasma An 
V+ MPs: rs=0.83, p=0.0001 (Figure 5-7).  
 
Children with active vasculitis and thrombotic events (n=7/15) had significantly higher peak 
thrombin, median 160 nM (113.9-191.9), p=0.0184 compared to children with active 
vasculitis without thromboses, median 91.5 nM (80.4-130) (Figure 5-8).  There were no 
significant differences between children with thrombosis in factor VIII levels 240 (110–320) 
IU/dL, fibrinogen 3.7 (3.1–7.2) g/L, platelet count 520 (420–650) x 109/L, white cell count 
16 (14–18) x 109/L) and those without thrombosis factor VIII 210 (144– 404) IU/dL, p = 0.7, 
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fibrinogen 3.4 (3.1–6.6) g /L), p = 0.3, platelet count 490 (400–620) x 109/L, p = 0.6, white 
cell count 15 (13–18) x 109/L, p = 0.7. 
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Figure 5-6: Microparticle mediated thrombin generation in children with systemic vasculitis. 
(A) Children with active vasculitis exhibited a significantly higher peak thrombin compared 
to the children with inactive vasculitis, p=0.002; and healthy controls, p=0.001.  
(B, C and D) For children with active vasculitis there was in addition a shorter lag time, 
higher velocity index and higher median endogenous thrombin potential (ETP) compared to 
children with inactive vasculitis and healthy controls. ***P< 0.0005 with Mann Whitney U 
test.  
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Figure 5-7: The peak thrombin generated correlated significantly with the total number of 
plasma Annexin V+ MPs: rs=0.83, p=0.0001.  
 
 
 
 
 
 
 
 
 
Figure 5-8: Microparticle mediated thrombin generation in children with systemic 
vasculitis and thromboses.  
Children with active vasculitis and thrombotic events (n=7/15) had significantly higher peak 
thrombin, median 160 nM (113.9-191.9 nM) compared to children with active vasculitis 
without thromboses, median 91.5 nM (80.4-130 nM), p=0.0184. *P<0.05 by Mann Whitney 
U test. 
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5.6.5 MP-mediated peak thrombin generation differentiates vasculitis 
patients with and without thrombosis 
 
ROC curve analysis of peak thrombin as a diagnostic test for thrombosis in children with 
systemic vasculitis was significant with an AUC of 0.93, SE 0.04 with 95% CI of 0.845-
1.000, p=0.0005 (figure 5-9). A cut-off peak thrombin >142.5nM with specificity of 95.65 % 
(95% CI of 78.05-99.89%) and sensitivity of 71.43% (95% CI of 29.04-96.73%) resulted in 
a positive likelihood ratio of 16.43 and negative likelihood ratio of 0.29 for thrombosis in 
children with systemic vasculitis with a positive predictive value of 94% (95% CI 85-98%). 
Table 5-2 summarises the diagnostic test characteristics of MP-mediated peak thrombin 
generation for thrombosis complicating active systemic vasculitis.  
 
 
 
 
 
 
 
  
 
Figure 5-9: Peak thrombin nM as a diagnostic test for thrombosis in childhood systemic 
vasculitis.  
Receiver operator curve (ROC) analysis of peak thrombin as a diagnostic test for 
thrombosis in children with systemic vasculitis was significant with an area under the curve 
(AUC) of 0.93 with 95% CI of 0.845-1.000, p=0.0005.  
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Peak 
thrombin 
nM 
 
Sensitivity 95% CI Specificity 95% CI LR+ LR- PPV NNV 
> 28.85 1.000 0.590-
1.000 
0.04348 0.001- 
0.2195 
1.05  0           51 100 
> 41.25 1.000 0.590-
1.000 
0.08696 0.010-
0.2804 
1.10  0       52 100 
> 42.95 1.000 0.590 -
1.000 
0.1304 0.02775
- 0.3359 
1.15  0             53.48 100 
> 44.25 1.000 0.590 -
1.000 
0.1739 0.04951
-0.3878 
1.21  0               54.64 100 
> 45.20 1.000 0.590 -
1.000 
0.2174 0.07460
-0.4370 
1.28  0              55.87 100 
> 47.65 1.000 0.590 -
1.000 
0.2609 0.1023-
0.4840 
1.35  0               57.47 100 
> 51.30 1.000 0.590 -
1.000 
0.3478 0.1638-
0.5727 
1.53  0               60.61 100 
> 53.10 1.000 0.590 -
1.000 
0.3913 0.1971-
0.6146 
1.64  0               62.11 100 
> 54.05 1.000 0.590- 
1.000 
0.4348 0.2319-
0.6551 
1.77  0             63.69 100 
> 57.25 1.000 0.590-
1.000 
0.4783 0.2682-
0.6941 
1.92  0              65.79 100 
> 60.50 1.000 0.590 - 
1.000 
0.5217 0.3059-
0.7318 
2.09  0               67.57 100 
> 66.15 1.000 0.590- 
1.000 
0.5652 0.3449-
0.7681 
2.30  0             69.44 100 
> 72.90 1.000 0.590 -
1.000 
0.6087 0.3854-
0.8029 
2.56  0              71.43 100 
> 86.35 1.000 0.590 -
1.000 
0.6522 0.4273-
0.8362 
2.88  0              74.07 100 
> 99.25 1.000 0.590- 
1.000 
0.6957 0.4708-
0.8679 
3.29  0               76.34 100 
> 107.1 1.000 0.590- 
1.000 
0.7391 0.5160-
0.8977 
3.83  0            78.74 100 
> 117.0 0.8571 0.421- 
0.996 
0.7391 0.5160-
0.8977 
3.29 0.19 75.89 82.95 
> 121.8 0.8571 0.421- 
0.996 
0.8261 0.6122 -
0.9505 
4.93 0.17 82.52 84.54 
> 126.8 0.7143 0.290- 
0.963 
0.8261 0.6122 -
0.9505 
4.11 0.34 79.78 73.87 
> 130.7 0.7143 0.290- 
0.963 
0.8696 0.6641- 
0.9722 
5.48 0.32 83.53 74.78 
> 135.7 0.7143 0.290- 
0.963 
0.9130 0.7196 -
0.9893 
8.21 0.31 88.75 75.83 
> 142.5 0.7143 0.290- 
0.963 
0.9565 0.7805 -
0.9989 
16.43 0.29 93.42 76.61 
> 152.5 0.7143 0.290- 
0.963 
1.000 0.8518 - 
1.000 
Infinity  0.28 100 77.52 
> 161.5 0.5714 0.184- 1.000 0.8518 - Infinity   0.42 100 69.63 
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Table 5-2: Test characteristics of microparticle peak thrombin generation for diagnosis of 
thrombosis in children with systemic vasculitis.  
CI= confidence intervals; LR+=Likelihood ratio for a positive test; LR- =likelihood ratio 
for a negative test; PPV=positive predictive value; NPV=negative predictive value.  
 
 
5.6.6 Total An V+ MPs, PMPs and EMPs are higher in vasculitis patients 
with thromboses 
 
Patients with active vasculitis and thromboses had significantly higher total AnV+ MPs 
(1487 x103/ml, range 331-2406 x103/ml); PMPs (940 x103/ml, range 470-1100 x103/ml); and 
EMPs (455 x103/ml, 240-749 x103/ml) than children with active vasculitis and no 
thromboses (total AnV+ MP 270 x103/ml (64-764 x103/ml), p=0.001; PMPs 234 x x103/ml 
(32-300 x103/ml),  p=0.02; EMPs 23.96 x103/ml (2-123 x103/ml), p=0.04;  (Figure 5-10). 
There was no significant difference in NMPs between these patient groups, p=0.514. 
 
Circulating TF+ MPs were found at lower levels than PMP or EMP in all patient groups. 
There was no significant difference in TF+ MPs in children with active vasculitis and 
thromboses (median 7 x103/ml, range 1.066-25.051/ x103/ml) compared to those patients 
0.901 1.000 
> 172.1 0.4286 0.098-
0.815 
1.000 0.8518 -
1.000 
Infinity   0.57 100 63.69 
> 186.5 0.2857 0.036-
0.709 
1.000 0.8518 -
1.000 
Infinity   0.71 100 58.14 
> 192.0 0.1429 0.036 -
0.578 
1.000 0.8518 -
1.000 
Infinity   0.85 100 53.76 
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with active vasculitis without thromboses (median 3. 350 x103/ml, range 2.1-3.8 x103/ml, 
p=0.4); or those with inactive vasculitis (median 2.5  x103/ml, range 2-3.6  5  x103/ml, 
p=0.14) and healthy controls median 2.15  x103/ml (range 0.1 -6.7 /ml x103/ml), p=0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-10: Circulating microparticle (MP) profiles in children with systemic vascultis 
and thrombosis.  
Platelet MPs were defined as CD41-TRICOLOR+AnV+; neutrophil derived MP as 
aCD11b+AnV+; and endothelial derived MP as CD62e+Anv+.  **P < 0.001 with Mann 
Whitney U test.  
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5.6.7 Relative contribution of PS and TF to MP mediated thrombin 
generation 
 
Increasing amounts of AnV protein (to bind and inhibit PS) completely abrogated thrombin 
generation mediated by MPs derived from LPS stimulated whole blood:  thrombin 
generation was reduced by 99% by 1 µg of AnV /106 MPs (figure 5-11). These results 
suggest that the procoagulant properties of MPs are largely due to the PS exposure.  
 
TF neutralisation (maximum inhibition established from previous experiments at a 
concentration of 20 µg/ 106 MPs- see methods section) had the most significant effect on the 
initial phase of thrombin generation resulting in prolongation to control values of lag time 28 
(24–30) min, whilst a purified IgG1 negative control blocking antibody had no effect (figure 
5-12).   
 
Incubation of MP suspensions obtained from patient samples with AnV at 1 µg/106 MPs 
again completely abolished thrombin generation. The effect of TF neutralization on MP 
mediated thrombin generation for children with vasculitis also was similar to that observed 
using MP generated using LPS from whole blood with a prolongation of lag time to 29 
(range 23-32 mins).  
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Figure 5-11: Increasing concentrations of Annexin V abolished microparticle mediated 
thrombin generation. 
 
 
 
 
 
 
 
 
Figure 5-12: Tissue factor inhibition of microparticle mediated thrombin generation. An 
anti-human tissue factor antibody resulted in an average prolongation of lag time by 10 min 
(8–12) to control values of median 28 (24–20) min whilst a purified IgG1 negative control 
blocking antibody had no effect.  
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5.6.8 Differential contributions of monocyte and platelet-derived 
microparticles towards thrombin generation  
 
Platelet and monocyte MPs resuspended in MPFP at a concentration of 106 /ml were 
compared as for their ability to initiate thrombin generation. 
Figure 5-13 A shows TF activity on monocyte derived MPs (12 ± 2 pM TF per 106 MP).  
However, PMPs, regardless of the agonist used for their derivation, did not generate FXa (1± 
0.6 pM TF per 106 MP) suggesting PMPs do not support tissue factor pro-coagulant activity. 
 
PMPs shortened the lag time 43.00 ± 2.646 min compared to 58.00 ± 1.528 min for PBS 
(p=0.008). PMPs also increased the peak thrombin 95.00 ± 2.887 nM over PBS controls 
1.000 ± 0.5774 nM, p=0.001 (figure 5-13 B and C). These activities were not blocked by 
anti-TF antibody (concentration 20 µg/ 106MP) peak thrombin 95.00 ± 2.887 nM at baseline 
and 90.33 ± 2.603 nM after TF neutralisation indicating this activity was TF independent.  
 
In contrast monocyte MPs significantly shortened the thrombin lag time 17.67 ± 0.8819 min 
compared to 58.00 ± 1.528 min for PBS (p=0.0001) and increased the peak thrombin nM 
170.0 ± 11.55 nM compared to 1.000 ± 0.5774 nM in control PBS (p=0.001) in a TF-
dependent manner (peak thrombin 116.7 ± 8.819 nM, p=0.003 following TF neutralisation).  
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These findings suggest MPs from different parent cells uniquely contribute to coagulation, 
and that the relative concentration of circulating MPs from different cell types influences 
thrombosis risk. 
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Figure 5-13: Monocyte-derived microparticles (MMPs), but not platelet-derived MPs 
(PMPs), promote thrombin generation in a tissue factor (TF)-dependent manner.  
(A) TF activity was determined by factor (F) Xa chromogenic substrate cleavage (n = 3). (B) 
and (C) Thrombin generation supported by  106 PMP or MMP was measured in the presence 
of anti-TF or control IgG. Thrombin lag time and peak thrombin nM are shown. 
PBS=phosphate buffer saline. **P < 0.001 using paired student’s t-test between anti-TF and 
IgG controls. 
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5.7 Discussion 
 
 
The mechanisms contributing to thrombosis in systemic vasculitis are poorly defined and the 
increased risk is not explained by conventional pro-thrombotic risk factors (Sebastian et al. 
2007; Tomasson, Monach, & Merkel 2009). This study demonstrates for the first time 
enhanced MP-mediated thrombin generation in children with active vasculitis, with 
significantly higher levels of thrombin generation in those with documented thrombotic 
events. Thrombin generation correlated significantly with the total number of plasma MPs, 
suggesting that the hyper-coagulability in vasculitis is directly related to the number of these 
circulating MPs. These data suggest that MP mediated thrombin generation provides a novel 
prothrombotic mechanism, which, in the context of endothelial injury and structural arterial 
damage (such as aneurysm formation and/or arterial stenoses), could explain the 
pathological thrombosis observed in vasculitis.  
 
Thrombo-embolic disease complicating systemic vasculitis is associated with significant 
morbidity and mortality (Tomasson, Monach, & Merkel 2009). Most VTEs occurred during 
or closely following periods of active disease (Merkel et al. 2005; Tomasson, Monach, & 
Merkel 2009; Weidner et al. 2006). Subsequently Sebastian et al. found no association 
between the presence of conventional prothrombotic risk factors and VTE in the same cohort 
of patients (Sebastian et al. 2007). This current study also now confirms lack of contribution 
of conventional prothrombotic risk factors to the increased thrombosis observed in children 
with vasculitis.  Vasculitis could increase thrombotic risk via several mechanisms including: 
endothelial injury and TF exposure on endothelial cells and monocyte; platelet activation; 
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structural arterial injury including aneurysm formation and /or stenoses resulting in altered 
shear stress forces and flow dynamics; anti plasminogen antibodies compromising 
fibrinolysis or other as yet undefined mechanisms (Berden et al. 2010; Brogan et al. 2009; 
Trifiletti, Scamardi, Bagnato, & Gaudio 2009). Our lack of clear understanding of the 
relative contribution of each of these possibilities makes primary thrombosis prevention 
strategies challenging, with lack of suitable biomarkers that could define risk in routine 
clinical practice.  
 
Previous studies have shown that it is possible to monitor endothelial injury in systemic 
vasculitis in children by the detection of circulating EMPs allowing non-invasive tracking of 
vasculitic disease activity, an observation now also confirmed in adults with ANCA 
associated vasculitides (Brogan et al. 2004; Clarke et al. 2010; Erdbruegger et al. 2008). The 
majority of these studies of circulating MPs in systemic vasculitis have been based on flow 
cytometric quantification of numbers of MPs in circulation rather than study of their 
functional properties (Brogan et al. 2004; Clarke et al. 2010; Erdbruegger et al. 2008). A 
modified thrombin generation assay was employed herein to explore for the first time the 
prothrombotic properties of MPs in children with systemic vasculitis. This is an important 
pathway to study in this context since the generation of thrombin is essential in haemostasis 
and thrombosis. Produced at sites of vascular injury in the vicinity of a thrombus, thrombin 
promotes clotting and clot stability by modulating fibrin properties, including its network 
structure and resistance to fibrinolysis (Wolberg 2007). Thrombin in addition promotes 
platelet activation and adhesion, and trafficking of inflammatory cells into sites of vascular 
injury (Davey et al. 1967; Strukova 2001). In addition, the important role of thrombin as a 
 252 
key molecule in relation to venous thrombotic disease is largely evident from medical 
practice where treatment and prevention of venous thrombosis require medication that 
diminish thrombin activity by either inhibiting prothrombin synthesis (vitamin K 
antagonists) increasing antithrombin activity (heparins), or by inhibiting thrombin directly 
(hirudin and small-molecular-weight reversible inhibitors) (van Geffen & van Heerde 2012). 
Automation of the thrombin generation assay by Hemker et al. has led to an increased use of 
the technique to appreciate hypecoagulable states in several conditions associated with 
increased thrombotic risk while the current methodology used is reproducible and well 
suited for clinical applications (Hemker, Willems, & Beguin 1986; Hemke et al.1993; 
Hemker et al. 2003; Hemker & Beguin 1995). Of note, a number of previous studies have 
suggested that contact factor activation may influence thrombin generation results (Hemker, 
Wielders, Kessels, & Beguin 1993; Luddington and Baglin 2004). Thus corn trypsin 
inhibitor (CTI) to inhibit contact pathway activation may be useful in measurements of 
plasma thrombin generating capacity particularly in those with low thrombin generating 
potential and was therefore used herein. In addition, no exogenous TF to initiate coagulation 
was added to the samples to allow for measurements of the TF present in patient MP.  
 
The present study demonstrates that MP-mediated thrombin generation is significantly 
elevated in children with active systemic vasculitis compared with those with inactive 
disease and healthy controls, and in patients with thrombosis compared with those without 
and significantly higher counts of total circulating MP as well as EMP, and PMP. Indeed, the 
number of circulating annexin V+MP (PS rich) correlated with peak thrombin generation 
suggesting that the MP hyper-coagulability is a direct consequence of their PS content. The 
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thrombin generating capacity of these MPs was almost completely abolished (99% 
reduction) after incubation with recombinant AnV, confirming that PS exposure is the major 
determinant of MP related coagulation in this context. Neutralisation with pure TF indicated 
that increasing TF shortens the TGA lag time in a dose-dependent manner to healthy control 
values but had a lesser effect on peak height. TF bearing MP (monocyte derived MPs) 
independently initiated thrombin generation while PMPs supported plasma thrombin 
generation in a TF independent manner. These findings suggest different roles of these MPs 
in haemostasis and thrombosis. MPs derived from different parent cells appear to uniquely 
contribute to TF-dependent and -independent activities that promote thrombus formation and 
growth, a finding replicated in recent studies (Aleman et al. 2011;van der Meijden et al. 
2012). 
 
The observations made in this thesis could have important clinical and therapeutic 
implications. ROC analysis of peak thrombin as a diagnostic test for thrombosis in systemic 
vasculitis was significant and suggests that the MP mediated thrombin generation assay 
could be useful in identifying children with vasculitis at risk of thrombosis. TGA in clotting 
blood or plasma can be used to assess the overall function of the coagulation cascade and 
define a unique coagulation phenotype for individual patients thus enabling risk stratification 
for thrombosis prophylaxis. Moreover, enhanced MP thrombin generation as a mechanism 
underlying thrombotic complications in systemic vasculitis could provide a rationale for the 
therapeutic use of oral direct thrombin inhibitors that are receiving attention as safe and 
effective alternatives to cumbersome anti-coagulation with warfarin (Di Nisio et al. 2005; 
Gustafsson 2003). Lastly, filtration through 0.2µm pore size filter (similar to the filter used 
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for therapeutic plasma exchange) effectively removed MP from plasma and abolished MP 
mediated thrombin generation.  Thus removal of procoagulant MP may be a target for 
therapeutic plasma exchange and justify the use of this intervention in severe cases of 
thrombosis and vascular injury.  
 
An important limitation of the present study is that blood was obtained for analysis after 
thrombotic events had occurred. Further prospective longitudinal studies of vasculitis 
patients are thus now warranted in order to assess whether this increase in MP mediated 
thrombin generation could be secondary to the thrombotic event. In addition, the study 
included only clinically apparent thromboses in the cohort described, thus potentially 
underestimating the true frequency of subclinical thrombotic events in systemic vasculitis.  
Furthermore, this was a heterogeneous and small patient population, since systemic 
vasculitis is rare in children. Studying paediatric patients has important advantages, 
however, since this young cohort was free of other co-morbid conditions such as 
atherosclerosis that could influence the risk of thrombosis via increased MP production 
(Chironi et al. 2006; Tan and Lip 2005).  Moreover, the in vitro capacity of plasma to 
generate thrombin over time must be distinguished from in vivo markers of thrombin 
generation as an ongoing clotting process in the body such as prothrombin fragments 1 and 2 
(F1+2), thrombin anti-thrombin complexes and fibrinopeptide A (Teitel et al. 1982). This 
increased or decreased in vitro thrombin generation means that the function of the 
coagulation process is abnormal, does not necessarily mean ongoing pathology but indicates 
an increased risk of thrombosis or bleeding. Furthermore, MP function was analyzed from 
isolated parent cells studied in vitro; MP produced in vivo may possess unique properties and 
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therefore it will be important to compare the contributions of MP from different parent cells 
in in vivo thrombosis models. Lastly, during the thrombin-generation assay, part of the 
thrombin formed binds to α2-macroglobulin in plasma and accumulates as thrombin–α2-
macroglobulin complexes that remain active against the fluorogenic substrate but do not 
activate coagulation, leading to a stable level of apparent residual thrombin activity at the 
end of the reaction. Some authors suggest that this residual thrombin–α2-macroglobulin 
activity may affect the results of the assay (Hemker, De Smedt, & Al Dieri 2007; 
Wagenvoord, Deinum, Elg, & Hemker 2010). Chandler et al. more recently have however 
shown that the correction for residual thrombin–α2-macroglobulin activity had only a minor 
effect on peak thrombin generation, producing results that were on average 2% lower than 
the uncorrected values with high correlation (r2 = 0.99) (Chandler and Roshal 2009). 
Therefore in this study no correction for residual thrombin–α2-macroglobulin activity was 
performed but it would be of considerable interest to further explore the need for this in 
future studies of children with systemic vasculitis and thrombosis. 
.  
In conclusion, this study supports an important role for cell-derived microparticles in 
thrombosis complicating systemic vasculitis of the young.  MP-mediated thrombin 
generation could provide a novel means of assessing prothrombotic risk in patients with 
systemic vasculitis, allowing improved risk stratification and targeting of primary 
thrombosis prevention. Elevated MP-dependent thrombin generation constitutes a new type 
of hypercoagulable state, deserving further exploration in other vascular disorders where 
thromboembolic phenomena prevail such as childhood AIS recurrence. The role of MP 
mediated thrombin generation in childhood AIS is explored in chapter 6. 
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6 Microparticle mediated thrombin generation in 
children with arterial ischaemic stroke  
 
6.1 Summary 
 
Background: Thrombosis is implicated in the pathogenesis of childhood arterial ischaemic 
stroke (AIS). Notably however the majority of children with childhood AIS have no 
identifiable traditional genetic or acquired thrombophilias to account for an increased 
thrombotic propensity. In chapter 4, children with recurrent AIS were demonstrated to have 
increased circulating MPs of endothelial, platelet and neutrophil origin compared to children 
with a single event. These cellular MPs are prothrombotic and may contribute to 
hypercoagulable states associated with AIS recurrence. In addition previous studies have 
suggested that Von Willebrand Factor (vWF) antigen levels provide evidence of endothelial 
dysfunction relating to cerebrovascular inflammation and thrombosis. 
Objective: To assess the procoagulant capacity of circulating MP in children with recurrent 
AIS compared to those with a monophasic disease course. Levels of vWF were also 
evaluated in the two study groups. 
Methods: Single centre cross-sectional study of 46 children with AIS and cerebral 
arteriopathy matched with 20 paediatric controls. AIS recurrence was defined as new acute 
neurological deficit with radiological evidence of further cerebral infarction. Patients were 
considered in two groups based on AIS recurrence. MP mediated thrombin generation was 
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assessed using a fluorogenic assay. vWF antigen levels were assessed using a commercially 
available ELISA.  
Results: Forty six children with AIS aged 8.4 (0.9-17.4) years and 20 paediatric controls 
aged 9 (1.2-16) years were included. Ten children had AIS recurrence while 36 had a single 
AIS event. Children with AIS recurrence had significantly enhanced MP-mediated peak 
thrombin generation compared to children with a single event, p=0.0001 and healthy control 
children, p=0.0020. MP mediated endogenous thrombin potential (ETP), lag time and 
velocity index were also significantly different between patient groups. Levels of plasma 
vWF antigen did not significantly differ between children with AIS recurrence and children 
with a single event, p=0.8700 but were higher compared to controls, p=0.0100. 
Conclusion: Enhanced MP-mediated thrombin generation was demonstrated in children 
with recurrent AIS. MP-mediated thrombin generation combined with endothelial injury and 
platelet activation contributes to the thrombotic events associated with childhood AIS 
recurrence.  
 
 
6.2 Introduction 
 
Thrombosis, the result of a complex interplay between platelet activation and activation of 
the coagulation cascade, is a key pathophysiological mechanism in many cardiovascular and 
cerebrovascular disorders, including childhood AIS (Fuster et al. 1988; Heemskerk et al. 
2002). Blood flow through the affected cerebral arteries may be reduced or absent, which 
results in focal ischaemia (Hinton 1998; Powers 1991). Because of poor collateral blood 
flow in the brain, infarction then occurs (Hinton 1998; Powers 1991). Under physiological 
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conditions, the haemostatic process controls haemorrhage after injury but at the same time, if 
overactive, may have the potential to precipitate diseases such as thrombosis associated with 
AIS (Dahlbäck 2000; Haywood, Liesner, Pindora, & Ganesan 2005). Inherited 
thrombophilia risk factors, particularly antithrombin, protein C, and protein S deficiency and 
elevated lipoprotein (a), have been found in small case series and case-control studies to be 
associated with AIS in children (Kenet et al. 2000; Kenet et al. 2010; Nowak-Gottl et al. 
1999). Furthermore, a recent metanalysis indicated that several genetic prothrombotic 
conditions appear to contribute to the risk of childhood AIS (Kenet et al. 2010).  As noted by 
Strater et al. it is likely however that in many instances thrombophilia is a permissive factor 
rather than an isolated cause for AIS (Sträter et al. 2002b). In addition transient acquired 
prothrombotic risk factors particularly in the setting of systemic infection may contribute to 
thrombosis in childhood AIS (Bernard et al. 2010; Manco-Johnson et al. 1996; van Ommen 
et al. 2002).  However our lack of clear understanding of the relative contribution of each of 
these factors to the thrombotic propensity underpinning childhood AIS recurrence makes 
prevention strategies challenging, with lack of suitable biomarkers that could define risk in 
routine clinical practice.  
 
Alternative approaches of quantifying the risk of thrombosis in relation to the composite 
effect of candidate thrombophilias, regardless of whether they are known or unknown and 
regardless of whether they are genetic or acquired are now emerging (van Geffen & van 
Heerde 2012;Van Veen, Gatt, & Makris 2008). Determination of the thrombin-generating 
potential as an alternative ‘global testing’ strategy has been validated in that context (van 
Geffen & van Heerde 2012; Van Veen, Gatt, & Makris 2008). A number of previous studies 
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have shown that thrombin generation capacity predicts likelihood of thrombosis recurrence 
with hazard ratios from 2.5 to 4.0 (van Geffen & van Heerde 2012; Van Veen, Gatt, & 
Makris 2008). Of note, Carcaillon et al. have recently reported a significant association 
between thrombin generation and the risk of AIS in adults and therefore suggested that 
hypercoagulability has an important role in the pathogenesis of AIS (Carcaillon et al. 2011). 
This was a prospective cohort including 9294 subjects compared with a random sample of 
1177 controls and follow up for 4 years (Carcaillon et al. 2011). A multivariate analysis 
showed that high levels of ETP and peak thrombin were associated with an increased risk of 
AIS (hazard ratio 1.16 with 95% CI, 0.90 to 1.50 and 1.31 with 95% CI, 1.01 to 1.69 for a 1 
SD increase, respectively) thus suggesting that thrombin generation is an independent 
predictor of AIS (Carcaillon et al. 2011). In addition to the investigation of ‘global 
haemostasis’ through the use of thrombin generation potential there is a current emerging 
interest in the contribution of cellular microparticles to increased risk of thrombosis (Morel 
et al. 2006; Piccin, Murphy, & Smith 2007; Zwicker, Trenor III, Furie, & Furie 2011). MPs 
are known to play a major role in propagating thrombus formation through PS exposure, TF 
expression and TF delivery in the vicinity of activated platelets (Morel et al. 2006; Piccin, 
Murphy, & Smith 2007; Zwicker, Trenor III, Furie, & Furie 2011). In chapter 5 an efficient 
method to measure the contribution of circulating MP to haemostasis using an in vitro MP 
mediated thrombin generation assay was established. This assay may be an invaluable tool to 
detect MP related hyper-coagulability in vascular disorders linked with thrombosis such as 
in childhood AIS.  
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Children with recurrent AIS have been previously shown to have elevated levels of 
circulating MP compared to those children with a single event and controls. These 
prothrombotic MPs could be contributing to AIS recurrence pathogenesis. To date however 
no study has investigated whether the MP mediated thrombin generation may be associated 
with childhood AIS recurrence.  
 
 
6.2.1 Von Willebrand Factor (vWF) and vascular disorders 
 
Von Willebrand factor (vWF) is released by endothelial cells when these are damaged, and 
thus vWf levels have been proposed as a possible indicator of endothelial cell dysfunction 
(Blann and McCollum 1994; Lip and Blann 1997). vWF is also known to have an important 
function in platelet aggregation and adhesion (Ikeda et al. 1991). In addition, several studies 
have suggested that high concentrations of vWF may be an indirect indicator of thrombosis 
(Martinelli 2005). For instance vWF appears to be an index of increased risk for reinfarction 
and mortality in patients with angina and myocardial infarction (Jansson et al. 1991; 
Montalescot et al. 1998). Interestingly, increased vWF levels are also well reported to be 
associated with ischaemic cerebrovascular events in adults (Blann et al. 1999; Catto et al. 
1997). The possible mechanisms for the association between vWF and cerebrovascular 
events in adults include endothelial dysfunction associated with cerebral thrombosis or other 
atherosclerosis related risk factors, such as hypertension or ischaemia induced release from 
infarcted tissue (Blann et al. 1993; Conlan et al. 1993). In a pilot study of 64 patients with 
acute stroke, Blann et al. we have recently demonstrated significant endothelial dysfunction 
with high vWF levels in conjunction to raised fibrinogen levels, plasma viscosity and raised 
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soluble adhesion molecule P-selectin levels (Blann, et al. 1999). These abnormalities may 
act synergistically to contribute to the pathogenesis of acute stroke and its complications. 
Furthermore, Hutchinson et al. in a study reporting on the treatment and long term outcomes 
of children with primary angiitis of the CNS (cPACNS), demonstrated vWF as a surrogate 
marker of cerebrovascular injury (Hutchinson et al. 2010). The median vWF levels in the 19 
children with biopsy proven cPACNS included in the study was 1.73 IU/ml (range 0.61-
3.74) with 5 children having significantly raised levels > 1.92 IU/ml (Hutchinson et al. 
2010). Therefore vWF may be a promising soluble marker of endothelial injury also linked 
to thrombosis that has not been previously studied in relation to childhood AIS recurrence.  
 
6.3 Aims 
The aim of this study was to compare the MP-mediated thrombin generating capacity 
between children with recurrent AIS and those with a single event. Levels of vWF as an 
additional soluble marker of endothelial injury linked to thrombosis were examined.  
 
 
6.4 Methods 
 
6.4.1 Patient population 
 
For inclusion/exclusion criteria, patient population clinical and radiological features as well 
as patient group classification, healthy controls and disease controls (children with cerebral 
AVM) see chapter 2.  
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6.4.2 Assessment of traditional prothrombotic risk factors 
 
Traditional prothrombotic risk factors were assessed based on methods described in chapter 
5. 
 
6.4.3 Microparticle mediated thrombin generation 
 
The MP mediated thrombin generation was assessed as described in chapter 5 using a 
fluorogenic thrombin generation assay (TGA). 
 
6.4.4 Von Willebrand factor antigen levels 
Levels of vWF antigen were assessed using a commercially available ELISA. 
6.5  Statistical analysis 
Values are presented as median (range) unless otherwise specified. The Kruskal-Wallis test 
was used to examine overall differences in experimental laboratory markers between the 
study groups. Following this, statistical differences between groups were determined by 
Mann-Whitney U test. Associations between cumulative MP counts and peak thrombin 
generated were assessed using Spearman’s rank correlation coefficient. A multivariable 
logistic regression was used to explore the relationship of peak thrombin to the outcome of 
AIS recurrence adjusted and unadjusted for age/sex and time from index AIS to evaluation. 
Results are expressed as OR with 95% CI. P-values of less than 0.05 (two sided) were 
regarded as significant. Statistical analysis was performed using SPSS version 16 and 17. 
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6.6 Results 
 
 
6.6.1 Traditional thrombophilia risk factors  
 
With regards to traditional thrombophilia risk factors screen one child in the group with 
recurrence was heterozygous for methylentetrahydrofolate reductase (MTHFR) mutations 
(10%) and one initially had low protein S (10%) that subsequently recovered to normal 
levels. In the group of children with no recurrence two patients had protein S deficiency 
(5%); one child was MTHFR mutation homozygous (3%) with 3 being heterozygous (8%); 
lastly one child was heterozygous for factor V Leiden deficiency (3%).   
 
 
6.6.2 Microparticle mediated thrombin generation in children with 
recurrent AIS  
 
Higher levels of AnV+ MPs (confirming high pro-coagulant phosphatidylserine content) 
were previously shown to be present in the circulation of children with AIS recurrence 
compared to those children with a single event (chapter 4). Having established a 
reproducible method to assess the capacity of MP to generate thrombin in chapter 5, a 
similar approach to examine the differences in the pro-coagulant properties of circulating 
MP in children with AIS recurrence compared to those with a monophasic disease course 
was used herein. TGA parameters for all studied groups are summarized in table 6-1. 
Children with AIS recurrence had significantly enhanced MP-mediated peak thrombin 
generation 127·3 nM (30-215nM) compared to children with a single event 28 nM (10-73·40 
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nM), p=0·0001; healthy control children 38·75 nM (17·70-61 nM), p=0·0020; and children 
with cerebral AVM 35 nM (17-65 nM), p=0·0030. MP mediated ETP was also significantly 
higher in those with recurrence 2620 nM x min (800-4671nM x min) compared to those with 
no recurrence 1118 nM x min (451-2218 nM x min), p=0·0002; child controls 1100 nM x 
min (501-1808 nM x min), p=0·0030; and children with cerebral AVM 1200 nM x min 
(600-1900 nM x min); p=0·0040.  Children with recurrent AIS had significantly shortened 
lag time 18 min (12-22 min) compared to those with non-recurrent AIS 26 min (22-31 min), 
p=0·0100; child controls 32 min (28-36 min), p=0·0010; and children with cerebral AVM 31 
min (25-38 min), p=0.0020.  Lastly patients with recurrence showed an increased velocity 
index 15·40 nM/min (5·7-21 nM/min) for thrombin generation compared to those with no 
recurrence 3·2  nM/min (2-8·6 nM/min), p=0·0010; healthy child controls 1·5 nM/min (0·6-
2·25 nM/min), p=0·0040; and children with cerebral AVM 2.5 nM/min (0.8-3.2 nM/min); 
p=0.0040. 
 
 
6.6.3 Correlation of circulating microparticles to thrombin generation 
 
The total circulating AnV+ MPs correlated significantly with MP-mediated peak thrombin 
nM,  rs=0.73, p<0.0001 consistent with the hypothesis that the hypercoagulability in  patients 
with AIS was directly related to the increased total number of PS expressing (AnV+) MPs 
(figure 6-1).   
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6.6.4 Von Willebrand factor (vWF) antigen levels 
 
Levels of plasma vWF antigen were not significantly different between children with AIS 
recurrence 0.850 IU/ml (0.330-2.250 IU/ml) and children with a single event 0.743 IU/ml 
(0·370-1·890IU/ml), p=0.8700. Levels of vWF were however significantly higher in the 
group of children with AIS recurrence compared to controls 0.34 IU/ml (0.31-0.7IU/ml), 
p=0.0100 and children with AVM 0.51 IU/ml (0.4-0.632 IU/ml), p=0.040 (table 6-1). 
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 AIS 
recurrence 
(n=10) 
 
AIS no 
recurrence  
(n=36) 
 
Healthy 
controls 
(n=10) 
Cerebral AVM  
(n=10) 
Peak thrombin 
nM   
Median(range) 
 
127·3 (30-215)  28 (10-73·40); 
p=0·0001 
38.75 (17·70-
61); 
p=0·0020 
35 (17-65); 
p=0·0030 
ETP nM x 
min  
Median(range) 
 
2620 (800-
4671)  
1118 (451-
2218); p=0·0002 
1100 (501-
1808); 
p=0·0030 
1200 (600-
1900); 
p=0·0040 
Lag time min 
Median 
(range) 
 
18 (12-22)  26 (22-31);  
p=0·0100 
32 (28-36);  
p=0·0010 
31 (25-38); 
p=0·0020 
 
Velocity index 
nM/ min 
Median(range) 
 
15.40 (5·7-21)  3.2 (2-8·6);  
p=0·0010 
1.5 (0·6-
2·25); 
p=0·0040 
2.5 (0.8-3.2); 
p=0.0040 
vWF antigen 
IU/ml 
Median(range) 
0·85(0·33-
2.25) 
0·743 (0·370-
1.890);  
p=0·8700 
0·34 (0·31-
0·7); 
p=0·0100 
0.51 (0.4-0.632); 
p=0·040 
 
 
 
 
Table 6-1: Thrombin generation parameters and von Willebrand Factor (vWF) antigen in 
children with arterial ischaemic stroke (AIS). 
vWF= von Willebrand Factor; AVM= arteriovenous malformation. ETP=endogenous 
thrombin potential (corresponding to the area under the curve for thrombin generation 
assay curves). The Kruskal-Wallis test followed by the Mann-Whitney U test was used to 
examine differences between the study groups. P values reported refer to comparison with 
the group of children with recurrent AIS. P-values of less than 0.05 (two sided) were 
regarded as significant. 
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Figure 6-1: Total circulating Annexin V microparticles correlated with peak thrombin 
generation in children with arterial ischaemic stroke (AIS), rs=0.73, p=0.0001.   
 
6.6.5 Logistic regression analysis of peak thrombin and AIS recurrence 
 
 
Logistic regression analysis was used to examine the relationship of peak thrombin to AIS 
recurrence unadjusted and adjusted for age/sex and time from index AIS to evaluation as 
these could be important confounding factors (table 6-2). AIS recurrence was associated 
with elevated peak thrombin in both non-adjusted OR 1.515 (95% CI 1.173-1.705), p=0.003 
and adjusted analysis OR 1.319 (95% CI 1.040-1429), p= 0.010.  
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Biomarker            Unadjusted  
 
  
OR        95%CI               P 
Adjusted (age/gender/time from    
AIS to evaluation) 
 
    OR          95%CI                 P 
Peak thrombin nM 1.515   1.173-1.705       0.003 1.319        1.040-1429       0.010 
 
Table 6-2: Unadjusted and adjusted odds ratios by multivariable logistic regression 
analysis for arterial ischaemic stroke recurrence (AIS).   
Adjusted odds ratios for age/gender/time from AIS to evaluation; OR=odds ratio; 
CI=confidence intervals. P<0.05 was considered significant. 
 
6.7 Discussion 
 
Children with recurrent AIS demonstrated enhanced MP-mediated thrombin generation 
compared to children with a single event, children with cerebral AVM and child controls. 
MP mediated thrombin generation provides a novel mechanism of hypercoagulability that 
may be implicated in the pathogenesis of childhood AIS. Prospective validation of these 
findings is now needed to establish the prognostic value of MP mediated thrombin 
generation in predicting recurrence of childhood AIS. Of note, vWF antigen levels did not 
effectively differentiate between patient groups but were significantly raised in children with 
recurrence compared to controls.  
 
Thrombus generation is one of the main causes for brain ischaemia in childhood onset AIS, 
whether the clot originates in the heart, the cervical arteries or the intracranial arteries 
(Hinton 1998). As thrombotic/embolic phenomena prevail in the pathophysiology of 
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childhood-onset AIS, investigation of the contribution of thrombophilias to risk of incident 
and recurrent AIS in childhood is critical. Although multiple types of genetic and acquired 
thrombophilia are established as independent risk factors for incident AIS, data supporting 
significant prognostic impact upon recurrence risk are limited to a few individual traits such 
as elevated lipoprotein (a), protein C deficiency, and the presence of multiple risk factors 
(Kenet et al. 2000; Kenet et al. 2010; Nowak-Gottl et al. 1999). In addition the majority of 
children with AIS have no identifiable traditional thrombophilia factors to account for the 
thrombotic/embolic phenomena associated with childhood AIS, a finding supported by this 
study too. As a result identifying prothrombotic tendencies relating to re-infarction remained 
to date a challenge. Thrombin generation, a reliable functional test of the haemostatic–
thrombotic system, could now provide an effective way of evaluating the relative 
contribution of hypercoagulability to childhood AIS recurrence.  
 
Enhanced MP mediated thrombin generation was demonstrated in children with recurrent 
AIS. This observation not only sheds light on the pathogenesis of childhood AIS recurrence 
but could also have several therapeutic implications. Provided that these results are 
confirmed in larger studies, prevention of childhood AIS recurrence should perhaps target 
the diminution of the thromboembolic risk together with prevention of endothelial 
dysfunction. In addition, novel oral anti-thrombin agents have been receiving attention as 
safe and effective alternatives to traditional anticoagulants (Gustafsson 2003). If excessive 
thrombin generation underpins childhood AIS recurrence these agents may be beneficial in 
secondary stroke prevention strategies. Monitoring of MP-mediated thrombin generation 
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may also allow risk-stratified approaches to antithrombotic therapy in order to optimise the 
balance between bleeding and recurrence risks. 
 
The finding that plasma levels of vWF did not differentiate between patient groups was 
unexpected. The small size of the study could have influenced the results. Another possible 
explanation is that interpretation of raised vWF levels may be complicated by its behaviour 
as an acute phase reactant. Elevated plasma vWF levels have been previously associated 
with the risk of vascular events, an association that may be explained by a reactive or 
secondary rise in plasma of vWF mainly during the acute phase of inflammation (Pottinger 
et al. 1989). In this study, children with recurrent AIS were not studied during the acute 
phase of stroke and this may have affected the results. Nevertheless, measurement of vWF 
levels may be more useful than that of acute phase reactants such as C-reactive protein or 
erythrocyte sedimentation rate (ESR) as vWF implies endothelial injury (Cellucci et al. 
2009; Cellucci, Tyrrell, Sheikh, & Benseler 2011; Cellucci, Tyrrell, Pullenayegum, & 
Benseler 2012; Cellucci & Benseler 2010). Lastly, treatment with aspirin is well established 
to decrease levels of vWF antigen (Pernerstorfer et al. 2001). All children with AIS studied 
herein were on aspirin at the time of recruitment and hence this could provide an additional 
explanation for lack of significant differences in vWF antigen levels between patient groups.  
 
Limitations of this study include the small size and heterogeneity of the population studied 
as childhood AIS is rare. In addition whether this increased hyper-coagulability is an 
epiphenomenon associated with established thrombosis or has a causal effect to AIS 
recurrence was not determined. It remains to be established  in prospective cohort studies 
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how testing of an expanded genetic repertoire and global haemostasis testing using the MP-
mediated thrombin generation will influence clinical decision-making in relation to long-
term anticoagulant therapy after index AIS. Whether this in vitro hypercoagulability is truly 
representative of what occurs in vivo remains unclear. However, the hypothesis that it may 
have clinical consequences is attractive and deserves further attention. 
 
In summary, these observations regarding MP mediated thrombin generation and childhood 
AIS recurrence constitute a new and potentially clinically important finding requiring 
validation in larger prospective populations. MP mediated thrombin generation provides a 
novel link between inflammation, endothelial injury and thrombosis that provides an 
exciting insight into the pathogenesis of childhood AIS. Novel antithrombotic strategies may 
in that context prove to be more effective in select cases.  
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7 Endothelial repair in children with arterial 
ischaemic stroke and cerebral arteriopathy 
7.1 Summary 
 
Background/aims: An emerging paradigm relating to vascular health is the concept of the 
balance between endothelial injury and repair. Endothelial progenitor cells (EPC) constitute 
a circulating pool of cells that counteract ongoing risk factor induced vascular injury and 
facilitate the replacement of dysfunctional endothelium. It is now becoming increasingly 
apparent that several vascular disorders can unfavourably alter this balance of endothelial 
injury and repair resulting in significant morbidity and mortality. To date, however, virtually 
nothing is known about endothelial repair responses in childhood arterial ischaemic stroke 
(AIS). 
Methods:  Children with AIS were considered in two groups based on recurrence, and 
compared with healthy controls. Circulating EPC were identified with flow cytometry as 
peripheral blood mononuclear cells (PBMCS) triple positive for: CD34/CD133/CD144; or 
CD34/CD133/VEGFR2. EPC function was evaluated by the potential of these cells to form 
colony forming units (CFU), and by their ability to incorporate into endothelial cell vascular 
structures in matrigel.  
 Results: Thirty five children, median age 12 years (5–16.5 years; 9 males) with AIS (10 
with recurrence) were studied. Circulating EPC triple positive for CD34/CD133/CD144 
were significantly raised in children with AIS recurrence: 0.07% of PBMC gated (range 
0.04-0.2%) compared to 0.02% (0-0.09%) in patients with no recurrence, p= 0.0001; and 
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0.03% (range 0-0.07%) in 20 child controls, p=0.0001. Similar differences were detected in 
PBMCs triple positive for CD34/CD133/VEGFR2 between the study groups. EPC- CFU 
were significantly reduced in children with AIS recurrence compared to those with no 
recurrence, p=0.04; and child controls, p=0.03. Compared with healthy controls, the number 
of EPC incorporated into the tubular network formed by HUVEC was reduced in children 
with AIS recurrence, p=0.02.  
Conclusions: Children with recurrent AIS had evidence of increased circulating 
CD34+/CD133+/KDR+ cells representing an attempt at endothelial repair in response to 
more severe neurological injury in these children. The ability of EPCs however to grow in 
culture, form colonies and incorporate into endothelial cell vascular networks was impaired 
in children with AIS recurrence. These data suggest that there could be impairment of a 
potentially important pathway for endothelial repair in these patients, leading to an 
unfavorable balance between endothelial injury and repair.  Further prospective studies with 
larger patient numbers are required to confirm this definitively.  
 
 
7.2 Introduction 
 
Neo/revascularization is a process to restore or regenerate the damaged blood vessels in the 
body (Freedman and Isner 2002;Lapergue et al. 2007). Revascularization involves: 
vasculogenesis that refers to the de novo formation of blood vessels (Freedman & Isner 
2002; Lapergue, Mohammad, & Shuaib 2007); and angiogenesis which involves the 
formation of new capillaries from the pre-existing vasculature, and is controlled by a number 
of growth factors and signalling pathways (Freedman & Isner 2002; Lapergue, Mohammad, 
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& Shuaib 2007). Thus, it is largely accepted that vasculogenesis may play a key role in 
embryogenesis, whereas angiogenesis occurs during both prenatal and postnatal life 
(Freedman & Isner 2002; Lapergue, Mohammad, & Shuaib 2007). Since the pioneer work 
by Asahara et al. however increasing evidence suggests that circulating adult bone marrow-
derived endothelial progenitor cells (EPC) play an important role in neo/re-vascularization 
under certain physiological and pathological conditions in adults through vasculogenesis 
(Asahara et al. 1997). In addition, a third process, arteriogenesis, completes the expansion 
and growth of the vascular system in adults since it refers to the development and growth of 
pre-existing arterioles into physiological relevant arteries that form collateral vessels 
(Freedman & Isner 2002; Lapergue, Mohammad, & Shuaib 2007).   
 
7.2.1 Endothelial progenitor cells (EPC) 
 
Under physiological conditions the endothelium is primarily quiescent with very low rates of 
replication (Hirschi, Ingram, & Yoder 2008; Yoder et al. 2007). However, in response to 
several factors such as inflammation, hypoxia, and oxidative stress causing endothelial 
activation and vascular injury, multiple circulating blood cells are recruited to the area of 
injury, with an additional but more delayed recruitment of resident endothelium, to re-
establish vascular integrity and blood flow (Haudenschild and Studer 1971; Haudenschild 
and Schwartz 1979; Richardson & Yoder 2011). The majority of endothelial repair probably 
results from the proliferation of neighbouring endothelial cells, although circulating cells are 
now also known to modulate vascular repair (Asahara et al. 1997; Asahara et al. 1999a; Hill 
et al. 2003; Richardson & Yoder 2011). In 1997 bone marrow derived progenitor cells, 
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termed endothelial progenitor cells (EPCs), were described that displayed a variety of 
endothelial specific cell surface proteins following culture in vitro; and that possessed the 
ability to localize and promote vascular regeneration at sites of ischaemia (Asahara et al. 
1997).  A wealth of studies have subsequently confirmed that these bone marrow derived 
EPCs incorporate into sites of neoangiogenesis and injury; however, the evidence that such 
cells actually become endothelial cells remains a topic of active debate (Rabelink, de Boer, 
& van Zonneveld 2010; Richardson & Yoder 2011). In addition, confusion has also arisen 
because the common term ‘EPC’ has been used for the description of what are now known 
to be completely different cellular subpopulations (table 7-1).  
 
In general, the methods for the isolation and quantification of EPCs can be grouped into two 
main approaches: 1. in vitro adhesion colony formation; and 2. flow cytometric 
identification of circulating cells with a defined cell surface phenotype. At the time of 
writing this thesis there is no consensus on specific unique cell surface molecules that permit 
isolation of an EPC in humans. That said, it is now established that that there are numerous 
cell types and lineages that participate in neovascularization (Rabelink, de Boer, & van 
Zonneveld 2010; Richardson & Yoder 2011). In addition, despite the lack of a unifying 
phenotypic definition for EPCs, an approach for addressing how all these different cells and 
cell lineages participate in the process of endothelial repair is emerging, and has provided 
new therapeutic strategies for enhancing (e.g. adults with peripheral vascular disease), or 
inhibiting (cancer medicine) the process of new blood vessel formation, depending on the 
clinical context (Dzau et al. 2005; Ferrara and Kerbel 2005). The following sections 
summarise our current knowledge and understanding of EPC biology. 
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7.2.1.1 Isolating EPC using in vitro adhesion and colony formation 
 
In the original paper defining EPC, Asahara et al reported that 15.7% of adult peripheral 
blood cells expressing CD34 could be isolated using immunomagnetic beads, and culture of 
this population on fibronectin-coated tissue culture wells led to the emergence of spindle-
shaped cells within 3 days (Asahara et al. 1997). At 7 days of culture, the attached cells 
expressed a variety of endothelial cell surface proteins such as CD31, Flk-1 (vascular 
endothelial growth factor 2 receptor), Tie-2, or E-selectin (Asahara et al. 1997). These 
cultured cells also displayed the ability to take up the lectin Ulex Europeaus agglutinin-1 
(UEA-1) and fluorescence labeled acetylated low density lipoprotein (acLDL) (Asahara et 
al. 1997). In addition, cells from the adherent population recovered from these cultures could 
home to and co-localize within capillaries of ischaemic limbs in rabbits or mice, resulting in 
improved blood flow (Asahara et al. 1997). Ito et al. modified the original EPC assay by 
allowing all mononuclear cells to attach to the fibronectin-coated dishes for 24 h before 
removing the non-adherent cells (Ito et al. 1999). The non-adherent fraction was replated on 
fibronectin coated plates, and the clusters that emerged at 7 days were named EPC colony 
forming units (Ito et al. 1999). Subsequently Hill et al. further modified the assay to include 
a 48-h pre-plating period prior to replating the non-adherent cells (Hill et al. 2003). The 
colonies of putative EPC that emerged from the cultured non-adherent human peripheral 
blood mononuclear cells were called CFU-Hill (Hill et al. 2003). It is now well established 
that there is an inverse relationship between the numbers circulating concentration of CFU-
Hill, and risk factors for development of atherosclerosis in humans; and one study linking 
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low CFU-Hill with increased mortality from atherosclerosis (Hill et al. 2003). The presence 
of lower levels and/or impaired function of such cells has been demonstrated in different 
disease states, particularly cancer, arterial hypertension, diabetes, pulmonary hypertension 
(amongst others), and suggest that they have an important role in the maintenance of 
vascular health (Diller et al. 2008; Fadini et al. 2005; Hill et al. 2003; Schmidt-Lucke et al. 
2005; Vasa et al. 2001; Werner et al. 2005). Recently, several groups have demonstrated that 
plating human peripheral blood or umbilical cord blood mononuclear cells on fibronectin-
coated plates (with or without preplating steps) results in colonies that are composed of 
round hematopoietic cells and include myeloid progenitor cells, monocytes, and T 
lymphocytes (Rohde et al. 2006; Rohde et al. 2007; Yoder et al. 2007). These spindle shaped 
cells expressing endothelial markers do not spontaneously form blood vessels when 
implanted in vivo in collagen gels (i.e. do not display postnatal vasculogenic activity), but 
readily ingest bacteria, more in keeping with their monocyte/macrophage lineage roots 
(Hirschi, Ingram, & Yoder 2008; Rabelink, de Boer, & van Zonneveld 2010; Richardson & 
Yoder 2011; Rohde et al. 2006; Rohde et al. 2007; Yoder et al.2007). It is now believed that 
these myeloid-derived EPC may be of great relevance to vascular repair through paracrine 
mechanisms, but are unlikely to become endothelial cells themselves (Hirschi, Ingram, & 
Yoder 2008; Rabelink et al. 2011). These cells are also (confusingly) referred to by different 
names including: pro-angiogenic haematopoetic progenitor cells, myeloid-EPC, early 
outgrowth EPC, or circulating angiogenic cells (amongst other names) (Richardson & Yoder 
2011). 
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In addition to this myeloid phenotype of EPC, other investigators have identified a different 
type of colony of cells emerging from the plated peripheral blood mononuclear cells. 
Endothelial colony forming cells (ECFC), also called late outgrowth endothelial cells (OEC) 
or blood outgrowth endothelial cells (BOEC), typically emerge from an adult blood sample 
in 14–21 days (Ingram et al. 2004; Lin, Weisdorf, Solovey, & Hebbel 2000). These ECFC 
emerge as tightly adherent colonies with a typical cobblestone appearance and are rare in 
adult human blood samples with approximately 1 colony/108 mononuclear cells plated 
(Ingram et al. 2004; Richardson & Yoder 2011). ECFC also possess clonal proliferative 
potential that can be observed in single cell cultures (Richardson & Yoder 2011).  ECFC 
have been shown to form functional vessels that connect to the host murine vessels when 
implanted in immunodeficient mice, thus providing evidence that they become structural 
cells of the endothelium in mature blood vessels (Melero-Martin et al. 2007; Yoder et al. 
2007).  This functional capacity of the ECFC is indicative of true postnatal vasculogenesis. 
Whether circulating ECFC are actively mobilized or passively sloughed off the endothelium 
due to shear stress remains to be determined. Impaired ECFC angiogenic tube formation is 
observed in some disease processes, including diabetes mellitus, and pulmonary arterial 
hypertension (Tan et al. 2010;Toshner et al. 2009).  
 
Interestingly Yoon et al. demonstrated that EPC of myeloid origin and ECFC may 
participate synergistically in neovascularization (Yoon et al. 2005). In a mouse hind limb 
ischemia model, as well as in a matrigel plug model, both these types of cells individually 
enhanced angiogenesis, but injecting of a mixture of both populations yielded the most 
robust angiogenic response (Yoon et al. 2005).  
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7.2.1.2 Defining EPC based on cell surface phenotype 
 
Another EPC phenotype comprises a bone marrow-derived subpopulation of haematopoietic 
stem cells which are positive for CD34 and co-express VEGFR2 (also known as KDR) as 
identified using flow cytometry (Hirschi, Ingram, & Yoder 2008; Rabelink, de Boer, & van 
Zonneveld 2010). Further analysis of the cell surface proteins expressed on this subset 
included identification of CD133, CD144, CXCR4, CD31, CD13, but not CD14 or CD15 
(Peichev et al. 2000; Rabelink, de Boer, & van Zonneveld 2010). Isolated CD34+ EPCs and 
CD34+VEGFR2+ EPCs are able to incorporate into endothelial mono layers in vitro and 
may contribute to in vivo repair of the endothelium (Peichev et al. 2000; Pelosi et al. 2002; 
Rookmaaker et al. 2005). Interestingly recent studies have suggested that activated platelets, 
platelet products and fibrin, appear to support the migration of these CD34+ cells to the site 
of vascular injury (de Boer et al. 2011).  Irrespective of their fate, the CD34+ EPC level may 
correlate with endothelial activation and dysfunction (Fadini et al. 2009; Surdacki et al. 
2008).  
 
To summarise several assays have been used over the years to determine whether a specific 
progenitor population has endothelial cell potential (table 7-1) (Richardson & Yoder 2011). 
Some phenotypic characteristics and behaviors that are often specifically attributed to 
endothelial cells are in fact shared by other cell types, notably myeloid cells. Currently 
different types of blood cells and endothelial cells are known to participate in vascular 
repair. The levels and impaired function of these cells as identified using flow cytometry and 
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a number of in vitro culture assays have been linked to cardiovascular disease burden, and 
poor long term outcomes.   
Year  Author 
 
Cell 
population 
Method Used to 
Isolate 
Marker to 
define 
Term 
1997  
 
Asahara  CD34 or 
KDR 
peripheral 
blood cells 
Immunomagnetic 
bead separation 
of CD34 or KDR 
positive adult 
peripheral blood 
cells 
CD45, CD34, 
CD31, 
Flk-1, Tie-2 
E-selectin, 
UEA-1, 
acLDL 
 
EPC 
2000  
 
Peichev  CD34, 
AC133, 
and KDR 
peripheral 
blood cells 
 
Immunomagnetic 
bead separation 
of CD34 positive 
adult peripheral 
blood cells 
CXCR4, 
CD31, CD13, 
acLDL, and 
not CD14 
or CD15 
CEP 
2001  
 
 
Lin  CD146 
(P1H12) 
peripheral 
blood cells 
Plating of 
mononuclear cell 
pellet or 
immunomagnetic 
bead separation 
of peripheral 
blood cells 
CD146 positive 
adult 
CD34, 
CD144, vWF, 
Flk-1, and not 
CD14 
 
BOEC 
2003  
 
Hill  Mononuclear 
cells 
 
48 h pre-plating 
period prior to 
replating non 
adherent blood 
mononuclear 
cells and colony 
formation 4–9 
days later 
CD31, Tie2, 
and KDR 
CFU-Hill 
2004  
 
Ingram  Mononuclear 
cells 
 
In vitro colony 
emergence and 
clonal 
proliferative 
potential 
 
CD34, 
CD146, 
CD31, 
CD105, and 
not CD45 
and direct 
demonstration 
of vessel 
formation in 
vivo 
ECFC 
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2007  Rohde  Mononuclear 
cells 
48 h pre-plating 
period prior to 
replating non-
adherent blood 
mononuclear 
cells and colony 
formation 4–9 
days later 
VEGF-R1, 2, 
and 3, CD31, 
CD34, 
CD146, vWF, 
and not CD14 
CD45 
CFU-EC 
2007  
 
Yoder  Mononuclear 
cells 
 
In vitro colony 
emergence and 
clonal 
proliferative 
potential and 
48 h pre-plating 
period prior to 
replating non-
adherent blood 
mononuclear 
cells and colony 
formation 4–9 
days later 
CD34, 
CD146, 
CD31, 
CD105, and 
not CD45 
and direct 
demonstration 
of vessel 
formation in 
vivo 
 
ECFC Vs. 
CFUHill 
 
2009  
 
Prokopi  Mononuclear 
cells 
 
Plating of 
mononuclear cell 
pellet on 
fibronectin-
coated 
dishes and at 72 h 
removed 
nonadherent cells 
CD31, vWF, 
UEA-1, 
CD4, and 
acLDL 
 
EPC 
2010  
 
Estes  CD34, 
AC133, 
CD45, CD31 
 
Polychromatic 
flow cytometry 
and cell sorting 
 
CD34, 
AC133, 
CD45, CD31 
Proangiogenic 
haematopoietic 
cell 
 
Table 7-1: Progenitor cells participating in endothelial repair responses.  
Adapted from Richardson et al.(Richardson & Yoder 2011). UEA-1, Ulex Europeaus 
agglutinin-1; acLDL, acetylated low density lipoprotein; CEP, circulating endothelial 
precursor; ECFC, endothelial colony forming cells; BOEC, blood outgrowth endothelial 
cells; vWF, von Willebrand factor; CFU-EC, colony forming unit-endothelial cell; CFU-
Hill, colony forming unit-Hill. 
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7.2.2 Endothelial progenitor cells in cerebrovascular diseases 
 
In the field of cerebrovascular diseases, previous clinical studies in adults with stroke have 
reported reduced EPC levels and/or function (Chu et al. 2008; Yip et al. 2008). Yip et al. 
showed that the levels of circulating CD34+EPCs examined by flow cytometry at 48 hours 
after stroke in 138 consecutive adult patients were significantly higher than in at-risk control 
subjects (P<0.05)(Yip et al. 2008). Additionally, EPC levels were significantly lower in 
patients with severe neurological impairment than in patients with less severe impairment 
(P<0.0001) (Yip et al. 2008). Low circulating EPC levels were independently predictive of 
severe neurological impairment at 48 hours and major adverse clinical outcomes (Yip et al. 
2008). Furthermore Chu et al. showed that the EPC colony forming capacity and tube 
formation ability in matrigel assays were significantly reduced in adult patients with acute 
stroke compared with patients with chronic stroke, or healthy controls (Chu et al. 2008). In a 
study by Sobrino et al. increased EPC colony forming units were also shown to be associated 
with improved neurological outcome in a cohort of 48 adults with stroke (Sobrino et al. 
2008). As far as childhood cerebrovascular diseases are concerned, Kim et al. studied 28 
children with moyamoya disease prior to any surgical treatment and compared their 
endothelial repair responses to 12 healthy childhood controls (Kim et al. 2010). They 
demonstrated less tube formation by CD34+CD133+KDR+EPC and increased senescent-
like phenotype in children with moyamoya disease (Kim et al.2010).   
 
These data suggest that altered EPC number and functional capacity are associated with 
endothelial dysfunction in adult stroke (Chu et al.2008; Yip et al. 2008). Several studies 
emphasize that EPC participate in the ongoing maintenance of endothelial integrity and that 
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insufficient endothelial cell repair by EPC may play a causal role in vascular disease 
progression. The endothelial repair responses in children with AIS have however never been 
explored.   
 
7.3 Hypothesis and aims: 
 
In this chapter the hypothesis that insufficient endothelial cell repair may play a causal role 
in vascular disease progression in children with AIS recurrence is examined. Defective 
endothelial repair could contribute to endothelial dysfunction and increased likelihood of 
stroke recurrence and/ or progressive arteriopathy. In this chapter endothelial repair 
responses in children with AIS recurrence are compared to those children with a single 
event.  
 
 
7.4 Methods 
 
7.4.1 Fluorescent activated cell sorting (FACS) for Endothelial Progenitor 
Cells (EPC) surface marker identification 
 
To analyse PBMC for expression of cell surface protein and identify the EPC population co-
expressing CD34/CD133/CD144 and CD34/CD133/VEGFR2, frozen PBMC were thawed 
rapidly at 370 C and re-suspended in warm FACS buffer (PRMI 1640 with 10% heat 
inactivated FCS) at a concentration of 2x106cells / ml. Fifty μl of Fc receptor blocking agent 
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was added per ml and the cells incubated in room temperature for 10 minutes. 100 μ l of cell 
suspension was placed in each well of a 96-well U bottomed plate. Plates were centrifuged at 
500g for 5 minutes at 40 C to obtain a cell pellet, and the solution removed by flicking. The 
cell pellet was re-suspended in 50 μl of FACS buffer containing the relevant antibodies at 
the specified dilution (chapter 2) incubated in the dark for 30 minutes at 40 C. For VEGFR2 
staining, the secondary antibody-streptavidin FITC-was added to the required wells and 
incubated for another 10 minutes in room temperature. After incubation, cells were washed 
twice with FACS buffer as above and re-suspended in 200 μl of fixative with 10% 
formaldehyde with 1% azide (BD, cell FIX) and transferred to small FACS tubes for flow 
cytometric analysis (FACS Calibur, BD).  
 
 
7.4.2 Flow cytometry data analysis 
 
Flow cytometric data were collected on a FACS Calibur; 20 x103 events were collected for 
each condition and cells gated by scatter properties. For the gating strategy used to identify 
the triple positive population for EPCs see figure 7-1. Non stained samples and 
fluorochrome matched isotype controls were used to define positivity. EPC sub-population 
was defined as cells co-expressing CD34 with combinations of the following endothelial and 
stem/progenitor cell markers: CD133, VEGFR2 and CD144. EPC numbers were expressed 
as a percentage of the mononuclear cell gate (figure 7-1). Data were analysed using FlowJo 
(Treestar Inc, Ashland, OR).  
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Figure 7-1: Flow cytometry for endothelial progenitor cells (EPCs).  
Peripheral blood mononuclear cells (PBMC) were stained for VEGFR2/CD133 and CD34 
and gated initially on their FSC and SSC characteristics (G1). Cells positive for CD34 were 
then identified (G2). G1 and G2 were combined in order to determine the proportion of 
VEGFR2 and CD133 positive cells.  The triple positive population could then be calculated 
(% of PBMCs stained for VEGFR2/CD133/CD34).  
 
 
 
 
 
7.4.3 Endothelial progenitor cell colony forming units (EPC-CFU) 
 
 
EPCs were further evaluated based on their in vitro ability to adhere and grow in culture 
giving rise to endothelial progenitor cell-colony forming unit (EPC-CFU). PBMC at 2x106 
isolated as described above were plated into 24 well culture plate pre-coated with human 
fibronectin 100ng/ml (Sigma Aldrich) and maintained in EGM-2 culture medium 
supplemented with growth factors as per manufacturers recommendations, 20% of FCS and 
40 ng/ml of VEGF. After 4 days in culture, non-adherent cells were removed by washing 
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with PBS and the adherent cells maintained in culture until day 7. Early EPC-CFU were 
identified as a central core of rounded cells surrounded by elongated spindled-shaped cells 
and counted on day 8. Figure 7-2 shows a representative EPC-CFU on day 8 from EPCs 
isolated from PBMCS from a child with AIS at acute presentation. Cell clusters without 
emerging spindle cells were not counted. Colonies were counted manually in a minimum of 
2 wells in 24-well plates by two independent observers who were unaware of clinical 
profiles; results are expressed as average number of CFUs per well. In selected samples, the 
endothelial phenotype was confirmed using specific indicators, that is, according to the 
uptake of Di-IAcLDL (Invitrogen). 
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Figure 7-2: Endothelial progenitor cell- colony forming units. Endothelial progenitor cell 
(EPCs) prepared from peripheral blood mononuclear cells (PBMCs) isolated from 5ml of 
blood from a healthy control child were plated into culture dishes coated with human 
fibronectin and maintained in EGM-2 supplemented with 20% fetal calf serum (FCS). After 
4 days in culture, non-adherent cells were removed by washing with phosphate buffered 
saline (PBS) and the adherent cells maintained in culture until day 8.  Early EPC colony 
formed units were counted in a minimum of 2 wells and expressed as average number of 
EPC-CFU per well. 
 
7.4.4 Human umbilical vein endothelial cell (HUVEC) capillary network 
formation on matrigel 
 
A number of studies have shown that EPCs can incorporate into vascular networks formed 
by endothelial cells on extracellular matrix formulations (Matrigel TM) recapitulating 
vasculogenesis events happening in vivo (Sieveking et al. 2008;Tepper et al. 2002). The 
50µm 
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optimal number of HUVEC needed to form a capillary network in the matrigel matrix was 
established initially. HUVEC grown overnight in EGM-2 were treated with Trypsin/EDTA 
and re-suspended in EGM-2 at  concentrations of 5000, 8000 and 10000 cells  in 100μl 
respectively prior to being seeded onto the matrigel coated 96-well flat bottomed plate. The 
formation of HUVEC vascular networks (tubule formation ie a structure exhibiting length 
four times its width) was examined with light microscopy (figure 7-4). A concentration of 
10000 per 150 μl were subsequently chosen as the optimal concentration of HUVEC for the 
EPC-HUVEC incorporation assay, as at this cell concentration  HUVEC exhibited maximum 
tubulogenesis (tubule length for 10000 cells/ 100 μl was 8mm/mm2, range 7.6-8.6 mm/mm2 
versus 4.1 mm/mm2, range 3.9-4.4 mm/mm2 for 8000 cells/100 μl, p=0.02 and 2.0 mm/mm2, 
range 1.2-2.2 mm/mm2 for 5000 cells/100 μl, p=0.02. 
 
 
 
 
7.4.5 Co-cultured endothelial progenitor cells (EPCs) and endothelial cells 
on matrigel 
 
 
To assess the ability of EPC to incorporate into HUVEC vascular networks the following 
protocol was derived:  Matrigel aliquots were thawed at 4 0 C overnight. Fifty μl of the 
matrigel were then seeded into wells of 96-well tissue culture plates and incubated at 37C for 
45 min to solidify. EPCs pre- labeled with 2μg/ml of Di-I-LDL for 2 hours were harvested 
by Trypsin/EDTA. Cells were washed 2 times with culture media (EGM-2) and then re-
suspended in EGM-2 at a density of 30, 000 cells/ml. Amplified EPCs  harvested and 
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labelled with Di -I-LDL as described above were then re-plated with HUVEC (ratio of 3000 
EPCs to 10000 HUVEC in 200 µl)  on top of a solidified matrigel layer and incubated at 37 
°C for 20 to 24 h. Incorporation of EPC into capillary networks of HUVEC onto matrigel 
was examined with fluorescence microscopy. Five independent fields were assessed for each 
well and the mean numbers of EPCs incorporated into the HUVEC vascular networks/ x200 
field were determined (figure 7-5).  
 
   
 
 
  
 
Figure 7-4: Human umbilical vein endothelial cell (HUVEC) capillary network formation 
on matrigel.  
HUVEC grown overnight were treated with trypsin and re-suspended in EGM-2 at varying 
concentrations of 5000, 8000 and 10000 cells in 100µl respectively prior to being seeded 
onto the matrigel coated 96-well plate. The formation of HUVEC vascular networks was 
examined with light microscopy to establish the optimal concentration of HUVEC for 
capillary network formation.  
 
 
5000 cells 8000 cells 10000  cells 
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Figure 7-5: Endothelial progenitor cell (EPC) incorporation into matrigel human 
umbilical vein endothelial cells (HUVEC) networks. 
 
EPCs were labeled with Di -I-LDL and then replated with HUVEC on top of a solidified 
matrigel layer and incubated at 37 °C for 24 h.  Incorporation of EPCs into HUVEC 
capillary networks was assessed by fluorescent microscopy. Five independent fields are 
assessed for each well, and the mean number of EPC incorporated into HUVEC vascular 
networks /×200 are determined. Figures 7-5A and 7-5 B display the reduced incorporation 
of EPCs and tubule formation (structure exhibiting length four times its width) in a patient 
with arterial ischemic stroke (A) compared to a healthy control child B).  
 
 
 
 
 
 
 
A B 
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7.5 Statistical analysis 
Values are presented as median (range) unless otherwise specified. The Kruskal-Wallis test 
was used to examine overall differences in experimental laboratory markers between the 
study groups. Following this, statistical differences between groups were determined by 
Mann-Whitney U test. P-values of less than 0.05 (two sided) were regarded as significant. 
Statistical analysis was performed using SPSS version 16 and 17. 
 
7.6 Results 
 
 
7.6.1 Subjects 
 
EPC were identified using flow cytometry in 35 children with AIS (10 with recurrence) and 
compared to 20 paediatric controls. The demographics, clinical and radiological data for the 
subpopulation of these 35 children with AIS in whom endothelial repair responses were 
assessed are summarised in table 7-2. In select subjects (5 in each group) the EPC ability to 
form colonies and incorporate into endothelial cell vascular structures were additionally 
evaluated.  
 
 
 
 
 292 
 
 
 
Demographics AIS recurrence 
n=10 (%) 
AIS no recurrence n=25 
(%) 
P value 
Sex (M:F) 6:4 16:9 1 
Age (median, range) years 8.2 (0.9-15.4)  9.4 (2.7-17.4)  0.681 
Clinical features    
Focal neurological deficit  10(100%) 25 (100%) 1.0000 
Diffuse neurological 
deficits 
7 (70%) 2 (8%) 0.0005 
Sebire et al. classification 
of cerebral arteriopathy 
(Sebire et al. 2004) 
N=3 Arterial 
dissection (30%) 
N=1 PACNS 
(10%) 
N=1 PVA (10%) 
N=1 Moyamoya 
(10%) 
N= 4 Unclassified 
(40%) 
N=16 TCA/FCA (64%) 
N=4 Arterial dissection 
(16%) 
N=3 PVA (12%) 
N=2 Moyamoya (8%) 
N/a 
ESR mm/h (median, 
range) 
(normal range 0-10 mm/h) 
5.4 (1-12) mm/h 6.6 (1-28) mm/h 0.561 
CRP mg/L (median, 
range) 
(normal range <10 mg/L) 
5 (3-16) mg/L 5 (3-6) mg /L 0.873 
MRI    
Multifocal  and bilateral 
lesions 
9 (90%) 5(20%) 0.0002 
MRA    
Multifocal and bilateral 
lesions 
9 (90%) 5(20%) 0.0002 
Anterior and posterior 
circulation 
7 (70%) 2(8%) 0.0005 
Collaterals 4 (40%) 2(8%) 0.04 
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Table 7-2: Study population characteristics.  
Focal neurological deficits included hemiparesis, facial weakness and hemisensory loss. 
Diffuse neurological deficits included neurocognitive dysfunction, personality changes and 
concentration difficulties. M=male; F=Female; TCA=Transient cerebral arteriopathy; 
FCA=Focal cerebral arteriopathy; PACNS=primary angiitis of the central nervous system; 
ESR=erythrocyte sedimentation rate; CRP=C-reactive protein; MTHFR= Methylene-
tetrahydrofolate reductase; PVA=Post varicella arteriopathy; N/a=not applicable; 
MRI=magnetic resonance imaging; MRA=magnetic resonance angiography.  P values were 
calculated using Fisher’s exact test for categorical data and Mann Whitney U for 
continuous variables. P-values of less than 0.05 (two sided) were regarded as significant. 
 
 
7.6.2 Flow cytometric identification of EPC in children with AIS and 
cerebral arteriopathy 
 
CD34/CD133/CD144 EPC were significantly raised in 10 patients with AIS recurrence 
median of 0.0.7% of PBMC  gated (range 0.04-0.2 %) compared to 25 patients with no 
recurrence median 0.02% (0-0.09%) of PBMC gated  p= 0.0001 and 20 child controls  
median 0.03% (range 0-0.07%) PBMC gated, p = 0.0001 (figure 7-5). 
 
 
CD34/CD133/VEGFR2 EPC were significantly raised in 10 patients with AIS recurrence 
median of 0.1% of PBMC gated (range 0.02-0.4 %) compared to 25 patients with no 
recurrence median 0.03% (0.01-0.09%) of PBMC gated  p= 0.005 and 20 child controls  
median 0.01% (range 0.-0.05%) PBMC gated, p = 0.0001 (figure 7-6). 
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Figure 7-5: Circulating CD34+CD133+CD144+ endothelial progenitor cells in children 
with arterial ischaemic stroke (AIS) and cerebral arteriopathy.  
CD34+CD133+CD144+ endothelial progenitor cells were significantly higher in patients 
with AIS recurrence compared to those with no recurrence, p=0.0001 and child controls, 
p=0.0001. ***P<0.0005 with Mann Whitney U test.  
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Figure 7-6: Circulating CD34+CD133+VEGFR2+ endothelial progenitor cells in children 
with arterial ischaemic stroke (AIS) and cerebral arteriopathy.  
CD34+CD133+VEGFR2+ endothelial progenitor cells were significantly higher in patients 
with AIS recurrence compared to those with no recurrence, p=0.005 and child controls, 
p=0.0001. ***P<0.0005 with Mann Whitney U test.  
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7.6.3 Endothelial progenitor cell- colony forming units (EPC-CFU) in 
children with AIS and cerebral arteriopathy 
 
EPC-colony forming units (EPC-CFU) were reduced in 5 children with AIS recurrence with 
a median 2/well (range 1-2/well) compared to 5 children with no recurrence median 6/well 
(range 3-9/well) p=0.04 and 5 healthy control children median 14/well (range 4-17/well), 
p=0.03 (figure 7-7). 
 
 
 
 
 
 
 
 
 
 
Figure 7-7: Endothelial progenitor cell-colony forming units (EPC-CFU) in children with 
arterial ischaemic stroke (AIS) and cerebral arteriopathy.  
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7.6.4 EPC incorporation into HUVEC vascular networks for children with 
AIS and cerebral arteriopathy 
 
Incorporation of EPCs into HUVEC vascular networks in matrigel was decreased for 5 
children with AIS recurrence median 124/ mm2 (range 0-193/mm2) compared to 5 children 
with no recurrence median 307/ mm2 (189-596/ mm2), p =0.022 and 5 healthy control 
children median 1478/ mm2 (range 1478-4478/ mm2), p=0.003 (figure 7-8). 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-8: Endothelial progenitor cell (EPC) incorporation into human umbilical vein 
endothelial cell (HUVEC) vascular networks.  
Endothelial progenitor cell (EPC) incorporation into human umbilical vein endothelial cell 
(HUVEC) capillary networks on matrigel as compared for children with AIS recurrence and 
those with a single event and child healthy controls. *P<0.05 with Mann Whitney U test.  
A
IS
 re
cu
rr
en
ce
A
IS
 n
o 
re
cu
rr
en
ce
H
ea
lth
y 
co
nt
ro
l
0
1000
2000
3000
4000
**
*
E
P
C
 i
n
c
o
rp
o
ra
ti
o
n
 (
p
e
r 
m
m
2
)
 298 
7.7 Discussion 
 
Children with AIS recurrence had significantly higher levels of circulating CD34+EPC as 
identified with flow cytometry compared to children with a single event, but impaired EPC 
functional capacity: the ability of these EPC to grow in culture, form colonies and 
incorporate into endothelial cell vascular networks was diminished. Therefore in parallel to 
endothelial-injury processes reflected in an increase in CECs and endothelial derived MPs, 
there could be an additional disturbance in endothelial repair in children with AIS 
recurrence.  
 
The balance between endothelial injury and regeneration is critical for the maintenance of 
vessel integrity (Sabatier et al. 2009). If baseline levels of CEC, EMP and EPC represent the 
physiological equilibrium of endothelium in healthy situations, any shift in this balance 
could be important clinically. Combining these indices of vascular injury and repair in a 
multi-biomarker strategy (CEC, MP and EPC) could provide a prognostic score based on 
endothelial phenotype for individual patients, potentially offering a novel means of assessing 
vascular risk and monitoring therapeutic efficacy. To date, however, little is known about the 
balance of endothelial injury and repair in childhood AIS. The present study is the first in 
this field, and demonstrates that in children with AIS recurrence there is altered endothelial 
repair responses, which could contribute to disease progression when considered in the 
context of the burden of excess endothelial injury described in preceding chapters.   
 
The finding of elevated levels of circulating CD34+EPC as identified with flow cytometry is 
intriguing, and consistent with observations in other paediatric vasculitides.  Mobilization of 
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EPCs from bone marrow in rapid response to tissue ischaemia could be an attempt to 
mediate vascular repair, and hence higher levels of EPCs could be reflective of the extent of 
the tissue injury. Consistent with this hypothesis is the observation that children with 
Kawasaki disease (KD) complicated by coronary artery aneurysms have higher circulating 
EPCs in the subacute phase of the illness than KD patients without coronary artery 
abnormalities, suggesting that EPC release is proportionate to the severity of the vascular 
injury in that scenario (Xu et al. 2010). Additionally, Clarke et al. observed that children 
with active systemic vasculitis mount a similar increased CD34+EPC response compared to 
healthy controls or children with inactive vasculitis, although the functional properties of 
EPC were not assessed in that study (Clarke et al. 2010). Interestingly, in conditions of acute 
vascular ischaemia and endothelial injury, an increase in the number of circulating 
CD34+/KDR+ cells has been observed in association with a concomitant increase in levels 
of mobilizing factors, such as VEGF and SDF-1, suggesting a causal relationship (Rabelink, 
de Boer, & van Zonneveld 2010). In addition recent studies proposed that CD34+/KDR+ 
cells are generated from CD34+cells at platelet rich sites of vascular injury thus reflecting 
the plasticity of CD34+cells and their capacity to respond to environmental cues (De Boer et 
al. 2006; De Boer et al. 2011).  In chapters 3 and 4 it was established that markers of 
endothelial injury and platelet activation are elevated in childhood AIS recurrence. These 
data would now suggest that the CD34+/KDR+ cell fraction increases in response to this 
vascular injury and platelet activation, perhaps representing an attempt to recruit to the 
injured vessel progenitor cells that are able to modulate vascular repair.   
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In contrast to the elevated CD34+EPCs, the colony-forming capacity and ability of EPC to 
incorporate into endothelial networks was impaired in children with recurrent AIS. This 
observation underscores the functional differences in cellular populations with potential to 
influence angiogenic responses, and is in keeping with observations in adults with 
rheumatoid arthritis (RA)(Egan et al. 2008). Egan et al. observed that whilst circulating 
levels of CD34+EPCs where unaffected in RA, colony-forming capacity was significantly 
reduced (Egan et al. 2008).  Thus it is possible that there is functional impairment of EPC 
responses in children with recurrent AIS, despite attempts to generate a reparative response 
(increased circulating CD34+ EPCs) in children with recurrent AIS, a situation observed in 
other systemic inflammatory diseases. In RA it is suggested that impaired colony-forming 
capacity is a consequence of chronic systemic inflammation and an unfavourable 
inflammatory milieu (Egan et al. 2008). Children with AIS, however, are conspicuous by the 
lack of apparent systemic inflammation, raising the possibility that local vascular 
inflammation in the central nervous system may be enough to adversely influence functional 
EPC responses. Alternatively, children with recurrent AIS may have subclinical levels of 
systemic inflammation not detected by routine assessment of acute phase reactants. 
 
Another important implication of impaired EPC function in children with recurrent AIS 
could relate to the influence of EPCs on neurogenesis, the process of generating neural cells 
from their progenitors (Eriksson et al. 1998). EPCs may promote a favourable angiogenic 
environment that facilitates effective neurogenesis after cerebral ischaemia (Eriksson et al. 
1998). Palmer et al. proposed the idea of a vascular niche based on the hypothesis that there 
is co-development of neurogenesis and vasculogenesis in neural tissue (Palmer et al. 2000). 
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Endothelial cells are now known to release factors or chemokines, such as brain-derived 
neurotrophic factor (BDNF) which stimulates the regeneration of both embryonic and adult 
neural stem cells and also promote the neuronal function (Shen et al. 2004a). Since EPCs are 
the precursors of endothelial cells, they may have the potential to promote neurogenesis after 
cerebral ischemia by providing a favourable environment for new neural cells through their 
paracrine effects (Shen et al. 2004b; Taguchi et al. 2004; Zhang et al. 2002). Taguchi et al. 
for instance administered human CD34+EPCs, to immunocompromised mice 48 h after 
stroke, and observed enhanced neovascularization at the border of the ischaemic zone, and 
endogenous neurogenesis (Lapergue, Mohammad, & Shuaib 2007; Taguchi et al. 2004). 
This neurogenesis was suppressed by an antiangiogenic agent (endostatin) and increased by 
a proangiogenic agent (erythropoietin), demonstrating the importance of an angiogenic 
environment to neurogenesis after stroke (Lapergue, Mohammad, & Shuaib 2007; Taguchi 
et al. 2004). Further studies to establish the exact relationship between angiogenesis and 
neurogenesis and the potential relevance to paediatric AIS are clearly needed. 
 
Longitudinal studies of EPC changes with time after the initial cerebrovascular event and in 
response to therapy would be of considerable interest in paediatric AIS and could enhance 
our understanding of EPC biology in this context. Overall interpretation of these preliminary 
novel observations remains challenging, however, as the true identity and phenotype of 
EPCs remains ill-defined and needs to be further explored. The initial observations made in 
this thesis are intriguing, however, and suggest that it may be possible to explore the 
endothelium non-invasively by defining an imbalance between endothelial damage and 
repair capacity for children with AIS. This multimarker approach combining endothelial 
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injury and repair indices to provide an overall ‘endothelial index’ could provide important 
prognostic information in relation to risk of recurrent AIS in children. Importantly, 
therapeutic strategies aiming to improve endothelial function could target the selective 
reduction of endothelial injury, or the promotion of regenerative mechanisms. At the 
individual level, such personalised therapeutic options could be tailored depending on the 
relative severity of injury and/or impaired repair to prevent AIS recurrence. Future studies 
are therefore needed to further understand the relevance of EPCs in AIS, including better 
isolation methods, and in-depth studies regarding the potential interplay between 
angiogenesis and neurogenesis. 
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8 General discussion and future directions 
 
8.1 Summary: endothelial injury and repair in childhood 
arterial ischaemic stroke (AIS) and cerebral arteriopathy 
 
Childhood AIS causes significant lifelong morbidity and mortality (Ganesan et al. 2002). 
Abnormalities of the cervical or intracranial circulation, termed arteriopathies are the leading 
mechanism of both cause and recurrence of childhood AIS but an incomplete understanding 
of pathophysiology has hindered the development of targeted therapies or prevention 
strategies (Ganesan et al. 2003; Mackay et al. 2011). Though it may represent one or 
multiple different diseases, a distinct pattern of large vessel arteriopathy is most commonly 
observed in otherwise healthy school aged children presenting with childhood AIS (Amlie-
Lefond et al. 2009; Benseler et al. 2006; Braun et al. 2009; Chabrier et al. 1998; Mackay et 
al. 2011). Many different terms have emerged to describe this syndrome, some of which 
directly imply an infectious or inflammatory mechanism: transient cerebral arteriopathy 
(TCA); focal cerebral arteriopathy (FCA); post varicella arteriopathy (PVA); and childhood 
primary angiitis of the central nervous system (cPACNS) (Amlie-Lefond et al. 2009; 
Benseler et al. 2006; Braun et al. 2009; Chabrier et al. 1998; Mackay et al. 2011). Of note, 
inferring an inflammatory pathophysiology has direct and immediate therapeutic 
implications with readily available anti-inflammatory and/or immunosuppressive 
medications. Confirming the inflammatory nature of childhood cerebral arteriopathies is 
challenging however because clinical presentation may be diverse, and there is an ever 
expanding list of genetic noninflammatory vasculopathies being discovered (Munot, Crow, 
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& Ganesan 2011a). Even for those cases where there is a true inflammatory vasculitic 
component to the vasculopathy, conventional acute phase reactants such as ESR and CRP 
are insensitive; CSF biomarkers thus far have proven to be non-specific; and biopsy of 
arteries and/ or brain/meningeal tissue to confirm vasculitis is rarely performed, and lacks 
sensitivity due to the patchy nature of the disease in any case (Benseler et al. 2006; Cellucci, 
Tyrrell, Sheikh, & Benseler 2011; Elbers et al. 2010). Imaging techniques, while steadily 
improving, may be normal or non-specifically abnormal (Aviv et al. 2006; Eleftheriou et al. 
2010). Therefore, there is an urgent need for more specific, non-invasive and sensitive 
diagnostic biomarkers for children with AIS, to be used in conjunction with imaging 
findings to provide: (i) novel insight into disease pathophysiology, especially the role of 
endothelial injury, inflammation and thrombosis; (ii) and to help guide clinical care 
including appropriate treatment options, facilitate prognostication, and to monitor over time. 
On the background of these challenges, this thesis explored novel biomarkers of endothelial 
injury/repair and hypercoagulability and compared patients with recurrent clinical disease 
course, to those children with a single event.  
 
A number of methods for detecting endothelial cell components allowing assessment of the 
molecular events associated with vascular injury were employed in this study: cellular MPs, 
and whole circulating endothelial cells (CECs) in blood. CEC effectively differentiated 
between children with recurrent AIS and those with a single event despite a wide range of 
radiological and clinical presentations. This approach was complimentary to current 
radiological and clinical predictors of AIS recurrence, and suggests that persistent 
endothelial injury is a feature of those with recurrent stroke. Consistent with this novel 
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observation, children with recurrent AIS had evidence of increased levels of total (AnV+) 
MPs; and in particular MPs of endothelial, platelet, neutrophil and monocyte origin. Notably 
these MPs were highly prothrombotic, mainly due to PS exposure providing a platform for 
the assembly and activation of coagulation factors; but also due to expression of TF on some 
MP.  
An efficient in vitro assay to assess MP-related hypercoagulability by quantifying MP-
mediated thrombin generation was developed and is discussed in chapter 5. Thrombin is the 
key product of the coagulation system and is produced following activation of factor X by 
tissue factor/factor VIIa (Hemker, Wielders, Kessels, & Beguin 1993). Measurement of 
thrombin generation, and in particular the enzymatic work potential of thrombin, provides a 
method for quantifying the composite effect of the multiple factors that determine 
coagulation capacity and the influence of the environment on these factors (Bidot et al. 2008; 
Hemker, Wielders, Kessels, & Beguin 1993; Hemker et al. 2003). Enhanced MP-mediated 
thrombin generation was higher in systemic vasculitis patients with thromboembolic events.  
A similar approach was then used to determine if the same was true in children with AIS by 
assessing the pro-coagulant properties of MPs in children with recurrent AIS compared to 
those with a monophasic disease course. Significant differences in peak thrombin, 
endogenous thrombin potential, velocity index and lag time were demonstrated between 
these patient groups and controls, confirming an increased prothrombotic tendency 
associated with re-infarction in these patients. Overall the observations made in this thesis 
suggest that a state of chronic endothelial activation and injury (increased CECs and EMPs), 
platelet activation (increased platelet MPs), and increased MP mediated thrombin generation 
could be important determinants of AIS recurrence, providing important links between 
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inflammation and infection, leucocyte, platelet and endothelial activation, and pathological 
procoagulant activity in children with AIS (summarised in figure 8-1). 
 
In addition, a disturbance in EPCs potentially important for endothelial repair in children 
with AIS recurrence was demonstrated in chapter 7. The ability of these progenitor cells to 
grow in culture, form colonies and incorporate into endothelial cell vascular networks was 
impaired. The clinical relevance of this observation remains uncertain, however, but could 
be compatible with further compromise of endothelial integrity and hence adverse prognostic 
outcome, as has been observed in adults with atherosclerosis (Hill et al. 2003; Werner et al. 
2005).  
 
There are a number of limitations to the data presented in this thesis many of which have 
already been discussed in the relevant results chapters. This chapter will highlight these 
limitations, and areas of further research that could address some of the unanswered 
questions will be discussed. Limited preliminary data will be presented to illustrate the sort 
of approaches that may be used in these future studies.   
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Figure 8-1: Circulating endothelial cells and cellular microparticles in childhood arterial 
ischaemic stroke (AIS) recurrence.  
One or more widely distributed infectious agents evoke an abnormal immunological 
response in genetically susceptible individuals, leading to vascular inflammation, cerebral 
endothelial injury. As a result whole endothelial cells are detached (circulating endothelial 
cells-CECs) and can be detected in the peripheral blood. In addition there is increased 
endothelial, leucocyte and platelet membrane vesiculation resulting in release of 
endothelial, platelet microparticles, and leucocyte (MPs). These MPs may induce further 
endothelial cell activation, and are prothrombotic due to phosphatidylserine (PS) and tissue 
factor content. In addition, TF+ MPs also express PSGL-1 responsible for binding of these 
TF+MP to activated platelets expressing P-selectin at the thrombus edge, and hence can 
contribute to clot propagation. Thus inflammation and infection causes cellular and platelet 
activation, and endothelial activation/injury. Increased MP release resulting from this 
inflammatory activation, leads to pathological MP-mediated thrombin generation, with 
possible for the contribution to AIS recurrence in those where these processes persist. 
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8.2 Biomarker specificity for childhood AIS and cerebral 
arteriopathy 
 
Apart from non-atherosclerotic arteriopathies, multiple other risk factors such as cardiac 
disease are commonly identified in childhood AIS (Ganesan et al. 2003; Mackay et al.  
2011). Several other neuroinflammatory disorders may also mimic stroke in childhood. 
Demyelinating disorders such as acute demyelinating encephalomyelitis (ADEM) and 
multiple sclerosis (MS) may be difficult to differentiate from small vessel arteriopathies 
causing AIS on clinical and neuro-imaging features alone (Cellucci & Benseler 2010; Elbers 
& Benseler 2008). There are also a number of newly recognised neuronal antibody-
associated inflammatory brain diseases triggered by the binding of antibodies to cell surface 
receptors, channels, or enzymes in the CNS that have with similar neurological 
presentations, and indistinguishable radiological findings mimicking AIS (Vincent et al. 
2011). These include: N-methyl-D-aspartate (NMDA) receptor antibody associated 
encephalitis, neuromyelitis optica (NMO), voltage-gated potassium channels (VGKCs), 
glutamic acid decarboxylase (GAD), GluR1/2 alpha-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors, and gamma-aminobutyric acid (GABAB) 
receptors antibody associated encephalitides (Vincent et al. 2011). The role of inflammation 
and endothelial injury in these conditions is currently poorly defined. Comparing circulating 
endothelial MP profiles and CEC in children with cardiac disease related stroke, MS, other 
neuroinflammatory disorders and childhood arteriopathic AIS would be of considerable 
interest and would help establish the specificity of our findings.   
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8.3 Prognostic value of studied biomarkers-need for 
prospective studies 
 
Whilst the preliminary prospective data presented herein would support the proposal that 
these markers may have important predictive value for identification of those children with 
high risk of stroke recurrence, the preliminary nature and the possibility that these 
observations represent epiphenomena is emphasized. Multicentre prospective validatory 
studies to confirm these observations are now needed, a significant challenge since 
paediatric AIS is rare, and the assays required and described in this thesis are non-routine. 
Longitudinal studies will also allow us to study the effect of treatment on the levels of these 
biomarkers. 
 
8.4 Pulse wave velocity-assessing arterial stiffness  
 
Arterial stiffness is one of the earliest detectable manifestations of adverse structural and 
functional changes within the vessel wall (Arnett et al. 1994 ;Blacher et al. 2001; Laurent et 
al. 2006; Weber et al. 2004). It is now widely recognised that changes in the arterial wall as 
early as in childhood are associated with altered levels of cardiovascular risk factors and 
eventually impact on longer term cardiovascular morbidity and mortality (Berenson et al. 
1998; Tounian et al. 2001). As a result, there is increasing interest in the determinants of the 
initiation and progression of early arterial disease and the potential for reversibility and 
prevention from a young age (Berenson et al. 1998; Tounian et al. 2001). Pulse wave 
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velocity (PWV) is the most validated method to noninvasively quantify arterial stiffness 
(Asmar et al. 1995; Barac et al. 2007; Laurent et al. 2006;Wilkinson et al. 2002). It is 
considered the gold standard index of arterial stiffness, given that is simple, accurate, 
reproducible, and strongly predicts adverse outcomes (Lehmann 1999; Millasseau et al. 
2005; Sutton-Tyrrell et al. 2005). PWV can be determined by measuring the pulse transit 
time from the pressure waveforms at the 2 sites along a vascular segment (figure 8-2) 
(Laurent et al. 2006; Lehmann 1999; Millasseau et al. 2005; Sutton-Tyrrell et al. 2005; 
Wilkinson et al. 2002). The distance (D) is divided by the wave foot-to-foot time it takes for 
that forward wave to reach the end measuring point. PWV is inversely related to vascular 
compliance (Laurent et al. 2006; Lehmann 1999; Millasseau et al. 2005; Sutton-Tyrrell et al. 
2005; Wilkinson et al. 2002). Hence, a stiffer vessel will conduct the pulse wave faster than 
a more distensible and compliant vessel. A number of previous studies have demonstrated 
that PWV obtained by non-invasive automatic devices is not only a marker of vascular 
damage but also a prognostic predictor of cardiovascular events and cardiovascular mortality 
in patients with different co-morbidities (Cheung et al. 2007; Lehmann 1999; Munakata et 
al. 2003; Sutton-Tyrrell et al. 2005). In children Cheung et al. have previously shown an 
increased PWV and hence decreased distensibility in the peripheral arterial segment in 
children with polyarteritis nodosa amplified during acute inflammatory exacerbation 
(Cheung et al. 2004; Cheung, Wong, & Ho 2007). This finding suggests that chronic 
vasculitis leads to a significantly reduced distensibility, the magnitude of which is amplified 
during the acute inflammatory stage of the disease (Cheung, Ho, Tam, & Yung 2004; 
Cheung, Wong, & Ho 2007).  
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The predictive value of arterial stiffness specifically for adult stroke was demonstrated in a 
longitudinal study that included 1715 patients with essential hypertension and measurements 
of carotid-femoral PWV at entry (Laurent et al. 2003). Over a mean follow-up period of 7.9 
years, during which 25 fatal strokes occurred, PWV significantly predicted stroke (relative 
risk = 1.39 [(95% CI 1.08, 1.72]; p = 0.02 for each 4 m/sec increase) independently of 
classical cardiovascular risk factors, including age, cholesterol level, diabetes mellitus, 
smoking and mean blood pressure (Laurent et al. 2003).  
 
Childhood AIS is commonly associated with non atheromatous arteriopathies confined to the 
CNS (Ganesan et al. 2003; Mackay et al. 2011). As such one would not expect any effect on 
central arterial segmental elasticity or changes in systemic arterial stiffness in children 
affected by this condition. To date however no study has explored whether children with AIS 
have a secondary sub-clinical systemic effect on the peripheral vasculature resulting in 
impaired arterial distensibility and maybe contributing to their long term cardiovascular 
morbidity. Future studies are now needed to explore this hypothesis. 
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Figure 8-2: Pulse wave velocity measurement. 
A=wave recorded by the proximal transducer; B=wave recorded by the distal transducer; 
ΔT=time delay between the foot waves; D=distance traveled by the wave. 
 
8.5 Phenotype of circulating endothelial cells (CEC) 
 
The phenotype of CEC was not examined in this thesis. Several lines of evidence suggest 
that CECs could also be pro-inflammatory (Kirsch et al. 2007; Solovey et al.1997). Under 
physiological conditions dying or dead cells are rapidly removed by macrophages or by 
neighbouring cells before their inflammatory potential can unfold (Henson et al. 2001). 
CECs may be present in high numbers in certain vascular disorders and therefore overwhelm 
the clearance mechanisms thus initiating a series of signalling processes and thereby gaining 
pathogenic importance. Kirsch et al. were able to demonstrate that apoptotic and necrotic 
endothelial cells and their fragments are rapidly internalized by healthy endothelium (Kirsch 
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et al. 2007). The authors also showed that endothelial cells exposed to apoptotic and necrotic 
cells exhibit enhanced adhesion properties for leukocytes, and that isolated CECs from 
patients with vasculitis aggravated this (Kirsch et al. 2007). These effects on binding 
properties could be explained, at least in part, by the release of the pro-inflammatory chemo-
attractants IL-8 and MCP-1 (Kirsch et al. 2007). Cytokine profiles may differ in various 
vascular disorders, and could therefore influence interactions between CECs and healthy 
endothelium. These interactions may also be influenced by the nature of neighbouring 
endothelial cells (microvascular versus macrovascular). As endothelial cells participate in 
the homeostasis of coagulation, detachment of these cells and loss of endothelial integrity is 
likely to significantly impact on haemostasis (George et al. 1993; Sabatier et al. 2009; 
Solovey et al. 1997). George et al. reported that some CECs contain thrombomodulin, but 
whether or not this molecule is still bio-active is unclear (George et al. 1993). Solovey et al. 
found that CECs in sickle cell disease expressed tissue factor that was functionally active 
(Solovey et al. 1997). Therefore CEC, in addition to providing a useful biomarker of 
endothelial injury, could also be important pathogenic mediators. Even though several lines 
of evidence suggest that CEC can amplify endothelial injury and inflammation, the cross 
sectional nature of my study precludes any causal effect to be determined. Future studies to 
address the hypothesis that these reported biomarkers are indicative of persistent vascular 
inflammation leading to further vascular damage, and not just an epiphenomenon/ 
consequence of stroke (and associated endothelial injury) are now needed. 
 
 
 314 
8.6 Microparticles in cerebrospinal fluid (CSF) 
 
It could also be important to investigate whether MPs are present in the cerebrospinal fluid 
(CSF) of children with AIS, possibly also resulting in enhanced thrombogenicity. Direct 
sampling of CSF could provide more sensitive detection of pathophysiological processes in 
paediatric AIS and cerebral arteriopathy. Morel et al. have previously shown that flow 
cytometric identification and enumeration of MPs in CSF is possible in patients with 
traumatic brain injury (Morel et al. 2008a). The presence of cellular MPs in the CSF may 
reflect injury of the blood-brain barrier, which could have prognostic significance for 
identifying patients at risk of AIS recurrence. These CSF MPs (if present) could also prove 
useful for the study of neuronal or vascular cell activation/apoptosis.  
 
8.7 Microparticles as shuttles of mRNA and microRNA  
MPs represent a novel mechanism of intercellular communication mediating inflammation 
and coagulation (Morel et al. 2006; Sabatier et al. 2009). Their effect on target cells was long 
attributed to their specific lipid composition, as well as to intravesicular chemokines (Morel, 
Toti, Hugel, & Freyssinet 2004; Morel et al. 2006; Sabatier et al. 2009). The hypothesis that 
MP can also affect protein expression of their target cells by delivering RNAs is intriguing. 
Preliminary observations suggest that MP contain mRNA. As depicted in figure 8-3. EMP 
harvested from supernatants of HUVEC stimulated with TNF-α 100 ng/ml for 4 hours 
expressed E-selectin mRNA.  
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These preliminary findings suggest that MPs could facilitate genetic exchanges between 
different tissues within the body. This may have implications for cell activation, phenotypic 
modification, and reprogramming of cell function. MP of different origin may contain 
different subsets of mRNA and different cell types may be specifically targeted by plasma 
MP. In addition, exploring the mRNA content of MPs may help us establish the anatomic 
origin of circulating MPs. In children with childhood AIS we confirmed the presence of 
endothelial derived EMP based on surface protein expression, but whether these are released 
from the cerebral endothelium remains uncertain. Kallman et al. have previously shown that 
there are significant differences in the mRNA profile of human cerebral microvascular 
endothelial cells and HUVEC (Kallmann et al. 2002). Taking this into account it is tempting 
to speculate that MP released from different vascular beds will contain mRNA indicative of 
their endothelial cell of origin.  
 
In addition, recent progress in the understanding of microRNA prompts the question of 
whether MP also affect their target cells via transferring endogenous microRNAs and 
whether these MP have different microRNA patterns than their maternal cells. MicroRNAs 
are a class of approximately 22 nucleotide noncoding RNAs that mediate post-transcriptional 
gene regulation by binding to and repressing specific messenger RNA targets (Bartel 2004). 
MicroRNAs are present in the human circulation in a cell-free form and are remarkably 
stable in plasma despite high circulating RNase activity (Bartel 2004). To date, 587 human 
microRNAs have been identified. A single microRNA can modulate several genes, and a 
single gene can be modulated by several microRNAs: about 10–30% of human genome 
expression is modulated by microRNAs (Bartel 2004). MicroRNAs play a critical role in the 
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control of: metabolism, cell-differentiation, cell-proliferation and cell-apoptosis (Bartel 
2004). Circulating microRNAs have also recently emerged as biomarkers for cardiovascular 
diseases (Lu et al. 2008; Small et al. 2010). Experiments to confirm the presence of 
microRNA in MP are ongoing at the time of writing this thesis.  
 
MPs as shuttles of microRNA may also play a significant role in either the promotion or 
inhibition of angiogenesis. Parallel microRNA and mRNA expression profiling in 
angiogenic-associated diseases in combination with functional studies on ECs and large-
scale proteomics could help us understand the complex microRNA-mediated gene regulatory 
networks in angiogenesis.  
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Figure 8-3: Messenger RNA content of microparticles. 
RNA for PCR was extracted using Trizol (Invitrogen). The total amount of RNA in the 
microparticle preparations was determined spectrophotometrically. cDNA was reverse-
transcribed from 1 µg of total RNA by use of a commercial reverse transcription system 
(Applied Biosystems). Real-time quantitative PCR for β-actin (Quantitect, Qiagen) and E-
selectin was performed on a 6000 Rotor Gene Sequence Detection System (Qiagen) using 
SYBR-Green (SYBR PCR Master Mix, Applied Biosystems). The following Eselectin primers 
were synthetised by Invitrogen: CCC AGA GCC TTC AGT GTA CC (forward) and CAG 
AGC CAT TCT GAG GCT GG (reverse). PCR conditions were:  95◦C for 15 min, followed 
by 40 cycles of 94◦C for 15 sec, 55◦C for 20 secs and 72◦C for 20s. Each reaction was 
performed in triplicate to ensure reproducibility. A standard curve (using standard cDNA 
extracted from HUVEC) was produced for each gene to calibrate the quantitation. Target 
PCR efficiency was between 95-100% and correlation coefficient for the standard curve was 
greater than 0.9. Melt curves for β-actin and E-selectin on endothelial derived MPs are 
shown. The x axis displays temperature and the y axis change in fluorescence. 
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8.8 VZV and cerebral arteriopathy in childhood arterial 
ischaemic stroke (AIS) 
 
Strong epidemiological data link VZV infection to FCA and childhood AIS (Askalan et al. 
2001; Lanthier, Armstrong, & Domi 2005; Sebire, Meyer, & Chabrier 1999). Nagel et al. 
have recently suggested that stroke in VZV vasculopathy may result from changes in arterial 
caliber and contractility produced in part by abnormal accumulation of smooth muscle cells 
and myofibroblasts in thickened neointima and disruption of the media (Nagel et al. 2011). 
Analysis of the morphology and composition of the thickened intima and media, and the 
location of viral antigen in the adventitia in early VZV vasculopathy, revealed clues to the 
possible mechanisms of VZV induced vascular remodelling that leads to arteriopathy and 
AIS (Nagel et al. 2011). After vascular injury adventitial fibroblasts can differentiate into 
myofibroblasts that proliferate and migrate to the intima (Nagel et al. 2011). These cells may 
secrete factors that create a proinflammatory environment, further contributing to vascular 
wall remodelling. Also they may interact with medial smooth muscle cells influencing their 
phenotype. These observations suggest that perhaps human cerebral adventitial fibroblasts 
may be important in the pathophysiology of childhood AIS (Nagel et al. 2011; Sartore et al. 
2001). Alternatively, adventitial dendritic cells have been shown to become activated and 
contribute to a proinflammatory environment leading to vascular wall remodelling in other 
cerebrovascular diseases (Inder et al. 2000). Studies of dendritic cell activation in VZV-
infected arteries would thus be of considerable interest.  
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8.9 Paracrine effects of bone marrow derived progenitor cells 
contributing to angiogenesis and neurogenesis 
 
Bone marrow derived progenitor cells are believed to augment neo-vascularization not only 
as incorporating cells into newly developing capillaries, but also in a paracrine fashion 
through the secretion of angiogenic growth factors (Asahara et al. 1999b; Hirschi, Ingram, & 
Yoder 2008;Rehman, Li, Orschell, & March 2003; Richardson & Yoder 2011). Recent 
evidence also suggests that brain repair involves a collection of natural mechanisms that are 
activated following stroke, including angiogenesis and neurogenesis (Palmer, Willhoite, & 
Gage 2000; Taguchi et al. 2004). It has been demonstrated that endothelial repair can 
promote neurogenesis by creating a favorable environment for neuroplasticity, leading to a 
beneficial impact on infarct volume, cell death and perhaps most importantly on functional 
recovery (Palmer, Willhoite, & Gage 2000; Taguchi et al. 2004). Whether the ability of 
circulating progenitor cells to secrete angiogenic and neurogenic support factors is impaired 
or not is unknown. If indeed this is pathway is dysregulated, further understanding of this 
mechanism could translate into the design of new agents for prevention and treatment of 
stroke in children.  
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Appendix 1 
 
The CASCADE Criteria Acute Primary Classification: Anatomic Features (adapted 
from Bernard et al., 2012). 
CASCADE= Childhood AIS Standardized Classification and Diagnostic Evaluation; 
AIS=Arterial ischaemic stroke; CTA=computed tomography angiography; MRA=magnetic 
resonance angiography. 
 
Primary Classification– 
Select One Only Definition 
 
Small-vessel arteriopathy of 
childhood 
 
a. Definitive–Confirmation of the definitive diagnosis of 
small-vessel arteriopathy of childhood requires 
multifocal arterial narrowing of small-caliber vessels 
on conventional angiogram and evidence of small-
vessel arteriopathy on biopsy, including evidence of 
intramural/vascocentric inflammation of the small 
muscular arteries, capillaries, and/or venules on brain 
biopsy. Supportive evidence can be obtained from 
electron microscopy demonstrating endothelial cell 
activations and/or tubular reticular inclusions. 
Perivascular demyelination and/or gliosis can be 
found; however, specific histological features of other  
inflammatory brain diseases of childhood must be 
absent (ie, diffuse parenchymal demyelination). 
 
b. Radiographic–Confirmation of the radiographic-
proven diagnosis of small-vessel arteriopathy of 
childhood requires multifocal arterial narrowing of 
small-caliber vessels on conventional angiogram. 
 
 
c. Biopsy–Confirmation of the biopsy-proven diagnosis 
of small-vessel arteriopathy of childhood requires 
evidence of small-vessel arteriopathy on biopsy, 
including evidence of intramural/vascocentric 
inflammation of the small muscular arteries, 
capillaries, and/or venules on brain biopsy. Supportive 
evidence can be obtained from electron microscopy 
demonstrating endothelial cell activations and/or 
tubular reticular inclusions. Perivascular demyelination 
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and/or gliosis can be found; however, specific 
histological features of other inflammatory brain 
diseases of childhood have to be absent (ie, diffuse 
parenchymal demyelination). 
 
d. Probable–Suspected small vessel arteriopathy is based 
upon a small vessel distribution of infarct (without 
another identified aetiology), non-invasive imaging, 
and/or a known disease process associated with small-
vessel arteriopathy (ie, meningitis or lupus). 
2. Unilateral focal-cerebral 
arteriopathy of childhood 
(FCA) 
 
 
 
a. Anterior circulation with collaterals (would include 
some types of possible moyamoya disease and some 
patients with progressive primary angiitis of the central 
nervous system of childhood ).–Confirmation of the 
diagnosis requires MRA, CTA or computed 
angiography (CA) displaying both (1) unilateral 
stenosis or vessel irregularity of a large intracranial 
artery (internal carotid artery, middle cerebral artery, 
anterior cerebral artery) supplying the territory of 
infarct, and (2) evidence of an excessive collateral 
network of vessels distal to the occluded artery. 
 
b. Anterior circulation without collaterals (would include 
conditions such as transient-cerebral arteriopathy, 
post-varicella arteriopathy, and large-vessel childhood 
primary angiitis of the central nervous system). 
Confirmation of the diagnosis requires MRA, CTA, or 
CA displaying both (1) unilateral stenosis or vessel 
irregularity of a large intracranial artery (internal 
carotid artery, middle cerebral artery, anterior cerebral 
artery) supplying the territory of infarct, and (2) no 
evidence of excessive collateral network of vessels 
distal to the occluded artery. 
 
c. Posterior circulation (would include conditions such as 
basilar artery stenosis)–Confirmation of the diagnosis of 
focal-cerebral arteriopathy within the cerebral posterior 
circulation requires MRA, CTA or CA displaying 
unilateral stenosis or vessel irregularity of a large 
intracranial artery (posterior cerebral artery, basilar or 
vertebral) supplying the territory of infarct and not 
meeting definition of dissection. 
 
d. Other–such as congenital anomaly. 
 
3. Bilateral cerebral a. With collaterals (would include conditions such as 
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arteriopathy of 
childhood 
 
 
moyamoya disease or Fibromuscular dysplasia)–
Confirmation of the diagnosis requires MRA, CTA, or 
CA showing (1) bilateral stenosis or vessel irregularity 
of a large intracranial artery (internal carotid artery, 
middle cerebral artery, anterior cerebral artery, 
posterior cerebral artery) supplying the territory of 
infarct, and (2) evidence of excessive collateral 
network of vessels distal to the occluded arteries. 
 
b. Without collaterals (would include some types of 
possible moyamoya disease)–Confirmation of the 
diagnosis requires MRA, 
CTA, or CA showing (1) bilateral stenosis or vessel 
irregularity of a large intracranial artery (internal carotid 
artery, middle cerebral artery, anterior cerebral artery, 
posterior cerebral artery) supplying the territory of infarct, 
and (2) no evidence of excessive collateral network of 
vessels distal to the occluded arteries. 
 
c. Other–such as congenital anomaly. 
 
4.Aortic/Cervical 
Arteriopathy 
 
 
 
a. Dissection–Confirmation of the diagnosis of 
intracranial- or 
cervical-arterial dissection requires CTA, magnetic 
resonance imaging/MRA, or CA with 1 of the following 3 
patterns: (1) angiographic findings of a double-lumen, 
intimal flap, or pseudo aneurysm, or, on axial T1 fat 
saturation magnetic resonance imaging images, a “bright 
crescent sign” in the arterial wall; (2) the sequence of 
cervical or cranial trauma, or neck pain, or head pain less 
than 6 weeks preceding angiographic findings of 
segmental arterial stenosis (or occlusion) located in the 
cervical arteries;  (3) angiographic segmental stenosis (or 
occlusion) of the vertebral artery at the at the level of the 
C2 vertebral body, even without known traumatic history. 
(Adapted from Sebire and colleagues, 2004) 
 
b. Takayasu arteritis–Confirmation of the diagnosis of 
Takayasu arteritis requires angiographic abnormalities 
(CA, CTA, or MRA) of the aorta or its major branches 
(mandatory criterion) plus at least 1 of the following 4 
features: 
– Decreased peripheral artery pulse(s) and /or claudication 
of the extremities 
– Blood pressure difference __10mm Hg 
– Bruits over aorta or its major branches 
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– Hypertension (related to childhood normative data) 
 
c. Other–such as congenital anomaly or cervical 
Fibromuscular Dysplasia 
 
 
5. Cardio- embolic  
 
a. Definite–High-risk for cardiac source of cerebral 
embolism 
(such as congenital heart disease with abnormal cardiac 
function, arrhythmia, or endocarditis) or cardiac procedure 
within 30 days of stroke and territory of large/medium-
sized cerebral artery or >1 arterial territory, may be large 
and/or haemorrhagic. 
 
b. Probable–_1 arterial territory, may be large and/or 
haemorrhagic in a child without another identifiable 
aetiology and 1 of the following: 
1) patent foramen ovale with right-to left shunt or other 
subtle cardiac anomaly; 
2) Occlusion: a discrete and abrupt blockage of an artery 
consistent with a clot, without any surrounding irregularity 
or 
stenosis suggestive of arteriopathy. (Modified from 
Wraige et al, 2005; and Ay et al, 2007) 
 
6. Other  a. Undetermined aetiology–aetiology unclear despite 
complete workup (including echocardiogram MRI, and 
vascular imaging of 
head and neck) 
b.  Other (ie, other location of identifiable disease that 
cannot be classified) 
7. Multi-factorial  
 
>1 anatomic site of disease (ie, patients who have >1 site 
of the primary classifications and in whom we are unable 
to 
determine the predominant site of disease 
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Appendix 2 
Arterial Ischaemic Stroke: Clinical Checklist  
 
This clinical checklist is not intended to be comprehensive; it is intended to supplement the 
conventional history and examination process by prompting the user to ask about or look for 
clinical factors which are potentially relevant to a child presenting with acute AIS. The 
aspects of the neurological examination which have been specifically highlighted are partly 
derived from items used in adult stroke severity scales but are not intended to replace more 
comprehensive clinical evaluation. If it is not possible to assess any of these parameters it is 
important to record this and the reasons for this (e.g. child was uncooperative or test was 
developmentally inappropriate)  
History  
Time of onset of symptoms  
Prior events e.g. TIA  
Seizures   
Prior trauma to the head or neck  
Chickenpox? If so, when?  
History of recent infection  
Head or neck pain?  
Past medical history (incl. history of thrombosis)  
Family history (incl. thrombosis, miscarriage)  
Medication (& recreational drugs)  
Development  
Examination  
Blood pressure  
Peripheral pulses (check for radio-femoral delay)  
Oxygen saturation  
Temperature  
Neurocutaneous signs  
Cardiovascular examination  
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Conscious level (use modified Glasgow Coma Scale)  
Neurological examination to include evaluation for:  
Cranial nerve function including:  
Eye movements (?gaze palsy)  
Visual fields  
Facial palsy  
? Horner’s syndrome  
Motor deficit (if present specify location and severity using MRC scale)  
Ataxia (if present specify location e.g. truncal or limb)  
Sensory dysfunction (if present specify location)  
Communication (including expressive and receptive language and articulation)  
Swallowing  
Neglect (if present specify location)  
 
Imaging  
Brain MRI*  
MRA circle of Willis*  
MRA neck *  
*These are all included when you request an acute “stroke protocol” MRI at GOSH  
Transthoracic echocardiogram  
Blood tests  
Full blood count  
Urea& electrolytes, liver function tests  
ESR  
CRP  
Haemoglobin electrophoresis if black or Mediterranean ethnicity  
Clotting profile  
Thrombophilia screen (at GOSH this will include protein C, protein S, antithrombin, 
plasminogen, DRVVT, Exner, APC resistance ratio, FVL, MTHFR and PT20210 gene 
mutations)  
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Anticardiolipin antibodies  
Plasma amino acids  
Total plasma homocysteine  
Plasma lactate  
Ammonia  
Cholesterol and triglycerides (random)  
Plasma urate  
Transferrin electrophoresis  
Lp(a) (please request on downtime form as lipoprotein (a), not available on PIMS, min. 
1ml clotted blood)  
Alpha galactosidase A (to exclude Fabry disease)  
Serum globotriaosylceramide (to exclude Fabry disease)  
Serology: mycoplasma, VZV, borellia  
Urine  
Organic acids  
Urinary globotriaosylceramide (to exclude Fabry disease)  
CSF  
Lumbar puncture is not routinely indicated and the need for this should be reviewed on a 
case-by-case basis. If a lumbar puncture is undertaken it is helpful to request CSF VZV PCR 
and antibodies and CSF lactate. 
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Appendix 3 
Plate plan for microparticles                   Plate plan for endothelial progenitor 
cells  
     No stain       No stain    
     AnV-FITC        PE-Isotype 
AnV-PE        PE-CY5 Isotype 
AnV-PECy5     FITC-Isotype 
CD42a PERCP     CD34-PERCP 
FITC Isotype      CD133-PE 
PE Isotype      KDR- FITC 
PE-CY5 Isotype       CD144-FITC     
PERCP Isotype     CD133/CD34/KDR   
CD42a PERCP/AnV-FITC    CD133/CD34/CD144 
CD42aPERCP/AnV-FITC/CD62P-PE 
CD42a PERCP/AnV-FITC/CD62E-PE 
CD42aPERCP/AnV-FITC/CD31-PE 
CD42a PERCP/AnV-FITC/CD106-PE 
CD42aPERCP/AnV-FITC/aCD11b-PE 
CD42aPERCP/AnV-FITC/CD54-PE 
TF-FITC/AnV-PE/CD14 Pe-Cy5  
TF-FITC/AnV-PECy5/CD162 PE 
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Appendix 4 
 
Flow cytometry instrument settings for microparticles 
 
Detector Voltage Amp gain Mode Threshold Compensation 
Forward 
scatter 
E01 5.57 Logarithmic 50 FL1-1.5%FL2 
FL2-14 % FL1 
FL2-0%FL3 
FL3-18.1% FL2 
 
Side scatter 364 1.00 Logarithmic 52 
FL1 (FITC) 690 1.00 Logarithmic 50 
FL2 (PE) 721 1.00 Logarithmic 52 
FL3 (CYC) 750 1.00 Logarithmic 52 
 
 
 
Flow cytometry instrument settings for endothelial progenitor cells 
 
Detector Voltage Amp gain Mode Threshold Compensation 
Forward 
scatter 
E00 1 Linear 50 FL1-0.5%FL2 
FL2-19% FL1 
FL2-10%FL3 
FL3-17%FL2 
 
Side scatter 480 1 Linear 50 
FL1 (FITC) 547 1 Logarithmic 50 
FL2 (PE) 627 1 Logarithmic 50 
FL3 (CYC) 437 1 Logarithmic 50 
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Appendix 5 
Human umbilical endothelial cells (HUVEC) 
 
Human umbilical endothelial cells commercially available (Promo cell) were stimulated with 
100 ng/ml of TNF-α for 24 hours. The surface expression of a number of endothelial surface 
markers and tissue factor (CD142) for stimulated an unstimulated (control) HUVEC using 
flow cytometry are shown below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TNF-α  
Control  
Isotype  
CD54 
CD105
 
 CD31 
CD62E CD142 
CD31
 
 CD31 
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Endothelial derived microparticles (EMP) 
 
 
Endothelial derived microparticles (EMP) harvested from supernatants of human umbilical 
endothelial cells (HUVEC) stimulated with 100 ng/ml of TNF-α for 24 hours were stained 
for a variety of endothelial surface markers and tissue factor (CD142) –flow cytometric plots 
are shown below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD105 
CD54 CD142 
MP 
gate 
CD62E 
CD31 
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Platelets 
 
Platelets were isolated from human peripheral blood donated by adult volunteers and 
stimulated with a number of stimuli (including calcium ionophore 10 nM and ADP 5 µM for 
1hour). The surface expression of platelet constitutively expressed (CD42a) and activation 
markers (CD62P) as well as CD142 (tissue factor) as assessed by flow cytometry is shown 
below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD42a CD62P Platelets 
CD142 
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Platelet derived microparticles 
 
Platelet derived microparticles were harvested from the supernatants of stimulated platelets 
(with calcium ionophore 10 nM or ADP 5 µM for 1hour) and stained with CD42a, CD62P 
and CD142 (tissue factor)-flow cytometric plots are shown below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD62P 
CD142 
CD42a 
MP 
gate 
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Monocytes 
 
Human monocytes were isolated from peripheral blood donated by adult healthy volunteers 
and stimulated with LPS (5 µg/ml for 4 hours). Surface expression of CD14 and tissue factor 
(CD142) were assessed with flow cytometry and are shown below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Monocyte MPs (MMP) 
 
Monocyte derive microparticles (MMP) were isolated from the supernatants of human 
monocytes stimulated with LPS (5 µg/ml for 4 hours) and stained with CD14 and tissue 
factor-flow cytometric plots are shown below.  
 
 
 
 
 
 
 
 
 
 
 
MMP 
CD14 CD142 
CD14 CD142 
Monocytes 
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Neutrophils 
 
Neutrophils isolated from human blood from adult volunteers and stimulated with fmlp (10 
µg/ml for 2 hours) were stained with constitutively expressed or activation surface markers 
and assessed with flow cytometry (shown below).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Neutrophil microparticles (NMP) 
 
Neutrophil microparticles were isolated from the supernatants of human neutrophils 
stimulated with fmlp (10 µg/ml for 2 hours) were stained for aCD11b and CD66b-flow 
cytometric plots are shown below. 
 
 
 
 
 
 
 
 
 
 
aCD11b CD66b 
aCD11b CD66b 
NMP 
Neutrophils 
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Appendix 6 
 
 
The Birmingham Vasculitis Activity Score (BVAS) 
(Luqmani, Bacon and others, 1994)  
 
Tick box only if abnormality is newly present or worsening within the previous 4 weeks and 
ascribable to vasculitis  
 
1. SYSTEMIC      3 (maximum total)  
none       0 
malaise      1 
myalgia       1 
arthralgia/arthritis     1 
fever (<38.5°C)     1  
fever (>38.5°C)     2  
wt loss (1-2 kg) within past month   2  
wt loss (>2 kg) within past month   3  
 
2. CUTANEOUS     6 (maximum total)  
none      0  
infarct      2  
purpura       2 
other skin vasculitis     2 
ulcer       4 
gangrene      6 
multiple digit gangrene     6 
 
3. MUCOUS MEMBRANES/EYES   6 (maximum total)  
none       0 
mouth ulcers      1 
genital ulcers     1  
conjunctivitis      1 
episcleritis      2 
uveitis       6 
retinal exudates     6  
retinal haemorrhage     6 
 
 
4. ENT       6 (maximum total)  
nil       0 
nasal discharge/obstruction    2 
sinusitis      2 
epistaxis      4 
crusting       4 
aural discharge     4 
otitis media      4 
new deafness      6 
hoarseness/laryngitis     2 
subglottic involvement     6 
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5. CHEST      6 (maximum total)  
none      0  
dyspnoea or wheeze     2 
nodules or fibrosis     2 
pleural effusion/pleurisy     4 
infiltrate      4 
haemoptysis/haemorrhage    4 
massive haemoptysis     6 
 
6. CARDIOVASCULAR    6 (maximum total) 
none       0 
bruits       2 
new loss of pulses     4 
aortic incompetence     4 
pericarditis      4 
new myocardial infarct     6 
CCF/cardiomyopathy     6 
 
7. ABDOMINAL     9 (maximum total) 
none      0  
abdominal pain      3 
bloody diarrhoea      6 
gall bladder perforation     9 
gut infarction      9 
pancreatitis     9 
 
8. RENAL      12 (maximum total)  
none      0  
hypertension (diastolic >90)    4 
proteinuria (>1 + or >0.2 g/24 h)    4 
haematuria (> 1 + or >10 rbc/ml)     8 
creatinine 125-249 mol/l    8 
creatinine 250-499 mol/1    10 
creatinine >500 mol/l     12 
rise in creatinine >10%     12 
 
9. NERVOUS SYSTEM    9 (maximum total) 
none      0         
organic confusion/dementia   3  
seizures (not hypertensive)   9  
stroke      9  
cord lesion      9      
peripheral neuropathy     6 
motor mononeuritis multiplex    9 
 
MAXIMUM SCORE    63 
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Appendix 7 
 
 
Thrombin generation assay calibration curve 
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